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Abstract 
Background: ALS is an incurable late onset neurodegenerative disease that is 
characterised by progressive loss of motor neurons. A (G4C2)n repeat expansion in 
C9ORF72 is the most common genetic cause of ALS, but it is unknown how the repeat 
causes pathogenesis, although a gain of toxic function is likely. 
Aims and Objectives: 1) Generate stable, isogenic motor neuron-like NSC34 cellular 
models that have tetracycline-inducible (G4C2)n repeat expression. 2) Characterise the 
cell models for C9ORF72-ALS pathology and biochemical alterations. 3) Identify 
biological functions and pathways that may be transcriptionally dysregulated by (G4C2)n 
repeat expression early in C9ORF72-ALS pathogenesis. 4) Identify and interrogate 
potential therapeutic targets for C9ORF72-ALS. 
Results: Stable, isogenic NSC34 cell models with tetracycline-inducible (G4C2)n 
expression were successfully generated. Sense RNA foci and RAN translation products 
were detected in the cell models. No antisense derived RNA foci or RAN translation 
products were detected. Expression of the (G4C2)102 caused subtle toxicity and 
recapitulated some aspects of C9ORF72-ALS pathology in the NSC34 (G4C2)102. The 
(G4C2)102 expression caused transcriptomic dysregulation in RNA metabolism, protein 
transport, the PI3K/Akt signalling pathway, and also caused splicing alterations. 
Transcriptomic dysregulation in the PI3K/Akt signalling pathway was also detected in 
LCM motor neurons from C9ORF72-ALS patients. Pten knock-down provided a rescue 
effect against the (G4C2)102 induced toxicity in the NSC34 (G4C2)102. 
Conclusions: Stable, isogenic motor neuron-like cellular models that had tetracycline-
inducible (G4C2)n expression were successfully generated, and allowed interrogation of 
the early biochemical effects associated with sense only (G4C2)n expression in a 
reductionist manner. Transcriptomic analysis of the NSC34 (G4C2)102 identified 
dysregulation in RNA splicing and the PI3K/Akt signalling pathway, which was 
corroborated by transcriptomic data from C9ORF72-ALS patient CNS tissue. This 
suggests dysregulation in these biological functions and pathways is disease relevant 
and an early biochemical event in C9ORF72-ALS pathogenesis. Pten is a potential 
therapeutic target that deserves further study. 
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Chapter 1. Introduction 
1.1. Background 
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, incurable and ultimately fatal 
late onset neurodegenerative disease. ALS is clinically heterogeneous, but is 
characterised by progressive loss of both upper and lower motor neurons. The 
progressive injury and death of motor neurons results in the failure of the 
neuromuscular system. This manifests as muscle weakness, muscle wasting, paralysis, 
and respiratory failure. Additionally, the pathogenesis of ALS is complex, with many 
genes and molecular mechanisms implicated in disease progression.  
1.2. Clinical Presentation 
ALS is the most common form of motor neuron disease (MND) accounting for 66% of 
cases, and is characterised by loss of both upper motor neurons (UMN) (including the 
Betz cells of the motor cortex) and lower motor neurons (LMN) (anterior horn cells of 
the spinal cord and brain stem nuclei) (Bäumer et al., 2014). Other less common sub-
types of MND are characterised by the motor neurons initially affected. Around 25% of 
MND cases are classified as progressive bulbar palsy (PBP), which is confined to the 
bulbar musculature at presentation and affects swallowing and speech. However, a 
recent study showed 87% of PBP cases eventually developed into ALS, suggesting these 
are bulbar onset ALS cases (Karam et al., 2010). Less than 5% of MND cases are classified 
as primary lateral sclerosis (PLS), which affects purely the UMN (Rowland and Shneider, 
2001). Finally, about 10% of MND cases are classified as progressive muscular atrophy 
(PMA), which affects purely the LMN at least at the time of presentation (Rowland and 
Shneider, 2001). 
ALS has a heterogeneous clinical presentation. Motor neuron degeneration and 
subsequent muscle weakness progress rapidly from the initial focus in an anatomically 
logical manner, culminating in paralysis and respiratory failure – which is the common 
cause of death (Ravits and La Spada, 2009). Disease onset most commonly occurs in the 
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limbs and represents approximately 66% of ALS cases (Gordon, 2013). Symptoms in the 
limbs can be bilateral or unilateral and include muscle wasting, distal weakness, 
proximal weakness, fasciculation, brisk reflexes, extensor plantar reflexes and an 
increased tendency to trip due to foot drop (Mitchell and Borasio, 2007). Bulbar onset 
presents in 30% of cases and can present with dysarthria, dysphagia, wasting and 
fasciculation of the tongue, and facial weakness (Mitchell and Borasio, 2007). Emotional 
lability, characterised by episodes of involuntary laughter and crying, is also 
symptomatic of bulbar involvement (Mitchell and Borasio, 2007). Around 5% of cases 
have respiratory onset, characterised by dyspnoea and orthopnoea (Gautier et al., 
2010).  
In addition to motor symptoms, up to 50% of ALS patients also show evidence of 
cognitive impairment during the disease course (Lomen-Hoerth et al., 2003; Wheaton 
et al., 2007).  Further, between 5 to 15% of ALS patients also have features of 
frontotemporal dementia (FTD) (Gordon, 2013; Lomen-Hoerth et al., 2003). Similarly, 
around 15% of behavioural variant FTD (bvFTD) patients also display signs of motor 
dysfunction, which can develop into ALS (Burrell et al., 2011; Lomen-Hoerth et al., 2002). 
BvFTD onset generally occurs between 50 and 60 years of age, (Achi and Rudnicki, 2012; 
McKhann et al., 2001; Ratnavalli et al., 2002), and is characterised by progressive 
degeneration of the frontal and temporal lobes of the cerebral cortex, which leads to 
impairment in behaviour and/or personality. These behavioural and personality changes 
include apathy and/or disinhibition, loss of empathy, emotional blunting, and ritualised 
behaviours (Lillo and Hodges, 2009). BvFTD and ALS are increasingly being considered 
as part of the same clinico-pathological spectrum in which different neurons are 
affected, due to clinical overlap, as well as similarities in neuropathology and genetic 
causes (Fiesel and Kahle, 2011). 
As with many other neurodegenerative diseases, age is a crucial risk factor for ALS. A 
meta-analysis calculated the median value of the reported mean age of ALS onset from 
several studies, and found the average age of onset was between 63 to 65 for Europe 
and New Zealand, and about 59 for North America and East Asia (Marin et al., 2015). 
Additionally, rare juvenile onset forms of ALS exist, in which symptom onset is under 18 
years of age (Shaw, 2005). Also based on a meta-analysis from studies on European and 
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North-American cases, the median survival time from ALS onset to death is between 25 
and 40 months (Marin et al., 2015). However, whilst the disease progresses more quickly 
in some patients, death occurring within a year of symptom onset, between 5 and 10% 
of ALS patients survive over a decade after disease onset (Chiò et al., 2009). 
1.3. Epidemiology 
Globally, ALS incidence increases with age, and will therefore be greater in ageing 
populations. The life time risk of developing ALS by the age of 70 is approximately 1 in 
400 (Chiò et al., 2013; Johnston et al., 2006), although this is estimated based on a study 
in London. ALS has a mean incidence of 2.8/100,000/year in Europe and 
1.8/100,000/year in North America, and a mean prevalence of 5.4/100,000 in Europe 
and 3.4/100,000 in North America (Chiò et al., 2013). In addition, there are geographical 
differences in ALS incidence and prevalence across Europe. Both ALS incidence and 
prevalence are considerably lower in other countries of non-European origin, although 
there are only a few epidemiological studies on populations outside Europe and North 
America and these may under estimate ALS incidence due to sub-optimal study design 
(Chiò et al., 2013). However, there is an increased incidence of ALS in a region of the 
Western Pacific, where the incidence is 7.0/100,000/year in the Chamorro people of 
Guam (Waring et al., 2004) and 9.5/100,000/year in the Kii peninsula of Japan (Yoshida 
et al., 1998), and the increased ALS incidence is thought to be caused by neurotoxins in 
the diets of these populations (Cheng and Banack, 2009; Kihira et al., 2012). Lastly, 
multiple studies suggest an increased ALS incidence in males compared to females (M:F 
1.2-1.5:1.0), although other later studies suggest the ratio may actually be more 
balanced (Abhinav et al., 2007; Logroscino et al., 2008; Worms, 2001).     
1.4. Neuropathology 
Insoluble protein aggregates found in neuronal and glial cells within the CNS are 
characteristic of neurodegenerative diseases. Ubiquitinated inclusions (UBIs) are the 
hallmark of ALS neuropathology; however other protein aggregates are often present. 
UBIs are observed as either filamentous skein aggregates or compact, round bodies in 
the degenerating motor neurons, but also in glial cells (Leigh et al., 1991). TDP-43 is the 
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major protein component within the UBIs in most ALS patients (excluding SOD1 and FUS 
related ALS cases) (Neumann et al., 2006). These UBIs stain positive for ubiquitin and 
phosphorylated-TDP-43 (p-TDP-43), but negative for tau and α-synuclein (Neumann et 
al., 2006). In ALS tissue, TDP-43 (predominantly a nuclear protein) becomes cytoplasmic. 
Hyperphosphorylated and C-terminal fragments of TDP-43 are also detected in the UBIs 
(Neumann et al., 2006). FUS-ALS pathology is characterised by FUS-positive cytoplasmic 
inclusions that are negative for TDP-43, tau and α-synuclein (Kwiatkowski et al., 2009; 
Vance et al., 2009). Mutant FUS mislocalises in the cytoplasm similarly to mutant TDP-
43. In addition, SOD1-related ALS patients contain UBIs positive for SOD1 (Bruijn et al., 
1998), and negative for TDP-43 (Mackenzie et al., 2007). 
Bunina bodies (BB) are another type of protein aggregate observed in the degenerating 
LMN of ALS patients. BB are small, round, eosinophilic cytoplasmic inclusions, present 
in approximately 85% of ALS patients (Piao et al., 2003). BB stain positive for cystatin C 
(Okamoto et al., 1993) and transferrin (Mizuno et al., 2006) but stain negative for TDP-
43 (Tan et al., 2007). However, the other protein components of BB remain unclear 
(Okamoto et al., 2008). The origin of BBs is also uncertain, but some studies suggest they 
could originate from the lysosomes, Golgi apparatus or endoplasmic reticulum (ER) 
(Okamoto et al., 2008). 
Hyaline conglomerate inclusions (HCIs) are another major aggregate type observed. 
Hyaline (meaning glassy) refers to HCIs appearance when stained with agents such as 
haematoxylin and eosin. HCIs are large multifocal inclusions that contain 
phosphorylated and non-phosphorylated neurofilament subunits, as well as entrapped 
organelles and proteins (Wood et al., 2003). HCIs are associated with the SOD1 I113T 
(p.I114T) mutation, and are not seen in sporadic ALS cases (Ince et al., 1998). HCIs and 
UBIs are rarely seen in the same ALS cases, which could suggest different pathological 
pathways that give rise to the disease (Ince et al., 1998). However, HCIs are also seen in 
other neurodegenerative diseases, making them a less specific marker of ALS compared 
with UBIs (Sobue et al., 1990). 
Recently, protein aggregates containing ubiquitin and the ubiquitin binding protein p62, 
but negative for TDP-43, FUS, tau, α-synuclein, α-internexin and neurofilament have 
been described in ALS patients (King et al., 2011). These inclusions can exist as 
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cytoplasmic globular or star-shaped inclusions, or smaller spherical intranuclear 
inclusions (Al-Sarraj et al., 2011). These inclusions can be found in both neuronal and 
glial cells in the granular layer, molecular layer and Purkinje cells of the cerebellum, and 
also in the pyramidal cells of the hippocampus. One study suggests these p62 positive, 
TDP-43 negative inclusions are specific to ALS and/or FTD cases that contain the (G4C2)n 
repeat expansion (C9ORF72-ALS/FTD) (Al-Sarraj et al., 2011). Another study confirms 
C9ORF72-ALS cases have much higher levels of these p62 positive, TDP-43 negative 
extra-motor neuronal inclusions in the hippocampus and frontal neocortex, compared 
to non-C9ORF72-ALS cases (Cooper-Knock et al., 2012). These inclusions could represent 
an alternative pathological mechanism to the TDP-43 aggregates occurring in many ALS 
cases. 
In addition, C9ORF72-ALS/FTD patients display other exclusive neuropathology. The 
(G4C2)n repeat expansion is transcribed in both sense and antisense directions, which 
forms sense (G4C2)n and antisense (C4G2)n RNA foci respectively in the CNS of 
C9ORF72-ALS/FTD patients (DeJesus-Hernandez et al., 2011; Gendron et al., 2013). 
Sense and antisense RNA foci have been detected in neuronal cells in the frontal cortex, 
the hippocampal dentate fascia, cerebellar granule cells and Purkinje cells, and LMN of 
the spinal cord (Cooper-Knock et al., 2015b; Cooper-Knock et al., 2014b; Mizielinska et 
al., 2013). Additionally, sense and antisense RNA foci are present in astrocytes, 
microglia, and oligodendrocytes (Mizielinska et al., 2013), as well as lymphoblasts, 
fibroblasts and iPSC-derived neurons from C9ORF72-ALS/FTD patients (Almeida et al., 
2013; Donnelly et al., 2013; Lagier-Tourenne et al., 2013). The majority of RNA foci are 
nuclear, but rare cytoplasmic RNA foci are also detected (Cooper-Knock et al., 2014b; 
Mizielinska et al., 2013). Numerous studies show the RNA foci also co-localise with 
various RNA binding proteins in patient CNS tissue (section 1.7.2) (Cooper-Knock et al., 
2014b; Haeusler et al., 2014; Lee et al., 2013; Mori et al., 2013b; Sareen et al., 2013). 
Lastly, the sense (G4C2)n and antisense (C4G2)n RNA undergoes unconventional repeat 
associated non-ATG (RAN) translation in all reading frames, forming aggregation-prone 
dipeptide repeat (DPR) proteins (section 1.5.4) (Ash et al., 2013; Mori et al., 2013c). The 
poly-GA, poly-GP, and poly-AP DPR protein species each form insoluble cytoplasmic 
aggregates, whilst the poly-GR and poly-PR DPR protein species both form insoluble 
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nuclear aggregates in C9ORF72-ALS/FTD patient CNS tissue (Ash et al., 2013; Mann et 
al., 2013; Mori et al., 2013a; Mori et al., 2013c; Zu et al., 2013). DPR pathology is highly 
consistent in C9ORF72-ALS/FTD patients regardless of disease phenotype, and DPR load 
is high in the cerebellum, all neocortical regions (frontal, motor cortex and occipital) and 
hippocampus, moderate in subcortical areas and minimal in LMN (Mackenzie et al., 
2013). Additionally, DPR proteins are present in the p62-positive, TDP-43 negative 
aggregates in C9ORF72-ALS/FTD patients, and could be the cause of these seemingly 
pathognomonic C9ORF72-ALS/FTD aggregates (Mann et al., 2013). 
1.5. Genetics 
ALS has two clinically defined subtypes: familial ALS (FALS) and sporadic ALS (SALS). The 
majority of ALS patients (around 95%) are defined as sporadic, with no family history of 
ALS (Renton et al., 2014). However, twin studies estimate SALS has a heritability of 38-
78% (Al-Chalabi et al., 2010). Patients with a first or second degree relative with ALS are 
clinically defined as familial cases, and represent an estimated 5% of total cases (Byrne 
et al., 2011). Incomplete evidence of inheritance can result in the incorrect assignment 
of familial cases as sporadic cases however, underestimating FALS as a proportion of the 
disease. As with other late-onset diseases, premature death from other causes in 
previous generations and incomplete penetrance can mask a history of family 
inheritance (Andersen, 2006). FALS is generally inherited in an autosomal dominant 
manner, but autosomal recessive and X-linked ALS causative mutations also exist 
(Renton et al., 2014). Currently, mutations in 24 known genes are thought to account 
for >68% of all FALS cases, and >11% of SALS cases (Table 1.1) (Renton et al., 2014). 
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Table 1.1 Genes associated with Familial ALS and Familial ALS/FTD. The genetic locus, gene name, implicated pathogenic mechanism, mode of 
inheritance, age of onset, disease phenotype, and reference to initial discovery are shown.  
Locus Chromosome Gene Implicated Pathogenic Mechanism Mode Onset Phenotype Reference 
ALS 1 21q22.11 SOD1 Oxidative stress; UPS; autophagy AD (AR) Adult ALS (Rosen, 1993) 
ALS 2 2q33.1 ALSIN Endosomal trafficking AR Juvenile ALS, HSP (Hadano et al., 2001; Yang et al., 2001) 
ALS 3 18q21 Unknown Unknown AD Adult ALS (Hand et al., 2002) 
ALS 4 9q34.13 SETX RNA metabolism AD Juvenile ALS, AOA2 (Chen et al., 2004) 
ALS 5 15q21.1 SPG11 DNA damage repair; axonal growth AR Juvenile ALS, HSP (Orlacchio et al., 2010) 
ALS 6 16p11.2 FUS RNA metabolism; stress granules AD (AR) Adult ALS, FTD (Kwiatkowski et al., 2009; Vance et al., 2009) 
ALS 7 20p13 Unknown Unknown AD Adult ALS (Sapp et al., 2003) 
ALS 8 20q13.32 VAPB Vesicle trafficking; UPR; ER stress AD Adult ALS, SMA (Nishimura et al., 2004) 
ALS 9 14q11.2 ANG RNA metabolism, Angiogenesis AD Adult ALS, FTD, PD (Greenway et al., 2006) 
ALS 10 1p36.22 TARDBP RNA metabolism AD Adult ALS, FTD, PD (Sreedharan et al., 2008) 
ALS 11 6q21 FIG4 Endosomal trafficking AD Adult ALS, CMT (Chow et al., 2009) 
ALS 12 10p13 OPTN Autophagy AD (AR) Adult ALS, POAG (Maruyama et al., 2010) 
ALS 13 12q24.12 ATXN2 Endocytosis, RNA translation AD Adult ALS, FTD, SCA2 (Elden et al., 2010) 
ALS 14 9p13.3 VCP Autophagy AD Adult 
IBMPFD/ALS, 
FTD, CMT, HSP 
(Johnson et al., 2010) 
ALS 15 Xp11.21 UBQLN2 UPS; autophagy XD Adult ALS/FTD (Deng et al., 2011) 
ALS 16 9p13.3 SIGMAR1 UPR; ER stress; proteasome AD Juvenile ALS/FTD (Al-Saif et al., 2011; Luty et al., 2010) 
ALS 17 3p11.2 CHMP2B Endosomal trafficking; autophagy AD Adult ALS, FTD (Parkinson et al., 2006) 
ALS 18 17p13.2 PFN1 Cytoskeleton; axonal growth AD Adult ALS, FTD (Wu et al., 2012) 
ALS 19 2q34 ERBB4 Neuronal development AD Adult ALS (Takahashi et al., 2013) 
ALS 20 12q13.13 HNRNPA1 RNA metabolism AD Adult IBMPFD/ALS (Kim et al., 2013) 
ALS 21 5q31.2 MATR3 RNA metabolism AD Adult ALS, VCPDM (Johnson et al., 2014) 
ALS 22 2q35 TUBA4A Cytoskeleton AD Adult ALS (Smith et al., 2014) 
ALS-FTD1 9p21.2 C9ORF72 
RNA metabolism; endosomal 
trafficking; autophagy 
AD Adult ALS/FTD 
(DeJesus-Hernandez et al., 2011; Renton et 
al., 2011) 
ALS-FTD2 22q11.23 CHCHD10 Mitochondrial maintenance AD Adult ALS/FTD (Bannwarth et al., 2014) 
ALS-FTD3 5q35.3 SQSTM1 Autophagy, protein degradation AD Adult ALS/FTD, PDB (Fecto et al., 2011) 
ALS-FTD4 12q14.2 TBK1 Autophagy, neuroinflammation AD Adult ALS/FTD (Cirulli et al., 2015; Freischmidt et al., 2015) 
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1.5.1. SOD1 
The first mutations associated with ALS were found in Cu/Zn superoxide dismutase 1 
(SOD1) (Rosen, 1993). There are over 170 known missense mutations that are found in 
each of the five exons of SOD1 (Andersen, 2006; Renton et al., 2014; Su et al., 2014). 
However, reliable genetic evidence linking the mutation to ALS pathogenicity still 
remains for a portion of these. SOD1 mutations account for 12-20% of FALS cases and 2-
7% of SALS cases (www.alsod.iop.kcl.ac.uk), however there is considerable phenotypic 
variability caused by different SOD1 mutations. For example, the A4V (p.A5V) mutation 
is autosomal dominant and causes a particularly aggressive form of ALS, typically leading 
to death within 1 year of disease onset (Cudkowicz et al., 1997). Whilst, the D90A 
(p.D91A) mutation is recessive and causes a slowly progressive form of ALS where 
patients survive over 10 years from disease onset on average (Andersen et al., 1996). 
SOD1 mutations were first proposed to cause ALS via a loss of function. SOD1 is 
ubiquitously expressed and converts superoxide radicals into molecular oxygen and 
hydrogen peroxide, and therefore, SOD1 loss of function was hypothesised as a cause 
of oxidative stress (Rosen, 1993). However, whilst most SOD1 mutations do reduce the 
SOD1 dismutase activity, there is no correlation between the disease severity and the 
SOD1 dismutase activity (Al-Chalabi et al., 2012). Further, the autosomal dominant 
inheritance of most SOD1 mutations indicates a toxic gain of function in mutant SOD1. 
WT SOD1 has a high propensity to misfold, which can be induced by oxidation and 
demetallation (Rakhit and Chakrabartty, 2006; Rakhit et al., 2004). In addition, ALS 
causative mutations in SOD1 also increase the protein’s propensity to misfold and 
aggregate (Stathopulos et al., 2006; Turner and Talbot, 2008; Vassall et al., 2006). 
Aggregated SOD1 is suggested to affect a range of cellular functions that could lead to 
neurotoxicity and ALS, and include oxidative stress, mitochondrial dysfunction, 
glutamate-mediated excitotoxicity, and axonal transport defects (Joyce et al., 2011). 
Further, misfolded and/or aggregated mutant SOD1 can be taken up by neuronal cells, 
and nucleate misfolding and aggregation of soluble endogenous mutant and wildtype 
SOD1 (Münch et al., 2011; Sundaramoorthy et al., 2013). This seeding of SOD1 
aggregation can then propagate from cell to cell in a prion-like manner, and could 
explain the anatomical progression of ALS.  
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1.5.2. TARDBP 
Mutations in the transactive response DNA binding protein 43kDa (TARDBP) gene, which 
encodes transactive response DNA binding protein 43kDa (TDP-43), also cause ALS 
and/or bvFTD (Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; Yokoseki 
et al., 2008). Mutations in TARDBP account for 4-5% of FALS and about 1% of SALS 
(Millecamps et al., 2010). There are currently 40 known mutations in the TARDBP gene 
that are associated with ALS, and these primarily occur in the C-terminus of TDP-43 
which is important for ribonucleoprotein binding and splicing (Millecamps et al., 2010; 
Renton et al., 2014). TARDBP mutations are also autosomal dominant and associated 
with a classical ALS phenotype. 
TDP-43 is a multifunctional heterogeneous nuclear ribonucleoprotein involved in a 
range of different RNA metabolism processes including transcription, mRNA splicing, 
RNA transport, mRNA stability and stress granule dynamics, and miRNA biogenesis 
(Buratti and Baralle, 2008, 2012). TDP-43 is expressed ubiquitously and is predominantly 
localised in the nucleus, where it performs the majority of its functions. However, TDP-
43 also shuttles between the nucleus and cytoplasm (Ayala et al., 2008; Winton et al., 
2008). In the majority of ALS patients, TDP-43 becomes mislocalised from the nucleus to 
the cytoplasm, where it then becomes ubiquitinated, phosphorylated, truncated and 
aggregated (section 1.4) (Neumann et al., 2006).  Taken together with the fact that 
TARDBP mutations cause ALS, TDP-43 is strongly implicated in the pathogenesis of most 
ALS cases.  
However, despite TDP-43 aggregates being the pathological hallmark of ALS, it is unclear 
whether TDP-43 aggregation causes toxicity through gain and/or loss of function in ALS 
pathogenesis. Several studies have shown that loss of nuclear TDP-43 causes splicing 
defects in cellular and animal models, as well as in motor neurons from TARDBP-ALS 
patients (De Conti et al., 2015; Highley et al., 2014; Ling et al., 2015). Importantly, TDP-
43 represses splicing of nonconserved cryptic exons and maintains intron integrity (Ling 
et al., 2015). A loss of this feature of TDP-43 could provide an important link to C9ORF72-
ALS, in which the intron containing a (G4C2)n repeat expansion is aberrantly licenced for 
export to the cytoplasm (section 1.7.3).  
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In addition to a loss of TDP-43 function, the cytoplasmic TDP-43 aggregates could also 
gain a toxic function. TDP-43 has a propensity to misfold and aggregate, and recent 
studies show misfolded TDP-43 can seed further TDP-43 misfolding and aggregation, 
which can also spread along axons and from cell to cell in a prion-like manner (Feiler et 
al., 2015; Zhu et al., 2014). Similarly to misfolded SOD1, this gain of prion-like function 
could explain the anatomically logical progression of motor neuron degeneration in the 
majority of ALS cases. However, a dominant negative mechanism proposes 
simultaneous gain and loss of TDP-43 function, in which the misfolded TDP-43 drives 
further TDP-43 aggregation and subsequently nuclear loss of TDP-43 and TDP-43 
function. 
1.5.3. FUS 
Fused in Sarcoma (FUS) shares functional homology with TDP-43. Mutations in FUS 
account for 4-5% FALS and slightly less than 1% SALS, and similarly to TARDBP, these 
mutations cluster in the RNA binding domain at the C terminus of the protein (Deng et 
al., 2014; Kwiatkowski et al., 2009; Renton et al., 2014; Vance et al., 2009). There are 
currently over 50 FUS mutations associated with ALS (Deng et al., 2014). Most of these 
mutations have an autosomal dominant mode of inheritance, although FUS mutations 
with a recessive pattern of inheritance were found in a family of Cape Verdean origin 
(Kwiatkowski et al., 2009). In addition, FUS mutations are associated with a classical ALS 
phenotype, with an earlier disease onset (Deng et al., 2014). 
FUS is involved in a range of RNA and DNA metabolic processes including transcription, 
mRNA splicing, mRNA transport, stress granule formation, miRNA biogenesis, and 
genome integrity (Deng et al., 2014). FUS is predominantly localised in the nucleus, but 
also shuttles between the nucleus and cytoplasm (Zinszner et al., 1997). FUS related ALS 
patients contain FUS aggregates (section 1.4), and similarly to TDP-43, it is unknown 
precisely how these aggregates confer neurotoxicity in the MN. However, a dominant 
negative mechanism of FUS mislocalisation, misfolding and aggregation, leading to 
depleted nuclear function is likely (Deng et al., 2014). Lastly, misfolded FUS is also 
hypothesised to spread in a prion-like manner similar to TDP-43 (King et al., 2012; 
Polymenidou and Cleveland, 2011), but there are currently no functional experiments 
to prove this hypothesis. 
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1.5.4. C9ORF72 
In 2011, two groups found a (G4C2)n hexanucleotide repeat expansion within a non-
coding region of Chromosome 9 open reading frame 72 (C9ORF72) that causes both ALS 
and FTD (Figure 1.1) (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Expansions 
of >30 (G4C2)n repeats are considered pathogenic (Beer et al., 2015; Byrne et al., 2014), 
but expansions of 200-5000 repeats are commonly detected in ALS patients (Cooper-
Knock et al., 2014a). The (G4C2)n repeat expansion is the most common mutation 
associated with ALS, and accounts for about 8% of SALS and 39% of FALS cases (Majounie 
et al., 2012). In addition, the (G4C2)n repeat expansion accounts for about 7% of 
sporadic FTD and 25% of familial FTD cases (Majounie et al., 2012). Further, there is a 
greater incidence of dementia in C9ORF72-ALS patients compared to non-C9ORF72-ALS 
patients (Cooper-Knock et al., 2012; Cooper-Knock et al., 2014a; Gijselinck et al., 2012; 
Stewart et al., 2012). It is currently unclear how the (G4C2)n repeat expansion causes 
ALS and/or FTD pathogenesis, although three mutually inclusive hypotheses have been 
suggested; C9ORF72 haploinsufficiency, RNA toxicity, and dipeptide repeat (DPR) 
protein toxicity (section 1.7). 
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Figure 1.1 Genomic C9ORF72 and transcript variants. The line represents introns and 
boxes represent exons - blue are translated and white are untranslated. The (G4C2)n 
repeat expansion is shown in an orange box, and is located between exons 1A and 1B. 
Transcript variants 1 and 3 encode C9ORF72 long form, whilst variant 2 encodes 
C9ORF72 short form. The transcription start site (arrow) is upstream of exon 1A and the 
(G4C2)n repeat in variants 2 and 3. Whilst in variant 1, the (G4C2)n repeat is upstream 
of the transcription start site and is thought to inhibit transcription (flat head arrow). 
The C9ORF72-ALS and classic ALS phenotypes are indistinguisable (Cooper-Knock et al., 
2012; Cooper-Knock et al., 2014a; Gijselinck et al., 2012; Murray et al., 2011). It is not 
clear whether the age of C9ORF72-ALS disease onset differs from non-C9ORF72-ALS, 
however disease duration is shorter in C9ORF72-ALS (Cooper-Knock et al., 2014a; 
Millecamps et al., 2012). The (G4C2)n repeat expansion is thought to be non-penetrant 
in those under 35 years of age, 50% penetrant by 58 years of age, and approaching full 
penetrance at 80 years of age (Benussi et al., 2014; Galimberti et al., 2014; Majounie et 
al., 2012). Additionally, genetic analysis shows there is a greater than expected incidence 
of the ALS associated mutations (including the (G4C2)n repeat expansion) co-occurring 
with a second ALS-linked mutation (Bury et al., 2015; Chiò et al., 2012b; van Blitterswijk 
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et al., 2012a). This suggests that a second genetic ‘hit’ (oligogenic inheritance) may be 
necessary for ALS pathogenesis (and more explicity, for C9ORF72-ALS pathogenesis) and 
could also influence age of onset, symptom presentation and/or disease progression. 
Additionally, the (G4C2)n repeat expansion is unstable. Within individuals, the (G4C2)n 
repeat length varies between different cell types, and even between different regions 
of the brain, which suggests somatic instability (Beck et al., 2013; Nordin et al., 2015; 
van Blitterswijk et al., 2013b). Further, families which carry the (G4C2)n repeat 
expansion have shown evidence of genetic anticipation, with the average age of ALS 
and/or FTD onset lower in successive generations (Benussi et al., 2014; Chiò et al., 
2012a). In addition, the (G4C2)n the repeat DNA is liable to both expansions and 
contractions in a length-dependent manner in both E.coli and HEK293 cells (Thys and 
Wang, 2015). However, there is no direct evidence, from southern blotting for example, 
to confirm whether the potential genetic anticipation in C9ORF72-ALS/FTD patients is 
due to expansion of the (G4C2)n repeat between generations. 
The C9ORF72 gene expresses three transcript variants (V1, V2, and V3), which in turn 
code for two different C9ORF72 protein isoforms (long and short). V2 and V3 include 
exon 1a, and contain the (G4C2)n repeat within intron 1, whilst V1 includes exon 1b and 
is transcribed downstream of the (G4C2)n repeat, which is therefore excluded from the 
mRNA transcript (DeJesus-Hernandez et al., 2011) (Figure 1.1). V1 and V3 encode the 
481 amino acid C9ORF72 long form, whilst V2 encodes the 222 amino acid C9ORF72 
short form (DeJesus-Hernandez et al., 2011). The murine C9ORF72 homolog is highly 
expressed at transcript level in neuronal cells throughout the CNS, including the cortex 
and spinal motor neurons, however expression appears much lower in glial cells 
(Atkinson et al., 2015; Suzuki et al., 2013). C9ORF72 protein shares homology with 
differentially expressed in normal and neoplasia (DENN) domain, which function as Rab-
GTPase GDP/GTP exchange factors (GEF), and are involved in membrane trafficking 
(Levine et al., 2013; Zhang et al., 2012). In vitro studies further implicate C9ORF72 
protein in membrane trafficking, and suggest the protein regulates endocytosis and 
autophagy (Farg et al., 2014). Additionally, C9ORF72 is suggested to localise in the 
nucleus, cytoplasm and synapses in human CNS tissue, although the specificity of 
currently available C9ORF72-antibodies is questionable and casts doubt over the validity 
14 
 
of these findings (Atkinson et al., 2015; Cooper-Knock et al., 2012; Snowden et al., 2012; 
Stewart et al., 2012; Xiao et al., 2015). 
1.5.5. Genes Involved in RNA Metabolism 
In addition to TARDBP and FUS, there are rarer mutations in several other genes involved 
in RNA metabolism that are associated with ALS. These genes include senataxin (SETX), 
angiogenin (ANG), ataxin 2 (ATXN2), heterogeneous nuclear ribonucleoprotein A1 
(HNRNPA1), and matrin 3 (MATR3). This implicates dysregulated RNA metabolism as a 
key mechanism in ALS pathogenesis and corroborates the RNA toxicity hypothesis 
suggested for C9ORF72-ALS (section 1.7.2). 
Mutations in SETX are associated with a juvenile onset form of ALS that has a much 
longer and slower disease progression (Chen et al., 2004; Hirano et al., 2011). SETX is a 
DNA/RNA helicase that plays a role in transcription, R-loop resolution, and DNA damage 
repair (Skourti-Stathaki et al., 2011). Currently it is unclear how SETX mutations cause 
ALS however. 
There are at least 20 known mutations in ANG that are associated with ALS, and have 
been found in both FALS and SALS patients (Greenway et al., 2006; Kirby et al., 2013; 
Pan et al., 2015). ANG is a member of the pancreatic ribonuclease A superfamily, and is 
neuroprotective to motor neurons. However, disease associated mutant ANG loses this 
neuroprotective function (Subramanian et al., 2008). Importantly, ANG binds RNA 
species with G-quadruplex secondary structure and induces stress granule assembly, 
which is critical for the neuroprotective effect (Ivanov et al., 2014). Interestingly, the 
sense RNA expressed from the C9ORF72 (G4C2)n repeat expansion also forms a G-
quadruplex secondary structure (Fratta et al., 2012; Haeusler et al., 2014; Reddy et al., 
2013b), which may impair the neuroprotective function of ANG. 
ATXN2 contains a (CAG)n repeat that encodes a polyglutamine (polyQ) tract in the ATXN 
protein. An intermediate polyQ tract (31-33 repeats) is associated with ALS, whilst 
longer polyQ expansions (>36 repeats) cause spinocerebellar ataxia 2 (Elden et al., 2010; 
Neuenschwander et al., 2014). ATXN2 is an RNA binding protein implicated in RNA 
metabolism (Satterfield and Pallanck, 2006; Shibata et al., 2000), as well as membrane 
trafficking (Nonis et al., 2008; Ralser et al., 2005) and stress granule function (Anderson 
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and Kedersha, 2006). ATXN2 interacts with TDP-43 in an RNA-dependent manner, and 
ATXN2 actually exacerbates TDP-43 induced toxicity in both yeast and Drosophila 
models (Elden et al., 2010). In addition, ATXN2 interacts with FUS, and ATXN2 containing 
intermediate length polyQ tracts also exacerbate mutant FUS induced toxicity in cellular 
models (Farg et al., 2013).  
Mutations in HNRNPA1 are also associated with ALS (Kim et al., 2013). Similarly to the 
other ALS associated genes involved in RNA metabolism, HnRNPA1 binds TDP-43 (Buratti 
et al., 2005; Ling et al., 2010). Additionally, HnRNPA1 is involved in RNA processing, 
splicing, and transport. 
Lastly, there are seven known mutations in MATR3 that associate with ALS; two of those 
were found in FALS patients, and five were found in apparent SALS patients (Fifita et al., 
2015; Johnson et al., 2014; Leblond et al., 2016; Lin et al., 2015; Millecamps et al., 2014). 
MATR3 is a nuclear matrix protein that can bind both DNA and RNA, but also directly 
interacts with TDP-43 (Ling et al., 2010). MATR3 is also suggested to have a range of DNA 
and RNA metabolic processes including chromatin organisation, DNA replication and 
repair, as well as transcription, RNA stability, RNA processing and RNA transport (Salton 
et al., 2011). 
1.5.6. Genes Involved in Protein Transport and Degradation 
In addition to RNA metabolism, there are also rare mutations in several genes involved 
in protein transport and/or degradation that are associated with ALS. Taken together 
with the fact that protein aggregation is a hallmark of ALS (and many other 
neurodegenerative diseases), protein degradation is particularly likely to be critical in 
ALS pathogenesis. Genes that are associated with ALS and are involved in endosomal 
transport include alsin (ALS2), vesicle-associated membrane protein-associated protein 
B (VAPB), charged multivesicular body protein B (CHMP2B), and phosphoinositide 5-
phosphatase (FIG4), whilst those involved in the ubiquitin-proteasome system (UPS) 
include ubiquilin 2 (UBQLN2), sequestosome 1 (SQSTM1), and sigma non-opoid 
intracellular receptor 1 (SIGMAR1), and finally, those involved in autophagy include 
optineurin (OPTN), valosin containing protein (VCP), and TANK-binding kinase (TBK1). 
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Additionally, this supports the proposed hypotheses of C9ORF72 haploinsufficiency 
(section 1.7.1) and/or DPR aggregate toxicity in C9ORF72-ALS (section 1.7.3). 
Mutations in ALS2 are associated with an autosomal recessive, juvenile onset form of 
ALS (Hadano et al., 2001; Yang et al., 2001). The majority of these mutations are thought 
to cause a loss of function. ALS2 encodes alsin, which is a Rab5 guanine nucleotide 
exchange factor (GEF) involved in the regulation of endocytosis and thereby implicates 
dysregulation of endocytic trafficking in ALS pathogenesis (Lai et al., 2009).  
Several mutations in VAPB are also associated with a slowly progressive form of ALS, 
however the pathogenicity of some of these mutations requires validation (Chen et al., 
2010; Ingre et al., 2013b; Kabashi et al., 2013; Nishimura et al., 2004; van Blitterswijk et 
al., 2012b).  VAPB is an integral ER protein and is involved in intracellular trafficking, the 
unfolded protein response (UPR), and regulates ER-mitochondria interactions (Lev et al., 
2008; Stoica et al., 2014). Additionally, the P56S VAPB mutation protein associated with 
ALS disrupts the UPR, anterograde axonal transport of mitochondria and calcium 
homeostasis (De Vos et al., 2012; Kanekura et al., 2006; Mórotz et al., 2012).  
Mutations in CHMP2B are associated with ALS that has a predominantly lower motor 
neuron phenotype (Cox et al., 2010; Parkinson et al., 2006). CHMP2B is highly expressed 
throughout the CNS, and is part of the ESCRT-III complex (endosomal sorting complex 
required for transport III) that sorts endosomal cargo for recycling or degradation in the 
lysosome (Cox et al., 2010; Skibinski et al., 2005). Additionally, mutant CHMP2B disrupts 
autophagy in transiently transfected cellular models (Cox et al., 2010). 
FIG4 mutations have been found in both FALS and SALS cases, and are thought to cause 
a loss of function (Chow et al., 2009). FIG4 regulates PI(3,5)P2 levels, which mediates 
retrograde trafficking of endosomal vesicles to the trans-golgi network (Chow et al., 
2009). Interestingly, FIG4 knock-down causes neurodegeneration in mice and motor 
defects in Drosophila models (Chow et al., 2007; Kyotani et al., 2016). 
There are at least ten mutations in UBQLN2 that are associated with dominantly 
inherited, X-linked ALS that can have either juvenile or adult onset (Deng et al., 2011; 
Gellera et al., 2013; Williams et al., 2012). UBQLN2 is a ubiquitin-like protein that 
functions in ubiquitin proteasome system (UPS) that is important for degrading and 
17 
 
recycling misfolded or damaged proteins. Importantly, several studies show mutant 
UBQLN2 impairs this proteolytic pathway (Chang and Monteiro, 2015; Deng et al., 2011; 
Osaka et al., 2015), but may also impair RNA metabolism as well (Gilpin et al., 2015). 
SQSTM1/p62 plays an important role in protein degradation via the UPS and the 
autophagy pathway (Bjørkøy et al., 2006; Seibenhener et al., 2004), and is found in the 
characteristic ubiquitinated aggregates in ALS patients including the p62-positive, TDP-
43 negative aggregates specific to C9ORF72-ALS pathology (section 1.4). Multiple 
mutations in SQSTM1 were found in both FALS and SALS patients, further implicating 
SQSTM1/p62 and impaired protein degradation in ALS pathogenesis (Fecto et al., 2011; 
Kwok et al., 2014; Teyssou et al., 2013). SQSTM1/p62 knock-down in a zebrafish model 
impaired autophagy and caused motor defects, which could be rescued with the 
autophagy inducer rapamycin (Lattante et al., 2015). 
Missense mutations in SIGMAR1 cause an autosomal recessive, juvenile onset form of 
ALS (Al-Saif et al., 2011). Addition mutations in the 3’UTR of SIGMAR1 are suggested to 
affect mRNA stability and are also associated with ALS (Luty et al., 2010), but their role 
in ALS pathogenesis remains unclear. Sigma-1 receptor (Sig-1R) is an ER receptor 
chaperone that is involved in calcium transport between the ER and mitochondria via 
the IP3 receptor, counteracts ER stress, and is neuroprotective (Fukunaga et al., 2015; 
Hayashi and Su, 2007). In addition, the p.E102Q Sig-R1 mutant protein reduces 
mitochondrial ATP production, inhibits proteasome activity and causes mitochondrial 
injury, and also aggravates ER-stress induced death in neuronal cell lines (Al-Saif et al., 
2011; Fukunaga et al., 2015). 
Several different types of mutation in OPTN are associated with either autosomal 
dominant or recessive ALS (Beeldman et al., 2015; Goldstein et al., 2016; Maruyama et 
al., 2010; van Blitterswijk et al., 2012c). OPTN regulates a range of cellular functions 
including protein degradation via the UPS and the autophagy pathway, and interacts 
with several other proteins associated with ALS including UBQLN2 and TBK1 (Gilpin et 
al., 2015; Morton et al., 2008). 
VCP mutations are associated with both FALS and SALS (Abramzon et al., 2012; Johnson 
et al., 2010; Koppers et al., 2012). VCP is an AAA+-ATPase and facilitates both UPS and 
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autophagy (Meyer and Weihl, 2014). Additionally, mutant VCP is suggested to cause 
mitochondrial uncoupling and a reduction in ATP production (Bartolome et al., 2013). 
Loss of function mutations in TBK1 are thought to cause ALS via haploinsufficiency 
(Cirulli et al., 2015; Freischmidt et al., 2015). TBK1 regulates both immune signalling and 
autophagy (Weidberg and Elazar, 2011). TBK1 also binds and phosphorylates the ALS-
related proteins OPTN and SQSTM1 (Pilli et al., 2012; Wild et al., 2011), strongly 
implicating protein degradation and autophagy in ALS pathogenesis. 
1.5.7. Genes Involved in Axonal Transport and Cytoskeleton 
There also several rare mutations in genes that are involved in axonal transport and 
cytoskeleton that are associated with ALS associated: implicating these similar biological 
functions in ALS pathogenesis. Motor neurons have long axons, and efficient transport 
of protein, lipid, RNA and organelle cargo along the cytoskeleton is necessary for correct 
cellular function. ALS associated genes that are involved in axonal transport and/or the 
cytoskeleton include spatacsin (SPG11), profilin 1 (PFN1), tubulin alpha 4A (TUBA4A). 
Several loss of function mutations in SPG11 are associated with an autosomal recessive, 
juvenile onset form of ALS with slow disease progression (Daoud et al., 2012; Orlacchio 
et al., 2010). The exact function of SPG11 is unknown, but SPG11 colocalises with the 
cytoskeleton and synaptic vesicles in neuronal axons and dendrites. Additionally, iPSC-
derived neuronal cells from SPG11 patients displayed axonal instability by 
downregulation of acetylated tubulin and impaired cargo transport (Pérez-Brangulí et 
al., 2014). 
Mutations in PFN1 are a rare cause a FALS, and the p.E117G variant is now recognised 
only as a moderate ALS risk factor, rather than fully penetrant (Fratta et al., 2014; Ingre 
et al., 2013a; Smith et al., 2015; Tiloca et al., 2013; van Blitterswijk et al., 2013a; Wu et 
al., 2012). PFN1 regulates actin filament dynamics, but is also implicated in stress 
granule regulation (Figley et al., 2014). ALS-linked mutant PFN1 variants are less stable, 
have a propensity to aggregate, impair stress granule dynamics, and reduce axon 
outgrowth and growth cone size (Boopathy et al., 2015; Figley et al., 2014; Wu et al., 
2012). Interestingly, other ALS-linked mutations in TARDBP, FUS, HNRNPA1, and VCP 
19 
 
also display altered stress granule dynamics suggesting another important mechanism 
in ALS pathogenesis (Figley et al., 2014). 
Lastly, at least five loss of function mutations in TUBA4A are associated with a classical 
ALS phenotype (Smith et al., 2014). TUBA4A is an important component of cytoskeletal 
microtubules, and ALS-linked mutant TUBA4A has an increased propensity to aggregate 
and impairs microtubule dynamics and stability through a dominant-negative 
mechanism (Smith et al., 2014). 
1.6. General ALS Pathomechanisms  
Extensive evidence shows multiple pathogenic mechanisms exist in ALS. However, in the 
majority of ALS cases, separating the initial toxic insult and exacerbating secondary 
pathways that drive ALS progression is difficult. Pathomechanisms suggested include 
oxidative stress, excitotoxicity, mitochondrial dysfunction, impaired axonal transport, 
dysregulated RNA metabolism, impaired protein homeostasis, and glial involvement. 
1.6.1. Oxidative Stress 
Oxidative stress arises from an imbalance between reactive oxygen species (ROS) 
production and removal, and/or an impaired ability of the biological system to repair 
oxidative damage. ROS cause oxidative damage to DNA, RNA, proteins and lipids, and 
also disrupt redox sensitive cellular signalling. Cumulative oxidative damage in post-
mitotic motor neurons may eventually overwhelm the homeostatic cellular mechanisms 
that cope with other toxic insults such as ALS-linked mutations, resulting in neuronal 
death later in older age (Turner et al., 2013). ALS-causative SOD1 mutations are thought 
to cause aberrant free radical handling in a gain of function mechanism, implicating 
oxidative stress in ALS pathogenesis (Barber and Shaw, 2010; Rosen, 1993). In addition, 
CNS tissue and biosamples from ALS patients show increased levels of oxidative damage 
(Chang et al., 2008; Ferrante et al., 1997; Fitzmaurice et al., 1996; Shaw et al., 1995; 
Shibata et al., 2001). 
1.6.2. Glutamate Excitotoxicity 
Excitotoxicity is a process in which excessive stimulation of glutamate receptors causes 
a large influx of calcium ions into the post-synaptic neurons, and results in toxicity. 
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Glutamate levels are elevated in the CSF of ALS patients, and correlates with disease 
severity (Spreux-Varoquaux et al., 2002). Motor neurons are also inherently vulnerable 
to glutamate excitotoxicity due to low glutamate receptor 2 (GluR2) expression (which 
limits the calcium permeability of AMPA receptors) and limited calcium-buffering 
capacity (Van Damme et al., 2007; Vanselow and Keller, 2000). Additionally, astrocytes 
express excitatory amino acid transporter 2 (EAAT2), which removes glutamate from the 
synaptic cleft. EAAT2 levels are reduced in both ALS patients and animal models (Bruijn 
et al., 1997; Rothstein et al., 1992), which is suggested to cause prolonged glutamatergic 
stimulation of the motor neurons, implicating both excitotoxicity and glial cell 
involvement in ALS pathogenesis. Lastly, the antiglutamatergic drug riluzole is the only 
effective treatment available for ALS, and improves patient survival by three months 
(Andreadou et al., 2008; Bensimon et al., 1994).  
1.6.3. Mitochondrial Dysfunction 
Mitochondria are critical for cell survival and generate ATP, buffer intracellular calcium 
and act as gatekeepers of the intrinsic apoptotic pathway. Impaired mitochondrial 
morphology and function (including ATP production, calcium buffering, mitochondria-
dependent apoptosis, respiratory complexes and redox balance) are described in ALS 
spinal motor neurons, as well as various cellular and animal models of ALS (Bowling et 
al., 1993; Cozzolino and Carrì, 2012; Dal Canto and Gurney, 1994; Ferri et al., 2006; Fujita 
et al., 1996; Grosskreutz et al., 2010; Menzies et al., 2002a; Sasaki et al., 2007; Shi et al., 
2010). Impaired ATP production would damage motor neuron function due to their high 
metabolic demand (Menzies et al., 2002b), whilst impaired calcium buffering could lead 
to excitotoxicity (section 1.6.2). Additionally, inefficient mitochondrial function 
increases ROS production, which in turn causes oxidative damage to mitochondrial 
components and leads to greater mitochondrial dysfunction – a vicious cycle that could 
be central to motor neuron degeneration in ALS (Kaal et al., 2000; Robberecht, 2000). 
1.6.4. Impaired Axonal Transport 
Motor neurons have very long axons, and depend on efficient transport of protein, 
lipids, RNA and organelle cargoes along the axons via the cytoskeleton and associated 
motor proteins. Several ALS associated genes are involved in axonal transport and/or 
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the cytoskeleton (section 1.5.7), suggesting impaired axonal transport plays a role in ALS 
pathogenesis. Also, impaired axonal transport is measured in several different genetic 
models of ALS (Alami et al., 2014; De Vos et al., 2007; Mórotz et al., 2012), and is 
suggested to be an early pathogenic event (De Vos et al., 2008). Impaired mitochondrial 
transport also supports a ‘dying-back’ axonopathy model of ALS disease progression (Shi 
et al., 2010). 
1.6.5. Dysregulated RNA Metabolism 
Aberrant RNA metabolism is strongly implicated in ALS. Firstly, due to the number of ALS 
associated genes that are involved in RNA metabolism (section 1.5.5). Secondly, because 
the RNA processing protein TDP-43 forms the characteristic neuronal inclusions in most 
ALS cases (section 1.4), and a loss of TDP-43 function is strongly suggested to play a role 
in ALS pathogenesis (section 1.5.2). Additionally, the (G4C2)n repeat expansion in 
C9ORF72, which is the most common cause of ALS, is thought to exert direct RNA toxicity 
by disrupting RNA metabolism (section 1.7.2). 
1.6.6. Impaired Protein Homeostasis 
Insoluble protein aggregates are the pathological hallmark of ALS (section 1.4), 
suggesting impaired protein homeostasis. Cytoplasmic protein aggregates have recently 
been suggested to cause nucleocytoplasmic defects (Woerner et al., 2016), although the 
exact mechanism is still unknown. Other suggested toxic mechanisms associated with 
aggregated SOD1, TDP-43, FUS, and DPR proteins are described elsewhere (sections 
1.5.1, 1.5.2, 1.5.3, and 1.7.3). Compellingly, SOD1, TDP-43 and DPR inclusions are all 
ubiquitinated, which suggests that the UPS and autophagy protein degradation systems 
are impaired in motor neurons in the majority of ALS cases. However, FUS-positive 
inclusions are not ubiquitinated, and suggests impairment to protein homeostasis may 
have less relevance in FUS-ALS. In addition, there is extensive evidence of ER stress in 
ALS patient CNS tissue, as well as cellular and animal models of ALS, suggesting an 
increased burden and inability to cope with misfolded proteins (Matus et al., 2013). 
Further, multiple other ALS associated genes are involved in protein trafficking or 
protein degradation (via the UPS and/or the autophagy), strongly implicating impaired 
protein homeostasis in ALS pathogenesis (section 1.5.6). 
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1.6.7. Non-Cell Autonomous Toxicity and Neuroinflammation 
Although ALS is characterised by motor neuron cell degeneration, various studies 
implicate glial cell involvement in disease progression. Astrocytes derived from either 
SOD1-ALS, C9ORF72-ALS or SALS fibroblasts are toxic toward wildtype neurons in co-
culture (Meyer et al., 2014), and murine SOD1-ALS models further suggest astrocytes 
and microglia are involved in non-cell autonomous toxicity (Beers et al., 2006; Boillée et 
al., 2006a; Boillée et al., 2006b; Clement et al., 2003; Nagai et al., 2007; Yamanaka et al., 
2008b). Additionally, astrocytes and microglia are in an activated state, with an increase 
in pro-inflammatory cytokines, in both CNS tissue from ALS patients and SOD1 mouse 
models, suggesting neuroinflammation may contribute to ALS pathogenesis (Alexianu et 
al., 2001; Engelhardt and Appel, 1990; Engelhardt et al., 1993; Hall et al., 1998; Nagy et 
al., 1994; Philips and Robberecht, 2011).  
1.7. C9ORF72 (G4C2)n Repeat Expansion Specific Pathomechanisms  
It is currently unknown how the (G4C2)n repeat expansion within C9ORF72 initiates ALS, 
and/or interacts with other pathomechanisms (section 1.6), but there are three 
mutually inclusive hypotheses: C9ORF72 haploinsufficiency, RNA toxicity, and dipeptide 
repeat (DPR) protein toxicity (Figure 1.2). 
1.7.1. C9ORF72 Haploinsufficiency 
Various reports demonstrate C9ORF72 mRNA is reduced in CNS tissue, lymphoblast 
cells, and iPSC-derived neurons of patients containing the (G4C2)n repeat expansion, 
suggesting C9ORF72 haploinsufficiency as a pathogenic mechanism (Figure 1.2A) 
(Almeida et al., 2013; Belzil et al., 2013; Ciura et al., 2013; DeJesus-Hernandez et al., 
2011; Donnelly et al., 2013; Mori et al., 2013c; Waite et al., 2014). Disrupted C9ORF72 
transcription could be caused by hypermethylation of the C9ORF72 locus and/or 
disruption of the core promoter region (Gijselinck et al., 2012; Gijselinck et al., 2015; Xi 
et al., 2013). In addition, one study shows reduced C9ORF72 protein in the frontal cortex 
of patients with the repeat expansion (Waite et al., 2014).  
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Figure 1.2 Pathomechanisms associated with C9ORF72 (G4C2)n repeat expansion. A) 
Transcriptional silencing of C9ORF72 via hypermethylation or transcription abortion 
results in less C9ORF72 mRNA and protein, which could result in C9ORF72 
haploinsufficiency. B) (G4C2)n and/or (C4G2)n repeat RNA binds and sequesters RNA 
binding proteins, and could result in dysregulated RNA metabolism and gene expression. 
C) The (G4C2)n and (C4G2)n repeat RNA is exported from the nucleus, and undergoes 
repeat associated non-ATG (RAN) translation producing dipeptide repeat (DPR) 
proteins. The DPR proteins aggregate and could cause toxicity. 
The function of C9ORF72 protein is currently unknown, although it may play a role in 
endocytosis and autophagy (section 1.5.4) (Farg et al., 2014; Levine et al., 2013). Knock 
out of C9ORF72 homologues in zebrafish and C. elegans caused defects in motor 
function (Ciura et al., 2013; Therrien et al., 2013). However, when C9ORF72 knock-down 
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(either partial or complete) was confined to the CNS in adult mice, there were no 
behavioural or motor defects, nor any signs of neuropathology associated with ALS and 
FTD (Koppers et al., 2015; Lagier-Tourenne et al., 2013). Furthermore, in human 
patients, the phenotype is no more severe in individuals with (G4C2)n repeat expansions 
in both C9ORF72 alleles (Cooper-Knock et al., 2013; Fratta et al., 2013), and there are no 
known coding mutations in C9ORF72 that result in disease (Harms et al., 2013). Taken 
together, these findings argue against haploinsufficiency as the only disease mechanism 
in C9ORF72-ALS, however, a partial loss of C9ORF72 protein function may disrupt 
autophagy, which could then exacerbate RNA toxicity and/or DPR toxicity. 
1.7.2. RNA Toxicity 
The second hypothesis suggests the RNA transcribed from the repeat may confer trans-
dominant toxicity. The (G4C2)n repeat expansion is transcribed in both sense and 
antisense directions, and forms sense (G4C2)n and antisense (C4G2)n RNA foci 
respectively. These RNA foci are predominantly nuclear, but rare cytoplasmic RNA foci 
are also detected in post mitotic cells which suggests the intronic (G4C2)n and (C4G2)n 
containing transcripts are abberantly licensed for nuclear export (Cooper-Knock et al., 
2015b; DeJesus-Hernandez et al., 2011; Gendron et al., 2013; Mizielinska et al., 2013; Zu 
et al., 2013). The RNA foci are present in C9ORF72-ALS/FTD brain and spinal cord 
(DeJesus-Hernandez et al., 2011; Gendron et al., 2013; Mizielinska et al., 2013; Zu et al., 
2013), and also in neuronal cells differentiated from C9ORF72-ALS/FTD patient derived 
iPSC (Almeida et al., 2013; Donnelly et al., 2013; Sareen et al., 2013). Interestingly, the 
relative abundancy of sense and antisense RNA foci varies in different neuronal 
populations in the CNS (Cooper-Knock et al., 2015b). Further, antisense RNA foci, but 
not sense RNA foci, are associated with TDP-43 nuclear loss in the motor neurons 
suggesting the antisense RNA foci and/or derived DPR (section 1.7.3) are the pathogenic 
species in C9ORF72-ALS (Cooper-Knock et al., 2015b). 
RNA foci potentially bind and sequester essential RNA binding proteins (RBP) conferring 
a trans-dominant toxicity by disrupting RNA processing, as seen in other repeat 
expansion disorders (Figure 1.2B) (Renoux and Todd, 2012). Therefore, several groups 
have performed in vitro pull downs using (G4C2)n and/or (C4G2)n repeat RNA to identify 
candidate RBP (Cooper-Knock et al., 2014b; Donnelly et al., 2013; Haeusler et al., 2014; 
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Lee et al., 2013; Mori et al., 2013b; Rossi et al., 2015; Xu et al., 2013). Several RBP were 
found to bind the repeat RNA including ADARB2, ALYREF, HnRNP A3, HnRNP H, NCL, 
PURA, SRSF1, and SRSF2. Subsequently, many of these RBP were shown to co-localise 
with the (G4C2)n and/or (C4G2)n RNA foci in either cell models or C9ORF72-ALS post 
mortem tissue, suggesting in vivo sequestration (Cooper-Knock et al., 2014b; Donnelly 
et al., 2013; Haeusler et al., 2014; Lee et al., 2013; Mori et al., 2013b; Rossi et al., 2015; 
Xu et al., 2013). Further, transcriptomic analysis of C9ORF72-ALS/FTD patient CNS tissue 
showed dysregulation in RNA splicing and processing, which may be caused by 
sequestration of RBP (Cooper-Knock et al., 2015a; Prudencio et al., 2015). In addition, 
several cellular and animal models have shown a gain of function toxicity from the 
(G4C2)n repeat, but these will be reviewed in section 1.8. Lastly, dysregulated RNA 
metabolism is strongly implicated in ALS pathogenesis (section 1.6.5), indicating RNA 
toxicity is likely involved in C9ORF72-ALS/FTD pathogenesis. 
1.7.3. Dipeptide Repeat (DPR) Protein Toxicity 
The last hypothesis suggests translation products from the repeat expansion may confer 
direct toxicity. The (G4C2)n and (C4G2)n repeat RNA also undergoes unconventional 
repeat associated non-ATG (RAN) translation in both the sense and antisense directions, 
forming aggregation-prone DPR proteins (Figure 1.2C) (Ash et al., 2013; Mori et al., 
2013a; Mori et al., 2013c; Zu et al., 2013). Interestingly, the (G4C2)n repeat expansion 
causes intron 1 retention in C9ORF72 mRNA, and could explain how the intronic (G4C2)n 
repeat becomes aberrantly licensed for nuclear export to the cytoplasm, where it then 
undergoes RAN translation (Niblock et al., 2016). A similar mechanism could also exist 
in the antisense (C4G2)n repeat containing transcripts. RAN translation occurs in all 
reading frames yielding five species of DPR: (GA)n and (GR)n are translated from the 
sense transcript, (AP)n and (PR)n from the antisense transcript, and (GP)n is translated 
from both sense and antisense transcripts (Figure 1.3).  
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Figure 1.3 Schematic representation of DPR proteins generated by RAN translation 
from sense (G4C2)n and antisense (C4G2)n repeats in all reading frames. 
DPR form insoluble inclusions in C9ORF72-ALS/FTD patient CNS tissue (section 1.4) (Ash 
et al., 2013; Mori et al., 2013a; Mori et al., 2013c; Zu et al., 2013). DPR proteins are toxic 
in cultured cells, and cause neurodegeneration in Drosophila models (section 1.8) (Kwon 
et al., 2014; May et al., 2014; Mizielinska et al., 2014; Tao et al., 2015; Wen et al., 2014; 
Yang et al., 2015; Zhang et al., 2014; Zu et al., 2013). The arginine rich DPR proteins (poly-
GR and poly-PR) appear particularly toxic, localise to the nucleolus, disrupt ribosomal 
RNA biogenesis and cause cell death (Kwon et al., 2014; Mizielinska et al., 2014; Tao et 
al., 2015; Wen et al., 2014; Yang et al., 2015). Also, in two elegant studies using 
Drosophila models, the toxicity of (G4C2)n repeats was dependent on the production of 
DPR, and not (G4C2)n RNA foci (Mizielinska et al., 2014; Tran et al., 2015). However in 
C9ORF72-ALS patients, DPR load is much lower in spinal motor neurons compared to 
other unaffected regions of CNS, and TDP-43 inclusions rarely co-localise with DPR 
suggesting they may not be the primary toxic insult in motor neuron degeneration 
(Davidson et al., 2015; Gomez-Deza et al., 2015; Mackenzie et al., 2013; Mackenzie et 
al., 2015). In fact, the expression level of DPR is likely to be very low in C9ORF72-ALS/FTD 
patient CNS, and the toxicity observed in model systems may be artificial due to high 
expression levels (Davidson et al., 2015). 
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1.8. C9ORF72-ALS Cellular and Animal Models 
Over the last five years, many cellular and animal models of C9ORF72-ALS have been 
generated, and as a result, we have a much better understanding of how the (G4C2)n 
repeat expansion may cause C9ORF72-ALS pathogenesis. The models described are 
either loss or gain of function, and these are summarised with their major findings in 
Table 1.2. Loss of function models were used to investigate the function of C9ORF72 
protein, and the potential effect of C9ORF72 haploinsufficiency. Currently, far fewer 
studies have interrogated the C9ORF72 loss of function hypothesis, and the most 
sophisticated loss of function models suggest C9ORF72 haploinsufficiency is not the 
major toxic insult in C9ORF72-ALS. The gain of function models however, have been 
used to study the biology and toxicity of the (G4C2)n repeat by studying the RNA, DPR 
or both. Initial studies looking at the (G4C2)n repeat showed clear gain of function 
toxicity, whilst more recent studies have used more sophisticated models to try and 
separate out the relative contributions of each potentially toxic species. 
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Table 1.2 Cellular and animal models of C9ORF72-ALS. The models are divided into loss of C9ORF72 function, and gain of (G4C2)n function, 
which are then separated into models that interrogate the (G4C2)n repeat, the RNA only or the DPR only. A brief summary of the model is 
included, the main findings discovered using the model, and the reference. 
Model Main Findings Reference 
Loss of function models   
Cellular   
C9ORF72 siRNA transfected into Neuro2a and SHSY5Y cells Impaired endosomal trafficking and autophagy. (Farg et al., 2014) 
C9ORF72 shRNA lentiviral transduced into rat cortical and 
motor neurons 
No toxicity. (Wen et al., 2014) 
Animal   
C9ORF72 knock out C.elegans Age dependent motor defects and degeneration. (Therrien et al., 2013) 
C9ORF72 knock-down Zebrafish Motor neuron axononopathy and motor function defects. (Ciura et al., 2013) 
Mouse with C9ORF72 sense ASO delivered to CNS No C9ORF72-ALS/FTD associated pathology, no motor defects, and minimal 
transcriptomic changes. 
(Lagier-Tourenne et 
al., 2013) 
Mouse with glial and motor neuron C9ORF72 knock out No motor neuron degeneration or motor defects. (Koppers et al., 2015) 
C9ORF72 knock out mouse Robust immune phenotype. Mild motor impairment. (Atanasio et al., 
2016) 
C9ORF72 knock out mouse Impaired macrophage and microglial function. (O'Rourke et al., 
2016) 
(G4C2)n Gain of function models   
Cellular   
(G4C2)n repeats transfected into Neuro2a cells Toxicity, which was rescued by PURA overexpression. (Xu et al., 2013) 
(G4C2)n repeats transfected into HEK293, HeLa, SYSHY5Y 
and mouse cortical neurons 
Neurotoxicity. Sense RNA foci colocalised with HnRNP H, SRSF1, and SRSF2. (Lee et al., 2013) 
(G4C2)n constructs tranfected into HEK293 cells Length dependent expression of DPR via RAN translation. (Mori et al., 2013c) 
(C4G2)n repeats transfected into HEK293 cells Antisense RNA foci and DPR produced. (Gendron et al., 
2013) 
(C4G2)n repeats transfected into HEK293 cells Antisense repeats cause toxicity. (Zu et al., 2013) 
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(G4C2)n repeats transfected into HeLa and NSC34 cells RNA foci colocalised with eIF2a, FUS, HnRNP H, and ILF3. Altered PURA 
distribution, stress granule dynamics, translation inhibition and mRNA nuclear 
retention. 
(Rossi et al., 2015) 
(G4C2)n constructs transfected into HEK293 and HeLa cells Nuclear retention of mRNA. (Freibaum et al., 
2015) 
(G4C2)n constructs transfected into S2 cells Disrupted nucleocytoplasmic transport (Zhang et al., 2015) 
(G4C2)n constructs transfected into HEK293 cells Length dependent repeat instability. Whole (G4C2) units gained or lost during 
expansion or contractions. Repeat caused replication fork stalling. 
(Thys and Wang, 
2015) 
Methylated and unmethylated (G4C2)66 transfected into 
HEK293 cells 
Methylation of the repeat reduced RNA foci and DPR production. (Bauer, 2016) 
Animal   
Drosophila expressing (G4C2)30 in the nervous system Embryonic lethality (Xu et al., 2013) 
Drosophila expressing (G4C2)30 in the motor neurons Motor defects. (Xu et al., 2013) 
Drosophila expressing (G4C2)30 in the eyes Eye degeneration, which was rescued by PURA. Genetic manipulation of 
nucleocytoplasmic transport modifies toxicity. 
(Xu et al., 2013; 
Zhang et al., 2015) 
Drosophila expressing (G4C2)n in the eyes Neurodegeneration associated with DPR (RNA only models showed no 
neurodegeneration). 
(Mizielinska et al., 
2014) 
Drosophila expressing a C9ORF72 minigene with (G4C2)n in 
intronic context 
Sense RNA foci, but no DPR in glia and motor neurons. No neurodegeneration or 
splicing defects. 
(Tran et al., 2015) 
Drosophila expressing (G4C2)36  Developmental lethality. (Tran et al., 2015) 
Drosophila expressing (G4C2)36 in the eyes Cytoplasmic RNA foci and DPR in glia and neurons. Neurodegeneration - taken 
together with intronic model, toxicity is associated with DPR. 
(Tran et al., 2015) 
Drosophila expressing (G4C2)n in the eyes Length dependent neurodegeneration (Freibaum et al., 
2015) 
Drosophila expressing (G4C2)n in the motor neurons or 
nerves system 
Developmental lethality, locomotor defects, NMJ abnormalities. (Freibaum et al., 
2015) 
Drosophila expressing (G4C2)n in the salivary glands Nucleocytoplasmic defects and mRNA nuclear retention. (Freibaum et al., 
2015) 
Mouse with tetracycline inducible, HnRNP promoter driven 
(G4C2)80 
Ubiquitin positive inclusions, but no TDP-43 or DPR pathology. (Hukema et al., 2014) 
Mouse expressing C9ORF72 gene containing approx. 
(G4C2)500 
Sense and antisense RNA foci, and DPR throughout CNS. No alteration to 
survival, motor function or cognitive function. 
(Peters et al., 2015) 
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Mouse expressing C9ORF72 gene containing approx. 
(G4C2)800 
Sense and antisense RNA foci, and DPR throughout CNS. DPR inclusions 
accumulate with age. No neurodegeneration or motor defects. 
(O'Rourke et al., 
2015) 
Mouse expressing (G4C2)66 in CNS via AAV delivery Sense RNA foci, sense derived DPR inclusions, phosphorylated TDP-43 inclusions 
in cortex and hippocampus. Neuronal cell loss and astrogliosis. Behavioural 
phenotype similar to C9ORF72-ALS/FTD. 
(Chew et al., 2015) 
(G4C2)n RNA only models   
Cellular   
(G4C2)n intronic constructs transduced via LV into rat 
cortical, motor and hippocampal neurons 
(G4C2)42 repeats in intronic context caused toxicity to cortical and motor 
neurons independently of RAN translation. 
(Wen et al., 2014) 
Animal   
Drosophila expressing RNA only (G4C2)n constructs in the 
eyes 
No neurodegeneration. (Mizielinska et al., 
2014) 
DPR only models   
Cellular   
Synthetic (PR)20 and (GR)20 applied to U2OS cells and 
astrocytes 
(PR)20 and (GR)20 cause toxicity, localise to nucleolus and impair rRNA 
biogenesis 
(Kwon et al., 2014) 
DPR constructs tranfected into HEK293 cells, or transduced 
via LV into rat hippocampal and cortical neurons 
(GA)n formed p62 positive inclusions, and caused neurotoxicity. (May et al., 2014) 
DPR constructs transfected into NSC34 cells, rat cortical and 
motor neurons, and human iPSC derived neurons 
(GR)n and (PR)n caused neurotoxicity. (Wen et al., 2014) 
DPR constructs transfected into HEK293 cells and mouse 
cortical neurons  
(GA)n formed ubiquitinated p62 positive inclusions, caused toxicity, ER stress, 
and impaired the proteasome. 
(Zhang et al., 2014) 
DPR constructs transfected into HEK293 and NSC34 cells Only arginine rich DPR were toxic. (PR)n and (GR)n caused nucleolar stress, and 
inhibit stress granule formation. 
(Tao et al., 2015) 
DPR constructs transduced via LV into rat hippocampal and 
cortical neurons 
(PR)n and (GR)n form nucleolar inclusions, whilst GA forms p62 positive 
inclusions. 
(Schludi et al., 2015) 
(PR)n and (GR)n transformed into yeast Length dependent toxicity of (PR)n and (GR)n. Genetic screening suggested 
nucleocytoplasmic transport modifies (PR)n induced toxicity. 
(Jovičić et al., 2015) 
(PR)50 transduced via LV into mouse cortical neurons (PR)50 caused toxicity which could be partly rescued by KPNA3 cotransduction. (Jovičić et al., 2015) 
Synthetic (GA)15 applied to, and (GA)80 constructs 
transfected into BE2C and Neuro2a cells 
(GA)15 was neurotoxic, and could be transmitted between cells. (Chang et al., 2016) 
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Animal   
Drosophila expressing DPR in the eyes Only arginine rich DPR cause emrbyonic lethality and neurodegeneration. (Mizielinska et al., 
2014) 
Drosophila expressing (PR)50, (GA)50 or (PA)50 in the eyes (PR)50 caused neurodegeneration. (Wen et al., 2014) 
Drosophila expressing (PR)50, (GA)50 or (PA)50 in the 
motor neurons 
(PR)50 caused developmental lethality. (Wen et al., 2014) 
Drosophila expressing (PR)80, (GA)80 or (PA)80 in the eyes (PR)80 and (GR)80 cause lethality and neurodegeneration. (GR)80 suppresses 
Notch signalling. 
(Yang et al., 2015) 
Drosophila expressing DPR in the eyes (GR)n caused developmental lethality, and neurodegeneration. Genetic 
screening suggested nucleocytoplasmic transport modifies (GR)n induced 
toxicity. 
(Freibaum et al., 
2015) 
C9ORF72-ALS patient derived models   
Fibroblasts Transcriptomic changes. C9ORF72 sense ASO ablated sense RNA foci, but did not 
restore transcriptomic changes. 
(Lagier-Tourenne et 
al., 2013) 
iPSC derived motor neurons RNA foci colocalised with HnRNP A1 and PURA. Transcriptomic changes, which 
could be ameliorated with C9ORF72 sense ASO. Altered electrophysiology. 
(Sareen et al., 2013) 
iPSC derived neurons RNA foci colocalised with ADARB2. Transcriptomic changes and susceptibility to 
glutamte mediated toxicity, both of which were restored by C9ORF72 sense ASO. 
(Donnelly et al., 
2013) 
iPSC derived neurons Repeat instability. No TDP-43 mislocalisation. Cells were more susceptible to 
stress 
(Almeida et al., 2013) 
Fibroblasts, lymphoblasts, iPSC derived motor neurons Morphological and functional signs of nucleolar stress (Haeusler et al., 
2014) 
iPSC derived motor neurons Altered electrophysiology. (Devlin et al., 2015) 
iPSC derived neurons C9ORF72 mRNA variant 2 was reduced from repeat expansion allele. Repeat 
expansion did not affect C9ORF72 mRNA splicing. 
(Tran et al., 2015) 
iPSC derived neurons Disrupted nuclear import, which was rescued with C9ORF72 sense ASO (Zhang et al., 2015) 
Fibroblast derived iNeurons Disrupted nucleocytoplasmic transport. (Jovičić et al., 2015) 
iPSC derived cortical neurons Nuclear retention of mRNA. (Freibaum et al., 
2015) 
iPSC derived neurons Notch signalling was dysregulated. (Yang et al., 2015) 
iPSC derived neurons and motor neurons Repeat instability. Repeat was progressively methylated during differentiation. (Esanov et al., 2016) 
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1.8.1. Loss of Function Models 
Several studies show a reduction in C9ORF72 expression in C9ORF72-ALS patients 
(section 1.7.1), and therefore a loss of C9ORF72 function may cause or contribute to 
C9ORF72-ALS pathogenesis. Initial zebrafish and C. elegans loss of function models 
showed knock out of C9ORF72 homologues caused motor function defects (Ciura et al., 
2013; Therrien et al., 2013). Additionally, C9ORF72 knock-down via siRNA transfection 
in Neuro2a and SHSY5Y neuronal cell lines caused defects in endosomal trafficking and 
autophagy (Farg et al., 2014). However, in a more sophisticated loss of function model, 
in which C9ORF72 knock-down was confined to the glia and motor neurons of adult 
mice, neither motor neuron degeneration or motor defects were observed (Koppers et 
al., 2015). Also, in different C9ORF72 knock out mouse models, either no or mild motor 
defects were described (Atanasio et al., 2016; O'Rourke et al., 2016). Further, C9ORF72 
knock-down by antisense oligonucleotide (ASO) treatment does not cause toxicity in cell 
and animal models (Donnelly et al., 2013; Lagier-Tourenne et al., 2013; O'Rourke et al., 
2015; Sareen et al., 2013; Zhang et al., 2015) and taken together suggests C9ORF72 loss 
of function is not the primary toxic insult derived from the (G4C2)n repeat expansion in 
C9ORF72. However, we cannot rule out a contributory effect of C9ORF72 loss of function 
in ALS pathogenesis, since no studies have looked at a potential additive effect of 
C9ORF72 loss of function combined with a (G4C2)n gain of function toxicity. 
1.8.2. Gain of Function Models 
1.8.2.1. Toxicity associated with the (G4C2)n  
Multiple studies have used cellular and animal models to interrogate the gain of function 
toxicity associated with the (G4C2)n. The earliest and most basic models were cell lines 
transfected with (G4C2)n repeat constructs. Interrupted and pure (G4C2)n repeat 
constructs cause toxicity when transfected into neuronal cell lines, but not in HEK293 
cells (Lee et al., 2013; Xu et al., 2013). In (G4C2)n transfected neuronal cells, various RNA 
binding proteins were shown to colocalise with RNA foci, many of which have been 
validated in C9ORF72-ALS CNS tissue (Lee et al., 2013; Rossi et al., 2015; Xu et al., 2013). 
Additionally, a construct expressing 31 G4C2 repeats (abbreviated as (G4C2)31) was 
transfected in NSC34 and HeLa cells, and affected PURA and FMRP distribution, and 
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inhibited stress granule formation, translation and mRNA export (Rossi et al., 2015). 
Transfection of antisense (C4G2)66 constructs into HEK293 cells also caused toxicity (Zu 
et al., 2013). However, the (G4C2)n expression level is much higher in these models than 
in C9ORF72-ALS patients, and only short term effects can be studied, making 
transfection models fairly poor at replicating the actual physiological effects of the 
(G4C2)n repeat. 
Several groups have also generated Drosophila and mouse models that express the 
(G4C2)n. Drosophila models that expressed an interrupted (G4C2)30 repeat specifically 
in the eyes or motor neurons displayed neurodegeneration and motor defects 
respectively (Xu et al., 2013). Additionally, the eye neurodegeneration could be rescued 
by PURA overexpression in the Drosophila. In a separate study, Drosophila models with 
either eye or pan-neuronal expression of either (G4C2)8 or (G4C2)58 repeats displayed 
length dependent eye degeneration or motor defects with neuromuscular junction 
defects respectively (Freibaum et al., 2015). Additionally, in both the (G4C2)30 and 
(G4C2)58 Drosophila models with eye specific expression, genetic screening identified 
nucleocytoplasmic transport as a potent modifier of (G4C2)n induced toxicity (Freibaum 
et al., 2015; Zhang et al., 2015). However, the (G4C2)n repeat is overexpressed in these 
Drosophila models, and the physiological relevance of fly eye degeneration to human 
motor neuron degeneration is questionable. Although, the defects in nucleocytoplasmic 
transport identified in the Drosophila models have also been validated in patient derived 
neuronal cells (section 1.8.2.2). 
In addition to the Drosophila (G4C2)n gain of function models described above, four 
mouse models have also been generated to study (G4C2)n gain of function toxicity. One 
mouse model expressed a (G4C2)80 repeat from a tetracycline inducible HnRNP 
promoter, and displayed ubiquitin positive inclusions in the CNS, but no TDP-43 
inclusions, DPR pathology, neurodegeneration or behavioural defects (Hukema et al., 
2014). Additionally, two other mouse models were generated that carry a patient 
derived C9ORF72 gene containing either 500 or 800 (G4C2)n repeats (O'Rourke et al., 
2015; Peters et al., 2015). Sense and antisense RNA foci as well as DPR were detected 
throughout the CNS, but there was no neurodegeneration, or alteration in survival, 
motor function or cognitive function in either of these mouse models (O'Rourke et al., 
34 
 
2015; Peters et al., 2015). Although the aforementioned mouse models do not support 
a (G4C2)n gain of function toxicity, another mouse model replicates several aspects of 
C9ORF72-ALS/FTD pathology (Chew et al., 2015). A (G4C2)66 repeat expressed from a 
strong promoter was delivered to the mouse CNS via adeno-associated virus, and brains 
of 6-month old mice subsequently displayed sense RNA foci, and sense derived DPR 
inclusions throughout the CNS. Additionally, the brains contained TDP-43 inclusions, 
cortical and cerebellar degeneration, and astrogliosis. Further, these mice also 
developed behavioural abnormalities similar to the clinical symptoms of C9ORF72-
ALS/FTD patients, including hyperactivity, anxiety, antisocial behaviour, and motor 
defects (Chew et al., 2015). Therefore, the mouse models suggest high level expression 
of the (G4C2)n repeat expansion is capable of causing neurodegeneration and C9ORF72-
ALS/FTD pathology. Equally, since ALS develops in older age, the (G4C2)n repeat may 
only cause toxicity in the aged human CNS environment, which is not replicated in the 
aforementioned mouse models. 
1.8.2.2. Patient Derived Cellular Models 
More advanced cellular models of C9ORF72-ALS are derived from patient cells. Some of 
the more sophisticated models convert fibroblasts to iPSC, which can be subsequently 
differentiated to neuronal or motor neuronal cultures. Whilst the (G4C2)n expression is 
certainly much closer to physiologically relevant levels, these models are not 
reductionist and are affected by (potential) C9ORF72 haploinsufficiency, 
(G4C2)n/(C4G2)n RNA, and all DPR species simultaneously. Similarly to transfected cells, 
C9ORF72-ALS patient derived cell lines show colocalisation between (G4C2)n RNA foci 
and various RNA binding proteins, including ADAR2B, HnRNPA1, and PURA (Donnelly et 
al., 2013; Sareen et al., 2013). Additionally, many functional defects are described in 
C9ORF72-ALS patient derived cells including nucleolar stress, susceptibility to glutamate 
mediated excitotoxicity and other cellular stresses, transcriptomic alterations, altered 
electrophysiology, and impaired nucleocytoplasmic transport (Almeida et al., 2013; 
Devlin et al., 2015; Donnelly et al., 2013; Freibaum et al., 2015; Haeusler et al., 2014; 
Lagier-Tourenne et al., 2013; Sareen et al., 2013; Zhang et al., 2015). Further, in many of 
these studies, ASO targeted to the C9ORF72 sense strand were used, which ablated 
sense derived RNA foci and DPR, and also partly or completely ameliorated the 
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functional defects. This strongly argues for a gain of function toxicity, and against a loss 
of function toxicity. 
1.8.2.3. DPR Toxicity Models 
Upon discovery of the (G4C2)n RAN translation products in C9ORF72-ALS, several groups 
have examined the toxicity of the DPR proteins. DPR constructs that are independent of 
the (G4C2)n repeat sequence have been transfected into various cell lines including 
HEK293 and NSC34 cells, or transduced via lentiviral vectors into primary neuronal 
cultures from rodents. The findings suggest that all the DPR species possess 
neurotoxicity, although the arginine containing (GR)n and (PR)n species appear to be the 
most toxic (Jovičić et al., 2015; Kwon et al., 2014; May et al., 2014; Schludi et al., 2015; 
Tao et al., 2015; Wen et al., 2014; Zhang et al., 2014). Further, the arginine rich DPR 
proteins are thought to mimic the SR domain found in splicing factors, which localises 
proteins to the nucleolus (Kwon et al., 2014). However, the (GR)n and (PR)n lack serine 
residues, so cannot be phosphorylated, and are therefore retained in the nucleolus. As 
a result, the arginine rich DPR proteins are suggested to cause nucleolar stress and RNA 
splicing dysregulation (Kwon et al., 2014).  
Similarly in Drosophila models, expression of the arginine rich DPR proteins in the eye 
caused neurodegeneration, and is suggested to disrupt Notch signalling (Freibaum et al., 
2015; Yang et al., 2015). In addition, two elegant studies using Drosophila models 
showed that the toxicity of the (G4C2)n repeats was dependent on the production of 
DPR, and not (G4C2)n RNA foci (Mizielinska et al., 2014; Tran et al., 2015). In the first 
study, Drosophila expressing either pure (G4C2)36 or 103 repeats in the eye displayed 
neurodegeneration, whilst flies expressing ‘RNA only’ repeats (which contained stop 
codons interspersed throughout the construct) did not develop neurodegeneration 
(Mizielinska et al., 2014). Importantly, the pure repeats produced DPR proteins whilst 
the ‘RNA only’ repeats did not (Mizielinska et al., 2014). Additional DPR only Drosophila 
models showed the arginine rich DPR species caused the most severe eye 
neurodegeneration (Mizielinska et al., 2014). Drosophila expressing (G4C2)160 in an 
intronic context displayed nuclear sense RNA foci in the glutamatergic neurons and glia 
cells, but displayed no signs of neurodegeneration or toxicity (Tran et al., 2015). 
However, a polyadenylated (G4C2)36 repeat mRNA expressed in a different Drosophila 
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model displayed far greater toxicity, and this was associated with (G4C2)n RNA export 
and much greater DPR expression in the affected cells (Tran et al., 2015).  
1.8.3. Other Genetic Phenomena Associated with the (G4C2)n Repeat 
Lastly, other pure biological aspects of the (G4C2)n repeat have been studied in various 
cellular and animal models. Several C9ORF72-ALS patient derived models show somatic 
instability in the (G4C2)n, specifically during differentiation of fibroblasts to iPSC, and 
from iPSC to neuronal and motor neuronal cultures (Almeida et al., 2013; Esanov et al., 
2016; Sareen et al., 2013). Further, HEK293 cells transfected with (G4C2)n repeat 
constructs showed length dependent instability, that whole (G4C2) units were lost or 
gained via contraction and expansions respectively, and also replication efficiency of the 
(G4C2)n decreased in a length dependent manner (Thys and Wang, 2015). C9ORF72-ALS 
patient derived cell models also show reduced expression of C9ORF72 mRNA variant 2 
from the allele containing the repeat expansion (Almeida et al., 2013; Donnelly et al., 
2013; Tran et al., 2015). The reduced C9ORF72 transcription is suggested to be caused 
by (G4C2)n expansion methylation, and in HEK293 cells that were transfected with 
methylated or unmethylated (G4C2)66 constructs, methylation of the (G4C2)n repeat 
reduced both RNA foci and DPR proteins (Bauer, 2016). 
1.9. Overall Aims and Objectives 
ALS is currently incurable, and therefore therapeutic agents which may slow or even 
prevent disease progression are vital. A (G4C2)n repeat expansion in C9ORF72 is the 
most common genetic cause of ALS, but it is still not fully understood how the (G4C2)n 
repeat expansion leads to motor neuron injury and ALS pathogenesis. Therefore, by 
using cellular models of C9ORF72-ALS, we may discover important therapeutic targets 
that could be directly translated into therapies for C9ORF72-ALS patients, and even 
more broadly for ALS patients as a whole. 
The overall aims of this project were to: 
1) Generate motor neuron like cellular models with tetracycline inducible 
expression of (G4C2)n repeats. 
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2) Characterise the cellular models for features of ALS and C9ORF72-ALS pathology, 
and interrogate biochemical effects of (G4C2)n repeat expression. 
3) Perform transcriptomic analysis to identify biological pathways and functions 
that may be dysregulated by (G4C2)n expression. 
4) Interrogate any potential therapeutic targets in rescue assays. 
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Chapter 2. Materials and Methods 
2.1. Materials 
Unless stated otherwise, all general materials and reagents were purchased from 
Thermo Fisher Scientific® Inc. Solutions were autoclaved in an MP25 autoclave (Rodwell) 
at 121°C, 15psi for 15mins where stated. 
2.1.1. General Materials 
Diethylpyrocarbonate (DEPC) was purchased from Applichem. Dextran Sulphate, 
Sodium salt, molecular biology grade was purchased from Calbiochem. Bromophenol 
blue powder; Chloroform; Glycerol; Methanol; and Sodium Chloride (NaCl), analytical 
grade; as well as Sodium Dodecyl Sulphate (SDS), general purpose grade were purchased 
from Fisher Scientific. Amersham™ Protran™ supported 0.2µm nitrocellulose membrane 
was purchased from GE Healthcare Life Sciences. Glycine; HEPES free acid; Tris 
(molecular biology grade); and Tris-HCl (molecular biology grade) were purchased from 
Melford Laboratories Ltd. Immobilon®-P Transfer Membrane, PVDF, 0.45µm was 
purchased from Merk Millipore. Acetic acid; Ammonium Persulphate (APS); β-
Mercaptoethanol; Dimethylformamide (DMF); Dithiothreitol (DTT); Formamide; Sodium 
Citrate Dehydrate; Sodium Phosphate Monobasic (NaH2PO4); Sodium Phosphate Dibasic 
(Na2HPO4); TEMED; Triton™ X-100; Trizma® base; and Tween® 20 were purchased from 
Sigma-Aldrich. EDTA, Disodium salt, Dihydrate was purchased from Thermo Fisher 
Scientific® Inc. Oxoid™ Phosphate Buffered Saline Tablets (Dulbecco A) were purchased 
from Thermo Scientific. 
2.1.2. General Buffers and Solutions 
2.1.2.1. Phosphate Buffered Saline (PBS)  
The PBS consisted of 137mM NaCl, 3mM KCl, 8mM Na2HPO4, and 1.5mM KH2PO4, at pH 
7.3: 10 Oxoid™ PBS tablets were dissolved in 1L dH2O, and the solution was autoclaved.  
2.1.2.2. 1X Tris Acetate EDTA (TAE) Buffer 
The 1X TAE buffer consisted of 40mM Tris, 40mM Acetate, and 1mM EDTA, at pH 8.0. 
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2.1.2.3. 20X Saline Sodium Citrate (SSC) Buffer 
The 20X SSC buffer consisted of 3M NaCl, and 0.3M Sodium Citrate, at pH 7.0, and was 
DEPC treated. 
2.1.2.4. 1M Sodium Phosphate Buffer pH 7.0 
The 1M Sodium Phosphate buffer was comprised of 39% (v/v) 1M NaH2PO4, and 61% 
(v/v) 1M Na2HPO4, at pH 7.0, and was DEPC treated. 
2.1.2.5. Diethylpyrocarbonate (DEPC) Treatment of Solutions 
Buffers and solutions used for RNA work were pre-treated with DEPC to inhibit RNase 
activity. 0.001 volumes of DEPC was added to the solution and stirred for at least 1h. 
The solution was then autoclaved to degrade the DEPC. 
2.1.3. Molecular Biology Materials 
HyperLadder™ I, HyperLadder™ II, HyperLadder™ III, HyperLadder™ IV, and 
HyperLadder™ V molecular weight markers and agarose (molecular grade) were 
purchased from Bioline. T4 Polynucleotide Kinase (PNK); Kinase 10X Reaction Buffer; 
alkaline phosphatase, shrimp (SAP); and 10X SAP Buffer were purchased from 
Boehringer Ingelheim. LB Broth, Miller (molecular genetics granular); and LB Agar, Miller 
(molecular genetics powder) were purchased from Fisher Scientific® Inc. DNA 
Polymerase I, large fragment (Klenow), and 10X Klenow Buffer were purchased from 
Invitrogen™. NucleoSpin Plasmid Kit (No Lid) was purchased from Macherey-Nagel. 5-α 
Competent E.coli (High Efficiency); β-10 Competent E.coli (High Efficiency); and SOC 
Outgrowth Media were purchased from New England BioLabs®. T4 DNA Ligase and 10X 
Ligase Buffer were purchased from Promega. QIAquick Gel Extraction Kit was purchased 
from QIAGEN. dATP; ethidium bromide; carbenicillin; spectinomycin; and synthesised 
TCGAC(G4C2)10 sense and ACGT(G2C4)10 antisense ssDNA oligonucleotides were 
purchased from Sigma-Aldrich. BamHI, DraI, EcoRV, HindIII, NcoI, SalI, and XhoI 
FastDigest restriction enzymes; 10X FastDigest Green Buffer; 2X ReddyMix PCR Master 
Mix were purchased from Thermo Fisher Scientific® Inc. The Translate tool and Compute 
pI/Mw tool were freely available at http://web.expasy.org/translate/ and 
http://web.expasy.org/compute_pi/ respectively.  
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Table 2.1 Primers used in generation of the cell models. All primers used for molecular 
biology methods were purchased from Sigma-Aldrich. 
Primer Sequence 
CMV-Forward 5’-CGCAAATGGGCGGTAGGCGTG 
BGH-Reverse 5’-TAGAAGGCACAGTCGAGG 
 
Table 2.2 Plasmid origins and manipulations. The individuals who provided the plasmid 
or performed the manipulation are referred to by their initials: Prof Stuart Wilson (SW); 
Dr Adrian Higginbottom (AH); Matthew Stopford (MS); Dr Padraig Mulchay (PM); Dr Kurt 
De Vos (KDV); and Dr Adrian Isaacs (AI). 
Plasmid Manipulations Company/ Origin 
(G4C2)n construction vectors 
pcDNA6.2-GW/EmGFP-miR 
 
N/A Gifted by 
SW 
 
pcDNA6.2-GW/EmGFP-miR-
(G4C2)10 
 
(G4C2)10 construct inserted into SalI and XhoI 
sites. 
Generated 
by AH 
pcDNA6.2-GW/EmGFP-miR-
(G4C2)51 
 
(G4C2)51 construct inserted into SalI and XhoI 
sites. 
Generated 
by AH 
pcDNA6.2-GW/EmGFP-miR-
(G4C2)102 
 
(G4C2)102 construct inserted into SalI and XhoI 
sites. 
Generated 
by AH 
pcDNA6.2-(G4C2)10 EmGFP removed from pcDNA6.2-GW/EmGFP-
miR-(G4C2)10 via DraI digest and relegation. 
 
Generated 
by MS 
pcDNA6.2-(G4C2)51 EmGFP removed from pcDNA6.2-GW/EmGFP-
miR-(G4C2)10 via DraI digest and relegation. 
 
Generated 
by MS 
pcDNA6.2-(G4C2)102 EmGFP removed from pcDNA6.2-GW/EmGFP-
miR-(G4C2)10 via DraI digest and relegation. 
 
Generated 
by MS 
pcDNA6.2-(C4G2)102 (G4C2)102 construct was inserted in the 
antisense orientation. 
  
Generated 
by PM 
FRT vectors 
pcDNA5/FRT/TO-GFP pcDNA5/FRT/TO-GFP was cut with BamHI and 
XhoI, end filled and ligated. 
Addgene 
pcDNA5/FRT/TO N/A 
 
Invitrogen™ 
pcDNA5/FRT/TO-HIS 6 x HIS Tag inserted into HindIII and BamHI 
restriction sites. 
 
Addgene 
pcDNA5/FRT/TO-HIS-
(G4C2)10 
(G4C2)10 cut from pcDNA6.2-(G4C2)10 using 
DraI and XhoI restriction sites, and inserted into 
EcoRV and XhoI sites in pcDNA5/FRT/TO-HIS. 
 
Generated 
by MS 
41 
 
pcDNA5/FRT/TO-HIS-
(G4C2)51 
(G4C2)51 cut from pcDNA6.2-(G4C2)51 using 
DraI and XhoI restriction sites, and inserted into 
EcoRV and XhoI sites in pcDNA5/FRT/TO-HIS. 
 
Generated 
by MS 
pcDNA5/FRT/TO-HIS-
(G4C2)102 
(G4C2)102 cut from pcDNA6.2-(G4C2)102 using 
DraI and XhoI restriction sites, and inserted into 
EcoRV and XhoI sites in pcDNA5/FRT/TO-HIS. 
 
Generated 
by MS 
pcDNA5/FRT/TO-(G4C2)10 HIS tag removed from pcDNA5/FRT/TO-HIS-
(G4C2)10 by HindIII and BamHI digest and 
relegation. 
 
Generated 
by MS 
pcDNA5/FRT/TO-(G4C2)51 HIS tag removed from pcDNA5/FRT/TO-HIS-
(G4C2)51 by HindIII and BamHI digest and 
relegation. 
 
Generated 
by MS 
pcDNA5/FRT/TO-(G4C2)102 HIS tag removed from pcDNA5/FRT/TO-HIS-
(G4C2)102 by HindIII and BamHI digest and 
relegation. 
 
Generated 
by MS 
Vectors for Flp-In™ T-REx™ cell line generation  
pPGKFLPobpA N/A 
 
Addgene 
pFRT/lacZeo N/A Invitrogen™ 
 
pcDNA6/TR N/A Invitrogen™ 
 
DPR expression vectors   
p(GA)68 
 
N/A Generated 
by KDV 
 
p(AP)100, p(GR)100, 
p(PR)100 
N/A Gifted by AI 
2.1.4. Cell Culture Materials  
Gelatin powder was purchased from BDH biochemical. Tetracycline-free foetal bovine 
serum (FBS), South American origin, sterile filtered was purchased from Biosera. 
Puromycin dihydrocholride; and BpV (Phen) were purchased from Calbiochem. NSC34 
cells were kindly gifted by Prof. Neil Cashman. Blasticidin S HCl powder; Flp-In™ T-REx™ 
Core Kit; Flp-In™ T-REx™ HEK293 cells; hygromycin B; Lipofectamine® 2000; Tetracycline 
hydrochloride powder; and Zeocin™ were purchased from Invitrogen™. Phenol red-free 
DMEM; Penicillin/Streptomycin; and 10X Trypsin, with versene were purchased from 
Lonza. 6-carboxy-2’,7’-dichlorodihydrofluorescein diacetate, di(acetoxymethyl ester) 
(DCFDA); and ethidium homodimer-1 (EthD1)  were purchased from Molecular Probes™, 
Life Technologies. Dulbecco’s modified eagle medium (DMEM); FBS; menadione sodium 
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bisuphate; Polyethylenimine (PEI); and 5, 10, 15, 20-tetrakis(1-methyl-4-
pyridino)porphyrin tetra(p-toluenesulfonate) (TMPyP) were purchased from Sigma-
Aldrich. Opti-MEM® Reduced Serum Medium, no phenol red was purchased from 
Thermo Fisher Scientific® Inc. 
2.1.5. Biochemical Assay Materials 
2X Brilliant III qPCR Master Mix; and 2X Brilliant III SYBR Green qPCR Master Mix were 
purchased from Agilent Technologies Ltd. Protein Assay Dye Reagent Concentrate was 
purchased from Bio-Rad®. BioScript™ Reverse Transcriptase kit (which contains 
BioScript™ Reverse Transcriptase; and 5X Reaction Buffer); and RiboSafe RNase Inhibitor 
were purchased from Bioline. EZ-RNA kit (which contains denaturing solution, and 
extraction and phase separation solution) was purchased from Biological Industries. 5’ 
TYE-563-labelled LNA sense (5’-CCCCGGCCCCGGCCCC) and (5’-GGGGCCGGGGCCGGGG) 
DNA probes (batch numbers 607323 and 515905 respectively) were purchased from 
Exiqon Inc. Bovine serum albumin (BSA) powder, Fraction V, microbiological grade were 
purchased from Fisher Scientific. Streptavidin Sepharose High Performance beads were 
purchased from GE Healthcare. Ultra-Pure ProtoGel® 30% (w/v) Acrylamide, 0.8% (w/v) 
Bis-Acrylamide Stock Solution (37.5:1), protein and sequencing electrophoresis grade; 
Prestained Blue Protein Ladder; and EZ-ECL Kit were purchased from Geneflow Ltd. 
Original dried skimmed milk powder was purchased from Marvel. DNase I recombinant, 
RNase-free; 10X DNase I Buffer; and Phosphatase inhibitor tablets (PhosSTOP™) (used 
at concentration stated by manufacturer) were purchased from Roche. Cyclohexamide, 
Paraformaldehyde (PFA), crystalline, reagent grade; SIGMAFAST™ Protease Inhibitor 
Cocktail (PIC) tablets, EDTA free (used at concentration stated by manufacturer); RNase 
A; Sodium Azide; and Thiozolyl Blue Tetrazolium Bromide (MTT) powder; were 
purchased from Sigma-Aldrich. TRIzol® LS Reagent was purchased from Thermo Fisher 
Scientific® Inc. Hard Set mounting medium with DAPI was purchased from Vector 
Laboratories Inc. 
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2.1.5.1. qRT-PCR Primers 
Table 2.3 qRT-PCR primer details. Target gene and primer sequences are shown. 
Primer Sequence 
Actb Forward 5’-CGGTTCCGATGCCCTGAGGCTCTT 
 
Actb Reverse 
 
5’-CGTCACACTTCATGATGGAATTGA 
Gapdh Forward 5’-ATGGTGAAGGTCGGTGTGAA 
 
Gapdh Reverse 
 
5’-TGGCAACAATCTCCACTTTGC 
Mouse 18S rRNA Forward 5’-GATGGTAGTCGCCGTGCC 
 
Mouse 18S rRNA Reverse 5’-GCCTGCTGCCTTCCTTGG 
 
Mouse 28S rRNA Forward 5’-AGAGGTAAACGGGTGGGGTC 
 
Mouse 28S rRNA Reverse 
 
5’-GGGGTCGGGAGGAACGG 
 
Mouse 45S rRNA Forward 5’-CGTAGGGAAGTCGGTCGTTC 
 
Mouse 45S rRNA Reverse 5’-GAGGGGGCTCCAGACATCC 
 
Mouse 5.8S rRNA Forward 5’-ACTCGGCTCGTGCGTC 
 
Mouse 5.8S rRNA Reverse 5’-CCGACGCTCAGACAGG 
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Table 2.4 PrimeTime® qPCR assay (Integrated DNA Technologies®) product details. Target gene, assay ID, RefSeq Accession number(s), gene 
region, primers sequences and probe sequences are shown. 
Gene PrimeTime® Assay ID Ref Seq Region Primer Sequence Probe Sequence 
Actb Mm.PT.58.33540333 
 
NM_007393 Exon 1-2 5’-ATGCCGGAGCCGTTGTC-3’ 
5’-GCGAGCACAGCTTCTTTG-3’ 
 
5’-/56-FAM/CCGCCACCA/ZEN/GTTCGCCATG/3IABkFQ/-3’ 
Akt1 Mm.PT.58.8333433 NM_009652 
NM_001165894 
 
Exon 2-3 5’-GCCGTTCCTTGTAGCCAAT-3’ 
5’-GACGTAGCCATTGTGAAGGAG-3’ 
5’-/56-FAM/TATTCCCCT/ZEN/CGTTTGTGCAGCCA/3IABkFQ/-3’ 
Mtor Mm.PT.58.28403918 NM_020009 
 
Exon 46-47 5’-TGCATCACTCGTTCATCCTG-3’ 
5’-AAGTCATCACATCCAAGCAGA-3’ 
 
5’-/56-FAM/CCCATTGCT/ZEN/GCCCATCAGAGTCA/3IABkFQ/-3’ 
Pten Mm.PT.56a.13345002 NM_008960 
 
Exon 8-9 5’-TCATTGTCACTAACATCTGGAGTC-3’ 
5’-GCCAACCGATACTTCTCTCC-3’ 
 
5’-/56-FAM/TTGAACTGC/ZEN/TAGCCTCTGGATTTGATGG/3IABkFQ/-3’ 
Srsf1 Mm.PT.58.32558636.g NM_173374 
NM_001078167 
 
Exon 2-3 5’-CATACATCACCTGCCTCACG-3’ 
5’-GGTCCGAGAACAGAGTGGT-3’ 
5’-/56-FAM/TGATCCTTT/ZEN/AAGTCCTGCCAGCTTCC/3IABkFQ/-3’ 
Srsf2 Mm.PT.58.7770373 
 
NM_011358 
 
 
Exon 2-3 5’-CCCAATGTCCTCTGTTAAGCC-3’ 
5’-CGAAGCGAGAGTCCAAGTCTA-3’ 
5’-/56-FAM/CAAGAGCCC/ZEN/ACCCAAGTCTCCAG/3IABkFQ/-3’ 
Trp53 Mm.PT.58.42581447 NM_011640 
NM_001127233 
Exon 8-10 5’-CTCCCGGAACATCTCGAAG-3’ 
5’-CAGGGAGCGCAAAGAGAG-3’ 
5’-/56-FAM/CGCCTCTCC/ZEN/CCCGCAAAAGAA/3IABkFQ/-3’ 
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Table 2.5 Primary antibodies used for Immunoblotting.Antibody specificity, species, 
type, dilution, blocking agent (5% (w/v) Milk/TBST (M) or 5% (w/v) BSA/TBST (B)) and 
source are shown. The individuals who provided the antibody are referred to by their 
initials: Prof Stuart Wilson (SW); Prof Stuart Pickering-Brown (SPB); and Prof Dieter 
Edbauer (DE). 
Antibody Specificity Species/type Dilution/blocking 
agent 
Source/product 
number/clone 
number 
Anti-β-actin Mouse monoclonal 1/10000 (M) Abcam, ab6276, clone AC-15 
 
Anti-Akt Rabbit polyclonal 1/1000 (M) Cell Signalling, #9272 
 
Anti-NCL Rabbit polyclonal 1/2000 (M) Proteintech, 10556-1-AP 
 
Anti-p53 Mouse monoclonal 
 
1/250 (M) BD Pharmingen™, 554147 
 
Anti-Phospho-Akt 
(Ser473) 
Rabbit monoclonal 1/1000 (B) Cell Signalling, #4060 
 
 
Anti-Phospho-PTEN 
(Ser380) 
Rabbit polyclonal 1/2000 (B) Cell Signalling, #9551 
 
 
Anti-poly(AP) Rabbit 1/5000 (M) SPB 
 
Anti-poly(GA) Mouse 1/500 (M) DE 
 
Anti-poly(GP) Rabbit 1/5000 (M) SPB 
 
Anti-poly(GR) Rabbit 1/5000 (M) SPB 
 
Anti-poly(PR) Rabbit 1/5000 (M) SPB  
 
Anti-PTEN Rabbit monoclonal 1/1000 (M) Cell Signalling, #9188 
 
Anti-RPL19 Rabbit polyclonal 
 
1/2000 (M) SW 
Anti-RPL29 Rabbit polyclonal 
 
1/500 (M) Sigma-Aldrich, R0655 
 
Anti-α-tubulin Mouse monoclonal 1/10000 (M) Sigma-Aldrich, ab7291, clone 
DM1A 
 
Table 2.6 Secondary antibodies used for Immunoblotting. Antibody specificity, species, 
type, dilution, blocking agent (5% (w/v) Milk/TBST (M) or 5% (w/v) BSA/TBST (B)) and 
source are shown. 
Antibody Dilution Source/product number/ 
clone number 
Polyclonal Goat Anti-Mouse-IgG HRP 1/10000 (M) Dako, P 0447 
 
Polyclonal Goat Anti-Rabbit-IgG HRP 1/10000 (M) Dako, P 0448 
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Table 2.7 Primary antibodies used for Immunocytochemistry. Antibody specificity, 
species, type, dilution (in 2% (w/v) BSA/PBS) and source are shown. 
Antibody Species/type Dilution Source/product 
number/clone number 
HnRNP A1 Mouse monoclonal 
 
1/500 Abcam, ab5832 
HnRNP F/H Mouse monoclonal 
 
1/1000 Abcam, ab10689 
SRSF1 Rabbit polyclonal 1/200 
 
Abcam, ab38017 
SRSF2 Mouse monoclonal 1/200 
 
Abcam, ab11826 
NCL Rabbit polyclonal 1/200 Protientech, 10556-1-AP 
 
Pur-α Rabbit polyclonal 
 
5µg/mL Abcam, ab79936 
ALYREF Mouse monoclonal 
 
1/500 Sigma-Aldrich, A9979 
TDP-43 Rabbit polyclonal 1/200 Proteintech, 10782-2-AP 
 
Table 2.8 Secondary antibodies used for Immunocytochemistry. Antibody specificity, 
species, type, dilution (in 2% (w/v) BSA/PBS) and source are shown. 
Antibody Dilution Source/product 
number/clone 
number 
Goat Anti-Rabbit IgG H&L (AlexaFluor® 488) preadsorbed 
 
1/1000 Abcam, ab150081 
 
Goat Anti-Rabbit IgG H&L (AlexaFluor® 594) preadsorbed 
 
1/1000 Abcam, ab150084 
 
Goat Anti-Mouse IgG H&L (AlexaFluor® 488) preadsorbed 
 
1/1000 Abcam, ab150117 
 
Goat Anti-Mouse IgG H&L (AlexaFluor® 594) preadsorbed 1/1000 Abcam, ab150120 
 
 
2.1.6. Gene Expression Profiling Materials 
The GeneChip® WT PLUS Reagent Kit (containing First-Strand Enzyme, First-Strand 
Buffer, Second-Strand Enzyme, Second-Strand Buffer, IVT Enzyme, IVT Buffer, 1mg/mL 
HeLa total RNA (Control RNA), 2nd-Cycle Primers, 2nd-Cycle ss-cDNA Enzyme, 2nd-Cycle 
ss-cDNA Buffer, RNase H, Nuclease-free water, magnetic Purification Beads, Poly-A 
Control Stock, Poly-A Control Dilution Buffer, 10X cDNA Fragmentation Buffer, 
10units/µL UDG, 1,000 units/µL apurinic/apyrimidinic endonuclease (APE) 1, 5X TdT 
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Buffer, 30units/µL TdT, 5mM DNA Labelling Reagent, RNase-free water, 20X Eukaryotic 
Hybridisation Controls (bioB, bioC, bioD, cre), 3nM Control Oligo B2); the GeneChip® 
Hybridisation, Wash and Stain Kit (containing DMSO, 2X Hybridisation Mix, Stain Cocktail 
1, Stain Cocktail 2, Array Holding Buffer, Wash Buffer A, and Wash Buffer B); GeneChip® 
Mouse Transcriptome Array 1.0 cartridges; GeneChip® Scanner 3000; GeneChip® 
Fluidics Station 450; GeneChip® Command Console Software; and Affymetrix® 
Expression Console; Affymetrix® Transcriptomics Analysis Console (TAC) Software, were 
all purchased from Affymetrix® Ltd. 5X Novex® Hi-Density TBE Sample Buffer; and 4-20% 
TBE Gel, 1.0mm were purchased from Life Technologies. 10mg/mL NeutrAvidin was 
purchased from Thermo Scientific. The Direct-zol™ RNA Kit (which contains TRI-
Reagent®, Zymo-Spin™ II Columns, collection tubes, Wash Buffer, 1units/µL DNAse I, 10X 
DNAse I Reaction Buffer, DNAse/RNAse-free water, RNA Wash Buffer, Direct-zol RNA 
PreWash) was purchased from Zymo Research. The Database for Annotation and 
Visualisation and Integrated Discovery (DAVID; bioinformatics resources 6.7) functional 
annotation clustering tool for gene ontology enrichment analysis was freely available at 
https://david.ncifcrf.gov/. The Integrated Molecular Pathway Level Analysis (IMPaLA; 
version 9; build January 2015) over-representation tool was freely available online at 
http://impala.molgen.mpg.de/. 
2.2. Methods  
2.2.1. Molecular Biology Methods 
2.2.1.1. Restriction Digests 
Restriction sites were utilised during plasmid manipulation, construction and screening. 
≤ 1 µg plasmid DNA was digested with FastDigest restriction enzyme according to 
manufacturer’s instructions. 
2.2.1.2. Blunt Ending DNA Fragments 
During plasmid cloning procedures that required blunt end ligation, Klenow was used to 
blunt 5’ and 3’ overhangs on DNA fragments and linearised plasmids. Klenow has 5’ to 
3’ polymerase activity and 3’ to 5’ exonuclease activity, and can therefore blunt both 5’ 
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and 3’ overhangs. ≤ 1µg of restriction digested plasmid was incubated with 20μL Klenow 
reaction solution (0.25units/μL Klenow, 1X Klenow Buffer in dH2O) for 1h at 37°C. 
2.2.1.3. 5’ End Phosphorylation of DNA Fragments 
Blunt ended insert fragments were 5’ phosphorylated with T4 polynucleotide kinase 
(PNK) during ligation of blunt ended DNA fragments into linearised, blunt ended 
plasmids. 5’ phosphorylation increases the efficiency of blunt ended ligation. ≤ 1µg of 
DNA fragment was incubated with 20µL PNK reaction solution (0.35units/μL PNK, 
500µM ATP, 1X Kinase Reaction Buffer in dH2O) for 30mins at 37°C. The PNK was 
inactivated by incubating for 15mins at 65°C. 
2.2.1.4. 5’ End Dephosphorylation of DNA Fragments 
5’ phosphate groups are necessary for ligation. Therefore, to minimise re-ligation of the 
linearised plasmid during ligation procedures, shrimp alkaline phosphatase (SAP) was 
used to remove the 5’ phosphate groups from the linearised plasmid. ≤ 1µg of linearised 
plasmid was incubated with 20µL SAP reaction solution (0.05units/μL SAP, 1 X SAP Buffer 
in dH2O) for 30mins at 37°C. The SAP was inactivated by incubating for 15mins at 65°C. 
2.2.1.5. Ligation of DNA Fragments 
T4 DNA Ligase was used to ligate DNA fragments and linearised plasmids. DNA 
fragments containing (G4C2)n constructs were incubated for 10mins at 70°C then snap 
cooled on ice for 5mins prior to ligation. ≤ 1µg of the linearised plasmid and DNA 
fragment insert (if applicable) were incubated with T4 DNA Ligase reaction solution 
(0.15units/μL T4 DNA Ligase, 1X Ligase Buffer in dH2O) overnight at room temp. The 
linearised plasmid and the DNA fragment to be inserted were mixed in a 1:3 ratio of 
absolute number of DNA molecules. In addition, re-ligation controls were set up that 
contained the same reagents described above, excluding the DNA fragment insert, and 
were used to measure the background number of E.coli colonies produced after 
transformation. 
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2.2.1.6. Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to separate linear DNA fragments produced by 
restriction digest or PCR. 1.5% agarose gels were prepared by adding 1.5g agarose 
powder to 100mL 1X TAE buffer. The solution was then heated in a microwave until the 
agarose powder had dissolved. Ethidium bromide was added at a final concentration of 
100ng/mL to the agarose solution, and the solution was then poured into a cassette. A 
gel comb was also placed into the agarose solution, and the solution was left for least 
30mins to cool and set. Agarose gels were then placed into an electrophoresis tank 
containing 1X TAE buffer. 2µL of a HyperLadder™ molecular weight marker was loaded 
into the first well, and was used to size the DNA fragments on the gel. Restriction digest 
and PCR samples were loaded into consecutive wells. The gel was run at 100-120V for 
45-60mins. Agarose gels were imaged using the GENi UV light imaging system (Syngene). 
2.2.1.7. DNA Extraction from Agarose Gel 
After agarose gel electrophoresis, the DNA bands were visualised using a UV 
transilluminator, and the desired DNA bands were manually cut out using a scalpel. The 
DNA was then extracted and purified using the QIAquick Gel Extraction Kit according to 
manufacturer’s instructions. 
2.2.1.8. LB Agar Plates 
Sterile LB agar (10g/L Tryptone, 5g/L Yeast extract, 10g/L NaCl, 15g/L Agar) was prepared 
by resuspending 40g LB agar powder in 1L dH2O, and autoclaving. The LB agar was then 
heated in a microwave until the LB agar had completely melted. The LB agar was left to 
cool for 5 mins, and then in sterile conditions either 50µg/mL carbenicillin or 50µg/mL 
spectinomycin selection was added to the melted LB agar. Still in sterile conditions, the 
LB agar solution was mixed and poured onto 10cm petri dishes. 
2.2.1.9. Plasmid Transformation into Competent E.coli 
Plasmid DNA or ligation mixtures were transformed into competent E.coli to clone the 
plasmid. ≤ 50ng of circular plasmid or the ligation mixture (section 2.2.1.5) were pre-
chilled on ice. 20µL competent E.coli were added to the DNA using a large-bore pipette 
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tip, and incubated for 10mins on ice. E.coli were heat shocked for 30s at 42°C and then 
incubated for 5mins on ice. In sterile conditions, 100µL SOC outgrowth media was added 
to the E.coli and they were incubated for 30mins at 37°C on a shaker. Also in sterile 
conditions, the SOC outgrowth media containing the E.coli was then spread onto an LB 
agar plate containing 50µg/mL carbenicillin or 50µg/mL spectinomycin selection 
(dependent on the plasmid’s antibiotic resistance) and incubated over-night at 37°C. 
Plasmids that contained the (G4C2)n constructs were transformed into β-10 competent 
E.coli (K12 strain, DH10B™ derivative) because they have reduced recombinase activity, 
which minimised the rearrangement of the repetitive (G4C2)n DNA sequences. All other 
plasmids were transformed into 5-α competent E.coli (K12 strain, DH5α™ derivative). 
2.2.1.10. Miniprep of Plasmid DNA 
Sterile LB Broth (10g/L Tryptone, 5g/L Yeast extract, 10g/L NaCl) was made by 
resuspending 25g LB Broth powder in 1L dH2O, and autoclaving. E.coli colonies 
containing the plasmid of interest were picked and grown in LB Broth with either 
50µg/mL carbenicillin or 50µg/mL spectinomycin selection (dependent on the plasmid’s 
antibiotic resistance) overnight at 37°C on a shaker. The plasmids were then purified 
using a NucleoSpin Plasmid Kit (No Lid) according to manufacturer’s instructions. DNA 
concentration was determined with a NanoDrop™ 1000 Spectrophotometer (Thermo 
Fisher Scientific® Inc). 
2.2.1.11. Colony PCR Screen 
PCR was used to screen for successful pcDNA5/FRT/TO-HIS-(G4C2)n and 
pcDNA5/FRT/TO-(G4C2)n plasmid ligations in the transformed E.coli colonies. Each E.coli 
colony was picked and then incubated with 6μL PCR reaction solution (0.42µM CMV-
Forward primer, 0.42µM BGH-Reverse primer, 1X ReddyMix PCR Master Mix in dH2O). 
Samples were incubated for 3mins at 95°C, followed by 35 amplification cycles of 30s at 
92°C, 30s at 55°C, and 60s at 72°C, followed by a final extension step of 5mins at 72°C.  
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2.2.2. Cell Culture Methods 
2.2.2.1. HEK293 Cell Line Maintenance 
HEK293 cells were cultured in 10mL supplemented DMEM (10% (v/v) FBS, 50units/mL 
penicillin/streptomycin) in 10cm plates in a 37°C / 5% CO2 incubator. HEK293 cells were 
split every 3-4 days. To split the HEK293 cells, the media was removed, and cells were 
washed in PBS. 1mL 1X trypsin was added to the cells, and cells were returned to 
incubator for 4mins. The plate was tapped to dislodge trypsinised cells from the plate, 
and 9mL supplemented DMEM was added. Cells were resuspended, and 1mL cell 
suspension was added to a new 10cm plate. Supplemented DMEM was added to a final 
volume of 10mL. 
2.2.2.2. HEK293 Sham and HEK293 (G4C2)n Cell Line Generation 
pcDNA5/FRT/TO, pcDNA5/FRT/TO-(G4C2)10, pcDNA5/FRT/TO-(G4C2)51, and 
pcDNA5/FRT/TO-(G4C2)102 were each co-transfected with pPGKFLPobpA into Flp-In™ 
T-REx™ HEK293 cells. 24h post-transfection, the HEK293 cells were split onto 4 new 
plates. Supplemented tetracycline-free DMEM was added containing 15μg/mL 
blasticidin and 150μg/mL hygromycin to select for transformed cells. 5 days post-
transfection, media was replenished with 50% HEK293 conditioned / 50% fresh media 
with selection. 15 days post-transfection, visible colonies of HEK293 cells were picked 
and transferred to a 48 well plate. The HEK293 colonies were grown on the 48 well plate 
until 60% confluent. The clones were then screened for Zeocin™ sensitivity, and 
blasticidin/hygromycin resistance. Clones that were blasticidin/hygromycin-resistant 
but Zeocin™-sensitive were expanded and cryopreserved. 
2.2.2.3. HEK293 Sham and HEK293 (G4C2)n Cell Line Maintenance 
HEK293 sham and HEK293 (G4C2)n cells were cultured in 10mL supplemented DMEM 
(10% (v/v) tetracycline-free FBS, 50units/mL penicillin/streptomycin) with 15µg/mL 
blasticidin, and 150µg/mL hygromycin, in 10cm plates in a 37°C / 5% CO2 incubator. 
HEK293 cells were split every 3-4 days, as described in section 2.2.2.1. 
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2.2.2.4. NSC34 Cell Line Maintenance 
NSC34 cells were cultured in 10mL supplemented DMEM (10% (v/v) FBS, 50units/mL 
penicillin/streptomycin), in 10cm plates in a 37°C / 5% CO2 incubator Media was 
removed and replenished every 2-3 days. NSC34 cells were split every 3-4 days. To split 
the NSC34 cells, the media was removed and 10mL supplemented DMEM was added to 
the plate. The NSC34 cells were dislodged from the plate into suspension by pipetting 
the media up and down. 1mL of the cell suspension was added to a new 10cm plate. 
Supplemented DMEM with the relevant selection agents was added to a final volume of 
10mL. 
2.2.2.5. Flp-In™ T-REx™ NSC34 Cell Line Generation 
A Flp-In™ T-REx™ NSC34 host cell line was generated using the Flp-In™ T-REx™ core kit 
according to the manufacturer’s instructions. Briefly, pFRT/lacZeo was transfected into 
WT NSC34 cells, and Zeocin™ selection was added to the NSC34 media to select for 
stable transformants. Zeocin™-resistant clones were picked, expanded, and 
cryopreserved. Genomic DNA was then extracted from these Flp-In™ NSC34 clones, and 
screened using Southern Blotting. Flp-In™ NSC34 clones that contained only one 
genomic FRT site were further analysed for the transcriptional activity of that FRT site. 
Flp-In™ NSC34 clones were transfected with pcDNA5/FRT/GFP, and hygromycin 
selection was added to the Flp-In™ NSC34 media to select for stable transformants. Flp-
In™ NSC34 clones were also negatively screened with Zeocin™ to check the insertions 
were not random. These Flp-In™ NSC34 GFP cells were then screened using a fluorescent 
microscope for GFP expression levels. Clones that expressed the highest GFP levels were 
transfected with pcDNA6/TR, and blasticidin/hygromycin selection was added to Flp-In™ 
NSC34 GFP media to select for stable transformants. These mixed populations of Flp-
In™ T-REx™ NSC34 GFP cells were screened for GFP repression at basal levels, and 
increased GFP expression with tetracycline induction.  
Once a Flp-In™ clone with repressible GFP expression was identified, the non-GFP T4E2A 
Flp-In™ T-REx™ NSC34 clonal line was transfected with pcDNA6/TR, and 
blasticidin/Zeocin™ selection was added to the Flp-In™ T-REx™ NSC34 media to select 
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for stable transformants. Blasticidin/Zeocin™-resistant clones were picked, expanded, 
and cyropreserved. Flp-In™ T-REx™ NSC34 clones were transfected with 
pcDNA5/FRT/GFP, and blasticidin/hygromycin selection was added to the Flp-In™ T-
REx™ NSC34 GFP media to select for stable transformants. Blasticidin/hygromycin-
resistant Flp-In™ T-REx™ NSC34 GFP clones were also screened for Zeocin™ sensitivity. 
Blasticidin/hygromycin-resistant, Zeocin™-sensitive Flp-In™ T-REx™ NSC34 GFP clones 
were then screened for GFP expression ± tetracycline induction. Flp-In™ T-REx™ NSC34 
clonal line B10-2 had modest GFP expression at basal levels, and high GFP expression 
when induced with tetracycline. Therefore B10-2 was selected as the parental Flp-In™ 
T-REx™ NSC34 host cell line for generating the isogenic, tetracycline-inducible Flp-In™ T-
REx™ NSC34 sham and (G4C2)n cell lines. 
2.2.2.6. Flp-In™ T-REx™ NSC34 Cell Line Maintenance 
All NSC34 cells were grown in 10cm plates in a 37°C / 5% CO2 incubator. Flp-In™ T-REx™ 
NSC34 cells were cultured in 10mL supplemented tetracycline-free DMEM with 
20µg/mL Zeocin™, and 5µg/mL blasticidin, in 10cm plates in a 37°C / 5% CO2 incubator. 
Media was removed and replenished every 2-3 days. The media that was removed was 
centrifuged at 400 x g for 4mins, and the media was transferred to a new flask and stored 
as conditioned media. NSC34 cells were split every 3-4 days, as described in section 
2.2.2.4. 
2.2.2.7. NSC34 Sham and NSC34 (G4C2)n Cell Line Generation 
pcDNA5/FRT/TO, pcDNA5/FRT/TO-(G4C2)10, pcDNA5/FRT/TO-(G4C2)51, and 
pcDNA5/FRT/TO-(G4C2)102 were each co-transfected with pPGKFLPobpA into Flp-In™ 
T-REx™ NSC34 cells. 48h post-transfection, the media was replenished, and the NSC34 
cells were split onto 3 new 10cm plates. 5μg/mL blasticidin and 100μg/mL hygromycin 
were added to the media to select for transformed clones. The media containing 
selection was replenished every 3 days. 10 days post-transfection, media was 
replenished with 50% conditioned / 50% fresh media with selection. Visible colonies of 
NSC34 cells were picked and transferred to a 48 well plate. The NSC34 colonies were 
grown on the 48 well plate until 60% confluent. The clones were then screened for 
Zeocin™ sensitivity, and blasticidin/hygromycin resistance. Clones that were 
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blasticidin/hygromycin-resistant but Zeocin™-sensitive were expanded and 
cryopreserved. 
2.2.2.8. NSC34 Sham and NSC34 (G4C2)n Cell Line Maintenance 
NSC34 sham and NSC34 (G4C2)n cells were cultured in 10mL supplemented tetracycline-
free DMEM with 5µg/mL blasticidin, and 100µg/mL hygromycin B, in 10cm plates in a 
37°C / 5% CO2 incubator. Media was removed and replenished every 2-3 days. NSC34 
cells were split every 3-4 days, as described in section 2.2.2.4. NSC34 sham and NSC34 
(G4C2)n cells were seeded onto gelatin-coated coverslips for RNA FISH and ICC methods. 
2.2.2.9. Cryopreservation of Cell Lines 
Media was removed from cells, and cells were resuspended in fresh media (either via 
trypsinising for HEK293 cellls (section 2.2.2.1) or dislodging the cells by pipetting for 
NSC34 cells (section 2.2.2.4)). Cells were centrifuged at 400 x g for mins, and then 
supernatant was removed. Approximately 5-10 x 106 Cells were resuspended in 800 µL 
10% (v/v) DMSO/ 90% (v/v) FBS, and transferred to a cryogenic vials. Cryogenic vials 
were placed in a CoolCell® SV2 (Biocision), which was then incubated for 2h at -80°C. 
The cryogenic vials were then transferred to liquid nitrogen for long term storage. 
2.2.2.10. Tetracycline Induction of Cell Lines 
10µg/mL tetracycline was added to HEK293 sham and HEK293 (G4C2)n cell media to 
induce expression of the construct. Unless stated otherwise, 0.5µg/mL tetracycline was 
added to NSC34 sham and NSC34 (G4C2)n cell media to induce expression of the 
construct. Tetracycline was added every 3 days (if applicable) to maintain concentration 
in the media. 
2.2.2.11. Plasmid Transfection of Cell Lines 
pcDNA5/FRT/TO and pPGKFLPobpA transfections – For the Flp-In™ T-REx™ HEK293 cells, 
10μL Lipofectamine® 2000, 6μg pPGKFLPobpA, and 4 μg pcDNA5/FRT/TO vector were 
used per 10cm plate. For the Flp-In™ T-REx™ NSC34 cells, 15μL Lipofectamine® 2000, 
9μg pPGKFLPobpA, and 6μg pcDNA5/FRT/TO vector were used per 10cm plate. 
Lipofectamine® 2000 was mixed with 1.5mL Opti-MEM®, and separately, the 
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pPGKFLPobpA and pcDNA5/FRT/TO plasmids were mixed with 1.5mL Opti-MEM®. Both 
mixtures were incubated for 10mins at room temperature. The two mixtures were then 
mixed together, and incubated for 10mins at room temperature. Media was removed 
from cells, and 3mL DNA/Lipofectamine® mixture was added to the cells. The cells were 
incubated for 6h, and then 10mL supplemented tetracycline-free DMEM containing 
blasticidin was added to cells. The media was removed and replenished 24h post 
transfection for the Flp-In™ T-REx™ HEK293 cells, and 48h post transfection for the Flp-
In™ T-REx™ NSC34 cells. 
(C4G2)102, (GA)68, (GR)100, (AP)100, (PR)100 – 14μg plasmid DNA and 50μg PEI were 
used per 1mL Opti-MEM®. Firstly, the plasmid DNA and PEI were mixed with Opti-
MEM®, and then incubated for 15mins at room temperature. The DNA/PEI mix was then 
added dropwise to HEK293 cells. 100μL of DNA/PEI mix was added per 1mL media on 
cells.  
2.2.2.12. Stable Lentiviral Transduction of Cell Lines 
NSC34 sham and (G4C2)102 cells were transduced with an estimated 0.1-0.2 Multiplicity 
of Infection (MOI) PTEN shRNA, GFP, or control shRNA lentiviral particles. 24h post-
transduction, media was removed and supplemented tetracycline-free DMEM with 
5μg/mL blasticidin, 100μg/mL hygromycin, and 1μg/mL puromycin selection was added. 
Blasticidin/hygromycin/puromycin-resistant cells were expanded and cryopreserved. 
2.2.2.13. MTT Cell Viability Assay 
The number of viable cells was measured using MTT reagent, which is metabolised to 
an insoluble purple formazan salt. Cells were grown in triplicate wells on 96 well plates 
for up to 7 days. 0.5µg/mL MTT reagent was added to media. Plates were incubated for 
90mins in a 37 °C / 5% CO2 incubator. 1 volume SDS/DMF lysis buffer (20% (w/v) SDS, 
50% DMF (v/v), pH 4.7) was added to lyse cells. 595nm absorbance of wells was 
measured using a PHERAstar FS plate reader (BMG labtech Ltd.). 
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2.2.2.14. EthD1 Cell Death Assay 
Dead cells were measured using EthD1, which is a cell-impermeant, high affinity nucleic 
acid stain that emits red fluorescence when bound to DNA. Cells were grown in triplicate 
wells on 96 well plates for up to 5 days. 1µM EthD1 was then added, and cells were 
incubated for 30mins at 37°C. The fluorescence of DNA-bound EthD1 was measured at 
Ex570nm/Em610nm using a PHERAstar FS plate reader (BMG labtech Ltd.). Cells were 
then freeze-thawed, and cell number was measured by adding an extra 1µM fresh EthD1 
to the medium. Fluorescence was measured at Ex570nm/Em610nm. EthD1 
measurements of dead cells were then calculated as a percentage of the EthD1 
measurements of total cell number to give values for % cells dead in each condition. 
2.2.2.15. DCF Reactive Oxygen Species Assay 
Cytosolic Reactive Oxygen Species (ROS) levels were measured using DCF fluorescence. 
Cells were grown in triplicate wells on 96 well plates for up to 5 days. Media was then 
replaced with supplemented phenol-red free DMEM (10% (v/v) tetracycline-free FBS). 
10µM DCFDA was then added, and cells were incubated for 90mins at 37°C. The 
fluorescence of oxidised DCF was measured at Ex485nm/Em520nm using a PHERAstar 
FS plate reader (BMG labtech Ltd.). Cells were then freeze-thawed, and cell number was 
measured by adding 1.5µM EthD1 to the medium. Fluorescence was measured at 
Ex570nm/Em610nm. Raw DCF data were then normalised to EthD1 measurement of cell 
number. 
2.2.2.16. Growth Curve 
1.5 x 106 cells were seeded onto a 10cm plate, and incubated for 4 days. Media was then 
removed, and cells were washed off in PBS. Cells were centrifuged at 400 x g for 4mins. 
PBS was removed and cell pellet was vortexed briefly by flicking. The cells were 
resuspended in 10mL media, and then counted using a haemocytometer. 1.5 x 106 cells 
were then re-seeded onto a new 10cm plate. This counting procedure was repeated and 
recorded every 4 days up to 16 days cell growth. 
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2.2.3. Biochemical Methods 
2.2.3.1. SDS-Polyacrylamide Gel Preparation 
Resolving gels of the desired acrylamide % (w/v) were prepared by mixing reagents 
described in Table 2.9. Spacer plates with 1.0 mm integrated spacers (Bio-Rad) and short 
plates (Bio-Rad) were assembled on the Mini-PROTEAN® Tetra Cell Casting Stand and 
clamps (Bio-Rad) with gaskets (Bio-Rad). Gels were poured into glass plates, and a layer 
of isopropanol was layered on top of the gels. The gels were left for at least 15 mins to 
set, and then the isopropanol was removed. 5 % Stacking gels were prepared by mixing 
reagents described in Table 2.9, and then poured onto the set resolving gels in the glass 
plates. 1.0 mm 15-well Mini-PROTEAN® Combs (Bio-Rad) were then inserted into the 
stacking gels, and left for at least 15 mins to set. 
 
 Table 2.9 Composition of 5% Stacking gels, 12% Resolving gels and 15% Resolving gels.  
 5% Stacking gel 12% Resolving 
gel 
15% Resolving 
gel 
dH2O 
 
5.8 mL 3.5 mL 2.5 mL 
30 % (w/v) Acrylamide 
 
1.7 mL 4.0 mL 5.0 mL 
Resolving buffer (1.5 M Trizma®, 
13.9 mM SDS, pH 8.8, filtered) 
 
- 2.5 mL 2.5 mL 
Stacking buffer (0.5 M Trizma®, 
13.9 mM SDS, pH 6.8, filtered) 
 
2.5 mL - - 
10 % (w/v) APS 
 
50 μL 50 μL 50 μL 
TEMED 20 μL 20 μL 10 μL 
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2.2.3.2. Sucrose Gradient Preparation 
Sucrose was dissolved in Sucrose Gradient Buffer (SGB) (20mM Tris, 140mM KCl, 5mM 
MgCl, pH 8.0, DEPC treated) to produce 7%, 17%, 27%, 37%, and 47% (w/v) sucrose in 
SGB. The sucrose/SGB solutions were filtered using a Minisart filter with 0.2µm pores. 
2.1mL of each sucrose/SGB solution was layered carefully on top of one another in 
centrifuge tubes (lowest to highest sucrose % solutions from top to bottom respectively) 
to produce a 7-47% (w/v) sucrose gradient. Sucrose gradients were stored overnight at 
4°C. 
2.2.3.3. Cell Lysis for Immunoblotting 
Media was removed, and cells were then washed with ice cold PBS. 150µL ice cold IP 
lysis buffer (150mM NaCl, 50mM HEPES, 1mM EDTA, 1mM DTT, 0.5% (v/v) Triton™ X-
100, PIC, pH 8.0) was added per well of the 6-well plate. PhosSTOP™ was additionally 
added to the IP lysis buffer if specific phosphorylated protein isoforms were probed for 
in immunoblotting. Cells were scraped into IP lysis buffer using a cell scraper, and 
incubated for 15mins on ice. To clarify, the lysate was then centrifuged at 17,000 x g for 
5mins at 4°C. The lysate supernatant was reserved whilst the pellet of debris was 
discarded. 
2.2.3.4. Bradford Assay 
Bradford assays were used to quantify the protein concentration of cell lysates. Firstly, 
the protein assay dye reagent concentrate was diluted in dH2O in a 1:4 ratio to make a 
working concentration of Bradford reagent. 1µL cell lysate was then added to 1mL 
Bradford reagent, and mixed. The Bradford reagent and protein sample was then loaded 
into a polystyrene cuvette with 1cm path length, and the optical density shift at A595nm 
(OD595nm) of the sample relative to a blank control was measured using a WPA S1200 
Diode Array Spectrophotometer (Biochrom®). The concentration of the protein lysate 
was then calculated and converted to µg/mL using the Beer-Lambert law (OD595nm = εcl; 
where ε = 1/15, and l = 1cm). 
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2.2.3.5. Polysome Profiling and Ribosome Fractionation 
1 X 106 NSC34 cells were seeded onto 10cm plates, and were grown for 3 days. The 
media was then removed, and cells were split onto 2 new 10 cm plates in fresh media. 
The cells were incubated for a further 3 days. The media was then removed, and 
polysomes were stalled by washing cells with ice cold 0.1mg/mL cyclohexamide in PBS. 
Cells from the 2 X 10 cm plates were then lysed and scraped in 500µL Sucrose Gradient 
(SG) lysis buffer (0.5mM DTT, 1% (v/v) Triton X-100, PIC, 80units/µL RiboSafe RNase 
Inhibitor, 100µg/mL cyclohexamide, in SGB) for 10mins on ice. The lysate was 
centrifuged at 2,400 x g for 5mins at 4°C. The supernatant was transferred to a new 
Eppendorf tube, and centrifuged again at 9,600 x g for 5mins at 4°C. The supernatant 
was transferred to a fresh tube, and the protein concentration was assessed by Bradford 
assay. 3mg stalled polysome protein lysate was loaded onto the 7-47% (w/v) sucrose 
gradients and centrifuged at 35,000rpm for 3h at 4°C in an SW41 Beckman rotor. The 
sucrose gradients were separated from top to bottom into 500µL fractions using an in 
house collection system coupled with an ÄKTA pure FPLC machine (GE Healthcare Life 
Sciences). UV-absorbance of the sucrose gradient was also measured to profile the 
ribosomal subunits, ribosomes and polysomes. 
2.2.3.6. SDS-Polyacrylamide Gel Electrophoresis 
Cell lysates were mixed with 4X Laemmli buffer (228mM Tris-HCl, 38% (v/v) glycerol, 
277mM SDS, 0.038% (w/v) bromophenol blue, 5% (v/v) β-mercaptoethanol, pH 6.8) and 
boiled for 5mins at 95°C to denature the proteins. 12% or 15% SDS-Polyacrylamide gels 
were loaded into a Mini-PROTEAN® Tetra Vertical Electrophoresis Cell (Bio-Rad), and the 
apparatus was filled with running buffer (25mM Tris, 3.5mM SDS, 20mM glycine). For 
general immunoblotting methods, 25µg of denatured protein was loaded per well onto 
the SDS-polyacrylamide gels. For the polysome profiling method, 40μL of denatured 
sucrose fractions were loaded per well onto the SDS-polyacrylamide gels. 2μL prestained 
protein ladder was loaded as a molecular weight marker in one well per gel. Gel 
electrophoresis was performed at 50V for 30mins, then 150V for approximately 1.5h 
until the dye front had reached the bottom of the gel. Gels were then removed from the 
electrophoresis cell, and assembled with transfer buffer (47.9mM Tris, 38.6mM glycine, 
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1.38mM SDS, 20% (v/v) methanol)-saturated Whatman paper, and transfer buffer-
saturated membrane in a semi-dry transfer apparatus. Nitrocellulose membranes were 
used routinely for immunoblotting, however, methanol pre-soaked PVDF membranes 
were used specifically when membranes were going to be probed with anti-AP, anti-GA, 
anti-GR, anti-GP, and/or anti-PR antibodies. Electrophoretic transfer of the proteins 
from the gels to the membranes was performed at 0.15A / gel transferred for 1h. 
Membranes were then stained with Ponceau stain (0.1% (w/v) Ponceau S, 5% (v/v) 
acetic acid), and trimmed. 
2.2.3.7. Immunoblotting 
For general immunoblotting, membranes were blocked in 5% (w/v) milk/Tris Buffered 
Saline, with Tween® 20 (TBST) (20mM Tris, 137mM NaCl, 0.2% (v/v) Tween® 20, pH 7.6) 
for 1h at room temperature on a roller. However, membranes were blocked in 5% (w/v) 
BSA/TBST for 1h at room temperature on a roller, if specific phosphorylated protein 
isoforms were being probed for. The membranes were incubated with primary antibody 
(see Error! Reference source not found. for dilutions, blocking agent and source) in the d
esignated blocking agent for 1h at room temperature or over-night at 4°C on a roller. 
The membranes were then washed 3 times in TBST for 15mins at room temperature. 
The membranes were then incubated with secondary antibody conjugated to 
horseradish peroxidase (HRP) (see Table 2.6 for dilutions and source) in 5% milk/TBST 
for 1h at room temperature on a roller. The membranes were then washed 3 times in 
TBST for 15mins at room temperature. The membranes were then incubated with ECL 
for 1mins and imaged using a G:BOX (Syngene). 
2.2.3.8. RNA Fluorescence in situ Hybridisation (FISH) 
Coverslips with NSC34 and HEK293 cells were fixed and permeabilised in 4% (w/v) PFA / 
0.2% (v/v) Triton™ X-100 in PBS for 20mins at room temperature. For the RNAse treated 
control, slides were incubated with 10μg/mL RNAse A in PBS for 30mins at 37°C. 
Coverslips were blocked with hybridisation solution (50% (v/v) formamide, 2X saline 
sodium citrate (SSC), 100mg/ml dextran sulphate, 50mM sodium phosphate pH 7.0) for 
1h at 66°C. The LNA probes were incubated at 80°C for 75s, then snap cooled on ice for 
5mins to denature the DNA secondary structure. Coverslips were then incubated with 
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400ng/ml denatured probe in hybridisation solution overnight at 66°C. After 
hybridization, slides were washed once in 2X SSC / 0.1% Tween® 20 for 5mins at room 
temperature and three times in 0.1X SSC for 30mins at 65°C. NSC34 cells that were 
subsequently dual stained by immunocytochemistry (ICC), were first irradiated on ice 
with 0.3J/cm2 UV, washed 3 times with PBS, and then ICC staining was performed. 
Coverslips were mounted with mounting medium containing DAPI. All solutions were 
made with DEPC-treated water.  
2.2.3.9. Immunocytochemistry (ICC) 
Coverslips with NSC34 cells were fixed and permeabilised in 4% (w/v) PFA / 0.2% (v/v) 
Triton X-100 at room temperature for 20mins. Slides were incubated with primary 
antibody in 2% (w/v) BSA/PBS at room temperature for 1h (see Table 2.7 for antibody 
dilution and source). Coverslips were washed 3 times in PBS for 15mins at room 
temperature. Coverslips were then incubated with secondary antibody in 2% BSA/PBS 
at room temperature for 1h (see Table 2.8 for antibody dilution and source). Coverslips 
were mounted with mounting medium containing DAPI. 
2.2.3.10. Microscopy Imaging and Image Analysis 
RNA foci and RNA Binding Protein (RBP) co-stain – Both sense (G4C2)n and antisense 
(C4G2)n RNA foci were visualised using an SP5 confocal microscope system (Leica) with 
a X63/1.4 oil immersion objective lens. The presence of foci was assessed within a high 
resolution (1433mm2 per image, 511 X 511 pixels) z-stack made up of images at 0.13µm 
intervals through the entire nuclear volume of the cell under consideration. The same 
imaging was used for sense (G4C2)n RNA foci and ALYREF, NCL, PURA, SRSF1, and SRSF2 
co-staining. For sense (G4C2)n RNA foci counts, 20 cells were imaged per condition in 3 
independent experiments, and RNA foci were quantified manually. For the sense 
(G4C2)n RNA foci and RBP co-stain, 50 NSC34 (G4C2)102 cells were analysed for co-
localisation, and co-localisation was quantified manually. 
NCL – NCL staining in the NSC34 cells was visualised using an SP5 confocal microscope 
system (Leica) with a X63/1.4 oil immersion objective lens. The NCL staining was 
assessed within a high resolution (3775 mm2 per image, 511 X 511 pixels) z-stack made 
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up of images at 0.5µm intervals through the entire nuclear volume of the cell under 
consideration. To quantify the area of the nucleolus relative to the nuclear area, the 
analysis previously described by Haeusler et al. 2014 was employed. Briefly, a threshold 
of 50-100 was set in FIJI to measure the nucleolar NCL area, relative to the nuclear area 
(defined by DAPI staining). 25 cells were imaged per condition in 3 independent 
experiments. 
TDP-43 – TDP-43 staining in NSC34 cells were visualised using a LV100ND microscope 
(Nikon) fitted with a DS Ri1 Eclipse camera (Nikon). 
2.2.3.11. RNA Extraction for qRT-PCR 
Sucrose gradient fractions – 750μL TRIzol® LS Reagent was mixed with 250μL sucrose 
gradient fraction (section 2.2.3.5). 150μL chloroform was added, and samples were 
shaken vigorously for 15s. Samples were incubated for 5mins at room temperature. 
Samples were centrifuged at 12,000 x g for 10mins at room temperature. 500µL aqueous 
phase was transferred to a new Eppendorf, and 5μg glycogen, 50μL 3M sodium acetate 
pH 5.0, and 100µL isopropanol was added. The samples were incubated overnight at -
20°C. Samples were then centrifuged at 12,000 x g for 20mins at room temperature. The 
supernatant was removed and the RNA pellet was washed in 70% (v/v) ethanol. Samples 
were centrifuged at 12,000 x g for 5mins at room temperature, and the wash was 
removed. The RNA pellet was air dried for 5mins at 37°C. The RNA pellet was 
resuspended in 50μL DNase I solution (1X DNase I buffer, and 0.2units/µL DNase I 
recombinant, RNase-free in dH2O) and incubated for 30mins at 37°C, then for 5mins at 
70°C. RNA yield and quality were assessed using the NanoDrop™ 1000 (Thermo Fisher 
Scientific® Inc.).  
NSC34 cell pellets for qRT-PCR – NSC34 sham and (G4C2)102 cells were grown identically 
to those used for microarray transcriptomic analysis (section 2.2.4.1), but stored as cell 
pellets in RNA Later. RNA was extracted from these cell pellets, and used for the qRT-
PCR validation experiments. 100µL denaturing solution was added to the cell pellet, and 
the solution was pipetted up and down. Samples were incubated for 10mins at room 
temperature. 150µL extraction and phase separation solution was added, and samples 
were shaken vigorously for 15s. Samples were then incubated for 10mins at room 
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temperature and then centrifuged at 12,000 x g for 10mins at room temperature. 100µL 
aqueous phase was transferred to a new eppendorf, and 100µL isopropanol was added. 
The samples were incubated over-night at -20°C. Samples were then centrifuged at 
17,000 x g for 20mins at room temperature. The supernatant was removed and the RNA 
pellet was washed in 70% (v/v) ethanol. Samples were centrifuged at 17,000 x g for 
5mins at room temperature, and the wash was removed. The RNA pellet was air dried 
for 5mins at 37°C. The RNA pellet was resuspended in 25μL DNase I solution (1X DNase 
I buffer, and 0.2units/µL DNase I recombinant, RNase-free in dH2O) and incubated for 
30mins at 37°C, then for 5mins at 70°C. RNA yield and quality were assessed using the 
NanoDrop™ 1000 (Thermo Fisher Scientific® Inc.).  
2.2.3.12. cDNA Synthesis for qRT-PCR 
Total RNA isolated from NSC34 cells was reverse transcribed into single-stranded 
complementary DNA (ss-cDNA). cDNA synthesis was performed using the BioScript™ 
Reverse Transcriptase kit according to manufacturer’s instructions. 2µg total RNA was 
mixed with 1µL 40µM random hexamer primers, 1µL 10mM dNTP mix, and a total 
reaction volume (14µL) made up in DEPC-treated dH2O. The samples were incubated for 
5mins at 70°C for mins, then incubated for at least 1mins on ice. 1X RT buffer, 2units/µL 
RiboSafe RNase Inhibitor, 10units/µL BioScript Reverse Transcriptase, to a total volume 
reaction volume (20µL) made up in DEPC-treated dH2O. A no-RT control was also 
prepared as described, without the addition of BioScript Reverse Transcriptase to check 
for the presence of potentially contaminating genomic DNA. Samples were mixed by 
gentle pipetting, and then incubated for 10mins at 25°C, then 60mins at 42°C, then 
5mins at 85°C. In each reaction there is an approximate 1:1 conversion of RNA to cDNA. 
cDNA samples were diluted to approximately 25ng/µL cDNA in DEPC-treated dH2O. 
Samples were stored at -20°C prior to qRT-PCR. 
2.2.3.13. Quantitative Real Time PCR (qRT-PCR) 
qRT-PCR was performed in triplicate 10µL reaction volumes with a no-RT control and a 
no template control (NTC), on 96-well qRT-PCR plates. Each well contained 25ng of 
cDNA, forward and reverse primers (Table 2.3) at optimised concentrations, 2X Brilliant 
III SYBR Green qPCR Master Mix and dH2O. Plates were briefly centrifuged to collect 
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samples at the bottom of the wells. Samples were run on a 3 step profile on a Stratagene 
Mx3000P™ Real Time Thermal Cycler (Agilent Technologies Ltd.). Samples were 
incubated for 10mins at 95°C, then 40 cycles of 30s at 95°C, 60s at 60°C, and 60s at 72°C. 
A final cycle was used to determine the primer dissociation curve. 
2.2.3.14. PrimeTime® qPCR Assays 
PrimeTime® qPCT assays were performed in triplicate 10μL reaction volumes with a no-
RT control and a NTC, on 96-well qRT-PCR plates. Each well contained 25ng of cDNA, 
500nM forward and reverse primer, and 250nM probe (Table 2.4) resuspended in TE 
buffer (10mM Tris-HCl, 1mM EDTA, pH 7.5), 2X Brilliant III qPCR Master Mix and dH2O. 
Plates were briefly centrifuged to collect samples at the bottom of the wells. Samples 
were run on a 3 step profile on a Stratagene Mx3000P™ Real Time Thermal Cycler 
(Agilent Technologies Ltd.). Samples were incubated for 10mins at 95°C, then 40 cycles 
of 30s at 95°C, 60s at 60°C, and 60s at 72°C. A final cycle used to determine the primer 
dissociation curve was also run. 
2.2.4. Gene Expression Profiling Methods 
2.2.4.1. RNA Extraction for Gene Expression Profiling Analysis 
0.5 x 106 NSC34 cells were seeded per well on a 6 well plate and were grown for 5 days 
until 80% confluent. Tetracycline was added to cells for either the final 5 days, final 3 
days, final day or not at all. Media (and tetracycline if applicable) was replenished after 
3 days. After 5 days growth, RNA was extracted from the cells using the Direct-zol™ RNA 
Kit. Briefly, media was removed and 1mL TRI-Reagent® was added to the cells. The 
solution was pipetted up and down to mix well. The samples were incubated for 10mins 
at room temperature. The samples were then centrifuged at 16,000 x g for 1mins at 
room temperature. The supernatant was romoved and reserved in a new eppendorf, 
whilst the particulate matter was discarded. 1mL ethanol was added to each of the 
samples, and then they were briefly vortexed. 700µL of each of the samples were loaded 
into Zymo-Spin™ II Columns, in collection tubes, and samples were centrifuged at 16,000 
x g for 1mins at room temperature. The flow-throughs were discarded, and the 
remaining samples were loaded and centrifuged on the respective columns as previously 
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described until all of the sample solutions had been centrifuged through the columns. 1 
mL Wash Buffer was then loaded onto each of the columns, and they were centrifuged 
at 16,000 x g for 1mins at room temperature. 80µL DNAse I Reaction Mix (5µL of 
1units/µL DNAse I, 8µL of 10X DNAse I Reaction Buffer, 3µL DNAse/RNAse-free water, 
64µL RNA Wash Buffer with ethanol added) was added directly to each of the columns, 
and incubated for 15mins at room temperature. The columns were centrifuged at 
12,000 x g for 1mins at room temperature. 400µL Direct-zol RNA PreWash was added to 
each of the columns, and the columns were then centrifuged at 16,000 x g for 1mins at 
room temperature. The flow-throughs were discarded and then the Direct-zol RNA 
PreWash step was repeated. 700µL RNA Wash Buffer was added to each of the columns, 
and the columns were then centrifuged at 16,000 x g for 1mins at room temperature. 
The flow-throughs were discarded and then the columns were centrifuged again at 
16,000 x g for 2mins at room temperature to completely remove the Wash Buffer. 30µL 
DNase/RNase-free water was added to the matrix and incubated for 5mins at room 
temperature to elute the RNA. The columns were centrifuged at 16,000 x g for 1mins at 
room temperature to collect the eluted RNA samples. The RNA samples were snap 
frozen using liquid nitrogen, and stored at -80°C. 
2.2.4.2. RNA Yield and Quality Assessment 
RNA concentration and purity were assessed using the NanoDrop™ 1000 
Spectrophotometer (Thermo Fisher Scientific® Inc.). The ratios of absorbance at 260nm 
and 280nm, as well as 260nm and 230nm are used to assess RNA yield and purity. All 
RNA samples had A260 nm/280 nm values of 2.0 ± 0.2, and A260 nm/230 nm values of 2.2 ± 0.2, 
indicating high purity. In addition, the RNA integrity was measured using a Nanochip and 
an Agilent 2100 Bioanalyser (Agilent Technologies Ltd.). Briefly, an electropherogram 
was produced to assess the RNA for the 18S and 28S rRNA peaks, the amount of RNA 
degradation, and provide a RNA Integrity Number (RIN) based on these variables. 
2.2.4.3. WT PLUS Amplification and Labelling Process  
The GeneChip® WT PLUS Reagent Kit was used to generate amplified and biotinylated 
sense-strand DNA targets from total RNA. The RNA was amplified and labelled in 3 
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separate batches; A, B and C (which are used in the array names). All manipulations took 
place on ice, unless stated otherwise. 
2.2.4.3.1. Poly-A RNA Control Preparation 
Poly-A RNA controls were prepared to include with each RNA sample, and provided 
exogenous positive controls to monitor the entire target preparation. Poly-A Control 
Stock was diluted 1 in 20, then 1 in 50, then 1 in 50, then 1 in 2 in Poly-A Control Dil 
Buffer to a final dilution of 1 in 100,000. 2 µL of the final Poly-A Control mRNA dilution 
was then added to 500ng RNA sample in dH2O to a final volume of 5µL. 
2.2.4.3.2. First-Strand cDNA Synthesis 
Total RNA was reverse transcribed using primers that contained a T7 promoter 
sequence, producing single-stranded complementary DNA (ss-cDNA) with a T7 
promoter sequence at the 5’ end. Firstly, the First-Strand Master Mix was prepared by 
mixing 42µL First-Strand Buffer and 10.5µL First-Strand Enzyme. 5µL First-Strand Master 
Mix was mixed with each of the 5µL total RNA samples. The samples were incubated for 
1h at 25°C, then for 1h at 42°C, then for 5mins at 4°C. The samples were centrifuged 
briefly to collect first-strand cDNA/RNA at bottom of the tube. 
2.2.4.3.3. Second-Strand cDNA Synthesis 
The ss-cDNA was then converted to double-stranded cDNA (ds-cDNA), which acted as a 
template for in vitro transcription. RNase H and DNA polymerase simultaneously 
degraded the RNA and synthesised second-strand cDNA. The Second-Strand Master Mix 
was prepared by mixing 189µL Second-Strand Buffer and 21µL Second-Strand Enzyme. 
20µL Second-Strand Master Mix was mixed with each of the (10µL) First-Strand 
cDNA/RNA samples for a total volume of 30µL. The samples were incubated for 1h at 
16°C, then for 10mins at 65°C, then for 5mins at 4°C. The samples were centrifuged 
briefly to collect ds-cDNA at bottom of the tube. 
2.2.4.3.4. Complementary RNA Synthesis by in vitro Transcription 
Complementary RNA (cRNA) was synthesised and amplified by in vitro transcription (IVT) 
of the ds-cDNA template using the T7 RNA Polymerase. The IVT Master Mix was 
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prepared at room temperature by mixing 252µL IVT Buffer and 63µL IVT Enzyme. 30µL 
IVT Master Mix was mixed with each of the (30µL) ds-cDNA samples at room 
temperature for a total volume of 60µL. The samples were incubated for 16h at 40°C, 
then at 4°C. The samples were centrifuged briefly to collect the cRNA at bottom of the 
tube, and stored at -20°C. 
2.2.4.3.5. cRNA Purification 
The cRNA samples were purified to remove enzymes, salts, inorganic phosphates, and 
unincorporated nucleotides to prepare the cRNA for Second-cycle ss-cDNA synthesis. 
The magnetic purification beads were briefly vortexed to resuspend, and then 100µL 
beads were added to each (60µL) cRNA sample, mixed by pipetting, and placed on a U-
bottom plate at room temperature. The samples were incubated for 10mins at room 
temperature to allow the cRNA to bind to the purification beads. The plate with samples 
was then placed onto a magnetic stand to capture the beads for 5mins at room 
temperature. The supernatant was removed, and the beads were washed 3 times with 
80% (v/v) ethanol for 1.5mins at room temperature. The supernatant was removed and 
the beads were air dried for 5mins at room temperature. The plate was then removed 
from the magnetic stand. Nuclease-free water was heated to 65°C, and then 27µL was 
added to each well to elute the cRNA. The beads and water were mixed and then 
incubated for 1mins at room temperature. The plate with samples was placed onto the 
magnetic stand to capture the beads, and incubated for 5 min at room temperature. The 
eluted cRNA was transferred to new nuclease-free tubes, and placed on ice. The cRNA 
yield and size distribution were assessed and then cRNA was stored at -20°C. 
2.2.4.3.6. cRNA Yield and Size Distribution Assessment 
cRNA concentration was assessed using the NanoDrop™ 1000 Spectrophotometer 
(Thermo Fisher Scientific® Inc.). The cRNA size distribution was assessed using a 
Nanochip and an Agilent 2100 Bioanalyser (Agilent Technologies Ltd.). 
2.2.4.3.7. Second-Cycle Single-Stranded cDNA Synthesis 
cRNA was reverse transcribed using 2nd-Cycle Primers producing sense-strand cDNA, 
which contained dUTP at a fixed ratio relative to dTTP. 15µg cRNA was diluted in 
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nuclease-free water to a final volume of 24µL. 4µL of 2nd-Cycle Primers were added. 
The samples were incubated for 5mins at 70°C, then for 5mins at 25°C, then for 2mins 
at 4°C. The 2nd-Cycle ss-cDNA Master Mix was prepared by mixing 84µL 2nd-Cycle ss-
cDNA Buffer and 42µL 2nd-Cycle ss-cDNA Enzyme. 12µL 2nd-Cycle ss-cDNA Master Mix 
was mixed with each of the (28µL) cRNA/2nd-Cycle Primers samples for a total volume 
of 40µL. The samples were incubated for 10mins at 25°C to allow the primers to anneal, 
then for 90mins at 42°C for cDNA synthesis, then 10mins at 70°C to inactivate the 
enzyme, and then samples were stored at 4°C. 
2.2.4.3.8. RNA Hydrolysis Using RNase H 
The cRNA template was hydrolysed by RNAse H, leaving ss-cDNA. 4µL RNase H was 
added to each of the (40µL) 2nd-Cycle ss-cDNA samples for a total volume of 44µL. The 
samples were incubated for 45mins at 37°C, followed by 5mins at 95°C, and then 2mins 
at 4°C. 11µL nuclease-free water was added to each (44µL) hydrolysed 2nd-Cycle ss-cDNA 
samples for a total volume of 55µL. Samples were stored at -20°C. 
2.2.4.3.9. Second-Cycle ss-cDNA Purification 
The 2nd-cycle ss-cDNA was purified to remove enzymes, salts, and unincorporated dNTPs 
to prepare the ss-cDNA for fragmentation and labelling. The magnetic purification beads 
were briefly vortexed to resuspend, and then 100µL beads were added to each (55µL) 
ss-cDNA sample, mixed by pipetting, and placed on a U-bottom plate at room 
temperature. 150µL 100% ethanol was added to each (155µL) ss-cDNA/beads sample. 
Samples were mixed well by pipetting up and down. Samples were then incubated for 
20mins at room temperature, during this time the ss-cDNA bound to the magnetic 
purification beads. The plate with samples was then placed onto the magnetic stand to 
capture the beads and bound ss-cDNA, and incubated for 5mins at room temperature. 
The supernatant was removed, and the beads were washed 3 times with 80% (v/v) 
ethanol for 1.5mins at room temperature. The supernatant was removed and the beads 
were air dried for 5mins at room temperature. The plate was then removed from the 
magnetic stand. Nuclease-free water was heated to 65°C, and then 30µL was added to 
each well to elute the ss-cDNA. The beads and water were mixed and then incubated 
for 1mins at room temperature. The plate with samples was placed onto the magnetic 
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stand to capture the beads, and incubated for 5mins at room temperature. The purified 
ss-cDNA was transferred to new nuclease-free tube, and placed on ice. The ss-cDNA 
yield and size distribution was assessed and then the ss-cDNA was stored at -20°C. 
2.2.4.3.10. ss-cDNA Yield and Size Distribution Assessment 
ss-cDNA concentration was assessed using the NanoDrop™ 1000 Spectrophotometer 
(Thermo Fisher Scientific® Inc.). The ss-cDNA size distribution was assessed using a 
Nanochip and an Agilent 2100 Bioanalyser (Agilent Technologies Ltd.). 
2.2.4.3.11. ss-cDNA Framentation and Labelling 
The ss-cDNA was fragmented by uracil-DNA glycosylase (UDG) and apurinic/apyrimidinic 
endonuclease 1 (APE 1) at the unnatural dUTP residues, breaking the DNA strand. The 
fragmented cDNA was then labelled by terminal deoxynucleotidyl transferase (TdT) 
using the Affymetrix propriety DNA Labelling Reagent that is covalently linked to biotin. 
5.5µg ss-cDNA was prepared in 31.2µL nuclease-free water. The Fragmentation Master 
Mix was prepared by mixing 105µL nuclease-free water, 50.4µL 10X cDNA 
Fragmentation Buffer, 10.5µL 10units/µL UDG, and 10.5µL 1,000 units/µL APE 1. 16.8µL 
Fragmentation Master Mix was mixed with each of the (31.2µL) ss-cDNA samples for a 
total volume of 48µL. The samples were incubated for 1h at 37°C, then for 2mins at 93°C, 
and then at 4°C. The Labelling Master Mix was prepared by mixing 126µL 5X TdT Buffer, 
10.5µL 5mM DNA Labelling Reagent, and 21µL 30units/µL TdT. 15µL Labelling Master 
Mix was mixed with each of the (45µL) fragmented ss-cDNA samples for a total volume 
of 60µL. The samples were incubated for 1h at 37°C, then for 10mins at 70°C, and then 
for 5mins at 4°C. 2µL of each of the fragmented and labelled ss-cDNA samples were 
removed for Gel-shift analysis, and the remaining samples were stored at -20°C. 
2.2.4.3.12. Gel-Shift Assay 
The efficiency of the biotin-labelling procedure was assessed by adding NeutrAvidin (or 
PBS as a negative control) to the ss-cDNA, and then performing gel electrophoresis. 
NeutrAvidin binds to biotin and therefore retards the biotin-labelled ss-cDNA movement 
during gel electrophoresis, causing a shift in molecular weight between the NeutrAvidin 
+ve and –ve treated ss-cDNA. 10mg/mL NeutrAvidin was diluted to 2mg/mL in PBS. 1µL 
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of the fragmented and labelled ss-cDNA samples were aliquoted to nuclease-free tubes, 
and then incubated for 2mins at 70°C. For the +ve gel-shift samples, 5µL 2mg/mL 
NeutrAvidin was added to the fragmented and labelled ss-cDNA samples, whilst for the 
-ve gel-shift samples, 5µL PBS was added to the fragmented and labelled ss-cDNA 
samples. The samples were then mixed and incubated for 5mins at room temperature. 
2.5µL 5X Novex® Hi-Density TBE Sample Buffer was mixed with each sample. Samples 
were loaded onto a 4-20% TBE Gel, 1.0 mm. Gel electrophoresis was performed at 100 
V for 2h. The gel was stained in 0.001% (w/v) ethidium bromide in 1X TAE buffer for 30 
mins at room temperature on a shaker. The gels were imaged using the GENi UV light 
imaging system (Syngene). 
2.2.4.4. WT Array Hybridisation 
The fragmented and labelled ss-cDNA was hybridised onto GeneChip® Mouse 
Transcriptome Array 1.0 using the GeneChip® Hybridisation, Wash and Stain Kit. Three 
separate batches of arrays were hybridised, washed, and stained on separate days and 
the arrays contained in each batch are listed in Appendix 4. All manipulations took place 
at room temperature, unless stated otherwise. The 20X Eukaryotic Hybridisation 
Controls (bioB, bioC, bioD, cre) were incubated for 5mins at 65°C. The Hybridisation 
Master Mix was prepared by mixing 40.7µL 3nM Control Oligo B2, 121µL 20X Eukaryotic 
Hybridisation Controls (bioB, bioC, bioD, cre), 1210µL 2X Hybridisation Mix, 169.4µL 
DMSO, and 240.9µL Nuclease-free water. Hybridisation cocktails were prepared by 
mixing 162µL Hybridisation Master Mix with 58µL (5.2µg) of each of the fragmented and 
labelled ss-cDNA samples, for total volumes of 220µL. The hybridisation cocktail was 
then incubated for 5mins at 95°C, then for 5 min at 45°C. 200µL of the hybridisation 
cocktail was loaded onto GeneChip® Mouse Transcriptome Array 1.0 cartridges. The 
arrays were then incubated in a GeneChip® Hybridisation Oven 640 (Affymetrix® Ltd) 
with 60rpm rotation for 16h at 45°C. 
2.2.4.5. Array Washing, Staining and Scanning 
Array washing and staining was performed on the GeneChip® Fluidics Station 450 
(Affymetrix® Ltd) according using the Whole Transcript (WT) Sense Target Labelling 
Manual for fluidics protocol FS450_0001 (Affymetrix® Ltd). After washing and staining, 
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the arrays were scanned on the GeneChip® Scanner 3000 (Affymetrix® Ltd) according to 
the Affymetrix® GeneChip® Command Console® User Manual, to generate CEL files 
containing the image of raw probe signal intensities. 
2.2.4.6. Bioinformatics Analysis 
2.2.4.6.1. Affymetrix® Expression Console Software 
CEL files containing the raw probe signal intensities were exported from the GeneChip® 
Command Console. Gene-level RMA-sketch normalisation and signal summarisation 
were performed in the Affymetrix® Expression Console (EC) software, converting the CEL 
files to RMA-GENE-FULL CHP files. In addition, Exon-level Alt Splice analysis 
normalisation and signal summarisation were performed in EC, converting the CEL files 
to RMA-ALT-SPLICE CHP files. Quality Control was performed in EC. Hybridisation 
controls, poly-A labelling controls, AUC, and signal distribution assessed in EC and were 
used for Quality Control assessment of the arrays.  
2.2.4.6.2. Qlucore Omics Explorer 
Gene-level expression analysis was performed in Qlucore Omics Explorer (version 3.0). 
All Affymetrix® RMA-GENE-FULL CHP files were opened in Qlucore Omics explorer, and 
normalised using the RMA-sketch method. Differentially expressed (DE) transcripts 
were defined when P value < 0.01 (using Student’s T-test) and fold change (FC) ≥ 1.2. 
PCA plots and Heat Maps were generated in Qluocore Omics explorer. Lists of DE 
transcripts were exported to Microsoft Excel 2010.  
2.2.4.6.3. Gene Ontology Enrichment Analysis 
Gene Ontology enrichment analysis was performed using the Database for Annotation 
and Visualisation and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/). The 
Entrez Gene IDs of the DE transcripts were imported to DAVID, and functional 
annotation clustering was subsequently performed using the GOTERM_BP_FAT gene 
ontology and KEGG_PATHWAY pathway terms, applying a Mus musculus background, 
and filtering using medium stringency.  Functional clusters with DAVID enrichment 
scores > 1.30 (equivalent to a P value < 0.05) were considered statistically significant. 
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2.2.4.6.4. Pathway Enrichment Analysis 
Integrated pathway-level enrichment analysis was performed by importing the gene 
symbols of DE transcripts to the Integrated Molecular Pathway Level Analysis (IMPaLA) 
over-representation (enrichment) tool (http://impala.molgen.mpg.de/). 
2.2.4.6.5. Affymetrix® Transcriptomics Analysis Console Software 
Differential splicing analysis was performed in the Affymetrix® Transcriptomics Analysis 
Console (TAC) Software. All Affymetrix® RMA-ALT-SPLICE CHP files were opened in TAC. 
Genes were defined as differentially spliced when at least one differential splicing event 
had a False Discovery Rate (FDR) corrected P value < 0.05 (using One-Way ANOVA) and 
Splicing Index (SI) ≤ -2.0 or ≥ 2.0. 
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Chapter 3. Generation of a Motor Neuron-Like Cell 
Model of C9ORF72-Amyotrophic Lateral Sclerosis 
with Tetracycline-Inducible (G4C2)n Repeat 
Expression 
3.1. Introduction 
The initial aim of the project was to generate and characterise stable, isogenic cell 
models with tetracycline-inducible expression of the (G4C2)n repeat constructs. 
Plasmids containing different lengths of interrupted (G4C2)n repeat constructs and an 
FRT site were engineered. The commercially available Flp-In™ T-REx™ HEK293 cells, and 
Flp-In™ T-REx™ NSC34 cells that were generated in house by Dr. Adrian Higginbottom, 
were used. These cell lines utilise the Flp-In™ system (Figure 3.1) which allowed genomic 
site specific insertion of the (G4C2)n repeats into both HEK293 cells and motor neuron-
like NSC34 cells. These cell lines also utilise the T-REx™ system (Figure 3.1), which allow 
for tetracycline-inducible expression of the (G4C2)n repeats. RNA Fluorescence in situ 
Hybridisation (FISH) and immunoblotting were used to confirm tetracycline-inducible 
expression of the (G4C2)n repeats at RNA and protein levels respectively. Finally, MTT 
cell viability assays, EthD1 cell death assays, and growth curves were used to assess the 
(G4C2)n expression for toxicity in the NSC34 cells. 
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Figure 3.1 Flp-In™ and T-REx™ systems used to generate isogenic cell lines with 
tetracycline-inducible expression of the gene of interest. The pcDNA5/FRT/TO 
expression vector containing the gene of interest (GOI) is co-transfected with a FLP 
recombinase into the Flp-In™ T-REx™ mammalian cell line. FLP recombinase catalyses 
homologous recombination between the genomic FRT site and the FRT site within the 
pcDNA5/FRT/TO expression vector. Successful integration of the pcDN5/FRT/TO 
plasmid confers hygromycin resistance and Zeocin™ sensitivity to the cell line. The gene 
of interest is repressed by the Tet repressor element (TetR). Addition of tetracycline to 
the cells induces expression of the GOI by de-repressing the CMV/TetO2 promoter. 
Figure is adapted from Invitrogen™. 
Interrupted (G4C2)n repeat constructs were generated to model the pathogenic 
(G4C2)n repeat expansion, because the GC pure repeat is technically very challenging to 
manipulate. PCR can only process through a small number of repeats before failing. Also, 
the (G4C2)n repeats form secondary structure in the DNA, making it challenging to clone 
via restriction digestion and ligation. In addition, the minimum number of (G4C2)n 
repeats required to cause ALS and/or FTD is unknown, the longest number of (G4C2)n 
repeats were generated as possible. The only technically feasible method of generating 
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larger (G4C2)n repeat constructs, was via restriction digest and ligation of smaller 
(G4C2)n repeats. Synthesised TCGAC(G4C2)10 sense and ACGT(G2C4)10 antisense 
ssDNA oligonucleotides were designed such that the dsDNA produced by annealing the 
oligonucleotides was flanked 5’ by SalI and 3’ by XhoI cut restriction sites. It is important 
to note that the SalI and XhoI restriction enzymes produce compatible cohesive ends. 
These (G4C2)10 were ligated into XhoI cut plasmid. Subsequent ligations involved 
digesting these vectors with XhoI and inserting further (G4C2)10 repeats. The 5’ SalI site 
of the inserted (G4C2)10 was destroyed whilst the 3’ XhoI site was retained – if the 
insertion orientation was correct. Vectors containing (G4C2)10, interrupted (G4C2)51 
and interrupted (G4C2)102 constructs were generated via this method (Figure 3.2). 
 
Figure 3.2 Sequences of the (G4C2)10, (G4C2)51 and (G4C2)102 constructs. 
The Flp-In™ and T-REx™ systems were used in both HEK293 and NSC34 cells to generate 
stable and isogenic cell models with tetracycline-inducible expression of the interrupted 
(G4C2)n repeats (Figure 3.1). A Flp recombination target (FRT) site, and a Tn10-encoded 
tetracycline resistance repressor element (TetR) were inserted into the mammalian cell 
line’s genome at specific locations independently of one another. The FRT site is a target 
for Flp recombinase-targeted integration. The TetR expresses a tet repressor (TetR) 
protein that binds the Tet Operator (TO) and inhibits expression from the CMV/TO 
hybrid promoter. Tetracycline binds the TetR protein and derepresses gene expression 
from the CMV/TO promoter.  
Plasmids containing an FRT site, in addition to the (G4C2)n repeat constructs under 
control of the CMV/TO promoter were also generated. These (G4C2)n plasmids were 
then integrated via Flp recombinase-mediated recombination into the genomic FRT site 
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in the mammalian cell lines. In addition, sham control cell lines were generated by 
integrating empty plasmids. Each of the resultant HEK293 cell lines were isogenic with 
one another, and each of the resultant NSC34 cell lines were isogenic with one another, 
and all cell lines had tetracycline-inducible expression of the (G4C2)n repeats.  
3.2. Aims and Objectives for Cell Model Generation and Characterisation 
1) Clone the (G4C2)10, (G4C2)51, and (G4C2)102 constructs into the 
pcDNA5/FRT/TO vector. 
2) Integrate the pcDNA5/FRT/TO-(G4C2)n plasmids into commercially available Flp-
In™ T-REx™ HEK293 cell line to validate (G4C2)n expression. 
3) Integrate the pcDNA5/FRT/TO-(G4C2)n plasmids into Flp-In™ T-REx™ NSC34 cell 
line. 
4) Characterise the NSC34 (G4C2)n cells for tetracycline-inducible expression of 
(G4C2)n RNA. 
5) Characterise the NSC34 (G4C2)n cells for antisense (C4G2)n RNA expression. 
6) Characterise the NSC34 (G4C2)n cells for RAN translation products. 
7) Investigate whether (G4C2)n expression causes NSC34 cell death or affects 
NSC34 cell viability. 
3.3. Results  
3.3.1. pcDNA5/FRT/TO-(G4C2)n Construction 
To stably integrate the (G4C2)n constructs into the genome of the host Flp-In™ T-REx™ 
cell line, vectors containing the (G4C2)n constructs (under control of a CMV/TO hybrid 
promoter), an FRT site, and a gene for hygromycin resistance were first generated. The 
pcDNA6.2-(G4C2)n plasmids were cut using DraI and XhoI restriction enzymes, and then 
the (G4C2)n constructs were purified via agarose gel electrophoresis and subsequent gel 
extraction. pcDNA5/FRT/TO-HIS was cut using EcoRV and XhoI restriction enzymes, and 
the linearised vector backbone was purified via agarose gel electrophoresis and gel 
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extraction. The linearised pcDNA5/FRT/TO-HIS vector backbone was then treated with 
Shrimp Alkaline Phosphatase (SAP) to reduce the chance of the vector religating. The 
DNA fragments containing the (G4C2)n constructs were then ligated into the 
pcDNA5/FRT/TO-HIS vector backbone in a forced orientation, due to the XhoI-cut and 
blunt ends of the DNA fragments. During initial cloning attempts, the ligation reactions 
containing the (G4C2)n repeats actually produced fewer E.coli colonies after 
transformation than the re-ligation control reactions. It was proposed that one end of 
the (G4C2)n repeat fragment was binding the cut pcDNA5/FRT/TO-HIS vector, but the 
other end was buried or unavailable to bind due to secondary structure formed by the 
(G4C2)n repeat, thus  inhibiting the ligation reaction. Importantly, it was discovered that 
heating the fragments containing the (G4C2)n constructs to 70 °C for 10 mins, followed 
by snap cooling on ice, dramatically improved the ligation efficiency. This heating and 
snap cooling step is suggested to denature and thus remove secondary structure 
inherent in the (G4C2)n repeat, allowing efficient ligation. The ligation mixtures were 
then transformed into β-10 competent E.coli, and subsequent colonies were screened 
for successful (G4C2)n construct insertion using PCR (Figure 3.3). The re-ligation control 
produced a PCR product of approximately 300 bp (Figure 3.3). Unexpectedly however, 
successful insertion of the (G4C2)10, (G4C2)51, or (G4C2)102 repeats into 
pcDNA5/FRT/TO-HIS all produced PCR products of a similar size around 400 bp (Figure 
3.3). This increase in PCR product size is not as large as expected because the PCR fails 
to completely process the full (G4C2)n repeat, and demonstrates why the (G4C2)n 
repeat could not be cloned via PCR.  
Colonies that tested positive for the (G4C2)n construct insertion into the 
pcDNA5/FRT/TO-HIS backbone vector were cultured and miniprepped. To size the 
(G4C2)n constructs, the pcDNA5/FRT/TO-HIS-(G4C2)n plasmids were digested using 
BamHI and XhoI restriction enzymes and run on an agarose gel (Figure 3.4). The correct 
size fragments for successful insertion of the (G4C2)10, (G4C2)51, and (G4C2)102 
constructs were 110 bp, 400 bp, and 750 bp respectively. pcDNA5/FRT/TO-HIS-(G4C2)n 
plasmids containing the correct size (G4C2)n insert (Figure 3.4) were sequenced using 
the CMV-Forward primer. This confirmed the (G4C2)n repeat lengths were correct in the 
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pcDNA5/FRT/TO-HIS-(G4C2)10, pcDNA5/FRT/TO-HIS-(G4C2)51, and pcDNA5/FRT/TO-
HIS-(G4C2)102 plasmids. 
 
Figure 3.3 Colony PCR screen for (G4C2)n ligation into pcDNA5/FRT/TO-HIS backbone 
vector. DNA fragments containing the (G4C2)10, (G4C2)51, and (G4C2)102 constructs 
were each ligated into pcDNA5/FRT/TO-HIS, and subsequently transformed into β10 
E.coli. Colonies were then picked and screened using PCR and gel electrophoresis. 
Colonies that produced a band shift (boxed in yellow) contain the (G4C2)n construct. A 
religated pcDNA5/FRT/TO-HIS was used as a negative control. Molecular weight markers 
are indicated (bp). 
 
Figure 3.4 Restriction digest of pcDNA5/FRT/TO-HIS-(G4C2)n plasmids to size the 
(G4C2)n constructs. The (G4C2)n constructs were cut from the pcDNA5/FRT/TO-HIS-
(G4C2)n plasmids using BamHI and XhoI restriction enzymes. Agarose gel 
electrophoresis was performed to size the (G4C2)n constructs. The correct size for bands 
containing (G4C2)10, (G4C2)51, and (G4C2)102 are shown with *, **, and *** 
respectively. Molecular weight markers are indicated (bp). 
The pcDNA5/FRT/TO-HIS-(G4C2)n vectors contain a HIS tag 5’ of, and adjacent to, the 
(G4C2)n construct. The HIS tag contains an ATG start codon and could therefore lead to 
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conventional translation of the (G4C2)n repeat. To prevent conventional translation of 
the (G4C2)n constructs in the mammalian cell models, the HIS tag and the associated 
ATG start codon were removed. The pcDNA5/FRT/TO-HIS-(G4C2)n vectors were cut 
using HindIII and BamHI restriction enzymes, blunt ended using DNA polymerase I 
(Klenow), treated with PNK, religated and then transformed into β-10 competent E.coli. 
Colonies containing potential pcDNA5/FRT/TO-(G4C2)n plasmids were cultured and 
miniprepped, then the plasmids were screened using NcoI restriction digestion and 
agarose gel electrophoresis (Figure 3.5). An NcoI site resides in the HIS tag, therefore 
plasmids containing the HIS tag produced 3 bands from the NcoI digest, whilst plasmids 
with the HIS tag removed produced 2 bands. A pcDNA5/FRT/TO-HIS plasmid was 
digested using NcoI, and served as a negative control for HIS tag removal (Figure 3.5). 
pcDNA5/FRT/TO-(G4C2)n plasmids that had the HIS tag removed were sequenced using 
the CMV-Forward primer to confirm the removal of the HIS tag and ATG start codon, as 
well as to sequence and confirm the exact length of the (G4C2)n construct. 
pcDNA5/FRT/TO-(G4C2)10, pcDNA5/FRT/TO-(G4C2)51, and pcDNA5/FRT/TO-
(G4C2)102 were all successfully generated, and the sequencing chromatograms for the 
(G4C2)n constructs are included in Appendices 1-3. 
 
Figure 3.5 Restriction digest of pcDNA5/FRT/TO-(G4C2)n plasmids to screen for HIS tag 
removal. pcDNA5/FRT/TO-(G4C2)n plasmids were cut using NcoI, and agarose gel 
electrophoresis was performed to check for the removal of the HIS tag and the 
associated ATG start codon. Two bands indicate removal of HIS tag (boxed in yellow), 
whilst three bands indicate the HIS tag is still present. pcDNA5/FRT/TO-HIS was used as 
a negative control. Molecular weight markers are indicated (bp). 
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3.3.2. Flp-In™ T-REx™ HEK293 (G4C2)n Cell Generation and Characterisation 
The pcDNA5/FRT/TO-(G4C2)n plasmids were first stably transformed into the 
commercially available Flp-In™ T-REx™ HEK293 cells, to test these plasmids in the Flp-
In™ and T-REx™ systems. pPGKFLPobpA (which expresses a codon optimised FLP DNA-
recombinase) was co-transfected with each of the pcDNA5/FRT/TO, pcDNA5/FRT/TO-
(G4C2)10, pcDNA5/FRT/TO-(G4C2)51, and pcDNA5/FRT/TO-(G4C2)102 plasmids 
separately. The FLP DNA recombinase catalysed recombination between the FRT site on 
the pcDNA5/FRT/TO-(G4C2)n plasmids and the genomic FRT site in the Flp-In™ T-REx™ 
HEK293 cells, stably inserting the empty sham vector or tetracycline-inducible (G4C2)n 
repeat constructs. The media was removed and replenished 24 h post transfection. 
Blasticidin and hygromycin selection was added to the media to select for cells which 
had pcDNA5/FRT/TO-(G4C2)n stably integrated into the genomic FRT site. A lot of the 
transfected Flp-In™ T-REx™ HEK293 cells were dead after 5 days of 
blasticidin/hygromycin selection. Therefore, the media was removed and replaced with 
conditioned media (containing blasticidin/hygromycin selection) to help support the 
successfully transformed Flp-In™ T-REx™ HEK293 cells. Colonies of hygromycin-resistant 
Flp-In™ T-REx™ HEK293 (G4C2)n cells were visible after 15 days of selection. These 
transformed colonies were then picked and expanded in media containing 
blasticidin/hygromycin selection on 48 well plates. When cells were at a sufficient 
confluency, they were screened for Zeocin™-sensitivity and blasticidin/hygromycin 
resistance. Zeocin™-resistance would suggest the pcDNA5/FRT/TO-(G4C2)n plasmid had  
integrated randomly into the genome, and not at the genomic FRT site in that particular 
clonal line. Each clone of the Flp-In™ T-REx™ HEK293 (G4C2)n cells were split into two 
separate wells, and each population was grown in either blasticidin/Zeocin™ or 
blasticidin/hygromycin selection. Clones that were sensitive to Zeocin™, but grew well 
in the blasticidin and hygromycin were expanded and frozen down. 
3.3.2.1. Flp-In™ T-REx™ HEK293 (G4C2)n Cells Express (G4C2)n RNA Foci 
RNA FISH was used to detect (G4C2)n RNA expression in the HEK293 (G4C2)n cells. The 
(G4C2)n repeat is transcribed and forms characteristic RNA foci in the CNS of C9ORF72-
ALS/FTD patients (DeJesus-Hernandez et al., 2011; Renton et al., 2011). RNA FISH was 
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performed using a sense-specific fluorescently labelled (C4G2)3 Locked Nucleic Acid 
probe, to check whether the Flp-In™ T-REx™ HEK293 (G4C2)n cells expressed the 
(G4C2)n repeat RNA. A confocal microscope was use to image RNA foci (section 
2.2.3.10). 
(G4C2)n RNA foci were not detected in the HEK293 sham cells ± tetracycline induction 
(Figure 3.6). (G4C2)n RNA foci were detected in the HEK293 (G4C2)102 cells ± 
tetracycline induction, however, there were more (G4C2)n RNA foci in tetracycline 
induced HEK293 (G4C2)102 cells (Figure 3.6). In addition, the RNA foci were visibly larger 
(Figure 3.6). The (G4C2)n RNA foci were predominantly nuclear, although rare 
cytoplasmic (G4C2)n RNA foci were also detected (Figure 3.6). Additionally, when 
HEK293 (G4C2)102 cells were treated with RNAse A prior to the RNA FISH stain, the 
(G4C2)n RNA foci were ablated (Figure 3.6). These observations were consistent in three 
experimental repeats. 
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Figure 3.6 HEK293 (G4C2)n cells have tetracycline-inducible (G4C2)n RNA expression, 
which forms RNA foci. HEK293 sham and HEK293 (G4C2)102 cells were cultured for 3 
days ±10µg/mL tetracycline. RNAse treated control cells were additionally treated with 
RNAse A after PFA fixation and prior to RNA FISH staining. Cells were stained with a 
fluorescently labelled Locked Nucleic Acid (C4G2)3 sense probe (Red) and Dapi (Blue). 
RNA foci were imaged using a confocal microscope within a high resolution z-stack 
through the entire nuclear volume. The images shown are projections of the z-stack to 
show all RNA foci imaged in the cells. Foci magnified 5X inset. Scale bar = 10µm.  
3.3.3. Flp-In™ T-REx™ NSC34 (G4C2)n Cell Generation 
To generate isogenic motor neuron-like NSC34 cell lines with tetracycline-inducible 
(G4C2)n repeat expression, a Flp-In™ T-REx™ NSC34 host cell line first had to be 
generated using the Flp-In™ T-REx™ core kit. pFRT/lacZeo and pcDNA6/TR plasmids 
were independently and stably transfected into the WT NSC34 cell line. pFRT/lacZeo 
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introduced a single FRT site into the NSC34 genome, which acted as an isogenic target 
site for pcDNA5/FRT/TO-(G4C2)n vector integration. pcDNA6/TR introduced a TetR 
element into the NSC34 cell line, which constitutively and stably expresses the TetR 
protein. The TetR protein binds the CMV/TO hybrid promoter and represses 
transcription of the (G4C2)n constructs. 
3.3.3.1. Flp-In™ T-REx™ NSC34 Host Cell Generation 
The work in section 3.3.3.1 was exclusively carried out by Dr Adrian Higginbottom. First, 
it was determined that 2.5μg/mL of blasticidin, 75μg/mL of hygromycin and 20μg/mL of 
Zeocin™ were the minimum respective concentrations that wild type (WT) NSC34 cells 
were sensitive to. pFRT/lacZeo was transfected into WT NSC34 cells to introduce a target 
FRT site within the NSC34 genome. Zeocin™ selection was added to the NSC34 media to 
select for Zeocin™-resistant Flp-In™ NSC34 cells stably transfected with pFRT/lacZeo. 
Zeocin™-resistant clones were picked, expanded, and banked. Genomic DNA was then 
extracted from these Zeocin™-resistant Flp-In™ NSC34 clones, and screened using 
Southern Blotting to test for the number of integrated FRT sites (Figure 3.7). The 
fibroblast negative control did not contain a genomic FRT site, whilst the Flp-In™ T-REx™ 
HEK293 positive control did contain one genomic FRT site (Figure 3.7). Flp-In™ NSC34 
clones that contained only one genomic FRT site were further analysed for the 
transcriptional activity of that FRT site. 
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Figure 3.7 Zeocin™-resistant Flp-In™ NSC34 clones were screened for single FRT 
integrations using Southern Blot. DNA bands containing a positive FRT fragment from 
the genomic DNA are boxed. Fibroblast (FIBCON) was used as a negative control, and 
Flp-In™ T-REx™ HEK293 (HEK293) was used as a positive control. Image courtesy of Dr. 
Adrian Higginbottom. 
Flp-In™ NSC34 clones that contained only one genomic FRT site were transfected with 
pcDNA5/FRT/TO-GFP to test the transcriptional activity of the FRT site. The level of GFP 
expression was used to determine what effect the chromosomal position of the FRT site 
had on its transcriptional activity. Hygromycin selection was added to Flp-In™ NSC34 
media to select for hygromycin-resistant Flp-In™ NSC34 GFP cells stably transfected with 
pcDNA5/FRT/TO-GFP. These Flp-In™ NSC34 GFP cells were then screened using a 
fluorescent microscope for GFP expression levels. Clones TC3, T42, T23 and T4E2A 
expressed the highest GFP levels and were transfected again with pcDNA6/TR. This 
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would determine which Flp-In™ NSC34 clone had a transcriptionally active FRT site also 
capable of being repressed by the TetR element. Blasticidin and hygromycin selection 
were added to Flp-In™ NSC34 GFP media to select for blasticidin/hygromycin-resistant 
Flp-In™ T-REx™ NSC34 GFP cells stably transfected with pcDNA6/TR. These clonal 
mixtures of stable Flp-In™ T-REx™ NSC34 GFP cells were screened for GFP expression ± 
tetracycline induction. Flp-In™ T-REx™ NSC34 clonal line T4E2A had the greatest 
increase in GFP expression upon tetracycline induction (Figure 3.8), indicating the FRT 
site was in a transcriptionally active genomic location, which was also capable of 
repression by the TetR element.  
 
Figure 3.8 Screen for Flp-In™ NSC34 cells with transcriptionally active but repressible 
FRT sites. Flp-In™ NSC34 cells were transfected with and selected for stable integration 
of pcDNA5/FRT/TO-GFP and subsequently pcDNA6/TR. Cells were then cultured for 2 
days ±5µg/mL tetracycline, and then Ex485/Em520nm fluorescence was measured to 
assess GFP expression levels. Data shown are mean and SD of technical replicates; n=1. 
pcDNA6/TR was transfected into the T4E2A Flp-In™ NSC34 clonal line to stably introduce 
the TetR element. Blasticidin and Zeocin™ selection was added to the Flp-In™ T-REx™ 
NSC34 media to select for blasticidin/Zeocin™-resistant Flp-In™ T-REx™ NSC34 cells 
stably transfected with pcDNA6/TR. Blasticidin/Zeocin™-resistant clones were picked, 
expanded, and banked. Flp-In™ T-REx™ NSC34 clones were transfected with 
pcDNA5/FRT/TO-GFP to identify a clone which had low basal GFP expression and high 
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GFP expression upon tetracycline induction. Blasticidin/hygromycin selection was added 
to the Flp-In™ T-REx™ NSC34 GFP media to select for blasticidin/hygromycin-resistant 
Flp-In™ T-REx™ NSC34 GFP cells stably transfected with pcDNA5/FRT/TO-GFP. 
Blasticidin/hygromycin-resistant Flp-In™ T-REx™ NSC34 GFP clones were also screened 
for Zeocin™ sensitivity, which indicates the pcDNA5/FRT/TO-GFP inserted at the 
genomic FRT site. Blasticidin/hygromycin-resistant, Zeocin™-sensitive Flp-In™ T-REx™ 
NSC34 GFP clones were then screened for GFP expression ± tetracycline induction. Flp-
In™ T-REx™ NSC34 clonal line E3 expressed very little GFP at basal levels, but there was 
also very little increase in GFP expression upon tetracycline induction (Figure 3.9). Clonal 
line C2 had high GFP expression at basal levels, and very high GFP expression when 
induced with tetracycline (Figure 3.9). It was decided that the E3 clone was too weak an 
inducer, and the C2 clone expressed the GFP too strongly at basal levels. Therefore 
neither E3 nor C2 were used as the parental Flp-In™ T-REx™ NSC34 line. However, the 
B10-2 clone had modest GFP expression at basal levels because the fluorescence 
intensity was similar to the background fluorescence seen in WT NSC34 cells (Figure 3.9). 
In addition, the B10-2 clone had high GFP expression when induced with tetracycline 
(Figure 3.9). Therefore clonal line B10-2 was selected as the parental Flp-In™ T-REx™ 
NSC34 host cell line for generating the isogenic, tetracycline-inducible Flp-In™ T-REx™ 
NSC34 (G4C2)n cell lines, as well as other lines with different genes of interest. 
3.3.3.2. Stable Integration of pcDNA5/FRT/TO-(G4C2)n Plasmids into Flp-In™ T-REx™ 
NSC34 Cells 
The same method described for the Flp-In™ T-REx™ HEK293 cells (section 3.3.3) was 
used to integrate the (G4C2)n repeat expansion vectors into the motor neuron-like 
NSC34 cell lines. However, the sensitivity of the Flp-In™ T-REx™ NSC34 cells to the 
hygromycin selection agent had to be determined first, because they were built in 
house. The Flp-In™ T-REx™ NSC34 cells were seeded onto a 24 well plate and left for 24 
h. After 24 h, hygromycin was added to the cells at various concentrations. The cells 
were left for 7 days in the selection media, and then observed. The NSC34 cells were 
completely devastated in media containing ≥100μg/mL hygromycin, partially devastated 
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at 75μg/mL and relatively unaffected at ≤50μg/mL. Therefore, 100μg/mL hygromycin 
was sufficient to detect stably transfected cells with resistance to hygromycin. 
 
Figure 3.9 Screen for Flp-In™ T-REx™ NSC34 cells with low basal GFP expression and 
high tetracycline-inducible GFP expression. Flp-In™ T-REx™ NSC34 cells were 
transfected with and selected for stable integration of pcDNA5/FRT/TO-GFP. Cells were 
then cultured for 2 days ±10µg/mL tetracycline, and then Ex4850/Em520nm 
fluorescence was measured to assess GFP expression levels. Data shown are mean and 
SD of technical replicates; n=1. 
The pcDNA5/FRT/TO-(G4C2)n plasmids were stably transformed into the Flp-In™ T-REx™ 
NSC34 cells. pPGKFLPobpA was co-transfected with each of the pcDNA5/FRT/TO, 
pcDNA5/FRT/TO-(G4C2)10, pcDNA5/FRT/TO-(G4C2)51, and pcDNA5/FRT/TO-
(G4C2)102 plasmids separately. 48 h post-transfection, the media was replenished, the 
NSC34 cells were split onto 3 new plates and 5μg/mL blasticidin and 100μg/mL 
hygromycin were added to the media to select for transformed clones. The media and 
dead floating cells were removed and replaced with fresh selection media every 3 days. 
50% conditioned/50% fresh media with selection was added to the plates once massive 
cell death had occurred and only very few cells remained alive on the plates. This was to 
ensure survival of any transformed colonies remaining on the plates. Once distinct 
colonies were visible on the plate, they were picked and transferred to a 48 well plate 
containing blasticidin and hygromycin selection. The NSC34 colonies were grown in the 
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48 well (each colony in a separate well) until 60% confluent. They were then split 50/50 
into two 48 wells: one containing Zeocin™, the other containing blasticidin/hygromycin. 
Clones that were blasticidin/hygromycin-resistant but Zeocin™-sensitive were expanded 
and cryopreserved. 
3.3.4. Characterisation of Flp-In™ T-REx™ NSC34 (G4C2)n Cells 
The Flp-In™ T-REx™ NSC34 (G4C2)n cells were then characterised for expression of the 
(G4C2)n repeat constructs. The (G4C2)n repeat expansion is transcribed bidirectionally 
and forms both sense (G4C2)n and antisense (G4C2)n RNA foci in C9ORF72-ALS/FTD 
patient CNS (DeJesus-Hernandez et al., 2011; Gendron et al., 2013; Renton et al., 2011). 
In addition, the (G4C2)n and (C4G2)n repeat transcripts are translated via RAN 
translation to form DPR proteins (Ash et al., 2013; Gendron et al., 2013; Mori et al., 
2013a; Mori et al., 2013c). Therefore, RNA FISH was performed (using both sense and 
antisense probes), and immunoblotting (using anti-DPR antibodies), to detect 
expression of the (G4C2)n repeats in the NSC34 cells. In addition, the concentration of 
tetracycline was optimised to minimise toxicity, but retain maximal induction of (G4C2)n 
expression. From now on, the Flp-In™ T-REx™ NSC34 (G4C2)n cells will be referred to as 
NSC34 (G4C2)n.  
3.3.4.1. NSC34 (G4C2)n Cells Express (G4C2)n RNA Foci 
RNA FISH was performed using the sense-specific fluorescent probe to characterise the 
NSC34 (G4C2)n cells for tetracycline-inducible (G4C2)n RNA expression. The number of 
sense (G4C2)n RNA foci was dependent on the (G4C2)n repeat size (Figure 3.10). NSC34 
sham cells contained 0.10±0.10 and 0.10±0.10 (G4C2)n RNA foci per cell, without and 
with tetracycline respectively. NSC34 (G4C2)10 cells contained 0.04±0.04 and 0.89±1.13 
RNA foci per cell, without and with tetracycline respectively. NSC34 (G4C2)51 cells 
contained 0.63±0.24 (G4C2)n and 1.91±1.31 (G4C2)n RNA foci per cell, without and with 
tetracycline respectively. NSC34 (G4C2)102 cells contained 7.12±3.71 (G4C2)n and 
17.69±5.37 (G4C2)n RNA foci per cell, without and with tetracycline respectively. 
However, whilst the number of (G4C2)n RNA foci increased in the NSC34 (G4C2)10, 
NSC34 (G4C2)51 and NSC34 (G4C2)102 cells when induced with 10µg/mL tetracycline 
(Figure 3.10), this increase was only significant (using a Two-Way ANOVA with Tukey’s 
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multiple comparisons post-hoc test) in the NSC34 (G4C2)102 cells (P<0.01). Additionally, 
the size of the RNA foci visibly correlates with the size of the (G4C2)n repeat within the 
NSC34 cells (Figure 3.10). Also, whilst the vast majority of RNA foci were nuclear, very 
rare cytoplasmic RNA foci were also observed in NSC34 (G4C2)102 cells (Figure 3.11). 
Finally, RNAse A treatment ablated foci in the NSC34 (G4C2)102 cells (Figure 3.11). 
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Figure 3.10 NSC34 (G4C2)n cells have tetracycline-inducible (G4C2)n RNA expression, 
which forms RNA foci. A) NSC34 sham, NSC34 (G4C2)10, NSC34 (G4C2)51, and NSC34 
(G4C2)102 cells were cultured for 3 days ±10µg/mL tetracycline. Cells were stained with 
a fluorescently labelled Locked Nucleic Acid (C4G2)3 sense probe (Red) and Dapi (Blue). 
RNA foci were imaged using a confocal microscope within a high resolution z-stack 
through the entire nuclear volume. The images shown are projections of the z-stack to 
show all RNA foci imaged in the cells. Foci magnified 5 X inset. Scale bar = 10µm. B) 
Average number of RNA foci per cell (**P<0.01; ****P<0.0001; Two-way ANOVA with 
Tukey’s multiple comparisons post hoc test; data shown are mean and SD; n=3). 
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Figure 3.11 Foci are ablated by RNAse A treatment. NSC34 (G4C2)102 cells were 
cultured for 3 days with 10µg/mL tetracycline. Cells were additionally treated with 
RNAse A prior to RNA FISH staining. Cells were stained with a fluorescently labelled 
Locked Nucleic Acid (C4G2)3 sense probe (Red) and Dapi (Blue). RNA foci were imaged 
using a confocal microscope within a high resolution z-stack through the entire nuclear 
volume. The images shown are projections of the z-stack to show all RNA foci imaged in 
the cells. Foci magnified 5X inset. Scale bar = 10µm. 
3.3.4.2. NSC34 (G4C2)n Cells Do Not Express Antisense (C4G2)n RNA Foci 
The (G4C2)n repeat expansion is also transcribed from a cryptic promoter in the 
antisense direction in C9ORF72-ALS/FTD patients, and forms characteristic antisense 
(C4G2)n RNA foci in the CNS of C9ORF72-ALS/FTD patients (Gendron et al., 2013). The 
(G4C2)n repeat is under control of a sense orientated CMV/TO promoter in the NSC34 
(G4C2)n cells, and should not be transcribed in the antisense direction. However, the 
exact insertion site of the FRT during the cloning process is unknown, and a promoter 
running in the antisense orientation is possible. Therefore, RNA FISH was performed 
using an antisense-specific fluorescently labelled (G4C2)3 Locked Nucleic Acid probe, to 
confirm the absence of antisense (C4G2)n RNA foci in the NSC34 (G4C2)102 cells. No 
antisense (C4G2)n RNA foci were detected in either the NSC34 sham or the NSC34 
(G4C2)102 cells (Figure 3.12). As a positive control for the antisense-specific FISH probe, 
(C4G2)102 constructs were transiently transfected into HEK293 cells (Figure 3.12). 
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Figure 3.12 NSC34 (G4C2)n cells do not transcribe (G4C2)n in the antisense direction. 
NSC34 sham and NSC34 (G4C2)102 cells were cultured for 3 days with 10µg/mL 
tetracycline. HEK293 cells transfected with a (C4G2)102 plasmid contain (C4G2)102 foci, 
and serve as a positive control for the antisense Locked Nucleic Acid probe. Cells were 
stained with a fluorescently labelled Locked Nucleic Acid (G4C2)3 antisense probe (Red) 
and Dapi (Blue). RNA foci were imaged using a confocal microscope within a high 
resolution z-stack through the entire nuclear volume. The images shown are projections 
of the z-stack to show all RNA foci imaged in the cells. Scale bar = 10µm. 
3.3.4.3. The (G4C2)102 Repeat RNA Is Translated in Both the NSC34 and HEK293 cells 
The (G4C2)n repeat expansion undergoes Repeat Associated Non-ATG (RAN) translation 
in cells throughout the CNS of C9ORF72-ALS/FTD patients (Ash et al. 2013; Gendron et 
al. 2013; Mori et al. 2013a; Mori et al. 2013b). The sense (G4C2)n and antisense (C4G2)n 
RNA are both translated in all three reading frames, generating five DPR proteins. (GA)n 
and (GR)n are produced specifically from the sense (G4C2)n RNA, (PA)n and (PR)n are 
produced specifically from the antisense (C4G2)n RNA, and (GP)n is produced from both 
sense and antisense RNA (Ash et al., 2013; Gendron et al., 2013; Mori et al., 2013a; Mori 
et al., 2013c). Therefore, bioinformatics and immunoblotting were used to investigate 
whether the (G4C2)102 repeats also undergo RAN translation in the NSC34 and HEK293 
cells. 
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The pcDNA5/FRT/TO-(G4C2)102 plasmid was integrated into the Flp-In™ T-REx™ NSC34 
and Flp-In™ T-REx™ HEK293 genomes, and therefore, the plasmid sequence was used to 
predict (G4C2)102 translation products in both cell lines. The pcDNA5/FRT/TO-
(G4C2)102 plasmid sequence was imported to the Translate tool in ExPASy 
(http://web.expasy.org/translate/). There were no ATG start codons in any reading 
frame preceding the (G4C2)102 repeat (Figure 3.13). RAN translation does not require 
an ATG start codon to initiate translation however. Predicted (G4C2)102 RAN translation 
products would contain all three sense DPR motifs ((GA)n, (GR)n, and (GP)n), due to the 
5 bp TCGAC interruptions between the (G4C2)n repeats (Figure 3.13). Some of the 
sequence flanking the (G4C2)n repeats could also be translated and included in these 
predicted translation products as well (Figure 3.13). Therefore, the maximum molecular 
weight of the RAN translation proteins were calculated by exporting the full peptide 
sequences, from each frame (Figure 3.13), to the Compute pI/Mw tool in ExPASy 
(http://web.expasy.org/compute_pi/). The predicted maximum molecular weights for 
the three reading frames were 20.6, 20.3, and 20.4kDa respectively. 
Cells were immunoblotted using anti-DPR antibodies to check whether the (G4C2)n 
repeats do undergo RAN translation. NSC34 sham and (G4C2)102 were cultured for 7 
days ±0.5µg/mL tetracycline (section 3.3.4.4), and HEK293 sham and (G4C2)102 were 
cultured for 3 days ±10µg/mL tetracycline, prior to immunoblotting. WT HEK293 cells 
were also transiently transfected with (GA)68, (GR)100, (AP)100, and (PR)100 expression 
plasmids, to act as positive controls for the respective antibodies. Unfortunately, no (GP) 
positive control was available.  
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Figure 3.13 Schematic of the predicted (G4C2)102 RAN translation products in NSC34 
(G4C2)102 and HEK293 (G4C2)102 cells. The translation products of the (G4C2)n in the 
NSC34 (G4C2)102 and HEK293 (G4C2)102 cells were predicted by importing the 
pcDNA5/FRT/TO-(G4C2)102 plasmid sequence into the Translate tool in ExPASy. 
Translation products (including Stop codons) from (G4C2)102 RNA construct in all three 
reading frames with GA, GP, and GR repeats highlighted in red, yellow, and green 
respectively. 
3.3.4.3.1. Anti-GA Detects Tetracycline-Inducible Protein(s) in NSC34 (G4C2)102 and 
HEK293 (G4C2)102 Cells 
The anti-GA antibody detected a protein band at approximately 40kDa in the NSC34 
sham and NSC34 (G4C2)102 cells ± tetracycline, and also in the WT HEK293 ± (GA)68 
transfection (Figure 3.14A). The anti-GA antibody detected a protein at approximately 
15kDa specifically in the positive control WT HEK293 transfected with (GA)68 (Figure 
3.14A). This band was not detected in NSC34 sham or NSC34 (G4C2)102 ± tetracycline, 
or the untransfected WT HEK293 cells (Figure 3.14A). However, the anti-GA antibody 
detected a 27kDa band in the NSC34 (G4C2)102 ± tetracycline, and a further 24kDa band 
in the NSC34 (G4C2)102 + tetracycline (Figure 3.14A). Neither of these bands at 24 or 
27kDa were detected in the NSC34 sham ± tetracycline (Figure 3.14A). Further, the 
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27kDa band was more abundant in the NSC34 (G4C2)102 induced with tetracycline 
compared to the NSC34 (G4C2)102 without tetracycline (Figure 3.14A).  
The anti-GA antibody detected a protein band at approximately 63kDa in the HEK293 
sham and HEK293 (G4C2)102 ± tetracycline (Figure 3.14B). However, the anti-GA 
antibody detected a 24 and 27kDa band in the HEK293 (G4C2)102 – tetracycline, with 
the 27kDa band being more abundant (Figure 3.14B). Further, the anti-GA antibody 
detected as many as 10 different bands ranging from 17 to 35kDa in the HEK293 
(G4C2)102 + tetracycline (Figure 3.14B). Also, the bands at 24 and 27kDa were much 
more abundant (Figure 3.14B). None of these bands were detected in the HEK293 sham 
± tetracycline (Figure 3.14B).  
3.3.4.3.2. Anti-GR Detects Tetracycline-Inducible Protein(s) in NSC34 (G4C2)102 and 
HEK293 (G4C2)102 Cells 
The anti-GR antibody detected protein bands at approximately 18.5 and 50kDa in the 
NSC34 sham and NSC34 (G4C2)102 cells ± tetracycline, and also in the WT HEK293 ± 
(GR)100 transfection (Figure 3.15A). Also, there was a band in the WT HEK293 ± (GR)100 
transfection at approximately 80kDa (Figure 3.15A). However, the anti-GR antibody 
detected protein bands at approximately 30, 35, and >100kDa specifically in the WT 
HEK293 transfected with (GR)68, which was not detected in NSC34 sham or NSC34 
(G4C2)102 ± tetracycline, or the untransfected WT HEK293 cells (Figure 3.15A). Also, the 
anti-GR antibody detected 24 and 27kDa bands in the NSC34 (G4C2)102 + tetracycline 
(Figure 3.15A). Neither of these bands at 24 or 27kDa was detected in the NSC34 sham 
± tetracycline, or NSC34 (G4C2)102 - tetracycline (Figure 3.15A). 
The anti-GR antibody detected protein bands at approximately 19, 30, 55, and 65kDa in 
the HEK293 sham and HEK293 (G4C2)102 ± tetracycline (Figure 3.15B). However, a 24 
and 27kDa band were detected only in the HEK293 (G4C2)102 + tetracycline (Figure 
3.15B).
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Figure 3.14 The anti-GA antibody detects RAN translation proteins from the (G4C2)102 RNA in the NSC34 (G4C2)102 and HEK293 (G4C2)102 
cells. A) NSC34 sham and NSC34 (G4C2)102 cells were cultured for 7 days ±0.5µg/mL tetracycline. HEK293 cells were transfected with (GA)68 
constructs to serve as a positive control for the anti-GA antibody. B) HEK293 sham and HEK293 (G4C2)102 cells were cultured for 3 days 
±10µg/mL tetracycline. Cells were lysed and immunoblotted with anti-GA and anti-tubulin. Molecular weight markers are indicated (kDa). 
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Figure 3.15 The anti-GR antibody detects RAN translation proteins from the (G4C2)102 RNA in the NSC34 (G4C2)102 and HEK293 (G4C2)102 
cells. A) NSC34 sham and NSC34 (G4C2)102 cells were cultured for 7 days ±0.5µg/mL tetracycline. HEK293 cells were transfected with (GR)100 
constructs to serve as a positive control for the anti-GR antibody. B) HEK293 sham and HEK293 (G4C2)102 cells were cultured for 3 days 
±10µg/mL tetracycline. Cells were lysed and immunoblotted with anti-GR and anti-tubulin. Molecular weight markers are indicated (kDa).
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3.3.4.3.3. Anti-GP Detects Tetracycline-Inducible Protein(s) in NSC34 (G4C2)102 and 
HEK293 (G4C2)102 Cells 
The anti-GP antibody detected a range of bands >65kDa in the NSC34 sham and NSC34 
(G4C2)102 cells ± tetracycline (Figure 3.16A). However, a 27kDa band was detected 
specifically in the NSC34 (G4C2)102 ± tetracycline, which was more abundant in the 
NSC34 (G4C2)102 with tetracycline (Figure 3.16A). In addition, a 24kDa band was 
specifically detected in the NSC34 (G4C2)102 + tetracycline (Figure 3.16A). Neither of 
these bands were detected in the NSC34 sham ± tetracycline (Figure 3.16A). 
The anti-GP antibody detected a range of protein bands >75kDa in the HEK293 sham 
and HEK293 (G4C2)102 ± tetracycline (Figure 3.16B). However, the anti-GP antibody 
detected a 27kDa band in the HEK293 (G4C2)102 ± tetracycline, with the 27kDa band 
being more abundant in the HEK293 induced with tetracycline compared to those 
without (Figure 3.16B). Further, the anti-GP antibody specifically detected a band at 
25kDa, and 4 different bands ranging from 15 to 19kDa in the HEK293 (G4C2)102 + 
tetracycline (Figure 3.16B). None of these bands were detected in the HEK293 sham ± 
tetracycline (Figure 3.16B).  
3.3.4.3.4. Anti-AP Does Not Detect Proteins Specifically in NSC34 (G4C2)102, but Does 
Detect a Large Protein in HEK293 (G4C2)102 Cells 
The anti-AP antibody detected an abundant protein band >100kDa, and 2 smaller 
protein bands at approximately 75 and 100kDa in the WT HEK293 transfected with 
(AP)100 (Figure 3.17A). The anti-AP antibody did not detect any other proteins in either 
the NSC34 sham or NSC34 (G4C2)102 ± tetracycline, or the untransfected WT HEK293 
cells (Figure 3.17A).  
The anti-AP antibody did detect a protein band >100kDa in the HEK293 (G4C2)102 ± 
tetracycline (Figure 3.17B). The abundance of the protein also seems increased by 
tetracycline induction (Figure 3.17B). 
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Figure 3.16 The anti-GP antibody detects RAN translation proteins from the (G4C2)102 RNA in the NSC34 (G4C2)102 and HEK293 (G4C2)102 
cells. A) NSC34 sham and NSC34 (G4C2)102 cells were cultured for 7 days ±0.5µg/mL tetracycline. B) HEK293 sham and HEK293 (G4C2)102 cells 
were cultured for 3 days ±10µg/mL tetracycline. Cells were lysed and immunoblotted with anti-GP and anti-tubulin. Molecular weight markers 
are indicated (kDa).
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Figure 3.17 The anti-AP antibody does not detects RAN translation proteins the NSC34 (G4C2)102but does detect protein in the HEK293 
(G4C2)102 cells. A) NSC34 sham and NSC34 (G4C2)102 cells were cultured for 7 days ±0.5µg/mL tetracycline. HEK293 cells were transfected with 
(AP)100 constructs to serve as a positive control for the anti-AP antibody. B) HEK293 sham and HEK293 (G4C2)102 cells were cultured for 3 days 
±10µg/mL tetracycline. Cells were lysed and immunoblotted with anti-AP and anti-tubulin. Molecular weight markers are indicated (kDa). 
101 
 
 
3.3.4.3.5. Anti-PR Does Not Detect Proteins Specifically in NSC34 (G4C2)102 or HEK293 
(G4C2)102 Cells 
The anti-PR antibody detected a range of different sized protein bands consistently and 
at low abundance in both the NSC34 sham and NSC34 (G4C2)102 ± tetracycline, and the 
untransfected WT HEK293 (Figure 3.18A). The anti-PR antibody also detected a range of 
protein bands, that were much more abundant and represented by a ‘smear’ on the 
membrane, in the WT HEK293 transfected with (PR)100 (Figure 3.18A). The anti-PR 
antibody did not detect any proteins specifically in the NSC34 (G4C2)102 cells. 
The anti-PR antibody detected a protein band >100kDa in the HEK293 sham and HEK293 
(G4C2)102 ± tetracycline (Figure 3.18B).  In addition, the abundance of the protein did 
not seem affected by tetracycline induction (Figure 3.18B) The anti-PR antibody did not 
detect any proteins specifically in the HEK293 (G4C2)102 cells. 
3.3.4.3.6. Summary of the Protein Species Detected Using Anti-DPR Antibodies in the 
NSC34 (G4C2)102 and HEK293 (G4C2)102 Cells 
Several protein bands were detected specifically in the NSC34 (G4C2)102 cells (with or 
without tetracycline induction) that were not detected in the NSC34 sham cells 
(regardless of tetracycline induction), suggesting that these proteins were derived from 
RAN translation of the (G4C2)102 repeat RNA. The same was found when comparing the 
HEK293 (G4C2)102 and HEK293 sham cells, although additional protein bands were 
detected in the HEK293 (G4C2)102 cells compared to the NSC34 (G4C2)102 cells. The 
RAN translation protein species, and their molecular weights, that were specifically 
detected in either the NSC34 (G4C2)102 and/or HEK293 (G4C2)102 cells are summarised 
in Table 3.1. 
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Figure 3.18 The anti-PR antibody does not detect RAN translation proteins in the NSC34 (G4C2)102 or HEK293 (G4C2)102 cells. A) NSC34 sham 
and NSC34 (G4C2)102 cells were cultured for 7 days ±0.5µg/mL tetracycline. HEK293 cells were transfected with (PR)100 constructs to serve as 
a positive control for the anti-PR antibody. B) HEK293 sham and HEK293 (G4C2)102 cells were cultured for 3 days ±10µg/mL tetracycline. Cells 
were lysed and immunoblotted with anti-PR and anti-tubulin. Molecular weight markers are indicated (kDa).
103 
 
 
Table 3.1 Summary of the protein species that are specifically detected in cells 
containing the (G4C2)102 repeat construct. The antibody used, the molecular weight 
(kDa), and the cell line that the protein bands were detected in are shown. * denotes 
protein bands that were only detected when the cell line was induced with tetracycline. 
Antibody (Sense (S) 
and/or Antisense 
(AS) derived) 
Molecular weight (kDa) of RAN translated protein species 
specifically detected in the following cells 
NSC34 (G4C2)102 HEK293 (G4C2)102 
Anti-GA (S) 24*, 27 Multiple bands ranging from 17-
35*, including 24, and 27 
Anti-GR (S) 24*, 27* 24*, 27* 
Anti-GP (S and AS) 24*, 27 15*, 16*, 17*, 19*, 25*, 27 
Anti-AP (AS) None >100 
Anti-PR (AS) None None 
 
3.3.4.4. 10 µg/mL Tetracycline Reduces NSC34 Cell Viability 
Initially, an MTT cell viability assay was performed on the NSC34 sham and NSC34 
(G4C2)102 cells to assess whether the (G4C2)102 expression reduces NSC34 cell 
viability. For the MTT assay, the NSC34 cells were grown for 7 days, and induced with 10 
µg/mL tetracycline for increasing lengths of time. The viability of the NSC34 sham cells 
was significantly reduced by 32.38±4.71% (P<0.0001), 43.61±7.79% (P<0.0001), and 
51.83±6.16% (P<0.0001) after 5, 6 and 7 days of 10µg/mL tetracycline induction 
respectively, compared to non-induced NSC34 sham cells (Figure 3.19A). Similarly the 
viability of the NSC34 (G4C2)102 cells was significantly reduced by 35.78±6.97% 
(P<0.0001), 52.56±3.14% (P<0.0001), and 60.31±8.07% (P<0.0001) after 5, 6 and 7 days 
of 10µg/mL tetracycline induction respectively, compared to non-induced NSC34 
(G4C2)102 cells (Figure 3.19A). Therefore, it appears 10µg/mL tetracycline is toxic to the 
NSC34 cells after prolonged exposure, although there is no detectable toxicity prior to 5 
days induction.  
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Figure 3.19 10 µg/mL tetracycline reduces NSC34 cell viability. A) NSC34 sham and 
NSC34 (G4C2)102 cells were cultured for 7 days, and were induced for various lengths 
of time with 10µg/mL tetracycline. Cell viability was measured using an MTT assay. 
(****P<0.0001; Two-way ANOVA with Tukey’s multiple comparisons post hoc test; data 
shown are mean and SD; n=3). B) NSC34 sham cells were cultured for 7 days with various 
concentrations of tetracycline. (****P<0.0001; One-way ANOVA with Dunnett’s 
multiple comparisons post hoc test; data shown are mean and SD; n=3). 
The toxicity of a range of lower concentrations of tetracycline was tested to find a non-
toxic concentration that would be taken forward for use in future experiments. NSC34 
sham cells were grown for 7 days, and incubated with a range of tetracycline 
concentrations. As before, 10µg/mL tetracycline reduced NSC34 sham cell viability by 
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57.37±1.67% (P<0.0001) compared to NSC34 sham cells treated with no tetracycline 
(Figure 3.19B). However, ≤1µg/mL tetracycline caused no significant reduction in NSC34 
sham cell viability compared to NSC34 sham cells treated with no tetracycline (Figure 
3.19B).  
To confirm that the (G4C2)n RNA expression can still be induced using lower tetracycline 
concentrations, NSC34 (G4C2)102 cells were induced with a range of tetracycline 
concentrations for 3 days, and then RNA FISH was performed. RNA foci were counted in 
25 cells for each condition (Figure 3.20). NSC34 (G4C2)102 cells without tetracycline 
treatment contained an average of 12.32 sense (G4C2)n RNA foci per cell, whilst NSC34 
(G4C2)102 cells treated with 0.1, 0.5, 1, and 10µg/mL tetracycline contained an average 
of 35.12, 26.96, 28.6, and 23.88 RNA foci per cell respectively. The average number of 
RNA foci was at least doubled for all tetracycline concentrations, and therefore, it was 
concluded that ≥0.1µg/mL tetracycline is sufficient to induce (G4C2)n RNA transcription 
in the NSC34 (G4C2)n cells. From here on, 0.5µg/mL tetracycline was used to induce 
(G4C2)n expression in the NSC34 cells, as this concentration of tetracycline does not 
affect NSC34 sham cell viability after 7 days in the MTT assay. 
3.3.4.5. (G4C2)102 Expression Reduces NSC34 Cell Viability  
Cell viability assays were repeated using a suitable concentration of tetracycline that did 
not affect NSC34 sham cell viability, but still achieved maximum induction of (G4C2)n 
RNA expression. For the MTT assay, the NSC34 cells were grown for 7 days, and induced 
with 0.5µg/mL tetracycline for increasing lengths of time. The viability of the NSC34 
(G4C2)102 cells was reduced by 29.9±8.6% (P<0.01) after 7 days tetracycline induction 
compared to NSC34 sham cells (Figure 3.21). However, there was no significant 
reduction in NSC34 (G4C2)10 or NSC34 (G4C2)51 cell viability after 7 days tetracycline 
induction. In addition, tetracycline did not reduce NSC34 sham cell viability (Figure 3.21). 
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Figure 3.20 ≥0.1µg/mL tetracycline induces increased (G4C2)102 transcription in 
NSC34 (G4C2)102 cells. NSC34 (G4C2)102 cells were cultured for 3 days with various 
concentrations of tetracycline. Cells were stained with a fluorescently labelled Locked 
Nucleic Acid (C4G2)3 sense probe (Red) and Dapi (Blue), and the number of RNA foci 
was counted in 25 cells per condition. (Data shown are mean; n=1). 
 
Figure 3.21 (G4C2)102 expression reduces NSC34 cell viability. NSC34 sham, NSC34 
(G4C2)10, NSC34 (G4C2)51, and NSC34 (G4C2)102 cells were cultured for 7 days, and 
were induced for various lengths of time with 0.5µg/mL tetracycline. Cell viability was 
measured using an MTT assay (**P<0.01; Two-way ANOVA with Tukey’s post hoc test; 
data shown are mean and SD; n=3). 
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3.3.4.6. (G4C2)102 Expression Does Not Cause NSC34 Cell Death 
A cell death assay was then used to confirm whether the reduced NSC34 cell viability 
was caused by increased cell death. Ethidium homodimer (EthD1) fluorescent dye is a 
cell-impermeant, high affinity nucleic acid stain that emits red fluorescence when bound 
to DNA. EthD1 fluorescence is therefore proportional to the number of dead cells. For 
the EthD1 assays, the NSC34 sham and NSC34 (G4C2)102 cells were grown for 7 days 
±0.5µg/mL tetracycline. The amount of dead cells was then assessed using the EthD1 
fluorescence. The cells were then freeze-thawed to lyse the cells, and a second EthD1 
fluorescence assay was performed. The amount of dead cells was normalised to the total 
number of cells. There was no significant difference in % dead cells in the NSC34 sham 
– tet and NSC34 sham + tet cells, with 7.01±6.42% and 10.11±6.27% dead cells 
respectively (Figure 3.22). Neither was there any significant difference in % dead cells in 
the NSC34 (G4C2)102 – tet and NSC34 (G4C2)102 + tet cells, with 27.43±11.73% and 
28.78±7.65% dead cells respectively (Figure 3.22). Finally, the % dead cells was not 
significantly increased in the NSC34 (G4C2)102 cells compared to the NSC34 sham cells 
± tet. 
3.3.4.7. (G4C2)102 Expression Reduces NSC34 Cell Growth Rate 
If induction of the (G4C2)102 expression did not increase NSC34 cell death, the other 
explanation for reduced cell viability is reduced growth rate. Therefore, a growth curve 
was also performed. The NSC34 sham and NSC34 (G4C2)102 cells were cultured for 16 
days in total, ±0.5µg/mL tetracycline. Viable cells were counted every 4 days, and 
1.5x106 cells were re-seeded and cultured. There was no significant difference in the 
number of viable cells between all conditions at days 4 or 8 (Figure 3.23). However, at 
days 12 and 16 there were significantly fewer viable NSC34 (G4C2)102 cells that were 
induced with tetracycline, compared to NSC34 sham ± tetracycline and NSC34 
(G4C2)102 cells without tetracycline induction. There were only 66.8±26.5% (P<0.001) 
and 52.4±11.6% (P<0.0001) NSC34 (G4C2)102 + tetracycline compared to NSC34 sham 
+ tetracycline at days 12 and 16 respectively (Figure 3.23). There were no significant 
differences in the number of NSC34 sham ± tetracycline and NSC34 (G4C2)102 without 
tetracycline induction.  
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Figure 3.22 (G4C2)102 expression does not increase NSC34 cell death. NSC34 sham and 
NSC34 (G4C2)102 cells were cultured for 7 days ±0.5µg/mL tetracycline. The number 
dead cells was measured using an EthD1 fluorescence assay, and the number of total 
cells was measured by lysing the cells and repeating the EthD1 fluorescence assay. The 
number of dead cells was normalised to the number of total cells to calculate % dead 
cells (Two-way ANOVA with Tukey’s post hoc test; data shown are mean and SD; n=3). 
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Figure 3.23 (G4C2)102 expression reduces NSC34 cell growth rate. NSC34 sham and 
NSC34 (G4C2)102 cells were cultured for 16 days ±0.5µg/mL tetracycline. The cells were 
counted every 4 days, and then 1.5x106 cells were reseeded. (***P<0.001; 
****P<0.0001; Two-way ANOVA with Tukey’s post hoc test; data shown are mean and 
SD; n=4). 
3.4. Discussion 
The first aim was to generate stable cell lines with tetracycline-inducible (G4C2)n repeat 
expression. To do this, the Flp-In™ and T-REx™ systems were used. Importantly, Flp-In™ 
T-REx™ HEK293 cells were used as a proof of principle, and showed the (G4C2)n 
constructs were compatible with the Flp-In™ T-REx™ systems. However, the NSC34 
(G4C2)n cells were the priority model of C9ORF72-ALS in this project, and were 
therefore characterised in greater detail.  A Flp-In™ T-REx™ NSC34 cell line was 
generated in house to use as a motor neuron-like cell model, as this was not 
commercially available. In addition, the (G4C2)n repeat expansion had to be cloned in 
vitro, and subsequently integrated into the Flp-In™ T-REx™ NSC34 cell host line. This 
required generating the (G4C2)n repeat constructs and then inserting them into a 
plasmid containing an FRT site. After stably transfecting the (G4C2)n plasmids into the 
Flp-In™ T-REx™ NSC34 cells, the cells were characterised for (G4C2)n expression, at RNA 
and protein levels. Finally, the tetracycline-inducible (G4C2)n repeat expression was 
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confirmed, and the tetracycline concentration had to be optimised to reduce toxicity, 
but maintain induction. 
3.4.1. Cloning the (G4C2)n Repeat 
The (G4C2)n hexanucleotide repeat DNA can form abnormal non B-form stable 
secondary structures. The sense (G4C2)n and antisense (C4G2)n DNA strands are both 
able to form G-quadruplex secondary structures (Haeusler et al., 2014; Zamiri et al., 
2015), whilst the (C4G2)n DNA strand can also form i-motifs and hairpin secondary 
structures (Kovanda et al., 2015). Additionally, RNA transcribed from the (G4C2)n repeat 
in either direction can form stable secondary structures with the template (G4C2)n DNA, 
forming RNA:DNA hybrid R-loops (Haeusler et al., 2014; Reddy et al., 2014). These non 
B-form secondary structures can interfere with normal cellular processes such as 
transcription and replication (Reddy et al., 2014; Thys and Wang, 2015). This makes the 
(G4C2)n repeat DNA unstable in both E.coli and mammalian cells, and the repeats are 
liable to both expansions and contractions in a length-dependent manner (Thys and 
Wang, 2015). Additionally, the G-quadruplexes cause polymerase slippage during DNA 
replication, and the (G4C2)n repeats  reduce replication efficiency in a length-dependent 
manner (Thys and Wang, 2015).  
The interference with biochemical processes makes the (G4C2)n repeat DNA technically 
challenging to clone and manipulate. Currently available PCR methods cannot amplify 
the (G4C2)n repeats when they are above a certain length. In our hands, PCR of the 
(G4C2)n repeat produced a mixture of different repeat lengths, even after extensive 
efforts to optimise the PCR using a range of DNA polymerases and the use of 7-
deazaguanasine. Further, commercial companies were not able to synthesise these 
repeats. However, other groups had previously cloned interrupted repeats to model 
repeat expansions, and this strategy was adopted for this project. 
Interrupted (CTG)n repeat expansion constructs had been cloned in Drosophila to model 
the (CTG)n repeat expansion that causes Myotonic Dystrophy 1 (de Haro et al., 2006). 
This methodological approach was used here to clone large interrupted (G4C2)n repeat 
constructs by ligating together smaller (G4C2)10 repeat fragments (see section 3.3.2), 
and (G4C2)10, (G4C2)51 and (G4C2)102 repeats were successfully generated in the 
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pcDNA6.2 vector. These (G4C2)n repeat constructs were also challenging to sub-clone 
via restriction digest and ligation, but after several rounds of optimisation, the repeats 
were sub-cloned into the pcDNA5/FRT/TO-HIS vectors. The size and sequence of the 
(G4C2)n repeats in the pcDNA5/FRT/TO-HIS vectors were confirmed by electrophoresis 
and sequencing respectively. Interestingly, the (G4C2)51 and (G4C2)102 repeat 
constructs do not contain (G4C2)10 repeat tracts followed by the TCGAG interruptions, 
as predicted. Instead, the larger (G4C2)n repeat constructs actually contain (G4C2)n 
repeat tracts of various lengths interspersed with the expected interruptions 
(Appendices 2 and 3). Further, the (G4C2)n repeats are always conserved as a full (G4C2) 
unit. This suggests that the (G4C2)n repeat constructs generated underwent expansion, 
contraction and/or recombination, even though recombination deficient β-10 E.coli 
were used to clone the (G4C2)n repeat constructs. 
3.4.2. Generating the Flp-In™ T-REx™ NSC34 Host Cell Line 
To model how (G4C2)n repeat expression may cause ALS in a reductionist manner, the 
initial aim was to generate isogenic NSC34 cells with tetracycline-inducible (G4C2)n 
expression. The NSC34 cell line was used because it displays many properties of motor 
neurons (Cashman et al., 1992), and the aim was to study how (G4C2)n expression may 
reveal disease mechanisms in ALS. Ideally, the NSC34 cells would have no or, more 
realistically, low (G4C2)n expression at basal levels because it was unknown how toxic 
the (G4C2)n repeat constructs would be in the NSC34 cell context. Equally, the NSC34 
cells would have high (G4C2)n expression upon tetracycline induction, such that the 
early biochemical effects of the (G4C2)n expression could be studied. In addition, the 
inducible nature of the (G4C2)n expression would potentially minimise the cell lines 
adapting to the (G4C2)n expression.  
Also, the isogenic nature of the NSC34 (G4C2)n cells was desirable as there would be 
minimal noise between cell lines in experiments. Flp-In™ T-REx™ NSC34 clonal line B10-
2 was generated and contained only one genomic FRT site, had low basal expression 
levels from the FRT site, and good tetracycline-inducible expression from the FRT site. 
After stable (G4C2)n construct insertion, the NSC34 (G4C2)n cells had the desirable 
characteristics described above. The ability to switch on (G4C2)n expression and the 
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isogenic nature of the cells were  two advantages that the NSC34 (G4C2)n cells had over 
other models such as transiently (G4C2)n transfected  cells or C9ORF72-ALS patient iPSC-
derived motor neurons.  
3.4.3. The HEK293 (G4C2)n and NSC34 (G4C2)n Cells Have Tetracycline-Inducible 
(G4C2)n RNA Expression 
The (G4C2)n repeat is transcribed in both sense and antisense directions, and forms 
characteristic sense (G4C2)n and antisense (C4G2)n RNA foci in the CNS of C9ORF72-
ALS/FTD patients (DeJesus-Hernandez et al., 2011; Gendron et al., 2013; Renton et al., 
2011). Similarly to the (G4C2)n DNA, the sense (G4C2)n RNA forms G-quadruplex 
secondary structures (Fratta et al., 2012; Haeusler et al., 2014; Reddy et al., 2013a). The 
antisense (C4G2)n RNA is suggested to form i-motif secondary structures however, 
although the actual secondary structure remains unresolved (Kovanda et al., 2015). The 
characteristic RNA foci are probably formed by the RNA secondary structure, and/or the 
binding with RNA binding proteins.  
RNA FISH was used to characterise the HEK293 (G4C2)n and NSC34 (G4C2)n cells for 
tetracycline-inducible (G4C2)n expression at the RNA level. As described previously, the 
(G4C2)n repeat cannot be amplified by PCR (section 3.4.1). Equally, there were no 
suitable regions flanking the (G4C2)n for qRT-PCR. RNA FISH, followed by confocal 
microscopy imaging and RNA foci counting was the only reliable method for (G4C2)n 
and (C4G2)n RNA detection in the NSC34 (G4C2)n and HEK293 (G4C2)n cells. Although 
this method is not strictly quantitative of total (G4C2)n or (C4G2)n levels, it did provide 
a relative measure of (G4C2)n and (C4G2)n expression in the cells. Also, the LNA probes 
bound specifically, but they did produce a diffuse background stain. Staining was 
classified as an RNA focus when the signal was strong, spherical in shape, and appeared 
in consecutive planes in the confocal z-stack images. RNase A treatment ablated these 
intense, spherical foci structures in both the NSC34 (G4C2)102 and HEK293 (G4C2)102 
cells, and confirmed that they were RNA foci. 
Using RNA FISH, the number of sense (G4C2)n RNA foci was dependent on the (G4C2)n 
repeat size. Intriguingly however, the number of RNA foci does not follow a linear trend 
with the (G4C2)n repeat size, as NSC34 (G4C2)51 cells induced with tetracycline contain 
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only 10.8±7.40% of the RNA foci number found in the NSC34 (G4C2)102 cells induced 
with tetracycline. Equally, the NSC34 (G4C2)10 cells induced with tetracycline contain 
46.6±59.2% of the RNA foci number found in the NSC34 (G4C2)51 cells induced with 
tetracycline. This is unexpected because the (G4C2)n repeats are all expressed from the 
same CMV/TO promoter from the same isogenic genomic location in the NSC34 (G4C2)n 
cells, suggesting there are the same amount of (G4C2)10, (G4C2)51, and (G4C2)102 RNA 
molecules transcribed. In absolute (G4C2)n repeat terms, the NSC34 (G4C2)102 should 
therefore express double the number of (G4C2)n RNA repeats as the NSC34 (G4C2)51, 
and was predicted to form double the number of RNA foci. 
Only two previous studies have looked at the correlation between RNA foci and (G4C2)n 
repeat length. SHSY5Y cells transfected with (G4C2)8 did not express any RNA foci, whilst 
cells transfected with (G4C2)38, and (G4C2)72 plasmids expressed 6 and 12 RNA foci per 
cell (Lee et al., 2013). This suggests a minimum number of repeats is necessary for RNA 
foci formation and/or detection using RNA FISH. In our hands, the cut off could be 
between 51 and 102 repeats, whilst it may be between 8 and 38 in this previous study. 
Above this number of (G4C2)n repeats there is a roughly linear correlation between RNA 
foci and (G4C2)n repeat length in cell lines however. Conversely, the number of RNA foci 
did not correlate with (G4C2)n repeat expansion length in C9ORF72-ALS iPSC-derived 
neurons (Almeida et al., 2013). Other genetic factors that arise from the great genetic 
diversity in these non-isogenic cells could affect the number of RNA foci however. 
Importantly, the size of the (G4C2)n RNA foci varies greatly even in the same cell line, 
and this is clearly demonstrated in the NSC34 (G4C2)102 (Figure 3.10 inset). Only RNA 
foci above a certain size must be detectable using RNA FISH and confocal microscopy, 
which means only the largest RNA foci formed in the NSC34 (G4C2)10 and NSC34 
(G4C2)51 cells are actually detectable, whilst the majority of RNA may exist as 
undetectable small RNA foci or soluble RNA molecules. Also, the (G4C2)102 RNA may 
aggregate more frequently, resulting in more detectable RNA foci. This could explain the 
lower RNA foci counts in the NSC34 (G4C2)10 and NSC34 (G4C2)51 cells. In addition, this 
suggests that soluble (G4C2)n RNA is not toxic, because (G4C2)10 and (G4C2)51 
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expression does not result in RNA foci and did not affect NSC34 cell viability (section 
3.3.4.5). In contrast, RNA foci and toxcitiy are observed in the the NSC34 (G4C2)102 cells. 
The NSC34 (G4C2)n cells do have tetracycline-inducible (G4C2)n RNA expression 
however. Staining was detected very rarely in the NSC34 sham, but the few foci that 
were detected are most likely non-specific staining. Also, the NSC34 sham cells have the 
same number of RNA foci with and without tetracycline, indicating that tetracycline 
treatment in itself is not sufficient to produce RNA foci. There are more RNA foci in the 
NSC34 (G4C2)10, NSC34 (G4C2)51, and NSC34 (G4C2)102 cells when treated with 
tetracycline compared to the respective non-induced controls, however the increases in 
RNA foci were only significant in the NSC34 (G4C2)102 cells. 
The HEK293 (G4C2)102 cells also have tetracycline inducible (G4C2)n RNA expression. 
RNA foci were detected at very low frequency in the HEK293 sham cells, and similarly to 
the NSC34 sham cells, this staining is most likely to be non-specific. RNA foci were 
abundant in the HEK293 (G4C2)102 cells, and more were detected in the tetracycline 
induced cells than the non-induced cells.  
3.4.4. The NSC34 (G4C2)n Cells Do Not Express Antisense (C4G2)n RNA Foci 
In C9ORF72-ALS/FTD patients, the (G4C2)n repeat is transcribed in the antisense 
direction from a cryptic promoter, and forms characteristic antisense (C4G2)n RNA foci 
(Gendron et al., 2013). There were no antisense (C4G2)n RNA foci detected in the NSC34 
(G4C2)102 cells. This is expected as the (G4C2)n repeats were only engineered under 
control of a sense CMV/TO promoter in the NSC34 (G4C2)n cells, and the antisense 
cryptic promoter found in the C9ORF72 gene context is absent. The antisense (C4G2)n 
RNA FISH probe did detect antisense (C4G2) RNA foci in HEK293 cells transiently 
transfected with (C4G2)102 constructs however, proving that the probe and assay do 
work. This means the NSC34 (G4C2)n cells specifically model sense (G4C2)n repeat 
expression independent of the C9ORF72 gene context. 
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3.4.5. The (G4C2)n Constructs Undergo RAN Translation in the HEK293 (G4C2)102 and 
NSC34 (G4C2)102 Cells 
The (G4C2)n undergoes non-canonical RAN translation in cells throughout the CNS of 
C9ORF72-ALS/FTD patients, producing DPRs (Ash et al. 2013; Gendron et al. 2013; Mori 
et al. 2013a; Mori et al. 2013b). There is also strong evidence that the (G4C2)n repeat is 
RAN translated in the NSC34 (G4C2)102 cells, and interestingly, this shows that the 
(G4C2)102 RNA can form the secondary structure necessary to drive RAN translation 
despite containing interruptions. Firstly, DPR expression plasmids were transfected into 
HEK293 cells and immunoblotted using DPR antibodies. This showed the antibodies 
recognise the relevant DPR proteins. The DPR antibodies that detect DPR translated 
from the sense (G4C2)n RNA (anti-GA, anti-GR, and anti-GP) detect proteins at 24 and 
27kDa specifically in the NSC34 (G4C2)102 cells treated with tetracycline, but not in the 
NSC34 sham cells. Secondly, tetracycline induction increases the amount of these 
proteins. Taken together with the RNA FISH result, which showed that NSC34 (G4C2)102 
cells have tetracycline-inducible (G4C2)n RNA expression (measured by number of RNA 
foci), it confirms that the expression of the (G4C2)102 translated proteins is dependent 
on the expression of the (G4C2)102 RNA. Thirdly, there are no detectable proteins 
containing the antisense-specific DPR (AP and PR) that are specifically expressed in the 
NSC34 (G4C2)102 cells, and not the NSC34 sham cells. This supports the lack of antisense 
(C4G2)n RNA foci, and by extension, the lack of (G4C2)n transcription in the antisense 
direction. Lastly, when the (G4C2)n repeats were cloned into the pcDNA5/FRT/TO-HIS 
plasmids, the HIS tag and associated ATG codon were removed. This was confirmed by 
restriction digest of the plasmid and sequencing. Therefore, translation of the 
(G4C2)102 repeats is via RAN translation in the absence of an ATG start codon. 
Several of the anti-DPR antibodies also detect non-DPR proteins, which is relatively 
unsurprising since the simple dipeptide motif that the antibodies recognise is likely to 
be contained in other proteins as well. Importantly, initial DPR immunoblot 
characterisation in the NSC34 (G4C2)n cells was performed solely using the anti-GA 
antibody, which failed to detect specific proteins in the NSC34 (G4C2)102 cells. This was 
because the anti-GA recognises a different protein at 40kDa that is much more abundant 
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than the (G4C2)102 translation products (Figure 3.14A). This made (G4C2)102 
translation product detection difficult. Only after interrogating the immunoblots using 
an increased exposure time were the (G4C2)102 translation products detected. 
The proteins translated from the interrupted (G4C2)102 repeats contain each of the 
three sense DPR motifs (Figure 3.13). This is because during translation of the 
interrupted (G4C2)n repeats, the 5 bp TCGAC interruptions cause a ‘frame shift’ to the 
next DPR motif. Therefore a different DPR motif is translated from each (G4C2)n repeat 
tract, but these different DPR motifs all exist in the same polypeptide. This means the 
protein bands at 24 and 27kDa detected by the anti-GA, anti-GR, and anti-GP are 
probably the same polypeptides, although this would require mass spectrometry to 
prove unequivocally. Unexpectedly however, the maximum predicted molecular weight 
for (G4C2)102 translation products is approximately 20.5kDa. The extra mass could be 
explained by post-translational modifications such as ubiquitination. 
The evidence for RAN translation in the NSC34 (G4C2)102 cells is also true in the HEK293 
(G4C2)102 cells. This shows the (G4C2)102 repeat construct is the necessary variable 
needed for RAN translation, in either the NSC34 or HEK293 cells. However, there are 
more detectable bands in the HEK293 (G4C2)102 cells treated with tetracycline using 
the anti-GA and anti-GP antibodies. This is possibly due to higher expression levels of 
the (G4C2)102 RAN proteins in the HEK293 (G4C2)102 cells compared to the NSC34 
(G4C2)102, because the RAN protein signal is greater relative to the non-specific bands 
on the blot. This is most apparent in the anti-GA immunoblot (Figure 3.14B). This also 
means that the (G4C2)102 may produce multiple different molecular weight RAN 
proteins in the NSC34 (G4C2)102 cells, but the signal is too weak to be detected by the 
imaging system. Also, unexpectedly, there are high molecular weight bands detected by 
the anti-AP antibody specifically in the HEK293 (G4C2)102 cells, but not the HEK293 
sham cells. This suggests that a promoter does control transcription of the (G4C2)102 
repeat in the antisense direction, producing a polypeptide with the poly(AP) motif. 
Similarly to the (AP)100 used as the positive control, this polypeptide appears to have 
been trapped in the loading well at the top of the gel. Due to the huge difference in 
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molecular weights however, the AP containing polypeptide is different to the sense RAN 
peptides containing GA, GR and GP motifs. 
3.4.6. (G4C2)102 Expression Reduces NSC34 Cell Growth Rate 
The (G4C2)102 reduces NSC34 cell growth rate, but does not cause cell death. During 
preliminary cell viability assays it was discovered that 10μg/mL tetracycline is actually 
toxic to NSC34 cells. Optimisation suggested 0.5μg/mL tetracycline was a better dosage, 
as it did not reduce NSC34 sham cell viability, but did still induce (G4C2)n RNA foci 
expression in NSC34 (G4C2)102 cells. The MTT cell viability assay showed that expression 
of the (G4C2)10 and (G4C2)51 do not affect NSC34 cell viability. However, expression of 
the (G4C2)102 significantly reduced NSC34 cell viability after 7 days tetracycline 
induction, and appears to be above a threshold repeat length necessary to cause toxicity 
in the NSC34 cells. The EthD1 cell death assays showed that the reduced NSC34 cell 
viability was not due to an increase in NSC34 cell death, because there was no significant 
difference in % dead cells between NSC34 (G4C2)102 induced with tetracycline for 7 
days, and non-induced NSC34 (G4C2)102. However, although not statistically significant, 
there was a greater % of dead cells in the NSC34 (G4C2)102 compared to the NSC34 
sham. This could suggest that long term basal (G4C2)102 expression does contribute to 
a greater rate of cell death. The best explanation for the reduced NSC34 cell viability 
measured in the MTT assay is a reduction in growth rate however. In the growth curve, 
NSC34 (G4C2)102 cells induced with tetracycline grew slower than NSC34 sham ± 
tetracycline, and NSC34 (G4C2)102 cells that were not induced with tetracycline. This 
suggests expression of the (G4C2)102 dysregulates the NSC34 cell metabolism at some 
level, and causes a reduction in growth rate. 
The toxic effects measured in the NSC34 (G4C2)102 cell model are similar to those 
described in previous (G4C2)n cell model studies (section 1.8.2.1), although the effects 
are more subtle in the NSC34 (G4C2)102 cells. Transient transfection of plasmids 
expressing (G4C2)30, but not (G4C2)3, reduce Neuro2a cell viability (Xu et al., 2013). 
Also, transient transfection of plasmids expressing (G4C2)38 and (G4C2)72, but not 
(G4C2)8, cause apoptosis in SHSY5Y neuronal cells (Lee et al., 2013). These plasmids do 
not induce apoptosis in HEK293 cells however (Lee et al., 2013). Further, several studies 
118 
 
 
using iPSC-derived neuronal cells and motor neuronal cells, derived from C9ORF72-ALS 
fibroblasts do not report reduced cell viability or increased cell death compared to 
control derived cells (Almeida et al., 2013; Devlin et al., 2015; Donnelly et al., 2013; 
Sareen et al., 2013). The expression level of C9ORF72 and the associated (G4C2)n 
repeats is likely to be much lower in iPSC derived neuronal cells than in the transient 
transfection models and the NSC34 (G4C2)n cells described here, which utilise strong 
promoters such as the CMV promoter. Therefore, the level of toxicity is probably a 
combination of the (G4C2)n repeat length, expression level, cell type, and ability of the 
(G4C2)n RNA to form secondary structure and/or DPR. 
Crucially, ALS disease onset is age related, and therefore C9ORF72-ALS pathogenesis 
requires a ‘second hit’ (such as reduced mitochondrial efficiency or neuroinflammation) 
in combination with the (G4C2)n repeat derived toxicity. Therefore, the (G4C2)n repeat 
expansion is likely to produce low, or at least well tolerated, toxicity in the motor 
neurons. With this hypothesis in mind, the subtler toxic phenotype described in the 
NSC34 (G4C2)102 cells likely represents a more relevant model of C9ORF72-ALS than 
those cellular models that display more severe toxicity. 
3.4.7. Summary 
In summary, stable, isogenic, motor neuron-like NSC34 cell lines with tetracycline-
inducible (G4C2)n expression have been successfully generated. The (G4C2)n is 
expressed in the NSC34 (G4C2)n cells in a tetracycline-inducible manner, and forms 
characteristic RNA foci. A unique advantage of the tetracycline-inducible (G4C2)n 
expression over other C9ORF72-ALS models, is that early biochemical effects can be 
studied. Additionally, the (G4C2)n RNA undergoes RAN translation to produce 
polypeptides containing all three sense DPR motifs (GA, GR, and GP). The NSC34 (G4C2)n 
cells express the (G4C2)n in the sense orientation only. Finally, tetracycline-induction of 
the (G4C2)102 RNA and/or RAN proteins reduces NSC34 cell growth rate. 
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Chapter 4 
 
Chapter 4. Biochemical Analysis of the NSC34 
(G4C2)n Cell Lines 
4.1. Introduction 
Initial characterisation of the NSC34 (G4C2)n cell lines showed that they have 
tetracycline-inducible expression of the (G4C2)n repeat, the (G4C2)n RNA forms RNA 
foci and is RAN translated, the (G4C2)n repeat is expressed in the (G4C2)n sense 
orientation only, and prolonged (G4C2)n expression reduced NSC34 (G4C2)102 growth 
rate. Next, biochemical analysis was performed to establish whether the NSC34 (G4C2)n 
cells recapitulate key pathological hallmarks of ALS in general, and specifically of 
C9ORF72-ALS. Importantly, NSC34 viability was only affected by (G4C2)102 expression, 
and not by (G4C2)51 or (G4C2)10 expression in the NSC34 (G4C2)n cell lines, and 
therefore, the early biochemical effects of (G4C2)n repeat expression would be most 
pronounced in the NSC34 (G4C2)102 cells. For that reason, and to conserve resources, 
only NSC34 sham and NSC34 (G4C2)102 cells were used in the biochemical 
characterisation experiments. 
4.2. Aims and Objectives for Biochemical Analysis of NSC34 (G4C2)n Cells 
1) Characterise NSC34 (G4C2)102 cells for TDP-43 aggregation and/or mis-
localisation, and oxidative stress. 
2) Characterise NSC34 (G4C2)102 cells for RNA foci and RNA binding protein co-
localisation. 
3) Interrogate potential biochemical effects of RNA binding protein sequestration 
using functional assays. 
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4.3. Results  
4.3.1. NSC34 (G4C2)102 Cells Do Not Display TDP-43 Mislocalisation or Aggregation 
TDP-43 is predominantly a nuclear protein that shuttles between the nucleus and 
cytoplasm of healthy cells. However, TDP-43 becomes mislocalised in the cytoplasm and 
forms aggregates in the neuronal and glial cells of most ALS patients (excluding SOD1 
and FUS related ALS cases, but including C9ORF72-ALS cases) (Neumann et al., 2006). 
These cytoplasmic TDP-43 aggregates are a pathological hallmark of ALS. ICC was 
performed on the NSC34 (G4C2)102 and NSC34 sham ± tetracycline to assess whether 
(G4C2)102 expression in this model system would cause TDP-43 aggregation or 
mislocalisation. In both the NSC34 sham and NSC34 (G4C2)102 cells ± tetracycline, TDP-
43 is predominantly nuclear with some cytoplasmic staining (Figure 4.1). There is no 
difference in nuclear and cytoplasmic TDP-43 distribution between the NSC34 sham and 
NSC34 (G4C2)102 cells (Figure 4.1). Also, TDP-43 is mainly diffuse in both the nucleus 
and cytoplasm, but there are also distinct small puncta structures in the nucleus and 
cytoplasm (Figure 4.1). There are no measurable changes in TDP-43 staining in the 
NSC34 (G4C2)102 compared to the NSC34 sham (Figure 4.1). In addition, tetracycline 
induction did not affect TDP-43 nuclear cytoplasmic distribution or staining in either the 
NSC34 sham or NSC34 (G4C2)102 cells (Figure 4.1). The TDP-43 ICC stained NSC34 sham 
and (G4C2)102 cells shown here were induced with tetracycline for 9 days, but showed 
the same results as NSC34 cells that were induced with tetracycline for shorter periods 
of time. The rationale was to induce (G4C2)102 for longer than 6 days (after which 
toxicity is observed in the NSC34 (G4C2)102 cells). If the (G4C2)102 expression did have 
an effect of TDP-43 localisation, it was predicted to have occurred by 9 days tetracycline 
induction. 
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Figure 4.1 (G4C2)102 expression does not cause TDP-43 mislocalisation or aggregation 
in NSC34 cells. NSC34 sham and (G4C2)102 cells were cultured for 9 days ±0.5µg/mL 
tetracycline. Cells were stained for TDP-43 (Green) and Dapi (Blue). Scale bar = 10µm. 
4.3.2. NSC34 (G4C2)102 Cells Do Not Have Increased Cellular Levels of Hydroxyl, 
Peroxyl, or Other Reactive Oxygen Species 
Oxidative stress occurs when the production of reactive oxygen species (ROS) and their 
removal becomes imbalanced, and/or the ability of the biological system to repair 
oxidative damage caused by ROS becomes impaired. ROS disrupt redox sensitive cellular 
signalling and also damage DNA, RNA, proteins and lipids. Post-mortem tissue from ALS 
patients is widely reported to show increased levels of oxidative damage (Chang et al., 
2008; Ferrante et al., 1997; Fitzmaurice et al., 1996; Shaw et al., 1995; Shibata et al., 
2001).  
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Hydroxyl, peroxyl and other ROS levels were assessed in the NSC34 sham and NSC34 
(G4C2)102 cells using the DCF assay. DCFDA is a cell permeant, fluorogenic dye. Once 
diffused through the plasma membrane, DCFDA is deacetylated by cellular esterases to 
produce a non-fluorescent, lipid membrane impermeant compound. Importantly, the 
removal of the acetyl group traps the compound inside the cell but also allows the DCF 
compound to be activated by hydroxyl, peroxyl and other cellular ROS, to produce 
fluorescent DCF. Therefore, DCF fluorescence directly measures the levels of these 
particular ROS within the cells. DCF data was normalised to total cell number, which was 
measured using EthD1 after freeze-thawing the cells. Firstly, as a positive control for the 
DCF assay, NSC34 cells were treated with menadione, which induces cellular ROS 
generation. The DCF fluorescence signal was significantly increased in the NSC34 sham 
and NSC34 (G4C2)102 cells treated with menadione, compared to the respective 
untreated control cells (Figure 4.2A). There was no significant difference in DCF signal 
between the untreated NSC34 sham and NSC34 (G4C2)102 cells either (Figure 4.2A). 
The significant increase in DCF signal caused by the menadione showed the assay could 
detect differences in cellular ROS levels. The NSC34 sham and NSC34 (G4C2)102 cells 
were then cultured for 5 days, and induced with tetracycline for various lengths of time. 
The hypothesis being, that ROS levels would increase with time if the (G4C2)102 
expression induced oxidative stress. There was no significant difference in DCF-
detectable ROS levels between NSC34 sham and NSC34 (G4C2)102 cells after any of the 
tetracycline inductions (Figure 4.2B). 
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Figure 4.2 (G4C2)102 expression does not cause oxidative stress in NSC34 cells. The 
level of Reactive Oxygen Species (ROS) in the NSC34 cells was measured using the DCF 
assay, and normalised to cell number (measured after cell lysis using EthD1 fluorescence 
assay). A) NSC34 sham and NSC34 (G4C2)102 cells were treated with 100mM 
menadione for 24 h as a positive control for the DCF assay. B) NSC34 sham and 
(G4C2)102 cells were cultured for 5 days, and were induced for various lengths of time 
with 0.5μg/mL tetracycline. (**P<0.01; ***P<0.001; Two-way ANOVA with Tukey’s post 
hoc test; Data are means ± SD; n=3). 
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4.3.3. RNA Foci Co-Localise with some RNA Binding Proteins in NSC34 (G4C2)102 Cells 
The RNA sequestration hypothesis was one of the first proposed to explain how the 
(G4C2)n repeat expansion causes C9ORF72-ALS. The (G4C2)n and/or (C4G2)n RNA is 
suggested to bind and sequester RNA binding proteins (RBP), resulting in disrupted RNA 
metabolism. Therefore, various groups (including our own) performed in vitro (G4C2)n 
RNA pull downs in conjunction with mass spectrometry and/or western blotting to 
identify candidate binding proteins (Cooper-Knock et al., 2014b; Donnelly et al., 2013; 
Haeusler et al., 2014; Lee et al., 2013; Mori et al., 2013b; Rossi et al., 2015; Xu et al., 
2013). Subsequently, many of these RBP were shown to co-localise with the (G4C2)n 
RNA foci in either cell models or C9ORF72-ALS post mortem tissue, suggesting in vivo 
sequestration (Cooper-Knock et al., 2014b; Donnelly et al., 2013; Haeusler et al., 2014; 
Lee et al., 2013; Mori et al., 2013b; Rossi et al., 2015; Xu et al., 2013).  
The NSC34 (G4C2)102 cells were co-stained for sense (G4C2)n RNA foci as well as a 
selection of these RBP that have previously been shown to bind and/or localise with the 
RNA foci. The aim was firstly to see whether the interrupted (G4C2)102 repeat RNA 
would model the (G4C2)n repeat expansion of C9ORF72-ALS, and secondly, to see 
whether the reduced growth rate caused by the (G4C2)102 expression in the NSC34 
(G4C2)102 could be caused by RBP sequestration. 50 cells were analysed for each RNA 
foci-RBP co-stain, and RNA foci-RBP co-localisation was performed manually. 
During the experimental work up it was discovered that following RNA FISH, the 
subsequent ICC procedure was washing away RNA FISH staining. This was possibly 
because the PBS used in antibody staining incubations and washes altered the salt 
concentration which caused the probe to wash off. Therefore, the protocol was 
optimised to include a crosslinking step (using UV or PFA) after the RNA FISH procedure, 
and before the ICC procedure. The crosslinking step using UV improved the RNA FISH 
stain, and was therefore incorporated into the co-stain method. UV crosslinking causes 
molecules to form new covalent bonds with other molecules in close proximity, and 
therefore, it was predicted to strengthen the binding between the RNA FISH probe and 
the (G4C2)n RNA. 
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4.3.3.1. (G4C2)n RNA Foci Co-Localise with SRSF1 in the NSC34 (G4C2)102 Cells 
Serine/Arginine-Rich Splicing Factor 1 (SRSF1/SF2/ASF) is an RBP that is involved in 
multiple gene expression processes including mRNA splicing (Ge and Manley, 1990; 
Krainer et al., 1990), nonsense-mediated mRNA decay (Sato et al., 2008; Zhang and 
Krainer, 2004), nuclear export of mRNA (Huang et al., 2003; Lai and Tarn, 2004; Tintaru 
et al., 2007), translation (Michlewski et al., 2008; Sanford et al., 2004), and miRNA 
processing (Wu et al., 2010). 19.5% of RNA foci in the 50 counted NSC34 (G4C2)102 cells 
co-localised with SRSF1 puncta (Figure 4.3). 
 
Figure 4.3 (G4C2)n RNA foci co-localise with SRSF1 in NSC34 (G4C2)102 cells. NSC34 
(G4C2)102 cells were induced with 0.5µg/mL tetracycline for 5 days. Cells were then 
stained with a Locked Nucleic Acid (C4G2)3 sense probe (Red), anti-SRSF1 (Green), and 
Dapi (Blue). 50 nuclei were imaged using a confocal microscope, and the RNA foci-SRSF1 
puncta colocalisation was quantified. The image shown is one z-plane imaged using the 
confocal microscope. Scale bar = 10μm, Inset = 5X magnification. 
4.3.3.2. (G4C2)n RNA Foci Co-Localise with SRSF2 in the NSC34 (G4C2)102 Cells 
Serine/Arginine-Rich Splicing Factor 2 (SRSF2/SC35) is another Serine/Arginine-Rich 
protein, and similarly to SRSF1, is involved in multiple gene expression processes 
including mRNA splicing (Fu and Maniatis, 1990; Fu et al., 1992), transcription elongation 
(Lin et al., 2008), nonsense-mediated mRNA decay (Zhang and Krainer, 2004). 11.9% of 
RNA foci in the 50 counted NSC34 (G4C2)102 cells co-localised with SRSF2 puncta (Figure 
4.4). 
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Figure 4.4 (G4C2)n RNA foci co-localise with SRSF2 in NSC34 (G4C2)102 cells. NSC34 
(G4C2)102 cells were induced with 0.5μg/mL tetracycline for 5 days. Cells were then 
stained with a Locked Nucleic Acid (C4G2)3 sense probe (Red), anti-SRSF2 (Green), and 
DAPI (Blue). 50 nuclei were imaged using a confocal microscope, and the RNA foci-SRSF2 
puncta colocalisation was quantified. The image shown is one z-plane imaged using the 
confocal microscope. Scale bar = 10μm, Inset = 5X magnification. 
4.3.3.3.  (G4C2)n RNA Foci Do Not Co-Localise with PURA in the NSC34 (G4C2)102 Cells 
 
Figure 4.5 (G4C2)n RNA foci do not co-localise with PURA in NSC34 (G4C2)102 cells. 
NSC34 (G4C2)102 cells were induced with 0.5μg/mL tetracycline for 5 days. Cells were 
then stained with a Locked Nucleic Acid (C4G2)3 sense probe (Red), anti-PURA (Green), 
and DAPI (Blue). 50 nuclei were imaged using a confocal microscope, and the RNA foci-
PURA puncta co-localisation was quantified. The image shown is one z-plane imaged 
using the confocal microscope. Scale bar = 10μm, Inset = 5X magnification. 
Purine-Rich Element Binding Protein A (PURA) is a multifunctional protein that binds 
single-stranded DNA and RNA, and is involved in transcription (Haas et al., 1993; Haas 
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et al., 1995; White et al., 2009), mRNA transport and translation (Ohashi et al., 2000; 
Ohashi et al., 2002), DNA replication (Chang et al., 1996; Jurk et al., 1996), and DNA 
repair (Wang et al., 2007). The PURA staining was fairly diffuse throughout the 
cytoplasm and nuclei, but occasional large PURA aggregates were also detected (Figure 
4.5). There was no evidence of RNA foci and PURA co-localisation in the NSC34 
(G4C2)102 cells (Figure 4.5). 
4.3.3.4. (G4C2)n RNA Foci Do Not Co-Localise with ALYREF in the NSC34 (G4C2)102 Cells 
ALY/REF Export Factor (ALYREF) is involved in mRNA nuclear export (Rodrigues et al., 
2001; Zhou et al., 2000). ALYREF staining was diffuse throughout the nuclei in the NSC34 
(G4C2)102 cells (Figure 4.6). There was no evidence of RNA foci and ALYREF co-
localisation in the NSC34 (G4C2)102 cells (Figure 4.6). 
 
Figure 4.6 (G4C2)n RNA foci do not co-localise with ALYREF in NSC34 (G4C2)102 cells. 
NSC34 (G4C2)102 cells were induced with 0.5μg/mL tetracycline for 5 days. Cells were 
then stained with a Locked Nucleic Acid (C4G2)3 sense probe (Red), anti-ALYREF (Green), 
and DAPI (Blue). 50 nuclei were imaged using a confocal microscope. The image shown 
is one z-plane imaged using the confocal microscope. Scale bar = 10μm, Inset = 5X 
magnification. 
4.3.3.5. (G4C2)n RNA Foci Co-Localise with Nucleolar NCL in the NSC34 (G4C2)102 Cells 
Nucleolin (NCL) is another multifunctional RNA binding protein that is most abundant in 
the nucleolus. NCL is involved in multiple RNA and DNA processing events including 
ribosomal RNA (rRNA) transcription, rRNA maturation, and ribosome biogenesis (Ginisty 
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et al., 1998; Ginisty et al., 2000; Roger et al., 2003), mRNA transcription (Uribe et al., 
2011), chromatin remodelling (Angelov et al., 2006; Yang et al., 1994), DNA replication 
(Seinsoth et al., 2003), telomere maintenance (Khurts et al., 2004), and DNA repair (Yang 
et al., 2009). 22.6% of RNA foci co-localised with the nucleolar NCL in the 50 counted 
NSC34 (G4C2)102 cells (Figure 4.7A). The RNA FISH-NCL co-stain was also performed on 
C9ORF72-ALS CNS tissue, and NCL co-localised with RNA foci in both cerebellar granule 
and Purkinje neurons (Figure 4.7B). 
 
Figure 4.7 (G4C2)n RNA foci co-localise with NCL in NSC34 (G4C2)102 cells and 
C9ORF72-ALS CNS tissue. A) NSC34 (G4C2)102 cells were induced with 0.5µg/mL 
tetracycline for 5 days. Cells were then stained with a Locked Nucleic Acid (C4G2)3 sense 
probe (Red), anti-NCL (green), and Dapi (Blue). 50 nuclei were imaged using a confocal 
microscope, and the RNA foci-nucleolar NCL co-localisation was quantified. The image 
shown is one z-plane imaged using the confocal microscope. Scale bar = 10μm, Inset = 
5X magnification. B) Cerebellar slices from C9ORF72-ALS cases were stained with a 
Locked Nucleic Acid (C4G2)3 sense probe (Red), anti-NCL (Green) and Dapi (Blue). The 
image shown is one z-plane imaged using the confocal microscope. Scale bar = 3µm. 
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4.3.4. (G4C2)102 Expression Does Not Cause Functional Nucleolar Stress in NSC34 
(G4C2)102 Cells 
4.3.4.1.  (G4C2)102 Expression Disrupts Nucleolar Morphology in NSC34 (G4C2)102 Cells 
NCL is a major functional protein of the nucleolus and sequestration by (G4C2)n RNA 
was hypothesised to cause nucleolar stress. Fragmented and/or enlarged nucleoli would 
indicate nucleolar stress in the NSC34 (G4C2)102 cells. NSC34 sham and NSC34 
(G4C2)102 cells were cultured ± tetracycline for 5 days, and then fixed and stained for 
NCL. NCL staining in the NSC34 cells was visualised using a confocal microscope. A z-
stack made up of images at 0.5µm intervals through the entire nuclear volume of the 
cells under consideration was imaged. The images shown in Figure 4.8A are a maximum 
projection of the z-stack, such that the total nucleolar area in each cell can be seen and 
quantified. NCL was localised abundantly in multiple compact globular nucleoli, but was 
also less abundantly localised diffusely throughout the nucleus in both the NSC34 sham 
and NSC34 (G4C2)102 ± tetracycline (Figure 4.8A). Extra-nuclear NCL puncta were also 
common in the NSC34 cells sham and (G4C2)102 ± tetracycline (Figure 4.8A). 
A previously published method was used to quantify the nucleolar area in the NSC34 
cells (Haeusler et al., 2014). A threshold of 50-100 was set in FIJI to measure the 
nucleolar NCL area, and exclude the diffuse nuclear NCL staining. The nucleolar NCL area 
was then normalised to the nuclear area, which was quantified by measuring the DAPI 
stained area. There was no significant difference in the nucleolar area (as a percentage 
of the nucleus) between NSC34 sham cells treated and untreated with tetracycline, 
where the nucleolar area was 23.7±1.8% and 22.1±3.3% respectively (Figure 4.8B). The 
nucleolar area was increased in the NSC34 (G4C2)102 cells, where the nucleolar area 
was 24.8 ± 1.3% and 30.6±2.2% in NSC34 (G4C2)102 cells untreated and treated with 
tetracycline respectively (Figure 4.8B). The nucleolar area was significantly increased in 
the NSC34 (G4C2)102 induced with tetracycline compared to NSC34 sham cells treated 
with tetracycline (P<0.01) (Figure 4.8B). 
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Figure 4.8 (G4C2)102 expression causes nucleolar fragmentation and dispersion in 
NSC34 (G4C2)102 cells. A) NSC34 (G4C2)102 cells were cultured with 0.5µg/mL 
tetracycline for 5 days. Cells were then stained with anti-NCL (Green), and Dapi (Blue) 
and imaged using a confocal microscope within a z-stack through the entire nuclear 
volume. The images shown are projections of the z-stack to show the maximum 
nucleolar area in the cells. The area of the nucleoli was measured as a percentage of 
total nuclear area. Scale bar = 10µm. B) Quantification of the nucleolar area as a 
percentage of nuclear area (**P<0.01; Two-way ANOVA with Tukey’s multiple 
comparisons post hoc test; Data are means ± SD; n=3). 
131 
 
 
4.3.4.2.  (G4C2)102 Expression Does Not Affect rRNA Levels 
To assess nucleolar function, the processing and maturation of 45S pre-rRNA, and the 
levels of mature rRNA species were measured. In the nucleolus, the precursor 45S pre-
rRNA is transcribed from rDNA genes, and is then processed to form the mature 18S, 
5.8S, and 28S rRNA species. The 45S pre-rRNA molecule is very short lived, and is 
considered a sign of new rRNA transcription (Uemura et al., 2012). In addition, the levels 
of mature rRNA species present would indicate the amount of rRNA available for 
ribosome biogenesis, and also the maturation from pre-rRNA to mature rRNA (when 
rRNA is normalised to pre-rRNA). Therefore, reduction in 45S pre-RNA and/or mature 
rRNA levels would indicate impaired nucleolar function.  
Total RNA was isolated from the NSC34 sham and NSC34 (G4C2)102 cells (both treated 
with tetracycline for 5 days), and qRT-PCR was performed to quantify the precursor 45S 
pre-rRNA, and the mature 18S, 5.8S and 28S rRNA species. There was no significant 
difference in 45s pre-rRNA, or any of the mature rRNA species in the NSC34 (G4C2)102 
compared to NSC34 sham cells (Figure 4.9A), indicating pre-rRNA transcription is 
unaffected. In addition, there was no significant difference in any of the mature rRNA 
species when normalised to the 45S pre-rRNA in the NSC34 (G4C2)102 compared to the 
NSC34 sham cells (Figure 4.9B), indicating pre-rRNA maturation is unaffected.  
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Figure 4.9 Ribosomal RNA maturation is not affected by (G4C2)102 expression in 
NSC34 cells. NSC34 sham and NSC34 (G4C2)102 cells were grown for 5 days with 
0.5μg/mL tetracycline. qRT-PCR was performed on 45S pre-rRNA, and mature 18S rRNA, 
5.8S rRNA, and 28S rRNA species, and normalised to β-actin (A) or 45S pre-rRNA (B) 
(Multiple t-tests; Data are means ± SD; n=3). 
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4.3.4.3. NSC34 (G4C2)102 Show Mild Translation Defects 
Mature rRNA is assembled into the 60S and 40S ribosomal subunits in the nucleolus 
(Kressler et al., 1999; Venema and Tollervey, 1999). The 60S and 40S ribosomal subunits 
are then exported to the cytoplasm, where they can assemble onto mRNA forming the 
80S translation initiation complex (Jackson et al., 2010). Once the 80S ribosome starts 
translating the mRNA, subsequent ribosomes can bind and translate the same mRNA 
molecule forming a polyribosome (polysome) complex (Jackson et al., 2010). Polysome 
profiling was performed to assess the translation efficiency in the NSC34 (G4C2)102 
cells. It was predicted that nucleolar stress would lead to reduced ribosomal biogenesis, 
and translation defects.  
NSC34 (G4C2)102 and NSC34 sham cells were cultured for 6 days with tetracycline, and 
then translation was stalled, cells were lysed, and ribosome fractionation was 
performed using sucrose density centrifugation. Ribosomes were separated into the 
soluble proteins, 40S and 60S ribosomal subunits, 80S initiation complex, and 
polysomes. Once the lysate was separated, the sucrose gradient protein content was 
measured by UV absorbance. NSC34 sham and NSC34 (G4C2)102 cells produced similar 
profiles in each of three experiments, and a representative profile is shown in Figure 
4.10A. There were slight differences between the polysome profiles from the NSC34 
(G4C2)102 and sham, but these differences were inconsistent across the three 
experimental repeats. The 40S peak was undetectable, but is likely in fraction 11 and 12 
and hidden in the large soluble shoulder peak (Figure 4.10A). The 60S ribosomal subunit 
is in fractions 11-13 (Figure 4.10A), and corresponds with the increased 60S Ribosomal 
Protein L26 (RPL26) detected by immunoblot of the sucrose fractions (Figure 4.10B). The 
80S initiation complex is in fractions 13-15 (Figure 4.10A), and corresponds with the 
abundant RPL26 bands detected by immunoblot (Figure 4.10B). The multiple peaks in 
fractions 16-21 (Figure 4.10A) also contain RPL26 (Figure 4.10B), confirming that they 
are the polysomes. The NSC34 (G4C2)102 cells appear to have slightly less RPL26 in 
fractions 11-21 compared to the NSC34 sham cells (Figure 4.10B), but this finding was 
weak and inconsistent across the three experimental repeats. There was consistently 
more RPL26 in fractions 2-7, which correspond to the soluble protein fractions (Figure 
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4.10B). The amount of soluble RPL26 was normalised to α-tubulin in those fractions, and 
there was 100±111% more soluble RPL26 in the NSC34 (G4C2)102 compared to NSC34 
sham cells (Figure 4.10C). 
4.3.4.4. (G4C2)102 Expression Increases p53 Protein Levels in NSC34 (G4C2)102 Cells 
Ribosome biogenesis consumes a huge amount of cellular energy, and therefore many 
metabolic and signalling pathways regulate or are affected by the nucleolus (James et 
al., 2014). The nucleolus acts as a principle stress sensor, and initiates p53-dependent 
cell cycle arrest, which can lead to senescence or apoptosis, under cellular stress (Rubbi 
and Milner, 2003). NCL itself is involved in p53 regulation, and binds the 5’UTR of p53 
mRNA inhibiting p53 translation (Takagi et al., 2005). NCL sequestration by the (G4C2)n 
RNA could therefore lead to increased p53 translation and cell cycle arrest or apoptosis. 
In addition, RPL26 also binds the 5’UTR of p53 mRNA, but unlike NCL binding, RPL26 
activates p53 translation (Takagi et al., 2005). 
p53 protein levels were increased by 191±95.8% (P<0.01) in NSC34 (G4C2)102 cells 
induced with tetracycline compared to NSC34 sham induced with tetracycline (Figure 
4.11A-B). p53 protein levels were not affected by tetracycline in the NSC34 sham cells 
(Figure 4.11A-B). To identify whether the increased p53 protein levels could be caused 
by an increase in p53 translation, RNA was extracted from sucrose fractions containing 
translating ribosomes in the polysome profiling experiment (Figure 4.10A-B), and qRT-
PCR was performed for p53 and actin. There was a 61±147% increase in p53 mRNA in 
the translating ribosomes in the NSC34 (G4C2)102 + tet compared to NSC34 sham + tet, 
although this difference was not statistically significant (Figure 4.11C). 
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Figure 4.10 (G4C2)102 expression increases soluble RPL26 in NSC34 cells. NSC34 sham 
and NSC34 (G4C2)102 cell were cultured for 6 days with 0.5μg/mL tetracycline. The 
translating ribosomes (polysomes) were stalled, cells were lysed, and the ribosomal 
subunits and complexes were separated using sucrose density gradient centrifugation. 
The polysome profiles were measured using a FPLC machine, and sucrose fractions were 
collected. A) A representative polysome profile from the NSC34 cells, showing ribosomal 
subunits, 80S initiation complex, and polysomes. B) Fractions were immunoblotted for 
RPL26 and α-tubulin. C) Quantification of soluble RPL26 (fractions 2-7) normalized to α-
tubulin. (Data are means ± SD; n=3). 
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Figure 4.11 (G4C2)102 expression increases p53 protein levels. NSC34 sham and NSC34 
(G4C2)102 cells were cultured for 6 days with or without 0.5μg/mL tetracycline. A) Cells 
were lysed and immunoblotted with anti-p53 and anti-α-tubulin. Molecular weight 
markers are indicated (kDa). B) Quantification of p53 protein normalised to α-tubulin 
(**P<0.01; Two-way ANOVA with Tukey’s multiple comparisons post hoc test; Data are 
means ± SD; n = 3). C) After polysome profiling, RNA was extracted from fractions 20 
and 21 (containing the translating polysomes) and qRT-PCR was performed on p53 and 
normalised to β-actin (t-test; Data are means ± SD; n=3).   
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4.4. Discussion 
4.4.1. There Is No TDP-43 Mislocalisation or Aggregation 
TDP-43 aggregates and mislocalisation are the pathological hallmarks of most genetic 
subtypes of ALS, including C9ORF72-ALS. However, it is unknown whether (G4C2)n 
expression, and/or C9ORF72 haploinsufficiency causes TDP-43 pathology in C9ORF72-
ALS. The NSC34 (G4C2)102 cells are an inducible model of C9ORF72-ALS, and any effects 
in this model are early biochemical effects. There was no evidence of TDP-43 
mislocalisation or aggregation in the NSC34 (G4C2)102 cells, and this is in agreement 
with the majority of other C9ORF72-ALS models (section 1.8.2). This is unsurprising 
however because TDP-43 mislocalisation and aggregation is not an early event in ALS 
pathogenesis.  
Important comparisons about whether (G4C2)n expression causes TDP-43 pathology 
can be drawn from several recently published C9ORF72-ALS mouse models. One of the 
models expresses high levels of (G4C2)66 throughout the CNS, and is the only model of 
C9ORF72-ALS that does show TDP-43 pathology (Chew et al., 2015). The (G4C2)66 
repeat is highly expressed from a chicken beta actin (CBA) promoter in the sense 
orientation only, and independently of the C9ORF72 gene context, throughout the CNS 
(Chew et al., 2015). Nuclear (G4C2)n RNA foci, sense DPR aggregates, and TDP-43 
aggregates were detected in the CNS of the mice at 6 months (Chew et al., 2015). 
However, two different C9ORF72 BAC transgenic mice express a much larger (G4C2)n 
repeat (approximately 500 or 800 repeats in size) from the C9ORF72 gene context, and 
do not show any signs of TDP-43 pathology even by 20 months (O'Rourke et al., 2015; 
Peters et al., 2015). Sense and antisense RNA foci, as well as DPR aggregates were 
detected in the C9ORF72 BAC transgenic mice, but the promoters associated with the 
C9ORF72 gene are much weaker than the CBA promoter used in the first mouse model 
(O'Rourke et al., 2015; Peters et al., 2015). Therefore, the (G4C2)n expression is much 
lower in the C9ORF72 BAC transgenic mouse compared to the (G4C2)66 mouse. 
Importantly, the models show that the sense (G4C2)n RNA and/or sense DPR proteins 
are sufficient to cause TDP-43 pathology, but only when over expressed, and over a 
significant length of time. 
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There are several reasons that potentially explain why the NSC34 (G4C2)102 cells, and 
other cellular models of C9ORF72-ALS, do not show TDP-43 aggregation and/or 
mislocalisation. Firstly, (G4C2)n expression may only cause TDP-43 aggregation in post-
mitotic CNS cells. Secondly, the (G4C2)n expression is not high enough, or expressed for 
long enough in the NSC34 cells. Thirdly, one of the pure DPR species may be responsible 
for the TDP-43 pathology, which the NSC34 (G4C2)102 cells do not express. Lastly, a 
second hit, either genetic or age-related, may be required in addition to the (G4C2)n 
expression to cause TDP-43 pathology, and could be particularly relevant for C9ORF72-
ALS pathogenesis. However, any effects that are detected in the NSC34 (G4C2)102 cells 
are early biochemical effects that could occur prior to TDP-43 pathology in C9ORF72-
ALS. 
4.4.2. There Is No Increase in Hydroxyl, Peroxyl, or other Cellular ROS Levels in the 
NSC34 (G4C2)102 Cells 
Oxidative stress is thought to be key mechanism in ALS pathogenesis, and many studies 
report increased levels of oxidative damage in post-mortem tissue and biosamples from 
SALS patients. There were increased 8-oxo-7,8-dihydroguanosine (8-OHG) levels in the 
motor cortex and cerebellum of sporadic ALS patients, which indicates increased 
oxidative damage to mRNA species (Chang et al., 2008). Also, there was increased 
protein carbonylation, a marker of oxidised protein, in both the motor cortex and spinal 
cord from SALS patients (Ferrante et al., 1997; Shaw et al., 1995), and elevated levels of 
8-hydroxy-2'-deoxyguanosine (OH8dG), a marker of oxidized DNA, in both the motor 
cortex and cervical spinal cord from SALS patients (Ferrante et al., 1997; Fitzmaurice et 
al., 1996). Additionally, increased levels of 4-hydroxy-2-nonenal (HNE) and 
crotonaldehyde (CRA) in the motor neurons and glial cells of spinal cord from SALS 
patients, indicate increased lipid peroxidation (Shibata et al., 2001). Finally, OH8dG 
levels were elevated in urine samples from SALS patients (Mitsumoto et al., 2008), HNE 
levels were elevated in serum, spinal fluid, and CSF samples from SALS patients (Simpson 
et al., 2004; Smith et al., 1998). 
However, the DCF assay did not detect increased levels of hydroxyl, peroxyl or other 
cellular ROS in the NSC34 (G4C2)102 cells. As described above in section 4.4.1, any 
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effects detected in the NSC34 (G4C2)102 cells are likely to be early biochemical effects, 
and suggests (G4C2)102 expression does not induce oxidative stress as an early 
biochemical effect. In addition, the vast majority of other C9ORF72-ALS models either 
make no comment on, or show no oxidative stress, which could suggest oxidative stress 
is not the primary toxic effect of (G4C2)n expression and/or C9ORF72 haploinsufficiency. 
In one study however, catalase transcript levels were significantly higher in C9ORF72-
ALS iPSC-derived motor neurons, which indicates oxidative stress (Kiskinis et al., 2014). 
There is stronger evidence for oxidative stress in other genetic models of ALS. Increased 
protein carbonylation, hydroxyl radicals, hydrogen peroxide, lipid peroxidation, and 
oxidative damage to DNA are described in SOD1(G93A) mouse models (Andrus et al., 
1998; Liu et al., 1999; Liu et al., 1998; Poon et al., 2005). Increased lipid peroxidation 
and oxidative stress were also measured in NSC34 cells stably transfected with 
SOD1(G93A) (Wang et al., 2014). In addition to the SOD1(G93A) models, NSC34 cells 
expressing mutant TDP-43 have increased nuclear NRF2, which indicates increased 
oxidative stress (Duan et al., 2010). Glutathione S transferase D1 (GstD1) expression and 
protein carbonylation were elevated (both markers of oxidative stress) in a Drosophila 
model that expresses TDP-43 in the motor neurons (Zhan et al., 2015). In addition to 
biochemical studies, transcriptome analysis of NSC34 cells expressing SOD1(G93A) 
showed dysregulation in antioxidant response genes, suggesting oxidative stress (Kirby 
et al., 2005). Therefore, transcriptomic analysis of the NSC34 (G4C2)102 cells may detect 
whether the (G4C2)102 expression does cause oxidative stress or the NSC34 cells’ ability 
to cope with oxidative stress.  
4.4.3. (G4C2)n RNA Foci Co-Localise with Splicing Factors SRSF1 and SRSF2 in the NSC34 
(G4C2)102 Cells 
The hypothesis was that the (G4C2)n RNA foci would bind and co-localise with RBP in 
the NSC34 (G4C2)102 cells, which would lead to dysregulated RNA metabolism. SRSF1 
and SRSF2 are both multifunctional RBP that co-localised with 19.5% and 11.9% of RNA 
foci counted in the NSC34 (G4C2)102 cells respectively, consistent with several in vitro 
studies. SRSF1 and SRSF2 were both pulled down from SHSY5Y whole-cell extract, 
SHSY5Y nuclear extract and dissected human cerebellum whole extract in vitro by 
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biotinylated-(G4C2)5 RNA (Cooper-Knock et al., 2014b). These interactions were 
confirmed to be direct, using UV crosslinking RNA pull down assays (Cooper-Knock et al., 
2014b). SRSF1 was also pulled down from NSC34 whole cell extract in vitro by 
biotinylated-(G4C2)31 RNA in a different study (Rossi et al., 2015). In addition, SH-SY5Y 
cells transfected with (G4C2)72 constructs displayed colocalisation between RNA foci 
and both SRSF1 and SRSF2 (Lee et al., 2013). There was evidence of (G4C2)n RNA foci 
and SRSF2 colocalisation, in both cerebellar granule cells and ventral horn motor 
neurons from C9ORF72-ALS patients (Cooper-Knock et al., 2014b). However, there was 
no evidence of (G4C2)n RNA foci and SRSF1 colocalisation in the C9ORF72-ALS CNS tissue 
in the same study.  In a different study, (G4C2)n RNA foci and both SRSF1 and SRSF2 co-
localisation was much rarer in the cerebellum of C9ORF72-ALS patients (Lee et al., 2013). 
In summary, it is far from clear whether these protein-RNA interactions are 
physiologically relevant, but also possibly highlights the dynamic nature of these 
interactions. 
SRSF1 and SRSF2 are both involved in mRNA splicing and several previous transcriptomic 
studies have shown splicing defects in C9ORF72-ALS cases. Splicing consistency is lower 
in C9ORF72-ALS lymphoblastoid cells compared to controls and non-C9ORF72-ALS cases 
(Cooper-Knock et al., 2015a). Extensive splicing and polyadenylation defects were found 
in C9ORF72-ALS patient cerebellum and frontal cortex (Prudencio et al., 2015). Further, 
amongst the spliced exons and introns with the splicing defects, binding motifs 
recognised by HnRNP H and/or SRSF1 were enriched (Prudencio et al., 2015). This 
certainly suggests that SRSF1 sequestration by (G4C2)n RNA could play a role in splicing 
dysregulation and neurodegeneration in C9ORF72-ALS. Differential splicing analysis of 
the NSC34 (G4C2)102 transcriptome also shows increased splicing defects caused by 
(G4C2)102 expression in the cellular model as well (section 5.3.4), suggesting splicing 
dysregulation is an early biochemical effect of (G4C2)n expression. Taken together, 
SRSF1 sequestration by the (G4C2)n RNA (either in RNA foci or soluble RNA molecules) 
could be a critical early pathological function of the (G4C2)n repeat expansion that 
contributes to C9ORF72-ALS. 
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4.4.4. (G4C2)n RNA Foci Do Not Co-Localise with either PURA or ALYREF in the NSC34 
(G4C2)102 Cells 
Unlike SRSF1 and SRSF2, there was no co-localisation between the (G4C2)n RNA foci and 
either PURA or ALYREF. This is inconsistent with several in vitro studies that show PURA 
and ALYREF both bound (G4C2)n RNA. PURA was pulled down from mouse spinal cord 
whole-cell lysate, dissected human cerebellum whole extract, and NSC34 whole-cell 
lysate in vitro by biotinylated-(G4C2)n RNA (Cooper-Knock et al., 2014b; Rossi et al., 
2015; Xu et al., 2013). PURA also co-localises with (G4C2)n RNA foci in C9ORF72-ALS 
patient iPSC-derived motor neurons (Sareen et al., 2013). ALYREF was also pulled down 
from SHSY5Y whole cell extract in vitro by biotinylated-(G4C2)5 RNA, and the interaction 
was confirmed to be direct (Cooper-Knock et al., 2014b). ALYREF also co-localised with 
RNA foci in both cerebellar granule cells and ventral horn motor neurons from C9ORF72-
ALS patients (Cooper-Knock et al., 2014b). 
There are several different studies that have used in vitro RNA pull down techniques to 
identify RBP that bind the (G4C2)n RNA. However, there are inconsistencies across these 
studies, as certain RBP are shown to bind the (G4C2)n RNA in one (or more) studies, but 
not in others. This is probably caused by several different variables: the cellular origin of 
the cellular lysates used for the RNA pull downs (and the differential enrichment of 
certain RBP in the respective lysate), the stringency of the pull down, and the secondary 
structure of the (G4C2)n RNA used in the pull down. For example, NCL and HnRNP U 
preferentially bound (G4C2)n RNA with a G-quadruplex structure compared to (G4C2)n 
RNA with a hairpin structure (Haeusler et al., 2014). Whilst the RNA pull downs and co-
localisation experiments are useful for identifying candidate RBP that may be 
sequestered by the (G4C2)n RNA, functional studies must be used to validate the 
importance of the RBP. For example, rescue assays, and detailed splicing analysis have 
been used to strengthen the case for PURA, and HnRNP F/H and SRSF1 sequestration by 
the (G4C2)n RNA respectively in C9ORF72-ALS pathogenesis (Prudencio et al., 2015; Xu 
et al., 2013). 
In addition, (G4C2)n expression may also affect PURA localisation, in a mechanism 
separate to sequestration in RNA foci. PURA was diffusely distributed in the cytoplasm 
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and nucleus of iPSC-derived motor neurons (Sareen et al., 2013), and untransfected 
NSC34 and HeLa cells (Rossi et al., 2015). Although PURA was much more abundant in 
the cytoplasm in the NSC34 and HeLa cells (Rossi et al., 2015). However, PURA formed 
cytoplasmic and nuclear granules in the NSC34 and HeLa cells that were transfected with 
(G4C2)31 repeat constructs (Rossi et al., 2015). Large, intensely stained PURA 
aggregates were also detected in the NSC34 (G4C2)102 cells. Interestingly, a recent 
study also suggests PURA is essential for stress granule formation (Daigle et al., 2016). 
Taken together, it suggests the (G4C2)n expression could drive stress granule formation, 
and is important because altered stress granule dynamics are hypothesised to play an 
important role in ALS pathogenesis (Li et al., 2013; Ramaswami et al., 2013).  
4.4.5. (G4C2)n RNA Foci Co-Localise with NCL, but There Is No Evidence for Functional 
Nucleolar Stress 
RNA foci co-localised with the nucleolar NCL in the NSC34 (G4C2)102 cells and also in 
cerebellar granule and Purkinje neurons from C9ORF72-ALS patients, consistent with 
several other studies. NCL was pulled down from HEK293T whole-cell extract in vitro by 
biotinylated-(G4C2)4 RNA with both a hairpin and G-quadruplex secondary structure, 
although NCL preferentially bound the G-quadruplex motif (Haeusler et al., 2014). NCL 
was also the most significantly pulled down protein from SHSY5Y whole cell extract, 
SHSY5Y nuclear extract and dissected human cerebellum whole extract in vitro by 
biotinylated-(G4C2)5 RNA (Cooper-Knock et al., 2014b). In addition, (G4C2)n RNA foci 
co-localised with the nucleolar NCL in the motor cortex of C9ORF72-ALS patient post-
mortem tissue (Haeusler et al., 2014). Taken together, the interaction between NCL and 
(G4C2)n RNA could be important in pathophysiology of C9ORF72-ALS. 
NCL is a major functional protein of the nucleolus, and therefore, NCL sequestration by 
(G4C2)n RNA could cause nucleolar stress. The (G4C2)102 expression in the NSC34 
(G4C2)102 cells increased nucleolar area compared to the NSC34 sham cells, indicating 
nucleolar stress. This finding is consistent with a previous study that showed nucleoli 
were more fragmented, dispersed and were larger in C9ORF72-ALS B lymphocytes, 
fibroblasts and iPSC-derived motor neurons compared to controls (Haeusler et al., 
2014). Additionally, the increased nucleolar size in the NSC34 (G4C2)102 cells induced 
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with tetracycline is comparable to the nucleolar size increase in the C9ORF72-ALS 
fibroblasts (Haeusler et al., 2014). However, (G4C2)102 expression does not affect rRNA 
levels or maturation in the NSC34 (G4C2)102 cells. Interestingly, rRNA maturation is 
significantly reduced in C9ORF72-ALS motor cortex tissue, but not in C9ORF72-ALS B 
lymphocytes (Haeusler et al., 2014). Nucleolar stress was also hypothesised to affect 
translation efficiency in the NSC34 (G4C2)102 cells. However, there were no consistent 
differences between polysome profiles from the NSC34 (G4C2)102 and sham cells, 
suggesting no gross translation defect. The amount of RPL26 in the soluble fraction was 
increased in the NSC34 (G4C2)102 cells however, which indicates a defect in ribosome 
subunit biogenesis, and nucleolar dysfunction.  
The (G4C2)n repeat expansion could also affect nucleolar function via the DPR proteins, 
in addition to potential NCL sequestration by the (G4C2)n RNA. Synthetic (GR)20 and 
(PR)20 peptides localise to the nucleolus in U2OS and cultured human astrocytes (Kwon 
et al., 2014). (GR)n and (PR)n DPR proteins also localised to the nucleolus in HEK293 cells 
transfected with DPR expression vectors (Tao et al., 2015). Further, the (GR)n and (PR)n 
induced signs of nucleolar stress in both these studies. The cultured human astrocytes 
treated with either (PR)20 or (GR)20 showed dysregulated rRNA metabolism, although 
it was unclear whether the defect was in the rRNA transcription and/or maturation 
process (Kwon et al., 2014). Also, the (GR)n and (PR)n caused an increase in nucleolar 
size in the transfected HEK293 cells (Tao et al., 2015). These nucleolar stress results are 
both consistent with the findings of Haeusler et al., in the C9ORF72-ALS tissue and 
actually suggests the DPRs could be contributing to some (if not all) of the nucleolar 
stress. This may also explain why the nucleolar defects are weak and inconsistent in the 
NSC34 (G4C2)102 cells, because no pure (GR)n or (PR)n DPRs are translated from the 
interrupted (G4C2)102 repeat (section 3.3.4.3). Although, this does not exclude the 
(G4C2)102 RAN proteins - which do contain stretches of the (GR)n motif - from causing 
subtle nucleolar stress. 
4.4.6. Increased p53 Protein in the NSC34 (G4C2)102 Cells Indicates Cellular Stress 
(G4C2)102 expression caused an increase in p53 protein levels in the NSC34 (G4C2)102 
cells, and this was hypothesised to be caused by nucleolar stress. The nucleolus acts as 
144 
 
 
a principal stress sensor, and initiates p53-dependent cell cycle arrest, which can lead to 
senescence or apoptosis, under cellular stress (Rubbi and Milner, 2003). The increased 
p53 levels in the induced NSC34 (G4C2)102 cells suggests that (G4C2)102 expression 
causes cellular stress and leads to cell cycle arrest, and is consistent with earlier results 
that showed (G4C2)102 expression reduced NSC34 (G4C2)102 growth rate (section 
3.3.4.7).  
NCL binds the 5’UTR of p53 mRNA inhibiting p53 translation (Takagi et al., 2005), and 
therefore, it was reasoned that NCL sequestration by the (G4C2)n RNA could lead to 
increased p53 translation. Likewise, free RPL26 (not in the ribosomal subunits) also binds 
the 5’UTR of p53 mRNA, but activates p53 translation (Takagi et al., 2005), and therefore 
the increased soluble RPL26 in the NSC34 (G4C2)102 cells was also predicted to increase 
p53 translation. However, qRT-PCR of the translating polysomes did not show any 
significant increase in p53 mRNA, and does not support either the NCL sequestration 
hypothesis or increased soluble RPL26 result. There are many other molecular pathways 
that lead to increased p53 protein levels, and the (G4C2)102 expression could lead to 
increased p53 protein via one of these rather than via NCL sequestration. 
4.4.7. Summary 
The NSC34 (G4C2)102 cells did not recapitulate TDP-43 mislocalisation or aggregation, 
or an increase in oxidative stress. However, the NSC34 (G4C2)102 cells did recapitulate 
some phenotypes specific to C9ORF72-ALS. Firstly, the (G4C2)n RNA foci colocalised with 
the splicing factors SRSF1 and SRSF2, and also with nucleolar NCL. Secondly, the 
nucleolar area is enlarged. However, there was no functional evidence of nucleolar 
stress. Reassuringly, the (G4C2)102 expression causes subtle biochemical effects in the 
NSC34 (G4C2)102 cell model, which is arguably more relevant to an age of onset disease. 
The model therefore warrants further study using transcriptomic analysis, which may 
provide more clues as to the early biochemical effects caused by the (G4C2)n expression 
in the NSC34 (G4C2)102 cells.   
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Chapter 5. Gene Expression Profiling of NSC34 
(G4C2)n Cell Lines 
5.1. Introduction 
Gene expression profiling (GEP) allows genome wide gene expression to be compared 
between disease and control patient tissue samples, animal models, or cellular models. 
GEP has been used to identify dysregulated biological pathways in various diseases, 
which could yield potential therapeutic targets. Microarray is a widely used and robust 
technique for GEP. Briefly, RNA is extracted from the cells or tissues of interest, 
amplified, and used to produce single-stranded complementary DNA (ss-cDNA), which 
is then fluorescently labelled. The labelled ss-cDNA is then hybridised to the microarray 
chip, which consists of an array of multiple ss-DNA probes fixed to a glass slide. These 
ss-DNA probes have a known target identity, and therefore the relative amount of 
labelled RNA in the starting material is proportional to the fluorescent signal intensity 
on the microarray chip. Thousands of copies of each probe allows for the quantification 
of many specific RNA transcripts simultaneously.  
GeneChip® Mouse Transcriptome Arrays (MTA) 1.0 were used to perform GEP on the 
NSC34 (G4C2)n cells. MTA 1.0 have probe sets that recognise >23,000 protein coding 
genes and additionally >55,000 non-coding genes, and there are approximately 10 probe 
sets that recognise each exon, and 4 that recognise each exon-exon splice junction. This 
allows robust analysis of differential gene expression at both the whole transcript level 
and the exon level. 
NSC34 sham, NSC34 (G4C2)10, NSC34 (G4C2)51, and NSC34 (G4C2)102 cells were 
induced with 0.5μg/mL tetracycline for 0, 1 or 5 days. However, as described previously, 
NSC34 viability was only affected by (G4C2)102 expression, and therefore the early 
transcriptomic effects of (G4C2)n repeat expression would be most pronounced in the 
NSC34 (G4C2)102 cells. Therefore, the main array comparisons were made between 
NSC34 (G4C2)102 and NSC34 sham cells. For brevity, the array names contain two 
numbers that correspond to the (G4C2)n repeat size (where 0 is sham), and the number 
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of days that the cells were induced with tetracycline for (0, 1, or 5) respectively, and a 
letter that denotes the biological repeat (A, B, or C). For example, the array for the first 
biological replicate of NSC34 (G4C2)102 cells that were induced with tetracycline for 5 
days is named 102_5_A.  
5.2. Aims and Objectives for Gene Expression Profiling of NSC34 (G4C2)n Cells 
1) Identify changes in gene expression at the gene level in the NSC34 (G4C2)102 
cells compared to NSC34 sham cells. 
2) Perform enrichment analysis to identify which biological pathways are most 
dysregulated in the NSC34 (G4C2)102 cells compared to NSC34 sham cells. 
3) Validate gene expression changes of key genes using qRT-PCR. 
4) Identify changes in differential splicing in the NSC34 (G4C2)102 cells compared 
to NSC34 sham cells. 
5.3. Results 
5.3.1. RNA Extraction Quality Control 
The RNA quality and yield were assessed using the NanoDrop™ 1000 
spectrophotometer, following RNA extraction from the NSC34 cell lines. An average 
yield of 21.71±8.78μg total RNA was obtained, and all RNA samples had A280/260 ratios 
close to 2.00 (1.99±0.033) (Table 5.1) indicating high quality RNA. An Agilent 2100 
Bioanalyzer was used to assess the RNA integrity, which is critical for successful 
microarray experiments. The RNA Integrity Number (RIN) describes the RNA integrity, 
where 0 is completely degraded and 10 is completely intact. However, the Bioanalyzer 
could not compute RIN values for most of the samples, and was displayed as N/A (Table 
5.1). This was likely due to the extraction of small RNA species using the RNA extraction 
columns, which produced an additional peak between 50 and 150 nt (Figure 5.1). This 
peak is unexpected by the Bioanalyzer RIN computation software. The 
electropherograms from samples with RIN values of N/A and ≥8.0 were very similar, and 
all samples produced distinct 18S and 28S rRNA peaks on the electropherograms (Figure 
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5.1). Also, all RNA samples had 28S/18S rRNA ratios close to 1.50 (1.50±0.12) (Table 5.1), 
indicating the RNA has high integrity. Additionally, very little degradation products were 
present between the small RNA, 18 S rRNA and 28 S rRNA peaks (Figure 5.1). 
 
Figure 5.1 Agilent 2100 Bioanalyzer assessment of extracted RNA integrity from NSC34 
cells. Example electropherograms and corresponding electrophoresis gels produced by 
the Agilent 2100 Bioanalyzer used to assess the RNA integrity of extracted RNA samples 
from NSC34 cells. Peaks corresponding to the 18S and 28S rRNA are labelled. The 
electropherogram from sample 0_0_B (top) is used here as a representative example to 
illustrate the integrity of extracted RNA samples with RIN values of N/A, whilst the 
electropherogram from sample 10_0_B (bottom) is used as a representative example to 
illustrate the integrity of the extracted RNA samples with RIN values ≥8.00. 
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Table 5.1 Quality and yield of RNA extracted from NSC34 cells. A NanoDrop™ 1000 
spectrophotometer and Agilent 2100 Bioanalyzer were used to measure the 
concentration and quality of RNA extracted from NSC34 cells. The RNA yield was 
calculated using the total volume collected multiplied by the RNA concentration. The 
RNA quality was defined using the ratio of A280/260. The RNA integrity was measured 
using an Agilent 2100 Bioanalyzer, and described using RNA Integrity Number (RIN) on 
a scale of 0-10 (0 being completely degraded, and 10 being completely intact). The 
sample name corresponds to the (G4C2)n repeat size (where 0 is sham), the number of 
days that the cells were induced with tetracycline for (0, 1, or 5) respectively, and a letter 
that denotes the biological repeat (A, B, or C). For example, sample 102_5_A 
corresponds to the first biological replicate of NSC34 (G4C2)102 cells that were induced 
with tetracycline for 5 days. 
Sample RNA yield (μg) A260/280 RIN 28S/18S rRNA ratio 
0_0_ A 14.40 1.95 N/A 1.3 
0_0_B 18.91 2.03 N/A 1.3 
0_0_C 13.89 1.97 N/A 1.4 
0_1_A 24.87 2.01 N/A 1.4 
0_1_B 23.94 2.01 N/A 1.4 
0_1_C 19.00 2.00 N/A 1.5 
0_5_ A 15.91 2.00 N/A 1.6 
0_5_B 24.47 2.02 8.7 1.7 
0_5_C 25.14 2.01 8.5 1.7 
10_0_A 18.91 1.99 N/A 1.6 
10_0_B 30.84 2.02 9.2 1.5 
10_0_C 26.24 2.02 8.7 1.3 
10_5_A 22.96 2.07 8.7 1.6 
10_5_B 15.52 2.02 N/A 1.5 
10_5_C 16.79 2.02 N/A 1.4 
51_0_A 46.16 2.00 8.7 1.5 
51_0_B 47.25 2.02 9.1 1.6 
51_0_C 38.38 1.99 8.4 1.7 
51_5_A 19.49 1.98 N/A 1.6 
51_5_B 22.91 1.98 N/A 1.6 
51_5_C 15.89 2.01 N/A 1.7 
102_0_A 19.69 1.99 N/A 1.4 
102_0_B 20.80 1.99 N/A 1.4 
102_0_C 15.66 1.97 N/A 1.4 
102_1_A 16.09 1.95 N/A 1.4 
102_1_B 17.51 1.97 N/A 1.5 
102_1_C 13.66 1.92 N/A 1.4 
102_5_A 18.15 1.99 N/A 1.5 
102_5_B 14.03 1.96 N/A 1.5 
102_5_C 13.70 1.91 N/A 1.5 
Mean ± SD 21.71 ± 8.78 1.99 ± 0.033 N/A 1.50 ± 0.12 
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5.3.1.1. RNA Amplification and Labelling 
500ng total RNA was reverse transcribed using a reverse transcriptase and primers 
containing the T7 promoter sequence at the 5’ end. This was followed by simultaneous 
RNAse H and DNA polymerase treatment to degrade the starting RNA template, and 
synthesise the second-strand of the cDNA, to produce double-stranded cDNA (ds-cDNA). 
Complimentary RNA (cRNA) was then synthesised and amplified from the ds-cDNA by in 
vitro transcription (IVT) using T7 RNA polymerase. cRNA was then purified and the yield 
and size distribution of the cRNA were assessed using the NanoDrop™ 1000 
Spectrophotometer and Agilent 2100 Bioanalyzer respectively. The mean cRNA yield 
was 62.18±21.66µg (Table 5.2). The cRNA was generated in batches A, B, and C 
(containing samples named respectively), to make sample handling more manageable. 
The cRNA yield was much higher in batch A compared to batches B and C, which 
accounts for the variability in cRNA yield between samples (Table 5.3). The cRNA profiles 
assessed by the Agilent 2100 Bioanalyzer showed the expected size distribution, with 
cRNAs ranging from 50 to 4500 nt in size, and most cRNAs ranging from 50 to 2000 nt in 
size (Figure 5.2). The distribution was also jagged as expected (Figure 5.2). 
5.3.2. GeneChip® Mouse Transcriptome Arrays 1.0 
Sense-strand cDNA was then synthesised from 15µg of cRNA in an in vitro reverse 
transcription reaction. dUTP was also incorporated into the ss-cDNA. RNAse H treatment 
then removed cRNA template leaving ss-cDNA only. After purification, the ss-cDNA yield 
and size distribution were assessed using the NanoDrop™ 1000 Spectrophotometer and 
the Agilent 2100 Bioanalyzer. The mean ss-cDNA yield was 24.28±2.61µg (Table 5.3). The 
ss-cDNA profiles assessed by the Agilent 2100 Bioanalyzer showed the expected sloped 
profile for the ss-cDNA size distribution, with most ss-cDNAs approximately 100 nt in 
size, and the median ss-cDNA size approximately 400 nt (Figure 5.3). 
5.5μg of ss-cDNA was then fragmented by uracil-DNA glycosylase (UDG) and 
apurinic/apyrimidinic endonuclease 1 (APE 1) at the unnatural dUDP residues. The 
fragmented cDNA was then labelled by terminal deoxynucleotidyl transferase (TdT) 
using the Affymetrix® proprietary DNA Labelling Reagent that is covalently liked to 
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biotin. A gel-shift assay was used to assess the biotin labelling of the cDNA, and showed 
all samples had been labelled. 
Table 5.2 Yield of cRNA post-amplification. 
Sample cRNA yield (μg) A260/280 
0_0_A 97.27 1.85 
0_0_B 30.87 2.2 
0_0_C 29.64 2.02 
0_1_A 91.17 1.96 
0_1_B 33.21 2.18 
0_1_C 38.47 2.16 
0_5_A 89.91 1.96 
0_5_B 67.93 2.13 
0_5_C 45.09 2.17 
10_0_A 70.14 2.1 
10_0_B 60.26 2.15 
10_0_C 65.15 2.14 
10_5_A 90.39 1.95 
10_5_B 58.43 2.14 
10_5_C 51.87 2.17 
51_0_A 93.88 1.88 
51_0_B 47.48 2.16 
51_0_C 35.1 2.16 
51_5_A 80.38 2.07 
51_5_B 48.62 2.16 
51_5_C 51.37 2.14 
102_0_A 82.49 2.07 
102_0_B 56.46 2.17 
102_0_C 53.16 2.15 
102_1_A 96.2 1.87 
102_1_B 50.71 2.17 
102_1_C 46.36 2.16 
102_5_A 82.15 2.06 
102_5_B 82.56 2.06 
102_5_C 38.79 2.15 
Mean ± SD 62.18 ± 21.67 2.09 ± 0.10 
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Table 5.3 Yield of ss-cDNA.  
Sample 
cDNA yield 
(μg) 
A260/280 
0_0_A 28.53 2 
0_0_B 22.69 2.06 
0_0_C 31.72 2.1 
0_1_A 24.53 2.08 
0_1_B 22.2 1.79 
0_1_C 22.9 2.08 
0_5_A 30.3 2.08 
0_5_B 25.86 2.1 
0_5_C 24.67 2.11 
10_0_A 25.43 2.08 
10_0_B 23.31 2.1 
10_0_C 26.71 2.09 
10_5_A 26.35 2.1 
10_5_B 23.04 2.11 
10_5_C 21.98 2.09 
51_0_A 26.55 2.08 
51_0_B 24.95 2.09 
51_0_C 23.27 2.09 
51_5_A 23.11 2.11 
51_5_B 21.29 1.74 
51_5_C 22.79 2.08 
102_0_A 23.65 2.11 
102_0_B 21.19 2.13 
102_0_C 22.65 2.11 
102_1_A 25.59 2.09 
102_1_B 22.13 2.12 
102_1_C 21.11 2.1 
102_5_A 24.43 2.1 
102_5_B 24.18 2.12 
102_5_C 21.21 2.09 
Mean 24.28 ± 2.61 2.07 ± 0.087 
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Figure 5.2 Agilent 2100 Bioanalyzer assessment of cRNA post-amplification. An 
example electropherogram and corresponding electrophoresis gel produced by the 
Agilent 2100 Bioanalyzer used to assess the cRNA amplification. The electropherogram 
from sample 0_0_A is used here as a representative example to illustrate the RNA 
amplification to cRNA. 
 
Figure 5.3 Agilent 2100 Bioanalyzer assessment of second-cycle ss-cDNA post-
amplification. An example electropherogram and corresponding electrophoresis gel 
produced by the Agilent 2100 Bioanalyzer used to assess the ss-cDNA amplification. The 
0_0_A sample is used here as a representative example to illustrate the amplification of 
the cRNA to ss-cDNA samples. 
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5.3.2.1. Affymetrix® Expression Console™ Quality Control Metrics 
To ensure the arrays in the experiment are reliable, there are several quality control 
metrics that each array must pass. For gene and exon expression arrays, Affymetrix® 
recommends monitoring of hybridisation, as well as interrogating the positive vs 
negative area under the curve (pos vs neg AUC), all probe set mean, all probe set Relative 
Log Expression (RLE) mean, RLE plot, and Percentage Presence Call (%P) metrics, to 
determine any outlier arrays. Outlier arrays may be excluded from further downstream 
statistical analysis. As a general rule, arrays that have metric values of more than 2 
standard deviations away from the mean of all array values are flagged as potential 
outliers. Arrays that are consistently flagged as outliers in two or more quality control 
parameters must be excluded from the study. 
5.3.2.1.1. Hybridisation Controls 
The Affymetrix arrays include four spike-in controls BioB, BioC, BioD (genes from the 
biotin synthesis pathway of E.coli,) and CreX (the recombinase gene from P1 
bacteriophage). The spike in controls were added with the fragmented and labelled ss-
cDNA in the hybridisation master mix at increasing concentrations (1.5, 5, 25, and 
100pM respectively) prior to the hybridisation step. The spike in controls are not 
predicted to cross-react with eukaryotic ss-cDNA, and therefore the signal intensities for 
the spike-in controls should follow the trend BioB<BioC<BioD<CreX. Any other pattern 
would indicate poor hybridisation. All of the arrays in this experiment show the correct 
trend (Figure 5.4). In addition, BioB (at 1.5pM) is at the probe detection limit on the 
GeneChip® MTA 1.0, and the detection of BioB on all of the arrays indicates good overall 
sensitivity. 
5.3.2.1.2. Positive vs Negative Area Under the Curve (AUC) 
Positive vs negative area under the curve (AUC) is a robust metric for assessing overall 
array data quality. The AUC value is a measure of the detection of positive controls 
against the false detection of negative controls, which effectively means the ability to 
distinguish the true signal from noise in the array data. Values of 1 indicate perfect 
distinction between true signal and noise, whilst values of 0.5 indicate no distinction 
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between positive and negative controls. Arrays with AUC values <0.8 should be flagged 
as potential outliers. All the arrays in this experiment have an AUC value of ≥0.88 (Table 
5.4), indicating that there are no significant differences in array data quality. 
 
Figure 5.4 Eukaryotic Hybridisation controls for NSC34 arrays. Signal intensities of the 
eukaryotic hybridisation controls BioB, BioC, BioD, and CreX (at 1.5, 5, 25, 100pM 
respectively) on NSC34 GeneChip® Mouse Transcriptome Arrays 1.0 using Affymetrix 
Expression Console. 
5.3.2.1.3. All Probe Set Mean 
The all probe set mean is the mean of the signal of all the probe sets in the analysis, and 
allows detection of bright or dim arrays. The average of the all probe set means is 5.82 
± 0.042 for the gene level analysis, and 6.29 ± 0.0089 for the exon level analysis (Table 
5.4). For the gene level analysis, the 102_5_A and 102_5_B arrays both have all probe 
set mean values slightly outside 2 standard deviations of the mean (both at 5.91) 
indicating potential outliers (Table 5.4). However, for the exon level analysis, all arrays 
have all probe set mean values within 2 standard deviations of the mean value (Table 
5.4).  
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Table 5.4 Summarised Quality control metrics for NSC34 gene and exon level arrays. 
The positive vs negative AUC, all probe set mean and all probe set RLE (for both gene 
level and exon level arrays), and percentage exon level probe present (%P) quality 
control metrics are displayed for all arrays, with the mean and SD for each metric 
included. Outlier values are highlighted in yellow. 
Sample  
 
Both Gene level analysis Exon level analysis 
Pos vs 
Neg AUC 
All probe 
set mean 
All probe 
set RLE 
mean 
All probe 
set mean 
All probe 
set RLE 
mean 
%P 
0_0_A 0.92 5.75 0.21 6.30 0.28 64.11 
0_0_B 0.89 5.83 0.15 6.29 0.25 77.50 
0_0_C 0.91 5.75 0.17 6.31 0.26 69.52 
0_1_A 0.90 5.82 0.13 6.29 0.22 73.72 
0_1_B 0.90 5.80 0.13 6.30 0.21 74.03 
0_1_C 0.90 5.79 0.14 6.29 0.22 70.79 
0_5_A 0.90 5.82 0.12 6.28 0.21 74.20 
0_5_B 0.90 5.81 0.16 6.28 0.26 78.83 
0_5_C 0.89 5.83 0.13 6.29 0.22 75.36 
10_0_A 0.92 5.77 0.23 6.29 0.31 61.32 
10_0_B 0.89 5.83 0.15 6.29 0.25 74.38 
10_0_C 0.89 5.82 0.18 6.28 0.29 76.33 
10_5_A 0.90 5.82 0.15 6.28 0.25 73.05 
10_5_B 0.91 5.81 0.17 6.29 0.26 70.69 
10_5_C 0.90 5.84 0.18 6.29 0.27 70.56 
51_0_A 0.90 5.80 0.12 6.29 0.21 71.28 
51_0_B 0.90 5.75 0.21 6.30 0.30 74.15 
51_0_C 0.88 5.85 0.18 6.29 0.27 75.82 
51_5_A 0.91 5.78 0.16 6.29 0.24 67.85 
51_5_B 0.91 5.79 0.19 6.30 0.29 64.78 
51_5_C 0.92 5.79 0.17 6.29 0.25 67.24 
102_0_A 0.89 5.85 0.15 6.29 0.25 76.25 
102_0_B 0.89 5.85 0.15 6.29 0.26 72.94 
102_0_C 0.89 5.87 0.19 6.29 0.31 73.91 
102_1_A 0.90 5.85 0.15 6.28 0.24 71.42 
102_1_B 0.89 5.83 0.14 6.28 0.24 77.72 
102_1_C 0.89 5.88 0.23 6.31 0.37 66.71 
102_5_A 0.88 5.91 0.23 6.27 0.33 75.52 
102_5_B 0.88 5.91 0.24 6.29 0.34 72.65 
102_5_C 0.89 5.87 0.24 6.30 0.38 66.97 
Mean ± 
SD 
0.90 ± 
0.011 
5.82 ± 
0.041 
0.17 ± 
0.037 
6.29 ± 
0.0089 
0.27 ± 
0.045 
71.99 ± 
4.34 
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5.3.2.1.4. Relative Log Expression (RLE) Signal 
The Relative Log Expression (RLE) signal is derived by comparing the signal of each probe 
set to the median signal value for that probe set across all arrays in the experiment. The 
deviation of the RLE for all probe sets on the array can be plotted, and provides a robust 
method for assessing data quality. Arrays of poorer quality will have a larger spread and 
should be flagged as potential outliers. For the gene level RLE plot, all arrays have a 
similar spread (Figure 5.5). Equally, in the exon level RLE plot, all arrays have a similar 
spread (Figure 5.6). Therefore, the RLE plots do not indicate any obvious outlier arrays. 
 
Figure 5.5 Relative log expression (RLE) box plots for GENE level arrays. The distribution 
of RLE values for the GENE level arrays are displayed as box plots. Potential outliers are 
highlighted in red boxes. 
 
Figure 5.6 Relative log expression (RLE) box plots for EXON level. The distribution of 
RLE values for the EXON level arrays are displayed as box plots. Potential outliers are 
highlighted in red boxes. 
In addition to the RLE plot, the all probe set RLE mean is the mean average of this 
deviation. Unusually high values may indicate the signals on the array are very different 
from the others in the experiment. The average of the all probe set RLE means is 0.17 ± 
0.037 for the gene level analysis, and 0.27 ± 0.045 for the exon level analysis (Table 5.4). 
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For the gene level analysis, all arrays have all probe set RLE mean values within 2 
standard deviations of the mean value (Table 5.4). For the exon level analysis, the 
102_1_C and 102_5_C arrays both have all probe set RLE mean values slightly outside 2 
standard deviations of the mean (0.37 and 0.38 respectively) indicating potential 
outliers (Table 5.4). 
5.3.2.1.5. Percentage of Exon Level Probe Sets Present (%P) 
Another metric specifically used to assess the quality of the exon level probe sets is the 
%P value, which measures the percentage of exon level probe sets detected based on 
the detection above background (DABG) algorithm. The average %P value for all arrays 
is 71.99±4.34, and only the 10_0_A array falls outside 2 standard deviations from the 
mean value at 61.32%P (Table 5.4). 
5.3.2.1.6. Quality Control Summary 
There are a few arrays with outlier metric values. However, there are no arrays which 
are consistently flagged up with outlier values in more than one quality control metric. 
Equally, all outlier values are only very slightly outside the two SD threshold. Therefore, 
all arrays passed the quality control assessment and were taken forward for statistical 
analysis. 
5.3.3. Gene Level Data Analysis 
5.3.3.1. Qlucore Omics Explorer to Define Transcriptomic Changes in NSC34 (G4C2)102 Cells 
5.3.3.1.1. Selecting Filtering Stringency to Define Differentially Expressed Transcripts in 
NSC34 Arrays 
The filtering stringency used to define differentially expressed (DE) transcripts between 
arrays first had to be selected before gene level analysis. When describing which 
transcripts are significantly DE, it is customary to filter using fold change (FC) and P value 
(using Student’t T-test). FC describes the magnitude of the difference in expression 
levels, and a higher FC is important for future validation in further experiments. P value 
describes the statistical significance of the differential expression being real, and is used 
to determine the number of false positives in the list of DE transcripts. The a priori 
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criteria for the filtering stringency were to define around 3,000 DE transcripts between 
the NSC34 102 + 5 d tet and NSC34 0 + 5 d tet arrays, with the lowest possible P value. 
This is because the DAVID functional enrichment analysis was going to be used 
downstream to identify enriched biological functions and pathways in the DE transcripts, 
and DAVID can analyse up to 3,000 transcripts. Also, since the NSC34 (G4C2)n cells were 
isogenic, there should be very little genetic background noise between the arrays, and 
a lower P value was desired to minimise the number of false positives. 
All Affymetrix® CHP files were opened in Qlucore Omics explorer (version 3.0), and 
normalised using the RMA-sketch method. Differentially expressed (DE) transcripts 
were defined for the NSC34 102 + 5 d tet vs NSC34 sham + 5 d tet array comparison 
using various combinations of filtering stringencies. P values of <0.05, <0.01, and <0.001, 
and FCs of ≥1.2, ≥ 1.5, and ≥2.0 were used, and the number of DE transcripts defined for 
the different filtering stringencies are displayed in Table 5.5. For the NSC34 102 + 5 d tet 
vs NSC34 sham + 5 d tet analysis, a ≥1.2 FC was selected, because ≥1.5 FC did not classify 
enough transcripts as DE for robust downstream enrichment analysis, even when 
P<0.05. At FC ≥1.2, 5572, 3069 and 788 transcripts were defined as DE using P values 
<0.05, 0.01, and 0.001 respectively (Table 5.5). Therefore, filtering criteria FC≥1.2 and 
P<0.01 were selected, as around 3000 transcripts were classified as DE in the NSC34 102 
+ 5 d tet vs NSC34 sham + 5 d tet analysis. 
Table 5.5 Number of transcripts classified as differentially expressed between NSC34 
(G4C2)102 + 5 tet vs NSC34 sham + 5 d tet using various P value and fold change 
filtering stringencies.  
   Fold change 
   1.2 1.5 2 
  0.05 5572 1028 135 
P value 0.01 3069 835 129 
 0.001 788 349 94 
 
5.3.3.1.2. Clustering Analysis of All NSC34 Arrays 
Clustering analysis was performed on all NSC34 arrays using multi-group analysis (two-
way ANOVA at P<0.01), and displayed as a PCA plot (Figure 5.7A). There are three 
distinct clusters: one cluster contains all NSC34 sham and NSC34 (G4C2)51 arrays, the 
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second cluster contains all NSC34 (G4C2)10 arrays, and the last cluster contains all the 
NSC34 (G4C2)102 arrays. Reassuringly, the NSC34 (G4C2)102 + 5 day tet arrays are the 
most different of all NSC34 (G4C2)102 arrays along axis 3 of the PCA plot compared to 
the other arrays, indicating that increasing (G4C2)102 expression further alters gene 
expression. In addition, the NSC34 (G4C2)102 + 5 day tet arrays were compared to all 
other NSC34 sham and NSC34 (G4C2)102 arrays using Hierarchical Clustering analysis 
(Student’s T-test at P<0.01, FC≥1.2) and displayed as a heat map (Figure 5.7B). The 
Hierarchical Clustering analysis showed there is a strong transcriptomic signal that 
distinguishes the NSC34 (G4C2)102 + 5 d tet arrays from the NSC34 (G4C2)102 at shorter 
tet induction timepoints and the NSC34 sham arrays (Figure 5.7B). 
5.3.3.2. NSC34 Sham + 5 d Tet vs NSC34 Sham + 0 d Tet Direct Array Analysis 
Firstly, the effect of tetracycline on the NSC34 cell transcriptome was assessed, because 
tetracycline had previously shown toxicity to the NSC34 cells, although at a higher 
concentration (section 3.3.4.4). Even at lower doses the tetracycline may affect gene 
expression. Therefore, NSC34 sham + 5 d tet arrays were compared to NSC34 sham 0 d 
tet arrays. There were only 28 DE transcripts (FC≥1.2 and P<0.01), where 10 (35.7%) 
were down-regulated and 18 (64.3%) were up-regulated. These 28 DE transcripts were 
compared to the 3089 DE transcripts in the NSC34 (G4C2)102 + 5 d tet vs NSC34 sham + 
5 d tet comparison in section 5.3.3.3, and there were only 3 transcripts in common. 
5.3.3.2.1. DAVID Functional Enrichment Analysis of NSC34 Sham + 5 d Tet vs NSC34 Sham 
+ 0 d Tet 
The Entrez Gene IDs of the DE transcripts from the NSC34 sham + 5 d tet vs NSC34 sham 
+ 0 d tet comparison were analysed using the functional annotation tool in DAVID 
bioinformatics resources 6.7. Total DE transcripts, as well as the down-regulated and up-
regulated transcripts from the gene lists were analysed separately. Functional 
annotation clustering was subsequently performed using the GOTERM_BP_FAT gene 
ontology and KEGG_PATHWAY terms, applying a Mus musculus background, and 
filtering using medium stringency.  Functional clusters with DAVID enrichment scores 
>1.30 (equivalent to a P value <0.05) were considered statistically significant. 
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Figure 5.7 Clustering analysis of NSC34 arrays. A) Multiple group analysis PCA plot using 
two-way ANOVA at P<0.01. B) Hierarchical clustering heat map of NSC34 (G4C2)102 + 5 
d tet compared to other NSC34 sham and NSC34 (G4C2)102 arrays using Student’s T-
test at FC≥1.2 and P<0.01.  
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Olfactory transduction was the only enriched functional annotation cluster, with a 
DAVID enrichment score of 2.37 in the total DE transcripts and 2.53 in the up-regulated 
transcripts. There were 8 (28.57%) transcripts in the largest cluster term for total DE 
transcripts and 7 (38.89%) transcripts in the largest cluster term for up-regulated 
transcripts. The most significant cluster term was GOTERM ‘G-protein coupled receptor 
protein signalling pathway’ for both total DE and up-regulated transcripts (P value = 
0.00076; Benjamini value = 0.026; and P value = 0.00015; Benjamini value = 0.0023 
respectively). Therefore, any transcriptional changes in genes from the ‘olfactory 
transduction’ biological process are likely to be caused by tetracycline, and would be 
excluded from further NSC34 (G4C2)102 +5 d tet vs NSC34 sham + 5 d tet analysis. 
5.3.3.3. NSC34 (G4C2)102 vs NSC34 Sham Direct Array Analysis 
The aim of the GEP was to determine which biological pathways are affected by the 
(G4C2)n expression, and to find any potential therapeutic targets for C9ORF72-ALS. The 
(G4C2)10 and (G4C2)51 expression caused no observable toxicity in the NSC34 cells, 
whereas expression of the (G4C2)102 did cause toxicity (section 3.3.4.5). Therefore, the 
strongest and most relevant transcriptomic changes related to (G4C2)n induced toxicity 
are most likely to be detected in the tetracycline induced NSC34 (G4C2)102 cells. 
Therefore the key array comparisons carried out were between the NSC34 (G4C2)102 
and NSC34 sham cells, particularly at the 5 day tetracycline induction time point.  
NSC34 (G4C2)102 arrays were compared to NSC34 sham arrays at each tetracycline 
induction time point to generate lists of DE transcripts (FC≥1.2 and P<0.01). In the NSC34 
(G4C2)102 + 0 d tet vs NSC34 sham + 0 d tet comparison, there were 1576 DE transcripts, 
where 1128 (71.6%) were down-regulated, and 448 (28.4%) were up-regulated (Figure 
5.8). In the NSC34 (G4C2)102 + 1 d tet vs NSC34 sham + 1 d tet comparison, there were 
1725 DE transcripts, where 1146 (66.4%) were down-regulated, and 579 (33.6%) were 
up-regulated (Figure 5.8). In the NSC34 (G4C2)102 + 5 d tet vs NSC34 sham + 5 d tet 
comparison, there were 3069 DE transcripts, where 1991 (64.9%) were down-regulated, 
and 1078 (35.1%) were up-regulated (Figure 5.8). Any potential overlap in the DE 
transcripts at the 0 and 5 day tet timepoints from the NSC34 (G4C2)102 vs NSC34 arrays 
was compared using a Venn diagram (Figure 5.9). 976 (61.9%) of 1576 DE transcripts in 
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the NSC34 (G4C2)102 0 d tet vs NSC34 sham 0 d tet comparison were also DE in the 
NSC34 (G4C2)102 + 5 d tet vs NSC34 sham + 5 d tet comparison.  
 
Figure 5.8 The numbers of differentially expressed transcripts with FC≥1.2 at a 
significance P<0.01 between NSC34 (G4C2)102 and NSC34 sham at 0, 1 and 5 days of 
tetracycline induction. Up regulated (red) and down regulated (blue) transcripts are 
displayed as a fraction of the total number of differentially expressed transcripts. 
 
Figure 5.9 Venn diagram comparing the number of differentially expressed transcripts 
between the NSC34 (G4C2)102 vs NSC34 sham array comparisons at + 0 d and + 5 d tet 
induction timepoints. Differentially expressed transcripts with FC≥1.2 at a significance 
P<0.01 from the NSC34 (G4C2)102 + 0 d tet and NSC34 sham + 0 d tet analysis were 
compared to differentially expressed transcripts from the NSC34 (G4C2)102 + 5 d tet 
and NSC34 sham + 5 d tet analysis on GeneVenn. 
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The 28 DE transcripts from the NSC34 sham + 5 d tet vs NSC34 sham + 0 d tet comparsion 
in section 5.3.3.2 were compared to the 3069 DE transcripts from the NSC34 (G4C2)102 
+ 5 d tet vs NSC34 sham + 5 d tet comparison. Only 3 transcripts (Olfr303, Olfr1396, and 
Atp5c1-ps) were found in both lists (Figure 5.10), and were removed from further 
analysis in the NSC34 (G4C2)102 + 5 d tet vs NSC34 sham + 5 d tet comparison. 
 
Figure 5.10 Venn diagram comparing the number of shared differentially expressed 
transcripts in the NSC34 (G4C2)102 + 5 d tet vs NSC34 sham + 5 d tet comparison and 
the NSC34 sham + 5 d tet vs NSC34 sham + 0 d tet comparison. Differentially expressed 
transcripts with FC≥1.2 at a significance P<0.01 from the NSC34 (G4C2)102 + 5 d tet and 
NSC34 sham + 5 d tet analysis were compared to differentially expressed transcripts 
from the NSC34 sham + 5 d tet and NSC34 sham + 0 d tet analysis on GeneVenn. 
5.3.3.3.1. DAVID Functional Enrichment Analysis of NSC34 (G4C2)102 + 5 d Tet vs NSC34 
Sham + 5 d Tet 
The Entrez Gene IDs of the DE transcripts from the NSC34 (G4C2)102 + 5 d tet vs NSC34 
sham + 5 d tet comparison were imported to the functional annotation tool in DAVID 
bioinformatics resources 6.7 (as described in section 5.3.3.2.1). The functional 
enrichment analysis of all 3069 DE transcripts is displayed in Table 5.6, the 1991 down-
regulated transcripts only in Table 5.7, and the 1078 up-regulated transcripts only in 
Table 5.8. Functional clusters that are enriched include protein transport, 
phosphorylation, cytoskeletal organisation, vesicle-mediated transport, RNA 
processing, mRNA transport, and GTPase signalling. 63.4% of genes were annotated to 
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a biological function using the GOTERM_BP_FAT Gene Ontology term, and 26.2% of 
genes were annotated to a biological pathway using the KEGG_PATHWAY Pathway term. 
5.3.3.3.2. IMPaLA Pathway Enrichment Analysis of NSC34 (G4C2)102 + 5 d Tet vs NSC34 
Sham + 5 d Tet 
The gene symbols of the DE transcripts from the NSC34 (G4C2)102 + 5 d tet vs NSC34 
sham + 5 d tet comparison were imported to the Integrated Pathway-level Analysis 
(IMPaLA; http://impala.molgen.mpg.de) and analysed using the pathway over-
representation (enrichment) analysis tool (Kamburov et al., 2011). Where there were 
pathways with high similarity in the IMPaLA output table (for example ‘EGF-EGFR 
signalling pathway’ and ‘signalling by EGFR’), only the most significantly enriched 
pathway was retained whilst others were excluded from the list. The pathway 
enrichment analysis of all 3069 DE transcripts is displayed in Table 5.9, and the 1991 
down-regulated transcripts only in Table 5.10. There were no significantly enriched 
pathways (FDR<0.25) in the 1078 up-regulated transcripts however, and therefore no 
table is displayed. The most enriched pathways in both the total DE and down-regulated 
transcripts included EGFR signalling, TOR signalling, insulin signalling, and FOXO 
signalling. Strikingly, the aforementioned pathways consistently mapped to a subset of 
pathways in the PI3K/Akt signalling super-pathway (Figure 5.11). In addition, pathways 
including axon guidance, membrane trafficking, lysosome, developmental biology, 
protein processing in the endoplasmic reticulum, and regulation of the microtubule 
cytoskeleton were highly enriched in both total DE and down-regulated transcripts. 
Processing of capped intron-containing pre-mRNA was also enriched in the down-
regulated transcripts. 47.4% of genes were annotated to a biological pathway using the 
pathway over-representation analysis tool. 
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Table 5.6 DAVID Functional Annotation Clustering Analysis for 3069 differentially expressed transcripts in NSC34 (G4C2)102 + 5 d tet vs NSC34 
sham + 5 d tet comparison with FC≥1.2 and P<0.01.   
 Cluster Term DAVID 
Enrichment 
score 
Number 
of genes 
% of 
gene list 
Most significant cluster term P value (most 
significant term) 
Benjamini (most 
significant) 
1 Protein transport 5.31 178 5.99 Protein localisation 7.00E-08 1.30E-04 
2 Phosphorylation 4.78 170 5.72 Phosphate metabolic process 1.20E-06 8.80E-04 
3 Cytoskeletal organisation 4.34 75 2.52 Cytoskeletal organisation 8.50E-06 5.20E-03 
4 Vesicle-mediated 
transport 
3.58 120 4.04 Vesicle-mediated transport 2.40E-08 8.80E-05 
5 RNA metabolism 3.51 85 2.86 mRNA metabolic process 8.70E-05 3.20E-02 
6 GTPase mediated 
signalling 
2.92 52 1.75 Regulation of small GTPase mediated 
signal transduction 
3.00E-04 6.60E-02 
7 Apoptosis 2.71 96 3.23 Cell death 1.60E-03 1.70E-01 
8 mRNA transport 2.16 19 0.64 RNA localisation 3.60E-03 2.50E-01 
9 Organelle organisation 2.1 34 1.14 regulation of protein complex 
disassembly 
4.20E-04 7.80E-02 
10 Glucose metabolism 1.99 40 1.35 Hexose metabolic process 5.10E-03 3.00E-01 
 
  
166 
 
 
Table 5.7 DAVID Functional Annotation Clustering Analysis for 1991 down-regulated transcripts in NSC34 (G4C2)102 + 5 d tet vs NSC34 sham 
+ 5 d tet comparison with FC≥1.2 and P<0.01.  
 Cluster Term DAVID 
Enrichment 
score 
Number 
of genes 
% of 
gene list 
Most significant cluster term P value (most 
significant term) 
Benjamini (most 
significant) 
1 Protein transport 8.71 155 7.79 Protein localisation 4.60E-12 1.50E-08 
2 RNA metabolism 6.29 80 4.02 mRNA metabolic process 8.30E-08 3.70E-05 
3 Phosphorylation 5.25 133 6.69 Phosphate metabolic process 5.60E-07 1.50E-04 
4 Vesicle-mediated 
transport 
4.72 104 5.22 Vesicle-mediated transport 2.60E-11 2.10E-08 
5 Cytoskeletal organisation 4.71 62 3.12 Cytoskeletal organisation 1.30E-06 3.00E-04 
6 Proteolysis 4.47 122 6.13 Ubiquitin-dependent protein catabolic 
process 
1.00E-06 2.50E-04 
7 mRNA transport 3.7 19 0.96 RNA localisation 7.90E-05 8.90E-03 
8 GTPase mediated 
signalling 
3.23 41 2.06 Regulation of Ras GTPase activity 9.70E-05 9.90E-03 
9 Chromosome organisation 2.48 62 3.12 Chromatin modification 8.80E-05 9.60E-03 
10 Response to abiotic 
stimulus 
2.38 40 2.01 Response to radiation 9.80E-04 6.30E-02 
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Table 5.8 DAVID Functional Annotation Clustering Analysis for 1078 up-regulated transcripts in NSC34 (G4C2)102 + 5 d tet vs NSC34 sham + 5 
d tet comparison with FC≥1.2 and P<0.01.  
 Cluster Term DAVID 
Enrichment 
score 
Number 
of genes 
% of 
gene list 
Most significant cluster term P value (most 
significant term) 
Benjamini (most 
significant) 
1 Immune response 2.79 36 3.65 Immune effector process 5.30E-06 1.10E-02 
2 Development 1.71 25 2.54 skeletal system development 5.40E-04 1.70E-01 
3 Cell proliferation 1.42 18 1.83 B cell proliferation 9.20E-03 4.60E-01 
 
Table 5.9 IMPaLA Pathway Enrichment Analysis for 3069 differentially expressed transcripts in NSC34 (G4C2)102 + 5 d tet vs NSC34 sham + 5 
d tet comparison with FC≥1.2 and P<0.01. Pathways highlighted in grey are part of the PI3K/Akt super-pathway. 
 Pathway Name Pathway 
Source 
Number of DE 
genes in pathway 
Total number of 
genes in pathway 
% 
overlap 
P Value (most 
significant term) 
FDR (most 
significant term) 
1 EGFR1 NetPath 106 447 23.7 1.06E-09 4.12E-06 
2 Axon guidance Reactome 77 310 24.8 2.72E-08 3.54E-05 
3 Membrane Trafficking Reactome 45 153 29.4 1.40E-07 1.20E-04 
4 Lysosome - Homo sapiens (human) KEGG 38 120 31.7 1.61E-07 1.20E-04 
5 TOR Signaling Wikipathways 17 33 51.5 1.81E-07 1.20E-04 
6 Developmental Biology Reactome 93 426 21.8 7.06E-07 3.50E-04 
7 Insulin signaling pathway - Homo sapiens 
(human) 
KEGG 39 136 28.7 1.90E-06 8.30E-04 
8 Protein processing in endoplasmic reticulum - 
Homo sapiens (human) 
KEGG 44 167 26.3 5.17E-06 1.35E-03 
9 Regulation of Microtubule Cytoskeleton Wikipathways 17 43 39.5 1.74E-05 2.71E-03 
10 FoxO signaling pathway - Homo sapiens 
(human) 
KEGG 34 127 26.8 4.16E-05 5.08E-03 
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Table 5.10 IMPaLA Pathway Enrichment Analysis for 1991 down-regulated transcripts in NSC34 (G4C2)102 + 5 d tet vs NSC34 sham + 5 d tet 
comparison with FC≥1.2 and P<0.01. Pathways highlighted in grey are part of the PI3K/Akt super-pathway. 
 Pathway Name Pathway 
Source 
Number of DE 
genes in pathway 
Total number of 
genes in pathway 
% 
overlap 
P Value (most 
significant term) 
FDR (most 
significant term) 
1 EGFR1 NetPath 91 447 20.4 3.20E-10 1.23E-06 
2 Membrane Trafficking Reactome 42 153 27.5 3.46E-09 4.51E-06 
3 TOR Signalling Wikipathways 17 33 51.5 5.09E-09 4.97E-06 
4 Lysosome - Homo sapiens (human) KEGG 35 120 29.2 1.28E-08 1.00E-05 
5 Protein processing in endoplasmic reticulum - 
Homo sapiens (human) 
KEGG 40 167 24.0 4.65E-07 1.70E-04 
6 Processing of capped intron-containing pre-
mRNA 
Reactome 38 155 24.5 4.80E-07 1.70E-04 
7 Axon guidance Reactome 61 310 19.7 9.88E-07 3.20E-04 
8 Regulation of Microtubule Cytoskeleton Wikipathways 16 43 37.2 3.61E-06 7.80E-04 
9 Developmental Biology Reactome 75 426 17.6 5.00E-06 9.80E-04 
10 Insulin signaling pathway - Homo sapiens 
(human) 
KEGG 34 135 21.9 2.51E-05 2.59E-03 
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5.3.3.4. Biological Pathways of Interest 
The IMPaLA enrichment analysis showed various pathways within the PI3K/Akt 
signalling super-pathway were highly enriched in both the total DE and down-regulated 
transcripts (Table 5.9). In addition, previous work showed PTEN and the PI3K/Akt 
signalling pathway are potential therapeutic targets for ALS (Kirby et al., 2011). 
Therefore, the PI3K/Akt signalling super-pathway was investigated further, with 
particular interest directed towards genes from the mTOR signalling, MAPK signalling, 
and insulin signalling pathways. 
 
Figure 5.11 PI3K/Akt signalling pathway (KEGG). Square boxes indicate gene products 
such as proteins; rounded boxes indicate additional pathways. Arrows indicate 
molecular interactions. The PI3K/Akt signalling pathway regulates many fundamental 
cellular functions such as proliferation, growth and survival.  PI3K phosphorylates 
PI[4,5]P2 to produce PI[3,4,5]P3, which then activates Akt. Active Akt promotes cell 
survival. Pten removes a phosphate group from PI[3,4,5]P3 to produce PI[4,5]P2, and 
therefore inhibits the PI3K/Akt signalling pathway. Transcripts that are DE in NSC34 
(G4C2)102 + 5 d tet vs NSC34 sham + 5 d tet are marked with stars (red for up regulation 
and blue for down regulation in a transcript that encodes the marked protein). 
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RNA metabolism and mRNA transport functional categories were highly enriched in the 
DAVID analysis, whilst the processing of capped intron-containing pre-mRNA pathway 
was also enriched in the down-regulated transcripts. RNA metabolism, and specifically 
mRNA splicing and mRNA export are hypothesised to be affected in C9ORF72-ALS 
(section 1.7.2). Therefore, the RNA metabolism and mRNA transport categories were 
also taken forward for further investigation. 
Finally, protein localisation and vesicle-mediated transport were the first and fourth 
most highly enriched functional categories respectively in the DAVID analysis, and have 
significant overlap. Equally, membrane trafficking, lysosome, and protein processing in 
the ER pathways were highly enriched in the IMPaLA pathway enrichment analysis. As 
mentioned above the DE transcripts in the mTOR signalling pathway are enriched, and 
the mTOR signalling critically regulates autophagy. Taken together the transcriptomic 
data suggests there could be a fault in protein homeostasis at the processing and/or 
degradation stages.  
5.3.3.4.1. PI3K/Akt Signalling Pathway 
The genes in the ‘PI3K/Akt signalling pathway’ provided on gene cards 
(http://pathcards.genecards.org/pathway/29) were used to define the genes in the 
PI3K/Akt signalling super-pathway, and Table 5.11 lists the 75 of these 345 transcripts 
in the PI3K/Akt signalling pathway that are DE (FC≥1.2; P<0.01). Where possible, the DE 
transcripts were mapped onto a diagram of the PI3K/Akt signalling pathway, provided 
by KEGG (Figure 5.11). The insulin signalling, mTOR signalling, MAPK signalling, and 
FOXO signalling pathways, as well as the direct regulation of PI3K/Akt contain many DE 
transcripts (Figure 5.11). 
The serine-threonine kinase Akt regulates a diverse set of cellular processes including 
cell survival, growth, proliferation, metabolism, transcription and protein synthesis 
(Figure 5.11). There are three highly related isoforms of Akt, of which Akt1 (FC=-1.22; 
P=0.0024) and Akt2 (FC=-1.21; P=0.00163) are DE in NSC34 (G4C2)102 + 5 d tet. The 
PI3K/Akt signalling pathway is activated by cell surface receptors. Signalling from the 
receptors activates phosphatidylinositol 3-kinases (PI3Ks), which phosphorylate 
phosphatidylinositol-4,5-P2 (PI[4,5]P2) to produce phosphatidylinositol-3,4,5-P3 
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(PI[3,4,5]P3). Akt is then recruited to the lipid membrane by PI[3,4,5]P3, where Akt is 
phosphorylated at Thr308 by phosphatidyl-dependent kinase (PDK), and Ser473 by 
various kinases including mTOR complex 2 (mTORC2) (Sarbassov et al., 2005). The 
phosphorylation of these two residues is critical for full activation of Akt (Bhaskar and 
Hay, 2007). Phosphatase and tensin homolog and deleted on chromosome 10 (Pten) 
however, inhibits the PI3K/Akt signalling pathway by dephosphorylating PI[3,4,5]P3 to 
produce PI[4,5]P2 (Stambolic et al., 2001) (Figure 5.11). Class I PI3K catalytic subunits 
PIK3CA (FC=-1.42; P=0.00977) and PIK3CB (FC=-1.32; P=0.00266) are downregulated, 
whilst Pten (FC=+1.67; P=0.00248) is upregulated in NSC34 (G4C2)102 + 5 d tet. 
The mTOR Complexes 1 and 2 are structurally related serine/threonine kinases that are 
both involved in the PI3K/Akt signalling pathway (Bhaskar and Hay, 2007). Whilst Akt is 
activated by mTORC2, Akt indirectly activates mTORC1 via TSC1/2 complex inhibition. 
Active mTORC1 inhibits autophagy and activates protein synthesis. mTORC1 and 2 both 
contain the catalytic subunit mammalian target of Rapamycin (mTOR) (FC=-1.51; 
P=0.000155), and mTOR associated protein, LST8 homolog (Mlst8) (FC=-1.47; 
P=0.000496) subunit. mTORC1 additionally contains regulatory associated protein of 
mTOR, complex 1 (Rptor) (FC=-1.27; P=0.00396), whilst mTORC2 contains Rptor 
independent companion of mTOR, complex 2 (Rictor) and Mitogen-Activated protein 
kinase associated protein 1 (Mapkap1) (FC=-1.35; P=0.00257).  
Akt1, mTOR, and Pten were taken forward for qRT-PCR validation. There was less Akt1 
in the NSC34 (G4C2)102 cells compared to the NSC34 sham cells at 0 (FC=-1.41; 
P=0.180), 1 (FC=-1.11; P=0.928) and 5 (FC=-1.79; P=0.117) days + tet, although none of 
these changes were significant (Figure 5.12). There was significantly less mTOR in the 
NSC34 (G4C2)102 cells compared to the NSC34 sham cells at either 0 (FC=-3.29; 
P=0.0139), 1 (FC=-3.56; P=0.00382), or 5 (FC=-4.09; P = 0.0309) days + tet (Figure 5.13). 
Finally, there was more Pten in the NSC34 (G4C2)102 cells compared to the NSC34 sham 
cells at 0 (FC=+1.20; P=0.267), 1 (FC=+1.42; P=0.264), and 5 (FC=+1.29; P=0.529) days + 
tet, although none of these changes were significant (Figure 5.14). 
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Table 5.11 Transcripts from the PI3K/Akt signalling pathway dysregulated in NSC34 
(G4C2)102 + 5 d tet cells. Genes involved in PI3K/Akt signalling pathway which are 
differentially expressed in NSC34 (G4C2)102 + 5 d tet cells compared to NSC34 sham + 
5 d tet cells. Transcripts highlighted in grey were taken forward for qRT-PCR validation. 
Gene Symbol Gene Name Fold Change P-value 
PI3K/Akt signalling pathway   
Ago1 argonaute RISC catalytic subunit 1 -1.33 3.42E-03 
Akt1 thymoma viral proto-oncogene 1 -1.22 2.40E-03 
Akt2 thymoma viral proto-oncogene 2 -1.21 1.63E-03 
Calm1 calmodulin 1 -1.92 1.00E-03 
Ccnd1 cyclin D1 -1.48 5.36E-05 
Ccne2 cyclin E2 -1.66 7.50E-03 
Cdkn1a/P21 cyclin-dependent kinase inhibitor 1A -1.65 7.07E-03 
Col4a1 collagen, type IV, alpha 1 +1.24 8.99E-03 
Col6a3 collagen, type VI, alpha 3 -1.38 3.64E-04 
Cxcl12 chemokine (C-X-C motif) ligand 12 +1.26 5.37E-04 
Egfr epidermal growth factor receptor +1.20 2.46E-04 
Fgf6 fibroblast growth factor 6 +1.25 6.81E-03 
Fyn Fyn proto-oncogene -1.62 4.11E-04 
G6pc glucose-6-phosphatase, catalytic +1.22 9.81E-03 
G6pc3 glucose 6 phosphatase, catalytic, 3 -1.55 3.65E-04 
Ghr growth hormone receptor +1.28 9.71E-03 
Gnb1 guanine nucleotide binding protein (G protein), beta 
1 
-1.64 4.04E-03 
Gnb4 guanine nucleotide binding protein (G protein), beta 
4 
-1.35 3.21E-03 
Gng5 guanine nucleotide binding protein (G protein), 
gamma 5 
-1.38 1.34E-03 
Gsk3a glycogen synthase kinase 3 alpha -1.54 6.44E-03 
Gys2 glycogen synthase 2 +1.23 2.52E-03 
Igf1r insulin-like growth factor I receptor -1.45 8.04E-04 
Il2ra interleukin 2 receptor, alpha chain +1.23 3.83E-03 
Il6 interleukin 6 -2.23 4.70E-03 
Il7r interleukin 7 receptor +1.26 7.45E-03 
Irs2 insulin receptor substrate 2 +1.98 4.36E-03 
Itch itchy, E3 ubiquitin protein ligase -1.57 7.04E-03 
Itga1 integrin alpha 1 +1.34 1.09E-03 
Itga3 integrin alpha 3 -1.29 2.42E-04 
Itga5 integrin alpha 5 -1.48 1.42E-05 
Itga8 integrin alpha 8 -1.96 7.99E-04 
Itgb5 integrin beta 5 -1.30 2.79E-03 
Jak1 Janus kinase 1 -1.71 1.55E-03 
Lama4 laminin, alpha 4 +1.25 5.13E-04 
Lamc1 laminin, gamma 1 -1.32 5.79E-03 
Lcp2 lymphocyte cytosolic protein 2 +1.26 1.60E-03 
Lpar3 lysophosphatidic acid receptor 3 +1.22 3.07E-03 
Lpar5 lysophosphatidic acid receptor 5 +1.28 7.72E-04 
Mapk8 mitogen-activated protein kinase 8 -1.54 1.66E-03 
Map2k1 mitogen-activated protein kinase kinase 1 -1.34 3.22E-03 
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Map3k7 mitogen-activated protein kinase kinase kinase 7  -1.53 2.86E-03 
Mapkap1 mitogen-activated protein kinase associated protein 
1 
-1.35 2.57E-03 
Mcl1 myeloid cell leukemia sequence 1 -1.61 7.59E-05 
Mlst8 MTOR associated protein, LST8 homolog (S. 
cerevisiae) 
-1.47 4.96E-04 
Mtor mechanistic target of rapamycin -1.51 1.55E-04 
Myb myeloblastosis oncogene -1.65 2.82E-03 
Ncstn Nicastrin -1.55 4.00E-03 
Nedd4 neural precursor cell expressed, developmentally 
down-regulated 4 
-1.78 5.36E-03 
Nras neuroblastoma ras oncogene -1.68 1.68E-03 
Pck2 phosphoenolpyruvate carboxykinase 2 -1.77 9.51E-04 
Pdgfra platelet derived growth factor receptor, alpha 
polypeptide 
+1.31 3.36E-03 
Pik3ca phosphatidylinositol 3-kinase, catalytic, alpha 
polypeptide 
-1.42 9.77E-03 
Pik3cb phosphatidylinositol 3-kinase, catalytic, beta 
polypeptide 
-1.32 2.66E-03 
Plcg1 phospholipase C, gamma 1 -1.52 1.63E-05 
Ppp2r2d protein phosphatase 2, regulatory subunit B, delta 
isoform 
-1.35 1.57E-03 
Ppp2r3c protein phosphatase 2, regulatory subunit B'', 
gamma 
-1.47 1.41E-03 
Ppp3ca protein phosphatase 3, catalytic subunit, alpha 
isoform 
-1.40 7.03E-03 
Prkca protein kinase C, alpha -1.24 4.26E-03 
Psenen presenilin enhancer 2 homolog -1.49 5.23E-03 
Pten phosphatase and tensin homolog +1.67 2.48E-03 
Ptk2 protein tyrosine kinase 2 -1.45 9.11E-03 
Rac1 RAS-related C3 botulinum substrate 1 -1.40 3.54E-03 
Rbl2 retinoblastoma-like 2 -1.37 5.40E-03 
Rheb Ras homolog enriched in brain -1.82 7.24E-04 
Rhoa ras homolog gene family, member A -1.74 4.92E-03 
Rptor regulatory associated protein of MTOR, complex 1 -1.27 3.96E-03 
Sos1 son of sevenless homolog 1 (Drosophila) -1.54 4.12E-03 
Stat3 signal transducer and activator of transcription 3 -1.22 1.06E-03 
Tmem189 transmembrane protein 189 -1.24 6.41E-03 
Tnrc6a trinucleotide repeat containing 6a -1.28 7.44E-03 
Trp53 transformation related protein 53 -1.66 5.73E-03 
Tsc2 tuberous sclerosis 2 -1.44 2.07E-04 
Yes1 Yamaguchi sarcoma viral (v-yes) oncogene homolog 
1 
-1.45 9.89E-03 
Ywhab tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta polypeptide 
-1.51 3.67E-03 
Ywhah tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta polypeptide 
-1.38 1.03E-03 
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Figure 5.12 qRT-PCR Validation of Akt1 levels. NSC34 sham and NSC34 (G4C2)102 cells 
were grown for 0, 1, or 5 days with 0.5μg/mL tetracycline. qRT-PCR was performed on 
Akt1, and normalised to GAPDH. (Multiple t-tests; Data are means ± SD; n=3). 
 
Figure 5.13 qRT-PCR Validation of mTOR levels. NSC34 sham and NSC34 (G4C2)102 cells 
were grown for 0, 1, or 5 days with 0.5μg/mL tetracycline. qRT-PCR was performed on 
mTOR, and normalised to GAPDH. (*P<0.05; Multiple t-tests; Data are means ± SD; n=3). 
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Figure 5.14 qRT-PCR Validation of Pten levels. NSC34 sham and NSC34 (G4C2)102 cells 
were grown for 0, 1, or 5 days with 0.5μg/mL tetracycline. qRT-PCR was performed on 
Pten, and normalised to GAPDH. (Multiple t-tests; Data are means ± SD; n=3). 
Finally, our group had previously performed GEP on laser captured microdissected 
(LCM) motor neurons from the spinal cord of C9ORF72-ALS patients (Cooper-Knock et 
al., 2015a). Dr Johnathan Cooper-Knock investigated the PI3K/Akt signalling pathway 
(KEGG) in this dataset, and careful statistical analysis revealed that this pathway was 
significantly dysregulated in LCM motor neurons from C9ORF72-ALS patients compared 
to controls (rank-product, P=0.01). Further, PTEN had the highest fold change of all DE 
transcripts (FC=+11.3, P=0.00001) within this dataset. Transcripts in the PI3K/Akt 
signalling pathway (KEGG) are listed with transcript ID, gene ID, fold change and P value 
for the C9ORF72-ALS LCM motor neurons in Appendix 5. 
5.3.3.4.2. RNA Metabolism and mRNA Transport 
Aberrant RNA metabolism is described in a wide range of neurodegenerative diseases 
including ALS (sections 1.5.5 and 1.6.5). However, RNA metabolism includes a diverse 
set of biological processes. There were 111 DE transcripts (FC≥1.2; P<0.01) related to 
RNA metabolism and/or mRNA transport in the NSC34 (G4C2)102 cells. Transcripts 
annotated for RNA metabolism only (Table 5.12), mRNA transport only (Table 5.13), and 
both RNA metabolism and mRNA transport (Table 5.14) were listed separately. The 111 
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DE transcripts were functionally annotated again using the DAVID functional annotation 
tool (section 5.3.3.2.1) and IMPaLA pathway enrichment analysis (section 5.3.3.3.2) to 
identify which RNA metabolic processes and/or pathways are mainly affected by the 
(G4C2)102 expression. The top three annotated sub-categories were RNA splicing 
and/or spliceosome (52), ncRNA processing (23), and mRNA transport (18) using the 
DAVID annotation tool. These 111 DE transcripts were also enriched for the Spliceosome 
(30), Processing of Capped Intron-containing Pre-mRNA (26), mRNA Splicing (19), and 
RNA Transport (15) using the IMPaLA pathway enrichment analysis. 
There are several splicing factors that bind (G4C2)n RNA (Cooper-Knock et al., 2014b) 
that are downregulated in the NSC34 (G4C2)102 + 5 d tet cells, including serine/arginine-
rich splicing factor 1 (SRSF1) (FC=-1.54; P=0.00299), SRSF2 (FC=-1.68; P=0.00488), 
heterogeneous nuclear ribonucleoprotein H1 (HnRNPH1) (FC=-1.29; P=0.00758), nudix 
(nucleoside diphosphate linked moiety X)-type motif 21 (Nudt21) (FC=-1.27; P=0.00467), 
SRSF3 (FC=-1.42; P=0.00483) and SRSF6 (FC=-1.79; P=0.000240). Other factors involved 
in splicing regulation that bind (G4C2)n RNA (Cooper-Knock et al., 2014b) that are also 
downregulated in the NSC34 (G4C2)102 + 5 d tet cells include RNA binding motif protein 
3 (RBM3) (FC=-1.74; P=0.00127), and serine/arginine-rich protein specific kinase 2 
(SRPK2) (FC=-1.31; P=0.00603). SRSF1 and SRSF2 were taken forward for qRT-PCR 
validation. There was significantly less SRSF1 in the NSC34 (G4C2)102 cells compared to 
the NSC34 sham cells at 0 (FC=-1.99; P=0.00363), 1 (FC=-1.78; P=0.0390) and 5 (FC=-
2.28; P=0.00442) days + tet (Figure 5.15). There was significantly less SRSF2 in the NSC34 
(G4C2)102 cells compared to the NSC34 sham cells at 0 (FC=-2.63; P=0.0175), 1 (FC=-
1.95; P=0.0344) and 5 (FC=-3.60; P=0.000395) days + tet (Figure 5.16).  
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Table 5.12 RNA Metabolism transcripts dysregulated in NSC34 (G4C2)102 + 5 d tet 
cells. Genes involved in RNA Metabolism which are differentially expressed in NSC34 
(G4C2)102 + 5 d tet cells compared to NSC34 sham + 5 d tet cells. Genes that are also 
functionally annotated as mRNA Transport in addition to RNA Metabolism are listed in 
Table 5.14. Transcripts highlighted in grey were taken forward for qRT-PCR validation. 
Gene Symbol Gene Title Fold change p-value 
RNA Metabolism     
9530036M11Rik RIKEN cDNA 9530036M11 gene +1.30 6.17E-03 
Adar adenosine deaminase, RNA-specific -1.28 1.62E-03 
Adat1 adenosine deaminase, tRNA-specific 1 -1.22 6.79E-03 
Ago1 argonaute RISC catalytic subunit 1 -1.33 3.42E-03 
Aplp1 amyloid beta (A4) precursor-like protein 1 -1.53 6.54E-03 
App amyloid beta (A4) precursor protein -1.31 3.77E-04 
Aqr Aquarius -1.60 2.26E-03 
Auh AU RNA binding protein/enoyl-coenzyme A 
hydratase 
-1.37 5.61E-05 
Celf1 CUGBP, Elav-like family member 1 -1.24 1.74E-03 
Celf3 CUGBP, Elav-like family member 3 -1.45 8.16E-03 
Cherp calcium homeostasis endoplasmic reticulum protein -1.39 4.86E-03 
Cpsf3l cleavage and polyadenylation specific factor 3-like -1.45 9.55E-04 
Crnkl1 Crn, crooked neck-like 1 (Drosophila) -1.43 7.02E-03 
Cstf1 cleavage stimulation factor, 3' pre-RNA, subunit 1 -1.31 5.44E-04 
Ctnnbl1 catenin, beta like 1 -1.33 3.79E-03 
Ddx20 DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 -1.37 7.27E-03 
Ddx46 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 -1.66 2.58E-03 
Ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 -1.24 9.92E-03 
Ddx51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 -1.25 8.60E-03 
Dgcr8 DiGeorge syndrome critical region gene 8 -1.35 3.89E-03 
Dhx15 DEAH (Asp-Glu-Ala-His) box polypeptide 15 -1.35 5.94E-03 
Eftud2 elongation factor Tu GTP binding domain containing 
2 
+1.23 6.30E-03 
Exosc10 exosome component 10 -1.67 6.31E-04 
Hnrnph1 heterogeneous nuclear ribonucleoprotein H1 -1.29 7.58E-03 
Hnrnpk heterogeneous nuclear ribonucleoprotein K -1.33 4.75E-03 
Hnrnpll heterogeneous nuclear ribonucleoprotein L-like -1.34 4.89E-03 
Ints3 integrator complex subunit 3 -1.57 1.89E-04 
Ints6 integrator complex subunit 6 -1.60 3.74E-03 
Ints7 integrator complex subunit 7 -1.35 5.68E-03 
Ints8 integrator complex subunit 8 -1.65 2.68E-03 
Mapkapk2 MAP kinase-activated protein kinase 2 -1.30 5.22E-03 
Nol3 nucleolar protein 3 (apoptosis repressor with CARD 
domain) 
-1.32 7.97E-04 
Nono non-POU-domain-containing, octamer binding 
protein 
-1.51 6.77E-03 
Nop14 NOP14 nucleolar protein homolog (yeast) -1.73 2.29E-03 
Nudt21 nudix (nucleoside diphosphate linked moiety X)-type 
motif 21 
-1.27 4.67E-03 
Plrg1 pleiotropic regulator 1, PRL1 homolog (Arabidopsis) -1.37 9.40E-04 
Pnrc2 proline-rich nuclear receptor coactivator 2 -2.43 3.28E-04 
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Pop4 processing of precursor 4, ribonuclease P/MRP 
family, (S. cerevisiae) 
-2.64 6.98E-03 
Ppp1r8 protein phosphatase 1, regulatory (inhibitor) subunit 
8 
-1.65 4.47E-03 
Ppp4r2 protein phosphatase 4, regulatory subunit 2 -1.27 9.43E-03 
Pqbp1 polyglutamine binding protein 1 -1.62 4.91E-03 
Prkra protein kinase, interferon inducible double stranded 
RNA dependent activator 
-1.36 4.08E-03 
Prmt5 protein arginine N-methyltransferase 5 -2.13 1.65E-03 
Prpf18 PRP18 pre-mRNA processing factor 18 homolog 
(yeast) 
-1.31 9.07E-03 
Prpf31 PRP31 pre-mRNA processing factor 31 homolog 
(yeast) 
-1.37 1.80E-03 
Prpf40b PRP40 pre-mRNA processing factor 40 homolog B 
(yeast) 
+1.23 1.94E-03 
Prpf8 pre-mRNA processing factor 8 -1.41 5.92E-03 
Ptbp1 polypyrimidine tract binding protein 1 -1.35 5.54E-03 
Ptbp2 polypyrimidine tract binding protein 2 -1.50 7.93E-03 
Pus10 pseudouridylate synthase 10 -1.32 7.36E-03 
Qtrtd1 queuine tRNA-ribosyltransferase domain containing 
1 
-1.33 2.32E-03 
Rbm22 RNA binding motif protein 22 -1.38 6.71E-03 
Rbm25 RNA binding motif protein 25 -1.34 6.14E-03 
Rbm3 RNA binding motif protein 3 -1.74 1.27E-03 
Rbm5 RNA binding motif protein 5 -1.27 2.80E-03 
Rbmx RNA binding motif protein, X chromosome -1.42 1.85E-03 
Rnasel ribonuclease L (2', 5'-oligoisoadenylate synthetase-
dependent) 
+1.31 7.61E-04 
Rnps1 ribonucleic acid binding protein S1 -1.44 9.39E-03 
Rpf1 ribosome production factor 1 homolog (S. cerevisiae) -1.45 8.11E-03 
Rrp1b ribosomal RNA processing 1 homolog B (S. 
cerevisiae) 
-1.21 2.48E-03 
Scgb1a1 secretoglobin, family 1A, member 1 +1.34 5.94E-03 
Sf3a3 splicing factor 3a, subunit 3 -1.36 5.85E-03 
Sf3b3 splicing factor 3b, subunit 3 -1.86 6.92E-05 
Sfswap splicing factor, suppressor of white-apricot homolog 
(Drosophila) 
-1.28 1.22E-03 
Slbp stem-loop binding protein -1.23 7.18E-03 
Snrnp200 small nuclear ribonucleoprotein 200 (U5) -1.73 5.32E-04 
Snrnp25 small nuclear ribonucleoprotein 25 (U11/U12) +1.21 1.01E-03 
Snrpb small nuclear ribonucleoprotein B -1.29 2.42E-03 
Srpk1 serine/arginine-rich protein specific kinase 1 -1.39 3.98E-04 
Srpk2 serine/arginine-rich protein specific kinase 2 -1.31 6.03E-03 
Srrm1 serine/arginine repetitive matrix 1 -1.54 3.08E-03 
Srsf1/SF2 serine/arginine-rich splicing factor 1 (SF2) -1.54 2.99E-03 
Srsf2/SC35 serine/arginine-rich splicing factor 2 (SC35) -1.68 4.88E-03 
Srsf3 serine/arginine-rich splicing factor 3 -1.42 4.83E-03 
Srsf6 serine/arginine-rich splicing factor 6 -1.79 2.40E-04 
Ssu72 Ssu72 RNA polymerase II CTD phosphatase homolog 
(yeast) 
-1.59 1.59E-03 
Syf2 SYF2 homolog, RNA splicing factor (S. cerevisiae) -1.42 7.23E-03 
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Syncrip synaptotagmin binding, cytoplasmic RNA interacting 
protein 
-1.34 6.48E-03 
Tcp11 t-complex protein 11 +1.29 6.00E-03 
Tfb2m transcription factor B2, mitochondrial -1.95 3.72E-03 
Trmt44 tRNA methyltransferase 44 -1.26 5.11E-03 
Tyw1 tRNA-yW synthesizing protein 1 homolog (S. 
cerevisiae) 
-1.33 2.40E-03 
U2af2 U2 small nuclear ribonucleoprotein auxiliary factor 
(U2AF) 2 
-1.37 8.54E-05 
U2surp U2 snRNP-associated SURP domain containing -1.61 7.29E-03 
Upf1 UPF1 regulator of nonsense transcripts homolog 
(yeast) 
-1.45 9.83E-04 
Wdr3 WD repeat domain 3 -1.32 2.96E-04 
Wdr55 WD repeat domain 55 -1.71 4.36E-03 
Zcchc11 zinc finger, CCHC domain containing 11 -1.68 5.15E-03 
Zcchc6 zinc finger, CCHC domain containing 6 -1.32 8.14E-03 
Zcrb1 zinc finger CCHC-type and RNA binding motif 1 -1.37 5.17E-03 
Zfc3h1 zinc finger, C3H1-type containing +1.28 6.57E-03 
Zfp36l2 zinc finger protein 36, C3H type-like 2 -1.86 2.19E-03 
 
Table 5.13 mRNA Transport transcripts dysregulated in NSC34 (G4C2)102 + 5 d tet cells. 
Genes involved in mRNA Transport which are differentially expressed in NSC34 
(G4C2)102 + 5 d tet cells compared to NSC34 sham + 5 d tet cells. Genes that are also 
functionally annotated as RNA Metabolism in addition to mRNA Export are listed in 
Table 5.14. 
Gene Symbol Gene Title Fold change p-value 
mRNA Transport  
Eif5a eukaryotic translation initiation factor 5A -1.26 5.90E-03 
Eny2 enhancer of yellow 2 homolog (Drosophila) -1.46 8.00E-03 
G3bp2 GTPase activating protein (SH3 domain) binding 
protein 2 
-1.58 1.71E-03 
Gle1 GLE1 RNA export mediator (yeast) -1.20 7.78E-03 
Nup133 nucleoporin 133 -1.50 3.38E-03 
Nup160 nucleoporin 160 -1.54 7.85E-03 
Nup214 nucleoporin 214 -1.53 9.19E-04 
Nup35 nucleoporin 35 -1.43 8.62E-03 
Nup93 nucleoporin 93 -1.54 4.35E-04 
Nupl1 nucleoporin like 1 -1.31 7.31E-03 
Nupl2 nucleoporin like 2 -1.43 1.93E-03 
Stau1 staufen (RNA binding protein) homolog 1 
(Drosophila) 
-1.38 1.14E-03 
Xpo7 exportin 7 -1.44 3.79E-04 
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Table 5.14 RNA Metabolism and mRNA Transport transcripts dysregulated in NSC34 
(G4C2)102 + 5 d tet cells. Genes involved in both RNA Metabolism and mRNA Transport 
which are differentially expressed in NSC34 (G4C2)102 + 5 d tet cells compared to NSC34 
sham + 5 d tet cells. 
Gene Symbol Gene Title Fold change p-value 
RNA Metabolism and mRNA Transport 
Ddx39b DEAD (Asp-Glu-Ala-Asp) box polypeptide 39B -1.52 4.75E-05 
Eif4a3 eukaryotic translation initiation factor 4A3 -1.35 4.79E-03 
Khsrp KH-type splicing regulatory protein -1.30 1.10E-03 
Qk Quaking -1.34 8.58E-03 
Srsf10 serine/arginine-rich splicing factor 10 -1.54 3.33E-03 
Thoc1 THO complex 1 -1.80 3.31E-03 
 
 
Figure 5.15 qRT-PCR Validation of SRSF1 levels. NSC34 sham and NSC34 (G4C2)102 cells 
were grown for 0, 1, or 5 days with 0.5μg/mL tetracycline. qRT-PCR was performed on 
SRSF1, and normalised to GAPDH. (*P<0.05, **P<0.01; Multiple t-tests; Data are means 
± SD; n=3). 
In addition, other factors involved in RNA and mRNA transport that are mutated in ALS 
and other motor neuron diseases are also DE in the NSC34 (G4C2)102 + 5 d tet. GLE1 
RNA export mediator (Gle1) (FC=-1.20; P=0.00778) is an essential multifunctional 
protein involved in both mRNA export and translation (Bolger et al., 2008; Murphy and 
Wente, 1996). Mutations in GLE1 cause the autosomal recessive foetal motor neuron 
diseases lethal congenital contracture syndrome (LCCS1) and lethal arthrogryposis with 
anterior horn cell disease (LAAHD) (Nousiainen et al., 2008). In addition, three rare GLE1 
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mutations are found only in SALS patients, and are absent in controls (Kaneb et al., 
2015). All three mutations cause loss of GLE1 function, indicating the importance of 
GLE1 in motor neuron survival and function. 
 
Figure 5.16 qRT-PCR Validation of SRSF2 levels. NSC34 sham and NSC34 (G4C2)102 cells 
were grown for 0, 1, or 5 days with 0.5μg/mL tetracycline. qRT-PCR was performed on 
SRSF2, and normalised to GAPDH. (**P<0.01; Multiple t-tests; Data are means ± SD; 
n=3). 
Adenosine deaminase, RNA-specific (Adar) (FC=-1.28; P=0.00162) is an important 
paralog of Adar2, which is downregulated in LCM motor neurons from sporadic ALS 
patients (Hideyama et al., 2012). The Adar2 downregulation disrupts A-to-I RNA editing 
of GluA2 (a subunit of the AMPA receptor) producing Ca2+ permeable AMPA receptors, 
and excitotoxicity as a result (Hideyama et al., 2012). Aquarius (Aqr) (FC=-1.60; 
P=0.00226) is an important paralog of Senataxin (SETX), and links pre-mRNA splicing and 
snoRNA biogenesis (Hirose et al., 2006). Missense mutations in SETX cause juvenile 
onset ALS (Chen et al., 2004). SETX was also found to be down regulated (FC=-1.38; 
P=0.00721), although it was not annotated in the RNA metabolism biological function 
category, and was identified through manual interrogation of the DE transcripts list. 
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5.3.3.4.3. Protein Transport and Vesicle-Mediated Transport 
Similarly to RNA metabolism, aberrant protein homeostasis is also described in a wide 
range of neurodegenerative diseases including ALS (section 1.6.6). There were 225 (178 
and 120) DE trancripts (FC≥1.2; P<0.01) related to protein transport and/or vesicle-
mediated transport in the NSC34 (G4C2)102 cells. Transcripts annotated for protein 
transport only (Table 5.15), vesicle-mediated transport only (Table 5.16), and both 
protein transport and vesicle-mediated transport (Table 5.17) were listed separately. 
The 225 DE transcripts were functionally annotated again using the DAVID functional 
annotation tool (section 5.3.3.3.1) and IMPaLA pathway enrichment analysis (section 
5.3.3.3.2) to identify which protein and vesicle-mediated transport processes and/or 
pathways are mainly affected by (G4C2)102 expression. The top three annotated sub-
categories were intracellular transport (91), membrane organisation (54), and secretion 
by cell (29) using the DAVID annotation tool. These 225 DE transcripts were also 
enriched for membrane trafficking (30), endocytosis (20), and trans-golgi network 
vesicle budding (10) using the IMPaLA pathway enrichment analysis. 
There are several genes involved in protein transport and/or vesicle mediated transport 
that are mutated in ALS or other neurodegenerative diseases that are downregulated in 
the NSC34 (G4C2)102 + 5 d tet cells. Mutations in valosin containing protein (Vcp) (FC=-
1.54; P=0.00148) cause ALS (Johnson et al., 2010; Koppers et al., 2012) and inclusion 
body myopathy with early-onset Paget disease and frontotemporal dementia (IBMPFD) 
(Watts et al., 2004). Vcp regulates a variety of cellular processes including ubiquitin-
dependent protein degradation, nuclear envelope construction, Golgi and ER assembly, 
and autophagosome maturation (Ju et al., 2009; Tresse et al., 2010). Mutations in 
charged multivesicular body protein 2B (Chmp2b) cause both ALS and FTD (Parkinson et 
al., 2006; Skibinski et al., 2005). Chmp2a (FC=-1.32; P=0.00398) is an important paralog 
of Chmp2b, and both proteins are components of the Endosomal Sorting Complex 
Required for Transport III (ESCRT-III) which is involved in protein cargo trafficking in the 
endolysosomal pathway and autophagy (Henne et al., 2011). A (CAG)n repeat expansion 
in Huntingtin (Htt) (FC=-1.63; P=0.000522) causes Huntington’s disease (HD). Htt 
interacts with hundreds of different proteins and is involved in many different cellular 
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functions (Marques Sousa and Humbert, 2013). Mutations in mitofusin-2 (Mfn2) (FC=-
1.43; P=0.000971) cause Charchot-Marie-Tooth disease (CMT), and have also been 
linked to ALS (Marchesi et al., 2011). Mfn2 is a transmembrabe GTPase involved in 
mitochondrial fusion and mitochondria-ER membrane interactions (Züchner et al., 
2004).  
Table 5.15 Protein Transport transcripts dysregulated in NSC34 (G4C2)102 cells. Genes 
involved in Protein Transport which are differentially expressed in NSC34 (G4C2)102 + 5 
d tet cells compared to NSC34 sham + 5 d tet cells. Genes that are also functionally 
annotated as Vesicle-mediated transport in addition to Protein Transport are listed in 
Table 5.17. 
Gene Symbol Gene Title Fold Change p-value 
Protein Localisation  
Actn4 actinin alpha 4 - 1.52 2.63E-03 
Adam10 a disintegrin and metallopeptidase domain 10 -1.36 6.89E-03 
Ank2 ankyrin 2, brain -1.22 1.58E-03 
Arfip1 ADP-ribosylation factor interacting protein 1 +1.21 8.94E-03 
Arntl aryl hydrocarbon receptor nuclear translocator-like -1.47 9.63E-03 
Atp7b ATPase, Cu++ transporting, beta polypeptide +1.30 1.87E-03 
Bbs4 Bardet-Biedl syndrome 4 (human) -1.78 9.29E-03 
Bet1l blocked early in transport 1 homolog (S. cerevisiae)-
like 
-1.25 3.02E-03 
Bin3 bridging integrator 3 -1.25 2.69E-03 
Cacnb1 calcium channel, voltage-dependent, beta 1 subunit +1.23 1.06E-03 
Cd27 CD27 antigen +1.21 4.45E-03 
Cdk5 cyclin-dependent kinase 5 -1.62 3.22E-05 
Cep290 centrosomal protein 290 +1.44 7.01E-03 
Chmp2a charged multivesicular body protein 2A -1.32 3.98E-03 
Cog1 component of oligomeric golgi complex 1 -1.30 6.15E-03 
Cog4 component of oligomeric golgi complex 4 -1.46 7.79E-03 
Dnajc14 DnaJ (Hsp40) homolog, subfamily C, member 14 +1.20 3.87E-03 
Dopey1 dopey family member 1 -1.38 5.13E-03 
Eif5a eukaryotic translation initiation factor 5A -1.26 5.90E-03 
Eps15 epidermal growth factor receptor pathway substrate 
15 
-1.21 1.52E-04 
Faf1 Fas-associated factor 1 -1.46 5.70E-03 
Fam125a family with sequence similarity 125, member A +1.36 2.78E-03 
Folr1 folate receptor 1 (adult) -1.27 5.13E-03 
Gabarap gamma-aminobutyric acid receptor associated 
protein 
-1.29 1.77E-03 
Gle1 GLE1 RNA export mediator (yeast) -1.20 7.78E-03 
Hgs HGF-regulated tyrosine kinase substrate -1.20 1.83E-03 
Hspg2 perlecan (heparan sulfate proteoglycan 2) -1.27 1.19E-03 
Ift46 intraflagellar transport 46 -1.53 1.33E-03 
Ipo4 importin 4 -1.40 1.65E-05 
Kif1b kinesin family member 1B -1.83 1.57E-03 
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Lax1 lymphocyte transmembrane adaptor 1 +1.26 2.93E-03 
Lcp2 lymphocyte cytosolic protein 2 +1.26 1.60E-03 
Lman2 lectin, mannose-binding 2 -1.37 1.72E-03 
Mecp2 methyl CpG binding protein 2 -1.29 7.89E-03 
Mlh3 mutL homolog 3 (E coli) +1.33 2.36E-03 
Mlph Melanophilin +1.21 4.39E-03 
Mtx2 metaxin 2 -1.80 5.76E-03 
Nckap1 NCK-associated protein 1 -1.63 2.32E-03 
Nefm neurofilament, medium polypeptide -1.53 3.69E-04 
Nup133 nucleoporin 133 -1.50 3.38E-03 
Nup160 nucleoporin 160 -1.54 7.85E-03 
Nup214 nucleoporin 214 -1.53 9.19E-04 
Nup35 nucleoporin 35 -1.43 8.62E-03 
Nup93 nucleoporin 93 -1.54 4.35E-04 
Nupl1 nucleoporin like 1 -1.31 7.31E-03 
Nupl2 nucleoporin like 2 -1.43 1.93E-03 
Nutf2 predicted gene 10349;  predicted pseudogene 9386; 
nuclear transport factor 2; nuclear transport factor 
2, pseudogene 1 
-1.26 4.05E-03 
Pcna proliferating cell nuclear antigen -1.49 9.91E-03 
Pdcd6ip programmed cell death 6 interacting protein -1.76 5.24E-03 
Pex1 peroxisomal biogenesis factor 1 -1.47 6.96E-04 
Pex14 peroxisomal biogenesis factor 14 -1.23 6.44E-03 
Ppp3ca protein phosphatase 3, catalytic subunit, alpha 
isoform 
-1.40 7.03E-03 
Rab11b RAB11B, member RAS oncogene family -2.11 3.15E-04 
Rab14 RAB14, member RAS oncogene family -1.31 3.21E-03 
Rab22a RAB22A, member RAS oncogene family -1.60 4.05E-04 
Rab31 RAB31, member RAS oncogene family -1.58 2.74E-03 
Rab35 RAB35, member RAS oncogene family -1.27 5.47E-04 
Rab39b RAB39B, member RAS oncogene family -1.54 4.15E-03 
Rab3c RAB3C, member RAS oncogene family -1.32 1.57E-03 
Rab4a RAB4A, member RAS oncogene family -1.37 1.21E-03 
Rab8a RAB8A, member RAS oncogene family -1.36 3.04E-03 
Ranbp3l RAN binding protein 3-like +1.27 4.13E-03 
Rrbp1 ribosome binding protein 1 -1.59 4.26E-04 
Scamp2 secretory carrier membrane protein 2 -1.51 6.37E-05 
Scamp3 secretory carrier membrane protein 3 -1.30 5.56E-03 
Sec61a1 Sec61 alpha 1 subunit (S. cerevisiae) -1.35 1.98E-03 
Sec61a2 Sec61, alpha subunit 2 (S. cerevisiae) -1.44 9.17E-03 
Selenbp2 selenium binding protein 2 +1.30 9.95E-03 
Sft2d2 SFT2 domain containing 2 -2.32 2.62E-03 
Shroom3 shroom family member 3 +1.27 7.77E-03 
Slc15a3 solute carrier family 15, member 3 +1.23 9.89E-03 
Slc15a5 solute carrier family 15, member 5 +1.25 4.86E-03 
Slc37a2 solute carrier family 37 (glycerol-3-phosphate 
transporter), member 2 
+1.22 2.73E-03 
Snx1 sorting nexin 1 -1.25 5.23E-04 
Snx12 sorting nexin 12 -2.01 3.34E-04 
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Snx14 sorting nexin 14 -1.75 2.77E-03 
Snx18 sorting nexin 18 -1.25 2.82E-03 
Snx25 sorting nexin 25 -1.36 3.12E-03 
Snx3 sorting nexin 3 -1.26 1.09E-03 
Snx9 sorting nexin 9 -1.69 1.04E-03 
Srpr signal recognition particle receptor (docking protein) -1.76 2.82E-03 
Srsf10 serine/arginine-rich splicing factor 10 -1.54 3.33E-03 
Stam2 signal transducing adaptor molecule (SH3 domain 
and ITAM motif) 2 
-1.62 6.55E-03 
Stau1 staufen (RNA binding protein) homolog 1 
(Drosophila) 
-1.38 1.14E-03 
Syngr2 synaptogyrin 2 -1.30 7.86E-04 
Timm17b translocase of inner mitochondrial membrane 17b -1.22 1.56E-04 
Timm23 translocase of inner mitochondrial membrane 23 -1.41 4.66E-03 
Tln1 talin 1 -1.27 3.25E-04 
Tmed3 transmembrane emp24 domain containing 3 -1.20 2.64E-03 
Tnfsf13b tumor necrosis factor (ligand) superfamily, member 
13b 
+1.35 1.22E-04 
Tnrc6a trinucleotide repeat containing 6a -1.28 7.44E-03 
Trpc4ap transient receptor potential cation channel, 
subfamily C, member 4 associated protein 
-1.52 1.22E-03 
Tsc2 tuberous sclerosis 2 -1.44 2.07E-04 
Uchl1 ubiquitin carboxy-terminal hydrolase L1 -1.86 2.61E-04 
Vcp valosin containing protein -1.54 1.48E-03 
Vps11 vacuolar protein sorting 11 (yeast) -1.61 1.18E-04 
Vps13b vacuolar protein sorting 13B (yeast) -1.41 4.90E-03 
Vps13d vacuolar protein sorting 13D (yeast) -1.35 1.56E-03 
Vps16 vacuolar protein sorting 16 (yeast) -1.31 3.49E-03 
Vps25 vacuolar protein sorting 25 (yeast) -1.53 6.33E-03 
Vti1a vesicle transport through interaction with t-SNAREs 
1A (yeast) 
-1.39 1.26E-03 
Xpo6 exportin 6 -1.24 3.85E-03 
Xpo7 exportin 7 -1.44 3.79E-04 
Ywhab tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta polypeptide 
-1.51 3.67E-03 
Ywhah tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta polypeptide 
-1.38 1.03E-03 
 
Table 5.16 Vesicle-mediated Transport transcripts dysregulated in NSC34 (G4C2)102 
cells. Genes involved in Vesicle-mediated Transport which are differentially expressed 
in NSC34 (G4C2)102 + 5 d tet cells compared to NSC34 sham + 5 d tet cells. Genes that 
are also functionally annotated as Protein Transport in addition to Vesicle-mediated 
Transport are listed in Table 5.17. 
Gene Symbol Gene Title Fold change p-value 
Vesicle-mediated Transport   
Abca1 ATP-binding cassette, sub-family A (ABC1), member 
1 
-2.18 1.31E-04 
Agrn Agrin -1.44 2.53E-04 
Aplp1 amyloid beta (A4) precursor-like protein 1 -1.53 6.54E-03 
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Arhgap17 Rho GTPase activating protein 17 -1.31 2.19E-03 
Cap1 CAP, adenylate cyclase-associated protein 1 (yeast) -1.65 8.84E-03 
Chrna7 cholinergic receptor, nicotinic, alpha polypeptide 7 -1.48 3.91E-04 
Cnih cornichon homolog (Drosophila) -1.38 3.98E-03 
Coro1c coronin, actin binding protein 1C -1.55 1.27E-03 
Cplx1 complexin 1 -1.42 5.45E-04 
Cstad CSA-conditional, T cell activation-dependent protein +1.25 3.91E-03 
Cttn Cortactin -1.30 7.99E-04 
Dennd1a DENN/MADD domain containing 1A -1.38 1.09E-03 
Dnm1 dynamin 1 -1.28 1.15E-03 
Dnm2 dynamin 2 -1.24 4.39E-03 
Dock1 dedicator of cytokinesis 1 -1.59 9.69E-05 
Ehd2 EH-domain containing 2 -1.55 5.24E-04 
Elmo2 engulfment and cell motility 2 -1.39 1.07E-03 
Eps15l1 epidermal growth factor receptor pathway substrate 
15-like 1 
-1.53 4.71E-03 
Fcgr3 Fc receptor, IgG, low affinity III +1.27 4.82E-03 
Fnbp1l formin binding protein 1-like -1.61 1.63E-03 
Gapvd1 GTPase activating protein and VPS9 domains 1 -1.59 3.43E-03 
Ghr growth hormone receptor +1.28 9.71E-03 
Glra1 glycine receptor, alpha 1 subunit +1.20 5.68E-03 
Gria1 glutamate receptor, ionotropic, AMPA1 (alpha 1) +1.26 6.17E-03 
Gsn Gelsolin -1.21 5.95E-03 
Gulp1 GULP, engulfment adaptor PTB domain containing 1 +1.21 6.32E-03 
Itga3 integrin alpha 3 -1.29 2.42E-04 
Mfge8 milk fat globule-EGF factor 8 protein -1.36 3.11E-04 
Nploc4 nuclear protein localization 4 homolog (S. cerevisiae) -1.50 2.11E-03 
Nras neuroblastoma ras oncogene -1.68 1.68E-03 
Pacsin2 protein kinase C and casein kinase substrate in 
neurons 2 
-1.28 1.23E-03 
Plcd4 phospholipase C, delta 4 +1.29 9.06E-05 
Rac1 RAS-related C3 botulinum substrate 1 -1.40 3.54E-03 
Rims3 regulating synaptic membrane exocytosis 3 -1.40 7.99E-06 
Rims4 regulating synaptic membrane exocytosis 4 -1.31 2.79E-03 
Rin2 Ras and Rab interactor 2 +1.22 3.40E-04 
Sgca sarcoglycan, alpha (dystrophin-associated 
glycoprotein) 
+1.25 2.61E-03 
Sgcb sarcoglycan, beta (dystrophin-associated 
glycoprotein) 
-1.72 4.15E-03 
Sirpa signal-regulatory protein alpha +1.24 8.33E-03 
Sort1 sortilin 1 -1.45 1.58E-03 
Syp Synaptophysin -1.20 8.45E-04 
Tac4 tachykinin 4 +1.32 6.65E-03 
Tfrc transferrin receptor -1.59 5.95E-04 
Trappc10 trafficking protein particle complex 10 -1.49 2.78E-04 
Trappc6b trafficking protein particle complex 6B -1.34 5.69E-03 
Vamp3 vesicle-associated membrane protein 3 -1.82 3.19E-03 
Zmpste24 zinc metallopeptidase, STE24 -1.70 2.59E-03 
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Table 5.17 Protein Transport and Vesicle-mediated Transport transcripts dysregulated 
in NSC34 (G4C2)102 cells. Genes involved in both Protein Transport and Vesicle-
mediated Transport which are differentially expressed in NSC34 (G4C2)102 + 5 d tet cells 
compared to NSC34 sham + 5 d tet cells. 
Gene Symbol Gene Title Fold change p-value 
Protein Localisation and Vesicle-mediated Transport 
Ap1g2 adaptor protein complex AP-1, gamma 2 subunit -1.37 4.14E-04 
Ap1m1 adaptor-related protein complex AP-1, mu subunit 1 -1.67 1.41E-03 
Ap1s2 adaptor-related protein complex 1, sigma 2 subunit -1.50 1.91E-03 
Ap2a2 adaptor protein complex AP-2, alpha 2 subunit -1.94 2.84E-04 
Ap3s2 adaptor-related protein complex 3, sigma 2 subunit -1.70 3.07E-03 
Ap4b1 adaptor-related protein complex AP-4, beta 1 -1.33 5.90E-03 
Ap4e1 adaptor-related protein complex AP-4, epsilon 1 -1.39 6.86E-03 
App amyloid beta (A4) precursor protein -1.31 3.77E-04 
Arcn1 archain 1 -1.65 9.16E-03 
Arfgap2 ADP-ribosylation factor GTPase activating protein 2 -1.33 1.18E-03 
Cadps Ca2+-dependent secretion activator -1.32 4.54E-03 
Cdc42 cell division cycle 42 -1.85 2.49E-03 
Chic2 cysteine-rich hydrophobic domain 2 -1.46 1.95E-03 
Chmp7 charged multivesicular body protein 7 -1.30 1.52E-03 
Cltb clathrin, light polypeptide -1.39 2.72E-03 
Cog3 component of oligomeric golgi complex 3 -1.29 8.10E-03 
Copb2 coatomer protein complex, subunit beta 2 (beta 
prime) 
-1.72 6.06E-03 
Copg1 coatomer protein complex, subunit gamma 1 -1.46 6.82E-03 
Cox16 COX16 cytochrome c oxidase assembly homolog (S. 
cerevisiae) 
-1.24 8.48E-03 
D230025D16Rik RIKEN cDNA D230025D16 gene -1.27 9.37E-03 
Dhcr24 24-dehydrocholesterol reductase -1.46 3.96E-03 
Ergic3 ERGIC and golgi 3 -1.65 4.70E-04 
Exoc1 exocyst complex component 1 -1.53 3.03E-03 
Exoc2 exocyst complex component 2 -1.53 6.12E-03 
Flna filamin, alpha -2.57 1.01E-05 
Golga5 golgi autoantigen, golgin subfamily a, 5 -1.33 3.38E-03 
Gria2 glutamate receptor, ionotropic, AMPA2 (alpha 2) +1.42 3.42E-03 
Htt Huntingtin -1.63 5.22E-04 
Kdelr1 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 1 
-1.21 9.00E-03 
Kdelr2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 2 
-1.33 8.67E-04 
Kdelr3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 3 
-1.54 3.31E-03 
Lin7a lin-7 homolog A (C. elegans) +1.22 1.63E-03 
Mapk8ip3 mitogen-activated protein kinase 8 interacting 
protein 3 
-1.20 5.06E-04 
Mfn2 mitofusin 2 -1.43 9.71E-04 
Napa N-ethylmaleimide sensitive fusion protein 
attachment protein alpha 
-1.35 2.73E-03 
Necap2 NECAP endocytosis associated 2 -1.65 6.17E-04 
Npc1 Niemann Pick type C1 -1.50 9.08E-03 
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Nrbp1 nuclear receptor binding protein 1 -1.74 3.47E-04 
Oxa1l oxidase assembly 1-like -1.64 4.64E-03 
Pldn Pallidin -1.46 6.57E-05 
Preb prolactin regulatory element binding -1.26 2.58E-03 
Rab27a RAB27A, member RAS oncogene family +1.25 3.12E-03 
Rab2a RAB2A, member RAS oncogene family -1.60 4.04E-03 
Rab6a RAB6A, member RAS oncogene family -1.63 8.00E-03 
Rhob ras homolog gene family, member B -1.87 1.02E-04 
Rims1 regulating synaptic membrane exocytosis 1 +1.22 8.36E-03 
Rint1 RAD50 interactor 1 -1.30 6.46E-03 
Scfd2 Sec1 family domain containing 2 -1.37 1.62E-03 
Sec13 SEC13 homolog (S. cerevisiae) -1.24 7.44E-03 
Sec23b SEC23B (S. cerevisiae) -1.45 7.08E-03 
Sec24c Sec24 related gene family, member C (S. cerevisiae) -1.24 1.72E-03 
Sec24d Sec24 related gene family, member D (S. cerevisiae) -1.31 2.49E-03 
Sec31a Sec31 homolog A (S. cerevisiae) -1.68 2.86E-03 
Slc30a6 solute carrier family 30 (zinc transporter), member 6 -2.08 2.06E-03 
Snap23 synaptosomal-associated protein 23 -1.52 5.48E-03 
Snx17 sorting nexin 17 -1.36 2.88E-03 
Spast Spastin -1.76 8.24E-04 
Steap2 six transmembrane epithelial antigen of prostate 2 -1.26 1.75E-03 
Stx12 syntaxin 12 -2.07 1.25E-04 
Stx16 syntaxin 16 -1.31 2.08E-03 
Stx18 syntaxin 18 -1.40 2.67E-04 
Stxbp1 syntaxin binding protein 1 -1.44 5.05E-04 
Stxbp2 syntaxin binding protein 2 +1.22 3.12E-03 
Stxbp3a syntaxin binding protein 3A -1.66 7.13E-04 
Trappc1 trafficking protein particle complex 1 -1.28 2.29E-03 
Trappc4 trafficking protein particle complex 4 -1.43 6.50E-03 
Trp53 transformation related protein 53 -1.66 5.73E-03 
Ulk1 Unc-51 like kinase 1 (C. elegans) -1.32 1.31E-04 
Uso1 USO1 homolog, vesicle docking protein (yeast) -1.78 3.24E-03 
Vps29 vacuolar protein sorting 29 (S. pombe) -1.36 9.28E-03 
Vps33b vacuolar protein sorting 33B (yeast) -1.36 7.45E-04 
Wasf2 WAS protein family, member 2 -1.48 9.50E-04 
Zw10 ZW10 homolog (Drosophila), 
centromere/kinetochore protein 
-1.24 4.23E-04 
 
5.3.4. Differential Splicing Analysis 
CEL files were normalised using RMA alt splice analysis in Expression Console, and saved 
as CHP files using Expression Console. The CHP files were then opened in TAC for 
alternative (differential) splicing analysis. To identify true differential splicing events 
between array conditions, the Splicing Index (SI) was used. The SI is the relative 
difference between a splicing event (such as exon level or an exon skipping event) 
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between two array conditions and is summarised in Figure 5.17. The SI can be likened 
to Fold Change, whereas it is the relative level of a splicing event being compared instead 
of the level of a particular transcript. Several criteria must be met for an exon to be 
considered for SI analysis however. The gene must be expressed in both conditions and 
the exon or junction must be expressed in at least one condition. Once these criteria are 
met, the signal intensity for each gene, and subsequently each exon and junction, is 
normalised. The normalised intensities are then compared between the two conditions 
using One Way Between-Subject ANOVA (unpaired), giving an SI value and FDR 
corrected P value. Differential spicing events were filtered to include only events with 
SI≥2.0 or ≤-2.0, and ANOVA FDR<0.05. 
 
Figure 5.17 Algorithm describing Splicing Index used to assess differential splicing 
events between two biological conditions.   
Differential splicing analysis was performed on the NSC34 sham and NSC34 (G4C2)102 
cells. There were 3029 differentially spliced transcripts in the NSC34 (G4C2)102 + 0 d tet 
compared to NSC34 sham + 0 d tet, 2455 differentially spliced transcripts in the NSC34 
(G4C2)102 + 1 d tet compared to NSC34 sham + 1 d tet, and 5834 differentially spliced 
transcripts in the NSC34 (G4C2)102 + 5 d tet compared to NSC34 sham + 5 d tet (Figure 
5.18). Thus the low level (G4C2)102 expression at basal conditions modestly disrupts 
splicing, but the increased (G4C2)102 expression at 5 days tetracycline induction causes 
more extensive splicing disruption. 
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Figure 5.18 Summary of the differentially spliced genes between NSC34 (G4C2)102 and 
NSC34 sham cells. The numbers of genes with at least one differential splice event with 
a splicing index >2 and with One-Way ANOVA (unpaired) P<0.05 between NSC34 
(G4C2)102 and NSC34 sham at 0, 1 and 5 days of tetracycline induction. 
5.4. Discussion 
5.4.1. Tetracycline Does Not Affect the NSC34 Transcriptome 
Previous experiments had shown 10μg/mL tetracycline was toxic to NSC34 sham cells 
(section 3.3.4.4). Therefore the NSC34 sham arrays with and without 5 days tetracycline 
induction were compared. There were only a few DE transcripts between the arrays 
which shows that 0.5μg/mL tetracycline has only a very small effect on the NSC34 
transcriptome. Functional enrichment analysis showed olfactory transduction was the 
only enriched functional annotation cluster. The 3 DE transcripts from this tetracycline 
analysis that overlapped with the DE transcripts in the NSC34 (G4C2)102 + 5 d tet vs 
NSC34 sham + 5 d tet analysis were removed from further analysis. Therefore, the DE 
transcripts, and functionally enriched biological processes and pathways identified in 
the NSC34 (G4C2)102 + 5 d tet vs NSC34 sham + 5 d tet analysis are not caused by 
tetracycline, but are caused by the (G4C2)102. 
191 
 
 
5.4.2. (G4C2)n Expression Alters the NSC34 Transcriptome 
GEP of the NSC34 cells shows that the (G4C2)102 expression alters the NSC34 
transcriptome. Firstly, the NSC34 (G4C2)102 arrays are clustered together, separate 
from the NSC34 sham, (G4C2)10 and (G4C2)51 arrays on the PCA plot. Secondly, the 
NSC34 (G4C2)102 + 5 day tet arrays are the most different of the NSC34 (G4C2)102 
arrays on the PCA plot. Thirdly, when compared to NSC34 sham cells, the number of DE 
transcripts increases from 1576 to 3069 in the NSC34 (G4C2)102 cells when induced with 
tetracycline for 0 and 5 days respectively. Importantly, The NSC34 (G4C2)102 still 
express the (G4C2)102 repeat at lower levels when not induced with tetracycline 
because RNA foci and RAN translation products are still detected under basal conditions 
(sections 3.4.3 and 3.4.5 respectively). The low basal expression of (G4C2)102 probably 
accounts for the transcriptomic differences, and could explain why the NSC34 
(G4C2)102 + 0 d tet arrays cluster with the NSC34 (G4C2)102 + 1 d and + 5 d arrays. 
Additionally, the (G4C2)102 DNA repeat in the genome could contribute to the DE 
transcripts and altered gene expression. However, the greater (G4C2)102 expression 
further alters the NSC34 cell gene expression and there is a high degree of overlap in the 
DE transcripts in the 0 and 5 day tet comparisons, which shows the (G4C2)102 
expression does alter gene expression.   
5.4.3. Enrichment Analysis  
Enrichment analysis identifies which biological functions and pathways are most altered 
at the transcript level in disease. Enrichment analysis was first performed here using 
DAVID to assess how (G4C2)102 expression affected the NSC34 cell transcriptome. Using 
DAVID, 63.4% of the DE transcripts were annotated to a biological function, whilst only 
26.2% of the DE genes were annotated to a KEGG pathway. The percentage of genes 
annotated to a biological pathway using DAVID seemed very low, and the actual 
biological pathway annotations are more informative and specific than the vaguer 
biological function annotations. Therefore, an alternative pathway enrichment analysis 
tool with greater annotation was used. IMPaLA annotates genes from 11 different public 
databases (including KEGG), and was used to repeat the pathway enrichment analysis. 
Using IMPaLA, 47.4% of genes were annotated to a biological pathway, which was nearly 
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double the coverage that DAVID provided, and was much more acceptable for pathway 
analysis. The DAVID and IMPaLA enrichment analyses identified several interesting 
biological functions and pathways including braches of the PI3K/Akt signalling super-
pathway, RNA metabolism, and protein transport which are discussed in greater detail 
below. 
5.4.4. Pathways of interest 
5.4.4.1. PI3K/Akt signalling 
The PI3K/Akt signalling pathway regulates a range of cellular functions including 
metabolism, cell growth, proliferation, survival, and protein translation. GEP of the 
NSC34 (G4C2)102 cells identified transcriptomic dysregulation in this pathway. More 
specifically, Akt1 and Akt2 are both downregulated at transcript level, suggesting the 
Akt levels and signalling may be reduced. Also, PI3K activates Akt, whilst Pten 
antagonises this activation, and the class I PI3K catalytic subunits PIK3CA and PIK3CB are 
downregulated at transcript level, whilst Pten is upregulated at transcript level in NSC34 
(G4C2)102, further suggesting reduced Akt activation and signalling. Finally, mTOR, 
which is a member of the Akt activating complex MTORC2, is also downregulated at 
transcript level again suggesting reduced Akt activation. Reduced Akt levels and activity 
would potentially cause a reduced growth rate, since Akt promotes cell growth and 
proliferation. The (G4C2)102 expression reduced NSC34 cell growth rate (section 3.4.6), 
and supports the reduced Akt signalling hypothesis. Further, the PI3K/Akt signalling 
pathway is also dysregulated at transcriptomic level in C9ORF72-ALS LCM motor 
neurons, and corroborates the GEP in the NSC34 (G4C2)102 cells. However, qRT-PCR 
analysis only validated the DE of mTOR, but not Akt1 or Pten in the NSC34 (G4C2)102 
cells. Further investigation of the PI3K/Akt signalling pathway at protein level is required 
to strengthen the hypothesis that (G4C2)102 expression in a motor neuronal context 
affects PI3K/Akt signalling. 
Previously, GEP on LCM motor neurons from spinal cord of SOD1-ALS patients identified 
transcriptomic changes in the PI3K/Akt signalling pathway (Kirby et al., 2011). 
Specifically, the transcriptomic data suggested the PI3K/Akt signalling pathway is more 
active in the surviving motor neurons, and actually contributes to their survival (Kirby et 
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al., 2011). This supports the finding that the PI3K/Akt signalling pathway is dysregulated 
at transcript level in both the NSC34 (G4C2)102 cells and the C9ORF72-ALS LCM motor 
neurons. However, the transcriptomic data and cellular assay data in the NSC34 
(G4C2)102 cells suggests (G4C2)102 expression results in reduced Akt signalling, rather 
than in a prosurvival manner. To understand how (G4C2)102 expression affects The 
PI3K/Akt signalling pathway, further biochemical investigation in the NSC34 (G4C2)102 
cells was required. 
Interestingly, Pten, which is a key negative regulator of the PI3K/Akt signalling pathway, 
has been identified as a potential therapeutic target in ALS and other motor neuron 
diseases (Kirby et al., 2011; Little et al., 2015; Ning et al., 2010). PTEN knock-down via 
siRNA promoted survival in SOD1-G93A NSC34 cells and motor neuron survival (Kirby et 
al., 2011) and axon growth in an SMA mouse model (Ning et al., 2010). Further, Pten 
knock-down by siRNA in an SMA mouse model tripled survival time, improved motor 
function, and motor neuron survival (Little et al., 2015). Interestingly, in the C9ORF72-
ALS LCM motor neuron transcriptomic dataset, PTEN had the highest fold change of all 
DE genes. As described above, Pten is upregulated at transcript level in the NSC34 
(G4C2)102 cells as well. This suggests that PTEN upregulation in C9ORF72-ALS may 
contribute to motor neuronal cell death. More specifically, the NSC34 (G4C2)102 data 
suggests the (G4C2)n expression may cause this PTEN upregulation. Therefore, Pten was 
taken forward as a potential therapeutic target in chapter 6. 
5.4.4.2. RNA Metabolism and mRNA Transport 
RNA metabolism is an important biological process involved in many levels of gene 
expression (Walsh et al., 2015). Dysregulated RNA metabolism is implicated in a wide 
range of neurodegenerative diseases including ALS (sections 1.5.5 and 1.6.5). GEP of the 
NSC34 (G4C2)102 cells identified transcriptomic dysregulation in RNA metabolism, but 
more specifically in RNA splicing, ncRNA processing and mRNA transport. This is in 
agreement with a previous transcriptomic study that showed RNA splicing is 
dysregulated in C9ORF72-ALS lymphoblastoid cells and LCM motor neurons (Cooper-
Knock et al., 2015a).  
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The (G4C2)n repeat expansion is hypothesised to cause neurotoxicity and 
neurodegeneration in C9ORF72-ALS via an RNA toxicity mechanism (section 1.7.2). 
Briefly, the (G4C2)n RNA transcribed from the repeat expansion is thought to bind and 
sequester RNA binding proteins. Therefore, several studies used in vitro (G4C2)n RNA 
pull downs to identify candidate binding proteins (Cooper-Knock et al., 2014b; Donnelly 
et al., 2013; Haeusler et al., 2014; Lee et al., 2013; Mori et al., 2013b; Rossi et al., 2015; 
Xu et al., 2013). Interestingly, several of the (G4C2)n RNA binding candidates identified 
by our group, including many splicing factors, were downregulated in the NSC34 
(G4C2)102 cells. These transcripts included SRSF1 and SRSF2, and the downregulation 
was validated by qRT-PCR. SRSF1 and SRSF2 had previously been shown to co-localise 
with the (G4C2)n RNA foci in the NSC34 (G4C2)102 cells (section 4.3.3) as well as in 
C9ORF72-ALS pathological tissue (Cooper-Knock et al., 2014b; Lee et al., 2013).  
The downregulation of (G4C2)n RNA binding candidates is contrary to a seemingly more 
obvious hypothesis: sequestration of RNA binding proteins by the (G4C2)n RNA would 
result in loss of activity of those specific RNA binding proteins, and the cell would 
therefore compensate by increasing expression of those RNA binding proteins. This is in 
fact what our group found in C9ORF72-ALS patient tissue. However, 20% and 10% of the 
identified binding candidates from the aforementioned study (Cooper-Knock et al., 
2014b) were DE in C9ORF72-ALS lymphoblastoid cells and LCM motor neurons 
respectively, where 89% and 77% of those DE transcripts were upregulated respectively 
(Cooper-Knock et al., 2015a). This casts some doubt over the physiological relevance of 
the transcriptomic changes identified in the NSC34 (G4C2)102 cells. 
The differential splicing analysis provides a functional readout of RNA splicing 
dysregulation in the NSC34 (G4C2)102 cells. The number of differentially spliced 
transcripts between the NSC34 (G4C2)102 and NSC34 sham increased from 3029 in basal 
conditions (no tetracycline) to 5834 when the cells were induced with tetracycline for 5 
days, and suggests that the (G4C2)102 expression alters splicing. The (G4C2)102 is 
expressed at low levels at basal conditions (section 3.4.3), which could cause some 
differential splicing events. However, the greater (G4C2)102 expression after 5 days 
tetracycline induction further disrupts splicing in the NSC34 cells. This importantly 
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suggests that RNA splicing defects are an early biochemical effect of (G4C2)n expression. 
This corroborates previous transcriptomic analysis that showed there are extensive 
splicing defects in C9ORF72-ALS frontal cortex and cerebellum (Prudencio et al., 2015). 
In addition, splicing is less consistent in C9ORF72-ALS lymphoblastoid cells compared to 
non-C9ORF72-ALS and control cells, although the actual number of differential splicing 
events was not altered (Cooper-Knock et al., 2015a). It is not clear whether the (G4C2)n 
RNA and/or the RAN translation products cause the RNA splicing defects, although the 
RNA sequestration hypothesis makes it more logical to attribute these effects to the 
(G4C2)n RNA. 
In addition to RNA splicing defects, dysregulated mRNA export is also thought to play an 
important role in C9ORF72-ALS pathogenesis. The (G4C2)n RNA binds RanGAP1 in 
transgenic fly models, C9ORF72-ALS iPSC-derived neurons and C9ORF72-ALS patient 
brain tissue (Zhang et al., 2015). The (G4C2)n RNA also disrupts nuclear import in 
transgenic fly models and C9ORF72-ALS iPSC-derived neurons (Zhang et al., 2015), and 
nuclear export of RNA in transfected NSC34 and HeLa cells, transgenic fly models, and 
C9ORF72-ALS iPSC-derived neurons (Freibaum et al., 2015; Rossi et al., 2015). In 
addition, genetic screening in transgenic fly models show proteins involved in 
nucleocytoplasmic transport modify toxicity caused by the (G4C2)n RNA (Freibaum et 
al., 2015), whilst a screen performed in S. cerevisiae identified components of 
nucleocytoplasmic transport as modifiers of DPR-induced toxicity (Jovičić et al., 2015). 
5.4.4.3. Protein Transport and Vesicle-Mediated Transport 
Protein transport and vesicle-mediated transport, in addition to protein degradation, 
are thought to be important biological processes in ALS pathogenesis (sections 1.5.6 and 
1.6.6). This is due to the number of ALS associated genes that are involved in protein 
homeostasis, and also because protein aggregates are pathological hallmarks of ALS, 
suggesting cellular protein homeostasis is inefficient or overwhelmed. GEP of the NSC34 
(G4C2)102 cells identified transcriptomic dysregulation in protein transport and vesicle-
mediated transport. Also, previous studies have suggested the (G4C2)n repeat and/or 
the DPR cause nucleocytoplasmic transport dysregulation (Freibaum et al., 2015; Jovičić 
et al., 2015; Zhang et al., 2015). 
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The (G4C2)102 repeat is transcribed to form RNA foci (section 3.3.4.1), but also 
undergoes RAN translation producing proteins that contain the (GA)n, (GR)n and (GP)n 
sense DPR motifs (section 3.3.4.3). The DPR proteins aggregate to form insoluble 
inclusions in vitro and also in C9ORF72-ALS CNS tissue (sections 1.4, 1.7.3, and 1.8.2.3). 
Whilst there is no direct evidence to show the RAN proteins in the NSC34 (G4C2)102 
cells aggregate, it is certainly possible. Therefore, the transcriptomic alterations in 
protein transport and vesicle-mediated transport may suggest a cellular response to 
potentially misfolded and aggregated RAN proteins within the NSC34 (G4C2)102 cells. 
Additionally, in times of stress, protein synthesis and cellular growth are inhibited, whilst 
autophagy is upregulated (Sarbassov et al., 2005). Critically, mTOR signalling favours 
growth and inhibits autophagy, and therefore the downregulation of mTOR in the NSC34 
(G4C2)102 cells fits with the reduced growth rate previously described in the NSC34 
(G4C2)102 cells (sections 3.3.4.7 and 3.4.6), but also suggests increased autophagy. 
5.4.5. Summary 
Early transcriptomic changes caused by the (G4C2)102 expression were identified in the 
NSC34 cells using microarray analysis. Importantly, the transcriptomic changes 
corroborate with previous transcriptomic studies in C9ORF72-ALS patient derived cells 
and post-mortem tissue. Specifically, RNA metabolism, and RNA splicing and mRNA 
transport in particular, were dysregulated at transcript level. Further, (G4C2)102 
expression increased the number of differentially spliced transcripts, suggesting 
functional splicing dysregulation. In addition, significant transcriptomic dysregulation 
was identified in the PI3K/Akt signalling pathway in the NSC34 (G4C2)102 cells. This was 
validated in LCM motor neurons from C9ORF72-ALS patients, and suggests this is an 
early transcriptomic change in C9ORF72-ALS pathogenesis. Lastly, since the PI3K/Akt 
signalling pathway regulates cellular survival it may represent a potent therapeutic 
target, and was taken forward for in vitro manipulation and rescue assays.  
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Chapter 6. Modulation of Pten and PI3K/Akt 
Signalling Pathway in NSC34 (G4C2)102 Cells 
6.1. Introduction 
PTEN and the PI3K/AKT signalling pathway have previously been described as potential 
therapeutic targets in ALS and other motor neuron diseases (see section 5.4.4.1). Pten 
was elevated at the transcript level in the NSC34 (G4C2)102 cells, as well as C9ORF72-
ALS LCM motor neurons. Further, the PI3K/AKT signalling pathway (or branches of the 
super-pathway) were also dysregulated at transcript level in the NSC34 (G4C2)102 and 
C9ORF72-ALS LCM motor neurons. Therefore, it was hypothesised that PTEN inhibition 
would activate the PI3K/Akt signalling pathway rescuing the NSC34 cells from (G4C2)102 
induced toxicity. Two different approaches were taken to inhibit PTEN activity: PTEN 
knock-down using commercial lentiviral Pten shRNA vectors, and pharmacological 
inhibition using the specific PTEN inhibitor bisperoxo(1,10-phenanthroline)oxovanadate 
(BpV(phen)). 
The PI3K/AKT signalling pathway is highly conserved, and regulates various cellular 
functions including cellular survival, cell proliferation, cell growth, metabolism, 
transcription and protein synthesis (Figure 5.11) (Hers et al., 2011). Phosphoinositide 3-
kinases (PI3K) are central to the PI3K/AKT signalling cascade, and are activated by a wide 
range of receptors such as receptor tyrosine kinases and G protein coupled receptors 
(Figure 5.11). Active PI3Ks phosphorylate phosphatidylinositol-4,5-P2 (PI[4,5]P2) to 
produce phosphatidylinositol-3,4,5-P3 (PI[3,4,5]P3) (Figure 6.1), which acts as a 
secondary messenger. Importantly, PTEN negatively regulates this signalling cascade via 
it’s intrinsic phosphatase activity, which converts PI[3,4,5]P3 back to PI[4,5]P2 thereby 
antagonising the PI3K signalling (Figure 6.1). PTEN activity can also be reduced by 
phosphorylation at Ser380 (Vazquez et al., 2000). 
AKT is activated downstream in the PI3K/AKT signalling cascade by the PI[3,4,5]P3. The 
three genes AKT1, AKT2, and AKT3 encode highly similar isoforms of AKT. The PH domain 
of AKT allows docking to PI[3,4,5]P3, and recruitment to the plasma membrane. Once 
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docked to PI[3,4,5]P3, AKT changes conformation allowing Thr308 and Ser473 residues 
to be phosphorylated by various phosphatidyl-dependent kinases (PDK). The 
phosphorylation of these two residues is critical for full activation of AKT (Bhaskar and 
Hay, 2007). Therefore, quantification of p-Akt(Ser473) levels is widely used to measure 
AKT signalling activity. 
 
Figure 6.1 PTEN antagonises PI3K/AKT signalling. PI3K phosphorylates 
phosphatidylinositol-4,5-P2 (PI[4,5]P2) to produce phosphatidylinositol-3,4,5-P3 
(PI[3,4,5]P3). PI[3,4,5]P3 recruits AKT at the plasma membrane, leading to AKT 
activation. PTEN antagonises this cascade by phosphatase activity, which converts 
PI[3,4,5]P3 to PI[4,5]P2. 
BpV(phen) is a competitive and reversible inhibitor of PTEN (Schmid et al., 2004), and is 
thought to reversibly oxidise the catalytic cysteine residue in the phosphatase active site 
of PTEN (Lee et al., 2015). BpV(phen), and other structurally related BpV compounds, 
increase pAKT(Ser473) levels in vitro in various cell lines, (Dimchev et al., 2013; Schmid 
et al., 2004; Zhao et al., 2013) and in in vivo models (Ding et al., 2013; Guo et al., 2013; 
Mao et al., 2013) indicating increased AKT signalling. However, although the BpV 
compounds inhibit PTEN, they do not increase p-PTEN(Ser380) levels (relative to total 
PTEN) in any models tested.  Additionally, the BpV compounds have also been shown to 
provide neuroprotective effects in a range of in vivo stroke models (Chen et al., 2015; 
Ding et al., 2013; Guo et al., 2013; Mao et al., 2015). 
Vanadium compounds, such as sodium orthovanadate have been recognized as 
inhibitors of several classes of phosphatase enzymes since the 1970s, in some cases with 
reasonable potency (eg. human liver alkaline phosphatase Ki <1μM) (Seargeant and 
Stinson, 1979; VanEtten et al., 1974). Although this broad spectrum phosphatase 
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inhibition by vanadate appears to be mediated by simple reversible competitive 
inhibition, a more selective irreversible inhibition of several members of the protein 
tyrosine phosphatase family appears to be achieved by aqueous peroxovanadium 
compounds due to oxidation of the active site cysteine thiol (Bevan et al., 1995; Huyer 
et al., 1997). Subsequently, peroxovanadium compounds such as bisperoxovanadium 
1,10 phenanthroline (bpV(phen)) and bisperoxovanadium 5-hydroxypiridine-2-carboxyl 
(bpV(HOpic)) were studied due to their increased biological potency and evidence that 
these vanadium complexes have greater target selectivity than the simple vanadate 
compounds. For example, bpV(phen) and bisperoxovanadium 2-carboxypyridine 
(bpV(pic)) were shown to inhibit Cdc25A with some selectivity, displaying IC50 
determined in vitro in the presence of 1mM DTT in the 10–50nM range (Scrivens et al., 
2003). 
6.2. Aims and Objectives for PI3K/Akt Signalling Pathway in NSC34 (G4C2)102 
Cells 
1) Validate changes in total Pten and total Akt protein levels in NSC34 (G4C2)102 
cells. 
2) Validate changes in PI3K/Akt signalling in NSC34 (G4C2)102 cells. 
3) Use lentiviral Pten shRNA vectors to knock-down Pten and rescue (G4C2)102 
induced toxicity. 
4) Use Pten inhibitor BpV(phen) to activate PI3K/Akt signalling pathway and rescue 
(G4C2)102 induced toxicity. 
6.3. Results 
6.3.1. Akt, p-Akt(Ser473), Pten and p-Pten(Ser380) Levels are Unaffected by (G4C2)102 
Expression in NSC34 Cells 
Immunoblotting was used to validate the DE of Akt and Pten transcripts after 5 days 
tetracycline induction (section 5.3.3.4.1), and also to investigate whether the PI3K/Akt 
signalling pathway was dysregulated at a biochemical level in the NSC34 (G4C2)102 cells. 
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NSC34 sham and NSC34 (G4C2)102 cells were grown for 5 days with or without 
tetracycline and then immunoblotted for total Akt, and Pten, as well as p-Akt(Ser473) 
and p-Pten(Ser380) phosphor-isomers. The anti-Akt and anti-p-Akt(Ser473) antibodies 
detected a protein band at 60kDa (Figure 6.2A), which is the expected molecular weight. 
There was no significant difference in total Akt levels between tetracycline treated and 
untreated NSC34 sham cells (Figure 6.2). Neither was there any significant difference in 
total Akt levels between tetracycline treated NSC34 (G4C2)102 cells and either 
untreated NSC34 (G4C2)102 or treated NSC34 sham cells (Figure 6.2). Also, there was 
no significant difference in p-Akt(Ser473) levels between tetracycline treated and 
untreated NSC34 sham cells, when normalised to either β-actin or total Akt levels (Figure 
6.2). Finally, there were slight increases in p-Akt(Ser473) levels in NSC34 (G4C2)102 cells 
compared to NSC34 sham cells, although these comparisons were not statistically 
significant. p-Akt(Ser473) levels were increased by 15.4 ± 9.5% (ns) and 29.3 ± 21.1% (ns) 
in untreated NSC34 (G4C2)102 cells compared to untreated NSC34 sham cells, when 
normalised to β-actin or total Akt levels respectively (Figure 6.2). p-Akt(Ser473) levels 
were also increased by 35.1 ± 41.0% (ns) and 30.0 ± 41.4% (ns) in tetracycline treated 
NSC34 (G4C2)102 cells compared to tetracycline treated NSC34 sham cells, when 
normalised to β-actin or total Akt levels respectively (Figure 6.2). 
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Figure 6.2 (G4C2)102 expression does not affect total Akt or phospho-Akt(Ser473) 
levels in NSC34 cells. A) NSC34 sham and NSC34 (G4C2)102 cells were cultured for 5 
days with or without 0.5μg/mL tetracycline. Cells were lysed and immunoblotted with 
anti-Akt, anti-p-Akt(Ser473) and anti-β-actin. A representative immunoblot is shown. 
Molecular weight markers are indicated (kDa). B) Quantification of Akt normalised to β-
actin, and p-Akt(Ser473) normalised to β-actin or Akt (Two-way ANOVA with Tukey’s 
multiple comparisons post hoc test; Data are means ± SD; n = 3).  
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The anti-Pten and anti-p-Pten(Ser380) antibodies detected a protein band at 54 kDa 
(Figure 6.3A), which is the expected molecular weight. There was no significant 
difference in total Pten levels between tetracycline treated and untreated NSC34 sham 
cells (Figure 6.3). However, total Pten levels were increased by 23.1 ± 40.8% (ns) in the 
untreated NSC34 (G4C2)102 cells and 24.1 ± 33.6% (ns) in the tetracycline induced 
NSC34 (G4C2)102 cells when compared to untreated and tetracycline treated NSC34 
sham cells respectively, although these increases were not statistically significant (Figure 
6.3). Similarly, there was no significant difference in p-Pten(Ser380)  levels between 
tetracycline treated and untreated NSC34 sham cells, when normalised to either β-actin 
or total Pten levels (Figure 6.3). However, p-Pten(Ser380) levels (normalised to β-actin) 
were increased by 15.1 ± 32.6% (ns) in the untreated NSC34 (G4C2)102 cells and 31.9 ± 
26.0% (ns) in the tetracycline induced NSC34 (G4C2)102 cells when compared to 
untreated and tetracycline treated NSC34 sham cells respectively, although these 
increases were not statistically significant (Figure 6.3). Finally, the ratio of p-
Pten(Ser380) to total Pten was not significantly different in either the untreated NSC34 
(G4C2)102 cells or tetracycline treated NSC34 (G4C2)102 cells compared to the 
untreated and tetracycline treated NSC34 sham cells respectively (Figure 6.3). 
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Figure 6.3 (G4C2)102 expression does not affect total Pten or phospho-Pten(Ser380) 
levels in NSC34 cells. A) NSC34 sham and NSC34 (G4C2)102 cells were cultured for 5 
days with or without 0.5μg/mL tetracycline. Cells were lysed and immunoblotted with 
anti-Pten, anti-p-Pten(Ser380) and anti-β-actin. A representative immunoblot is shown. 
Molecular weight markers are indicated (kDa). B) Quantification of Pten normalised to 
β-actin, and p-Pten(Ser380) normalised to β-actin or Pten (Two-way ANOVA with 
Tukey’s multiple comparisons post hoc test; Data are means ± SD; n = 3). 
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6.3.2. Pten Inhibition Using a Lentiviral Vector Encoding Pten shRNA 
6.3.2.1. Puromycin Dose-Response in NSC34 Sham and (G4C2)102 Cells 
Pten was knocked down by stably integrating shRNA into the NSC34 sham and 
(G4C2)102 cell genome by lentiviral delivery. The lentiviral vectors used all confer 
puromycin resistance, and therefore cells containing stably integrated lentivirus can be 
selected using puromycin selection. Therefore, the minimum concentration of 
puromycin that would kill NSC34 sham and NSC34 (G4C2)102 had to be identified. 
NSC34 sham cells were cultured for 7 days with various concentrations of puromycin, 
and then an MTT assay was performed to assess cell viability. ≤0.01μg/mL puromycin 
did not affect NSC34 sham or NSC34 (G4C2)102 cell viability (Figure 6.4). 0.05 and 
0.1μg/mL puromycin partially reduced NSC34 sham and NSC34 (G4C2)102 cell viability, 
whilst ≥0.5μg/mL puromycin completely devastated NSC34 sham and NSC34 (G4C2)102 
cells (Figure 6.4). Therefore, puromycin was used at 1μg/mL to select for stable lentiviral 
transduced NSC34 cells. 
 
Figure 6.4 Dose-response of NSC34 sham and NSC34 (G4C2)102 cell viability against 
puromycin. NSC34 sham cells were cultured for 7 days with various concentrations of 
puromycin. Cell viability was measured using an MTT assay (Data shown are means and 
SD; n = 1). 
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6.3.2.2. Lentiviral ShRNA Vectors Reduced Total Pten Levels in Stably Transduced NSC34 
Sham and (G4C2)102 Cells 
NSC34 sham and NSC34 (G4C2)102 cells were transduced with either GFP control 
lentiviral particles or Pten shRNA (mouse) lentiviral particles. The media was removed 
and replenished 24 hours after transduction. Puromycin selection was added to the 
media to select for cells which had the lentivirus stably integrated into the genome. Over 
the next week there was a lot of cell death, but visible puromycin-resistant colonies 
could be seen growing. The stable transformants were expanded as mixed populations, 
and frozen down. Later, in a separate procedure, control shRNA lentiviral particles were 
also stably transduced into NSC34 sham and NSC34 (G4C2)102 cells, as described above. 
The second transduction using the control shRNA was performed because initial 
experiments using the GFP control produced encouraging results, and a better control 
was desired for the Pten shRNA. The GFP transduced cells only controlled for viral 
transduction, whilst the control shRNA transduced cells additionally controlled for 
shRNA expression, and therefore represent a more robust control for the Pten shRNA 
transduced cells. 
The effect of the stably transduced Pten shRNA was assessed by immunoblot. Pten was 
knocked down by 63.0 ± 14.4% (P<0.05) in the NSC34 sham Pten shRNA compared to 
NSC34 sham GFP control cells (Figure 6.5). Whilst Pten was knocked down by 62.5 ± 22.2 
(P<0.01) in the NSC34 (G4C2)102 Pten shRNA compared to NSC34 (G4C2)102 GFP 
control cells (Figure 6.5), there was no significant difference in the Pten levels between 
NSC34 sham GFP and NSC34 (G4C2)102 GFP control cells, or NSC34 sham Pten shRNA 
compared to NSC34 (G4C2)102 Pten shRNA cells (Figure 6.5). 
In a separate set of experiments, the effect of Pten shRNA was also assessed compared 
to the control shRNA cell lines. Unexpectedly however, the NSC34 sham Pten shRNA 
cells no longer showed a significant Pten knock-down, and were removed from later 
experiments where the control shRNA cell lines were used as the control rather than the 
GFP lines. Pten was knocked down by 70.0 ± 4.5% (P<0.01) in the NSC34 (G4C2)102 Pten 
shRNA compared to NSC34 (G4C2)102 control shRNA cells (Figure 6.6). 
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Figure 6.5 Pten shRNA reduces Pten levels in stably transduced NSC34 sham and 
(G4C2)102 cells. A) NSC34 sham and (G4C2)102 cells were stably transduced with either 
LV GFP or Pten shRNA LV.  Cells were lysed and immunoblotted with anti-Pten and anti-
β-actin. A representative immunoblot is shown. Molecular weight markers are indicated 
(kDa). B) Quantification of Pten normalised to β-actin (*P<0.05, **P<0.01; One-way 
ANOVA with Tukey’s multiple comparisons post hoc test; Data are means ± SD; n=3). 
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Figure 6.6 Pten shRNA reduces Pten levels in stably transduced NSC34 (G4C2)102 cells. 
A) NSC34 sham and (G4C2)102 cells were stably transduced with either LV control 
shRNA or Pten shRNA LV.  Cells were lysed and immunoblotted with anti-Pten and anti-
β-actin. A representative immunoblot is shown. Molecular weight markers are indicated 
(kDa). B) Quantification of Pten normalised to β-actin (*P<0.05, **P<0.01; One-way 
ANOVA with Tukey’s multiple comparisons post hoc test; Data are means ± SD; n=3). 
6.3.2.3. Pten Knock-Down Rescues NSC34 Cells from (G4C2)102 Induced Toxicity 
The hypothesis was that Pten knock-down would rescue the NSC34 (G4C2)102 cells from 
the (G4C2)102 induced toxicity (which had previously been described in section 3.3.4.5). 
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A rescue assay was performed that was modelled on the MTT cell viability assay 
performed in section 3.3.4.5, which showed (G4C2)102 expression reduced NSC34 cell 
viability after 7 days of tetracycline induction. NSC34 sham GFP, NSC34 sham Pten 
shRNA, NSC34 (G4C2)102 GFP and NSC34 (G4C2)102 Pten shRNA cells were cultured for 
7 days with or without tetracycline, and then cell viability was assessed using an MTT 
assay. Neither NSC34 sham GFP control cell nor NSC34 sham Pten shRNA cell viability 
was affected by tetracycline induction (Figure 6.7). As expected, NSC34 (G4C2)102 GFP 
cell viability was reduced by 16.9 ± 11.3% (P<0.01) when cells were induced with 
tetracycline compared to NSC34 (G4C2)102 GFP cell untreated with tetracycline (Figure 
6.7). However, there was no significant reduction in NSC34 (G4C2)102 Pten shRNA cell 
viability when cells were induced with tetracycline compared to NSC34 (G4C2)102 Pten 
shRNA cells untreated with tetracycline (Figure 6.7), indicating Pten knock-down 
provides a rescue effect against the (G4C2)102 induced toxicity. 
 
Figure 6.7 Pten knock-down rescues (G4C2)102 induced toxicity in NSC34 cells. NSC34 
sham GFP, sham Pten shRNA, (G4C2)102 GFP and (G4C2)102 cells Pten shRNA cells were 
cultured for 7 days with or without 0.5μg/mL tetracycline. Cell viability was measured 
using an MTT assay (**P<0.01; Two-way ANOVA with Sidak’s multiple comparisons post 
hoc test; Data are means ± SD; n=4). 
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In a similar set of experiments, NSC34 sham control shRNA, NSC34 (G4C2)102 control 
shRNA and NSC34 (G4C2)102 Pten shRNA cells were cultured for 7 days with or without 
tetracycline, and then cell viability was assessed using an MTT assay. NSC34 sham GFP 
control cell viability was not affected by tetracycline induction (Figure 6.8). NSC34 
(G4C2)102 control shRNA cell viability was reduced by 15.0 ± 5.0% (P<0.01) when cells 
were induced with tetracycline compared to NSC34 (G4C2)102 control shRNA cells 
untreated with tetracycline (Figure 6.8). In a repeat of the above experiments, there was 
no significant reduction in NSC34 (G4C2)102 Pten shRNA cell viability when cells were 
induced with tetracycline compared to NSC34 (G4C2)102 Pten shRNA cells untreated 
with tetracycline (Figure 6.8), further demonstrating Pten knock-down provides a rescue 
effect against the (G4C2)102 induced toxicity. 
 
Figure 6.8 Pten knock-down stops (G4C2)102 induced toxicity in NSC34 cells. NSC34 
sham GFP, sham Pten shRNA, (G4C2)102 GFP and (G4C2)102 cells Pten shRNA cells were 
cultured for 7 days with or without 0.5μg/mL tetracycline. Cell viability was measured 
using an MTT assay (**P<0.01; Two-way ANOVA with Sidak’s multiple comparisons post 
hoc test; Data are means ± SD; n=4). 
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6.3.2.4. Akt Signalling Analysis in NSC34 Pten ShRNA Cells 
Pten knock-down was hypothesised to increase Akt signalling in the NSC34 cells. NSC34 
sham control shRNA, NSC34 (G4C2)102 control shRNA, and NSC34 (G4C2)102 Pten 
shRNA cells were cultured for 5 days with or without tetracycline, and then 
immunoblotted for total Akt and p-Akt(Ser473). There was no significant difference in 
total Akt levels between tetracycline induced NSC34 sham control shRNA, NSC34 
(G4C2)102 control shRNA or NSC34 (G4C2)102 Pten shRNA compared to their respective 
control cells untreated with tetracycline (Figure 6.9). In addition, there was no significant 
difference in total Akt levels between either the NSC34 (G4C2)102 control shRNA cells 
or the NSC34(G4C2)102 Pten shRNA cells compared to the NSC34 sham control shRNA 
cells (Figure 6.9). Lastly, there was no significant difference in total Akt levels between 
the NSC34 (G4C2)102 control shRNA cells and the NSC34(G4C2)102 Pten shRNA cells 
(Figure 6.9).  
There was no significant difference in p-Akt(Ser473) levels (normalised to both β-actin 
and total Akt) between tetracycline induced NSC34 sham control shRNA, NSC34 
(G4C2)102 control shRNA or NSC34 (G4C2)102 Pten shRNA compared to their respective 
control cells untreated with tetracycline (Figure 6.9). However, there was significantly 
more p-Akt(Ser473) (normalised to both β-actin and total Akt) in NSC34 (G4C2)102 
control shRNA cells compared to NSC34 sham control shRNA cells (P<0.001) (Figure 6.9). 
Also, there was significantly more p-Akt(Ser473) (normalised to both β-actin and total 
Akt) in NSC34 (G4C2)102 Pten shRNA cells compared to NSC34 sham control shRNA cells 
(P<0.001) (Figure 6.9). There was no significant difference in p-Akt(Ser473) (normalised 
to both β-actin and total Akt) in NSC34 (G4C2)102 Pten shRNA cells compared to NSC34 
(G4C2)102 control shRNA cells however (Figure 6.9). 
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Figure 6.9 p-Akt levels are increased in NSC34 (G4C2)102 cells stably transduced with 
Lentivirus compared to NSC34 sham cells stably transduced with Lentivirus. A) NSC34 
sham control shRNA, (G4C2)102 control shRNA and (G4C2)102 Pten shRNA cells were 
cultured for 5 days with or without 0.5μg/mL tetracycline. Cells were lysed and 
immunoblotted with anti-Akt, anti-p-Akt(Ser473) and anti-β-actin. A representative 
immunoblot is shown. Molecular weight markers are indicated (kDa). B) Quantification 
of Akt normalised to β-actin, and p-Akt(Ser473) normalised to β-actin or Akt 
(***P<0.001; Two-way ANOVA with Tukey’s multiple comparisons post hoc test; Data 
are means ± SD; n=3). 
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From these results, the following can be concluded: 1) total Akt levels are unaffected by 
Pten knock-down; 2) total Akt levels are unaffected by tetracycline induction and/or 
increased (G4C2)102 expression; 3) p-Akt(Ser473) levels are increased in NSC34 cells 
that contain both the genomic (G4C2)102 repeat and a stably integrated lentiviral 
vector; 4) (G4C2)102 expression does not affect p-Akt(Ser473) levels in the lentiviral 
transduced NSC34 cells; 5) Pten knock-down does not measurably alter p-Akt(Ser473) 
levels at the 5 day timepoint. 
6.3.3. Pten Inhibition Using BpV(phen) 
6.3.3.1. BpV(phen) Viability Dose-Response in NSC34 Sham Cells 
To validate the Pten knock-down rescue effect in the shRNA lentiviral transduced NSC34 
(G4C2)102 cells, Pten inhibitors were used to pharmacologically inhibit Pten activity. The 
hypothesis was to treat NSC34 (G4C2)102 cells with the potent Pten inhibitor BpV(phen) 
(Schmid et al., 2004), to see whether Pten inhibition, and Akt signalling activation, would 
rescue the (G4C2)102 induced toxicity. Firstly however, a dose-response of BpV(phen) 
concentration and NSC34 sham cell viability was performed to identify a sub-lethal dose 
of BpV(phen) to use in these rescue assays. NSC34 sham cells were cultured for 6 days 
with various concentrations of BpV(phen), and then an MTT assay was performed to 
assess cell viability. ≤1μM BpV(phen) did not affect NSC34 sham cell viability, whilst 
≥3μM BpV(phen) completely devastated NSC34 sham cells (Figure 6.10). This was 
unsurprising since the cells appeared dead upon visual observation. 1μM BpV(phen) was 
taken forward as the highest sub-lethal dose. 
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Figure 6.10 Dose-response of NSC34 sham cell viability against BpV(phen). NSC34 sham 
cells were cultured for 6 days with various concentrations of BpV(phen). Cell viability 
was measured using an MTT assay (data shown are mean and SD; n=1). 
6.3.3.2. 1 μM BpV(phen) Effect on Pten and Akt Activity in NSC34 Sham Cells 
1µM was the highest sublethal dose of BpV(phen) tested in the NSC34 sham cells, and 
this concentration was taken forward to establish whether BpV(phen) could inhibit Pten 
and activate Akt in the NSC34 sham cells. To do this, NSC34 sham cells were treated with 
1μM BpV(phen) for various lengths of time, and then immunoblotted for total Akt, p-
Akt(Ser473), total Pten and p-Pten(Ser380). There was no significant difference in p-
Pten(Ser380) levels (normalised to either β-actin or total Pten) between the untreated 
NSC34 sham cells and the NSC34 sham cells treated with BpV(phen) for 12, 24 or 48 
hours (Figure 6.11). There was no significant difference in p-Akt(Ser473) levels 
(normalised to either β-actin or total Akt) between the untreated NSC34 sham cells and 
the NSC34 sham cells treated with BpV(phen) for 12, 24 or 48 hours (Figure 6.12). 
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Figure 6.11 Time-response of Pten inhibition by 1μM BpV(phen) in NSC34 sham cells. 
A) NSC34 sham cells were cultured for various lengths of time with 1μM BpV(phen). Cells 
were lysed and immunoblotted with anti-Akt, anti-p-Akt(Ser473) and anti-β-actin. A 
representative immunoblot is shown. Molecular weight markers are indicated (kDa). B) 
Quantification of Pten normalised to β-actin, and p-Pten(Ser380) normalised to β-actin 
or Pten (One-way ANOVA with Sidak’s multiple comparisons post hoc test; Data shown 
are mean and SD; n=3).   
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Figure 6.12 Time-response of Akt activation by 1μM BpV(phen) in NSC34 sham 
cells.NSC34 sham cells were cultured for various lengths of time with 1μM BpV(phen). 
Cells were lysed and immunoblotted with anti-Akt, anti-p-Akt(Ser473) and anti-β-actin. 
A representative immunoblot is shown. Molecular weight markers are indicated (kDa). 
B) Quantification of Akt normalised to β-actin, and p-Akt(Ser473) normalised to β-actin 
or Akt (One-way ANOVA with Sidak’s multiple comparisons post hoc test; Data shown 
are means and SD; n=3). 
216 
 
 
6.3.3.3. Higher Dose (Short Time) Effect on Pten and Akt Activities in NSC34 Sham Cells 
≥1μM doses of BpV(phen) were tested for Akt activation and Pten inhibition in the 
NSC34 sham cells, because 1μM BpV(phen) did not elicit an increase in p-Akt(Ser473) 
levels or p-Pten(Ser380) levels. NSC34 cells were cultured with various concentrations 
of BpV(phen) for 2 days, and then immunoblotted for total Akt, p-Akt(Ser473), total Pten 
and p-Pten(Ser380). The higher the BpV(phen) dose, the lower the p-Pten(Ser380) levels 
(normalised to either β-actin or total Pten) were in the NSC34 sham cells (Figure 6.13). 
However, p-Akt(Ser473) levels (normalised to either β-actin or total Akt) were far 
greater in the NSC34 sham cells treated with 3μM BpV(phen) compared to cells treated 
with ≤1µM BpV(phen) (Figure 6.14). This suggested that 3µM BpV(phen) did activate the 
Akt signalling pathway, and was therefore re-tested for toxicity in the NSC34 sham cells 
at shorter dose lengths. To note however, this experiment was only performed once. 
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Figure 6.13 3μM BpV(phen) decreases p-Pten levels in NSC34 sham cells. A) NSC34 
sham cells were cultured with various concentrations of BpV(phen).  Cells were lysed 
and immunoblotted with anti-Pten, anti-p-Pten(Ser380) and anti-β-actin. Molecular 
weight markers are indicated (kDa). B) Quantification of Pten normalised to β-actin, and 
p-Pten(Ser380) normalised to β-actin or Pten (Data are means; n=1). 
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Figure 6.14 3μM BpV(phen) increases p-Akt levels in NSC34 sham cells. A) NSC34 sham 
cells were cultured with various concentrations of BpV(phen).  Cells were lysed and 
immunoblotted with anti-Akt, anti-p-Akt(Ser473) and anti-β-actin. Molecular weight 
markers are indicated (kDa). B) Quantification of Akt normalised to β-actin, and p-
Akt(Ser473) normalised to β-actin or Akt. n=1.  
6.3.3.4. Time-Response of NSC34 Sham Cell Viability Against 3µM BpV(phen) 
NSC34 sham cells were cultured for one week, and 3µM BpV(phen) was added to the 
media for various lengths of time. An MTT assay was then performed to assess the 
NSC34 sham cell viability. The NSC34 sham cell viability was not affected after 6 hours 
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of 3 µM BpV(Phen) treatment (Figure 6.15). However, NSC34 sham cell viability was 
reduced by 18, 73 and 87% after 24, 48 and 144 hours of 3µM BpV(Phen) treatment 
respectively (Figure 6.15). Therefore, NSC34 (G4C2)102 cells would be dosed with 3µM 
BpV(phen) for 6 hours on day 2 and 5 of a 7 day cell viability rescue assay. 
 
Figure 6.15 Time-response of NSC34 sham cell viability against 3µM BpV(phen). NSC34 
sham cells were cultured for various lengths of time with 3 μM BpV(phen). Cell viability 
was measured using an MTT assay. n=1. 
6.3.3.5. BpV(phen) Rescue Assay in NSC34 Sham and NSC34 (G4C2)102 cells 
The hypothesis was that Pten inhibition, and Akt signalling activation, would rescue the 
NSC34 (G4C2)102 cells from the (G4C2)102 induced toxicity (which had previously been 
described in section 3.3.4.5). A rescue assay was performed that was modelled on the 
MTT cell viability assay performed in section 3.3.4.5, which showed (G4C2)102 
expression reduced NSC34 cell viability after 7 days of tetracycline induction. NSC34 
sham and NSC34 (G4C2)102 cells were cultured for 7 days with or without tetracycline, 
and cells were additionally dosed with either 3µM BpV(phen) or a vehicle control for 6 
hours on days 2 and 5. NSC34 cells were given 24 hours to adhere to the plates prior to 
BpV(phen) treatment for two reasons. Firstly, because the cells could be more 
susceptible to any BpV(phen) induced toxicity when not adhered to the plate. Secondly, 
because the media was removed and replaced after 6 hours of BpV(phen) (or vehicle 
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control) dosing, an initial 24 hours was necessary to ensure all NSC34 had a chance to 
adhere before any media was removed. 
NSC34 sham cell viability was not affected by tetracycline induction in cells that were 
dosed with the vehicle control (Figure 6.16). Neither was NSC34 sham cell viability 
affected by tetracycline induction in cells that were dosed with BpV(phen) (Figure 6.16). 
However, NSC34 sham cell viability was reduced by 20.7 ± 4.9% (P<0.0001) in cells 
treated with BpV(phen) but not tetracycline, compared to the vehicle control cells also 
untreated with tetracycline (Figure 6.16). In addition, NSC34 sham cell viability was 
reduced by 28.3 ± 2.8% (P<0.0001) in cells treated with BpV(phen) and tetracycline, 
compared to the vehicle control cells also treated with tetracycline (Figure 6.16).  
 
Figure 6.16 BpV(phen) rescue assay of (G4C2)102 toxicity in NSC34 cells. NSC34 sham 
and (G4C2)102 cells were cultured for 7 days with or without 0.5μg/mL tetracycline. 
NSC34 cells were dosed with 3μM BpV(phen), or a vehicle control, for 6 h twice (on day 
2 and day 5). Cell viability was measured using an MTT assay (****P<0.0001; Two-way 
ANOVA with Sidak’s multiple comparisons post hoc test; Data are means ± SD; n=3). 
NSC34 (G4C2)102 cell viability was reduced by 25.3 ± 4.1% (P<0.0001) in tetracycline 
induced cells compared to NSC34 (G4C2)102 cells untreated with tetracycline, where 
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both cells were additionally dosed with the vehicle control (Figure 6.16). NSC34 
(G4C2)102 cell viability was also reduced by 25.4 ± 1.4% (P<0.0001) in tetracycline 
induced cells compared to NSC34 (G4C2)102 cells untreated with tetracycline, where 
both cells were additionally dosed with BpV(phen) (Figure 6.16). Similarly to the NSC34 
sham cells, NSC34 (G4C2)102 cell viability was reduced by 29.0 ± 2.0% (P<0.0001) in cells 
treated with BpV(phen) but not tetracycline, compared to the vehicle control cells also 
untreated with tetracycline (Figure 6.16). Finally, NSC34 (G4C2)102 cell viability was 
reduced by 29.1 ± 1.3% (P<0.0001) in cells treated with BpV(phen) and tetracycline, 
compared to the vehicle control cells also treated with tetracycline (Figure 6.16). 
6.4. Discussion 
6.4.1. There are no Significant Differences in Pten or Akt Protein levels in NSC34 
(G4C2)102 Cells 
There was no significant difference in total Akt protein levels in the NSC34 (G4C2)102 
cells, suggesting that the (G4C2)102 expression does not affect total Akt expression. This 
protein result supports the Akt1 qRT-PCR result in section 5.3.3.4.1, which showed that 
there was no significant difference in Akt1 mRNA levels in the NSC34 (G4C2)102 cells. 
Neither of these results validate the GEP, which showed Akt1 and Akt2 mRNA levels 
were decreased by 22 and 21% respectively. Importantly however, there are three 
different Akt genes (Akt1, Akt2, and Akt3) that each express highly similar isoforms of 
Akt protein. AKT1 is ubiquitously expressed (Hers et al., 2011), AKT2 is highly expressed 
in muscles and adipose tissue (Cho et al., 2001), whilst AKT3 expression is restricted to 
the testes and brain (Yang et al., 2003). The polyclonal anti-AKT antibody used in this 
study recognises Akt protein expressed from all three Akt genes, due to the high 
similarity in the three Akt isoforms. Also, given that NSC34 cells are derived from 
embryonic spinal cord cells and neuroblastoma cells, Akt3 expression is likely to 
contribute substantially to total Akt protein levels in the NSC34 cell line. Slight 
reductions in Akt1 and Akt2 expression may be masked by the potentially unaffected 
Akt3 expression levels, and therefore have an insignificant effect on overall Akt protein 
levels, explaining why total Akt protein is the same in the NSC34 (G4C2)102 cells 
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compared to NSC34 sham cells. Akt1, Akt2, and Akt3 specific monoclonal antibodies 
could be used to determine the actual levels of each of the Akt isoforms in the NSC34 
(G4C2)102 cells. 
In addition, there was no significant difference in total Pten protein levels in NSC34 
(G4C2)102 cells within the timeframe studied. This again supports the qRT-PCR result in 
section 5.3.3.4.1, which showed that there was no significant difference in Pten mRNA 
levels in the NSC34 (G4C2)102 cells. As with total Akt, the Pten immunoblotting and qRT-
PCR results do not validate the GEP. However, whilst neither the qRT-PCR nor the 
immunoblots showed statistically significant alterations, the Pten protein and mRNA 
levels were both slightly elevated in the NSC34 (G4C2)102 cells compared to NSC34 
sham cells, regardless of tetracycline induction time. This does suggest that Pten 
expression may be slightly elevated in the NSC34 (G4C2)102 cell line, but the increase in 
Pten is so small the qRT-PCR and immunoblot quantification failed to detect any 
significance. 
The differences in sensitivity between the microarray technology and the qRT-PCR and 
immunoblot methods used to validate the results may account for the apparent lack of 
validation. The GeneChip® MTA 1.0 arrays use a median of 30 probes per gene which 
target regions throughout the mRNA, whilst the qRT-PCR uses only one probe (primer 
pair). Therefore, mRNA levels are quantified by measuring several or only one small 
defined region of the mRNA using the microarray and qRT-PCR respectively. This means 
differences in mRNA splice isoforms could cause differences in the measured mRNA 
levels using the different techniques. To minimise any differences, primers were 
selected for qRT-PCR that recognised all splice variants, however, differences in splice 
variant levels may still affect the microarray measurements. Also, the microarray and 
qRT-PCR experiments were performed using different experimental samples, which may 
have contributed to the differences between the microarray and qRT-PCR results. Lastly, 
for the protein levels, DE at mRNA level does not always result in DE at protein level due 
to post-transcriptional regulation of gene expression. However, despite the lack of 
validation using qRT-PCR and immunoblotting, the main strength of the GEP results 
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come from the fact that the PI3K/Akt pathway shows dysregulation not only in the 
NSC34 (G4C2)102 but also in the C9ORF72-ALS LCM motor neurons. 
6.4.2. PI3K/Akt Signalling is not Altered at the Biochemical Level in NSC34 (G4C2)102 
cells 
Whilst the total Akt protein levels were unaffected by (G4C2)102 expression, they do 
not provide a good read out for PI3K/Akt signalling in the cells. Phosphorylation of AKT 
at Serine 473 is required for AKT activation, and therefore, the p-AKT(Ser473) to total 
AKT ratio is a better, and widely used, measure of AKT signalling. The p-Akt(Ser473)/total 
Akt levels were slightly elevated in the NSC34 (G4C2)102 cells compared to the NSC34 
sham cells (with or without tetracycline treatment), although the increases were not 
significant. Therefore, in the experimental conditions used, our data provided no 
evidence to suggest the PI3K/Akt signalling pathway was affected by (G4C2)102 
expression. The GEP analysis did detect alterations in the PI3K/Akt signalling pathway 
however, and the biochemical data does not disprove that the PI3K/Akt signalling 
pathway is altered, because the pathway is hugely complex and integrates many stimuli. 
Under different experimental conditions, for example in serum starvation or stimulation 
with specific growth factors or cytokines, the (G4C2)102 expression may result in altered 
Akt activation. 
Previous studies looking at p-AKT(Ser473) levels in ALS models have mainly been 
performed in SOD1(G93A) models, and have produced conflicting results. There were 
no changes in p-Akt(Ser473) levels in the spinal cord motor neurons of SOD1(G93A) mice 
compared to controls, p-Akt(Ser473) levels did not change with disease progression and 
they were also consistent in healthy and degenerating motor neurons in the 
SOD1(G93A) mice (Peviani et al., 2007). However, p-Akt(Ser473) levels were elevated in 
astrocytes and microglia in these SOD1(G93A) mice (Peviani et al., 2007). In a different 
study, p-Akt(Ser473) staining was much stronger in the spinal cord motor neurons of 
SOD1(G93A) mice compared to controls, and p-Akt(Ser473) levels were increased in the 
spinal cord of a SOD1(G93A) mice (Ilieva et al., 2003). However, in a motor neuron-like 
in vitro model of SOD1(G93A)-ALS, p-Akt(Ser473) levels were decreased when compared 
to control cells (Koh et al., 2004). Therefore, because of the conflicting results, and the 
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use of models with a different genetic variant of ALS, it is difficult to say how the results 
in the NSC34 (G4C2)102 cells fit with previous studies. In addition, no studies have 
looked at pAKT(Ser473) levels in other C9ORF72-ALS models, such as C9ORF72-ALS iPSC 
derived motor neurons. 
6.4.3. Pten Knock-Down Provides Rescue from (G4C2)102 Induced Toxicity in the NSC34 
(G4C2)102 Cells Independently of Increased Akt Signalling 
The NSC34 sham and NSC34 (G4C2)102 were successfully transduced with Pten shRNA 
and control lentiviral vectors. Importantly, NSC34 cells were first transduced with GFP 
control lentivirus to visually confirm using a fluorescence microscope that the cells had 
been stably transduced, and also used as a control for lentiviral transduction. Later, 
when rescue was observed, NSC34 cells were then transduced with a control shRNA 
lentivirus that served as a control for the Pten shRNA expression off target effects. 
NSC34 (G4C2)102 cells that were transduced with the Pten shRNA had significant Pten 
knock-down over several passages, indicating stable transduction. Unexpectedly 
however, the NSC34 sham cells that were transduced with Pten shRNA only had 
significant Pten knock-down for a few passages, after which the Pten levels returned to 
the same as control cells. This suggests there was potentially an outgrowth of clones 
that contained the lentivirus intergrated at a silent genomic locus (ie weak expression 
of the Pten shRNA, and poor knock-down). Additionally, a transient burst of lentiviral 
expression may have accounted for the Pten knock-down in the early passages. For that 
reason, the initial immunoblot and rescue experiments (that used the GFP control lines) 
include the NSC34 sham Pten shRNA line, whilst the later experiments that used the 
control shRNA lines, do not include the NSC34 sham Pten shRNA line. Ideally, clonal 
transformants would have been selected and characterised for Pten knock-down, but 
there was insufficient time for clonal selection and therefore the mixed population of 
transduced cells was taken forward. 
Another unexpected result was that p-Akt(Ser473) levels were elevated in both the 
NSC34 (G4C2)102 Pten and control shRNA cells compared to the NSC34 sham control 
shRNA cells. Firstly, this suggests that Pten knock-down had no effect on Akt signalling. 
Secondly, the lack of elevated Akt signalling in the NSC34 sham control shRNA cells 
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suggests that a double hit from the genomic (G4C2)102 repeat and lentivirus caused the 
increase in Akt signalling. Increased (G4C2)102 expression has no effect on the Akt 
signalling in the NSC34 (G4C2)102 lentiviral transduced cells. Also, the presence of the 
(G4C2)102 repeat alone had no effect on Akt signalling in the NSC34 cells (as described 
in section 6.4.1). However, viral vectors alone can activate the PI3K/AKT signalling 
pathway (Philpott et al., 2004; Tan et al., 2005; Tan et al., 2006), and stable transduction 
of the lentivirus into the NSC34 cells may be the cause of the increased Akt signalling. 
Alternatively to the double hit hypothesis, the NSC34 sham cells may have only been 
transiently transduced, or kicked out the control shRNA lentiviral vector (as was 
suspected with the Pten shRNA in the NSC34 sham cells described above), explaining 
the lack of elevated p-Akt(Ser473) levels. 
The hypothesis was that Pten knock-down in the NSC34 cells would increase Akt 
signalling, providing a protective effect to the NSC34 (G4C2)102 cells. However, the Pten 
knock-down did not elevate p-Akt(Ser473) levels. This is contrary to previous work using 
Pten siRNA in both cultured motor neurons and mice. Pten siRNA delivered by lentivirus 
into cultured murine motor neurons caused Pten knock-down and increased p-
Akt(Ser473) levels compared to cells transduced with control siRNA lentivirus (Kirby et 
al., 2011; Ning et al., 2010). In addition, Pten siRNA delivered by adeno associated virus 
9 (AAV9) into mice also knocked down Pten and increased p-Akt(Ser473) levels in the 
skeletal muscle compared to mice transduced with control siRNA lentivirus (Little et al., 
2015). In all three studies, the level of Pten knock-down was similar to that in the NSC34 
(G4C2)102 Pten shRNA cells.  
Whilst the Pten knock-down did not activate Akt signalling to a measurable level, it did 
provide a protective effect against the (G4C2)102 induced toxicity in the NSC34 
(G4C2)102 cells. This rescue effect was detected in two separate sets of experiments, 
whilst both the NSC34 (G4C2)102 GFP and NSC34 (G4C2)102 control shRNA cell lines 
both displayed reduced viability after 7 days of increased (G4C2)102 expression. This 
suggests that the rescue effect derived from Pten knock-down in the NSC34 (G4C2)102 
cells was independent of PI[3,4,5]P3 metabolism and PI3K/Akt signalling modulation. 
Pten is suggested to have functions independent of PI[3,4,5]P3 metabolism, including 
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DNA repair and sensitivity to genotoxic stress, cell migration, and protein phosphatase 
activity (Bassi et al., 2013; Leslie et al., 2007; Shi et al., 2014; Song et al., 2011). Pten 
knock-down has previously been shown to provide neuroprotective effects in both ALS 
and SMA models, although these effects were attributed to increased PI3K/AKT 
signalling (Kirby et al., 2011; Little et al., 2015; Ning et al., 2010). However, loss of 
PI3K/AKT independent Pten functions cannot be ruled out as providing some 
neuroprotective effects in these studies. 
6.4.4. BpV(phen) was not Suitable as a Pten Inhibitor in the NSC34 Cells 
BpV(phen) was tested for toxicity and Pten inhibition in the NSC34 sham cells to 
establish whether it could be used as a Pten inhibitor in rescue assays. The aim was to 
perform a rescue assay using BpV(phen) on NSC34 (G4C2)102 cells that were induced 
with tetracycline for 7 days. This is because previous experiments had shown (G4C2)102 
induced toxicity was detectable after 7 days tetracycline induction (section 3.3.4.5). 
Therefore, the toxicity of various BpV(phen) concentrations at 6 days treatment was 
tested in NSC34 sham cells. 1µM was the highest sub-lethal dose of BpV(phen) in the 
NSC34 sham cells tested in the initial 6 day BpV(phen) dose-response experiment. This 
sub-lethal BpV(phen) concentration is fairly consistent with other in vitro studies. For 
example BpV(phen) caused mild cytotoxicity after 48 hours treatment at ≥2µM in 
BEAS2B cells (Lai et al., 2007), 24 hours treatment at ≥20µM in H9c2 cardiomyoblasts 
(Tian et al., 2012), and 2 hours treatment at ≥100µM in NIH3T cells (Schmid et al., 2004). 
However, Akt signalling was not increased in NSC34 sham cells treated with 1µM 
BpV(phen), suggesting Pten was not inhibited. This is inconsistent with other previous 
in vitro studies that have used ≤1µM BpV(phen) to inhibit Pten and activate AKT 
signalling. In one study, Pten was activated and p-AKT(ser473) levels were elevated in 
BEAS2B cells treated for 30 minutes with as little as 0.1µM BpV(phen) (Lai et al., 2007). 
BpV(phen) is also known to be relatively stable in cell culture conditions, and can be 
incubated in media over night without any reduction in its ability to inhibit Pten (Schmid 
et al., 2004). In addition, increased AKT signalling was maintained over several days in 
BEAS2B cells by BpV(phen) treatment (Lai et al., 2007). Therefore, alterations in Akt 
signalling should have been detectable between 12 and 48 hours BpV(phen) treatment. 
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1µM BpV(phen) was too low a concentration to use as a Pten inhibitor in the NSC34 
cells.  
When the NSC34 sham cells were treated with a higher dose of 3µM BpV(phen) for 48 
hours, there was an increase in p-Akt(Ser473) levels, indicating Pten inhibition. This was 
important because no previous studies had shown that BpV(phen) could inhibit Pten in 
the NSC34 cell line. Rather contradictorily however, 3µM BpV(phen) caused cytotoxicity 
in the NSC34 sham cells after only 24 hours. This actually suggests the elevated p-
Akt(Ser473) levels were in fact due to the NSC34 activating the prosurvival pathway in a 
last ditch attempt to avoid BpV(Phen) induced toxicity. A shorter 6 hour dose of 3µM 
BpV(phen) (which did not cause detectable cytotoxicity) was taken forward for the 
rescue assay, but did not rescue the NSC34 (G4C2)102 cells from (G4C2)102 induced 
toxicity, and actually caused slight cytotoxicity to the NSC34 cells. In conclusion, there 
was no suitable concentration of BpV(phen) that would inhibit Pten, activate Akt 
signalling and was not cytotoxic. 
6.4.5. Summary 
GEP identified transcriptomic dysregulation in the PI3K/AKT signalling pathway in NSC34 
(G4C2)102 cells, and also in C9ORF72-ALS LCM motor neurons. This suggests that 
transcriptomic dysregulation in this pro-survival pathway is an early biochemical event 
in C9ORF72-ALS, and could therefore serve as a potent therapeutic target for protecting 
motor neurons in ALS pathogenesis. However, there was no measurable effect on Akt 
or Pten protein levels in the NSC34 (G4C2)102 cells, nor was the PI3K/Akt signalling 
pathway altered under basal conditions. Although, the reduced sensitivity of 
immunoblotting as a technique compared to the microarray technology used is the likely 
cause for the apparent lack of validation. Importantly, Pten knock-down did provide a 
rescue effect against the (G4C2)102 induced toxicity, independently of the Akt signalling 
pathway, and suggests Pten deserves further study in different models of C9ORF72-ALS 
as a potential therapeutic target. Lastly however, BpV(phen) was not a useful Pten 
inhibitor in the NSC34 cells, because there was no sub-lethal dose that activated the Akt 
signalling pathway.  
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Chapter 7. Conclusions and Future Work 
ALS is an incurable neurodegenerative disease characterised by progressive loss of both 
upper and lower motor neurons. The most common genetic cause of ALS is a (G4C2)n 
repeat expansion in intron 1 of C9ORF72. This project aimed to understand how the 
(G4C2)n repeat expansion could cause motor neuron cell death, and to identify potential 
therapeutic targets for neuroprotection. To do this, motor neuron like cellular models 
were generated using NSC34 cells that expressed different lengths of the (G4C2)n in a 
tetracycline inducible manner. Initially, these NSC34 (G4C2)n cells were characterised 
for C9ORF72-ALS pathology using a range of biochemical techniques. Analysis of gene 
expression was then employed to assess how expression of the (G4C2)n affects the 
transcriptome in a motor neuron like context. Additionally, the transcriptomic analysis 
identified biological pathways that may hold therapeutic potential for C9ORF72-ALS 
patients. In the last part of the project, one of the potential therapeutic targets was 
assessed in the NSC34 (G4C2)n cells to see whether modulation would provide rescue 
effects and could therefore serve as a potential therapeutic target. 
When the project was started, I attempted to use RNA tagging systems with the (G4C2)n 
constructs that would allow detection of (G4C2)n expression, but which would also allow 
the (G4C2)n RNA to be studied in live cells. The MS2 system and tRSA systems were 
employed (Bertrand et al., 1998; Iioka et al., 2011), to facilitate visualisation of the 
(G4C2)n RNA in live cells and direct (G4C2)n RNA pull down from live cells respectively. 
Whilst the MS2 and tRSA tags were each cloned upstream of the (G4C2)n repeat 
constructs, I was unable to optimise either system to detect (G4C2)n RNA expression in 
the live cells. Also, at the time, the locked nucleic acid (LNA) probe and FISH 
methodologies were developed, which allowed detection of the (G4C2)n RNA expressed 
from the repeat, and could be employed to measure (G4C2)n expression in the cellular 
model system. Given that the main aim of the project was to develop a cellular model 
that expressed the (G4C2)n repeat expansion, and to use the model to identify potential 
therapeutic targets, I decided to discontinue the RNA tag work. However, with 
improvements in future technology, these sorts of live cell RNA tagging tools would be 
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incredibly useful for further understanding the molecular biology of the (G4C2)n repeat. 
Particularly, visualisation of the (G4C2)n RNA in live cells could help elucidate how the 
(G4C2)n RNA is exported from the nucleus, how dynamic the (G4C2)n RNA foci and 
(G4C2)n RNA-protein interactions are, and also how and where the (G4C2)n RNA is RAN 
translated to produce DPR proteins. 
At present, it is still not fully understood how the (G4C2)n repeat expansion in C9ORF72 
causes motor neuron cell death in ALS pathogenesis. Therefore, generating stable 
cellular models that expressed the (G4C2)n repeat in a motor neuron cell context was 
designed to better understand this problem. Many early studies that also aimed to 
elucidate the potentially toxic mechanisms associated with the (G4C2)n repeats either 
used transiently transfected cell lines, C9ORF72-ALS patient derived cells or post-
mortem tissue (sections 1.7 and 1.8). However, I wanted to generate a reductionist 
model that would interrogate only the effect of the (G4C2)n expression independent of 
the C9ORF72 gene context. Also, I specifically used the FRT system to generate isogenic 
control and disease model cell lines, because random insertion of the (G4C2)n repeats 
could have had off target effects unrelated to the (G4C2)n expression itself. Additionally, 
overexpression of a gene of interest can provide misleading results, and tetracycline-
inducible expression had the advantage of allowing control of the (G4C2)n expression 
level. Another unique advantage of the tetracycline inducible expression is that the early 
biochemical effects of the (G4C2)n expression could be studied. Stable and isogenic 
NSC34 (G4C2)n cell lines were successfully generated that had tetracycline inducible 
(G4C2)n expression. The (G4C2)n repeat forms characteristic sense RNA foci, but not 
antisense RNA foci, in the NSC34 (G4C2)n cells. In addition, the interrupted (G4C2)102 
repeat underwent RAN translation to produce proteins containing all sense DPR motifs 
((GA)n, (GR)n and (GP)n). Therefore, the NSC34 (G4C2)n cells are sense only (G4C2)n 
gain of function models of C9ORF72-ALS, with tetracycline inducible expression allowing 
identification of early biochemical effects. 
Expression of the (G4C2)102 reduced NSC34 cell growth rate, indicating that the RNA 
and/or RAN proteins were causing mild toxicity or posed a metabolic burden in the cells. 
This is in agreement with other (G4C2)n gain of function models of C9ORF72-ALS that 
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also describe (G4C2)n induced toxicity (section 1.8.2). However, the more subtle toxic 
effects described in the NSC34 (G4C2)102 cells may actually represent a more 
physiologically relevant model compared to the more severe phenotypes described in 
other cellular models. ALS onset generally occurs later in life, and therefore any toxicity 
associated with the (G4C2)n repeat expansion is likely to be well tolerated and fairly low. 
However, the (G4C2)n must provide some toxic burden that aged motor neurons and/or 
other cells in the CNS fail to handle. Although many cellular and animal models suggest 
that the arginine rich DPR species are the main toxic entity associated with the (G4C2)n 
repeat expansion, the NSC34 (G4C2)102 cells do not produce these pure DPR, which may 
also explain the mild toxic phenotype. Further, in house work with Guillaume 
Hautbergue suggests that pure (G4C2)n repeats produce far more RAN translation 
products compared to the interrupted (G4C2)102 repeats used in this project 
(unpublished data). 
In addition, the NSC34 (G4C2)102 cells recapitulated some other aspects of C9ORF72-
ALS pathology. Firstly, the sense RNA foci colocalised with SRSF1, SRSF2, and nucleolar 
NCL, but not with PURA or ALYREF. Secondly, the (G4C2)102 expression caused mild 
disruption to the nucleolar morphology in the NSC34 cells comparable to previously 
published data, although there was no clear evidence of functional nucleolar stress. 
However, (G4C2)102 expression did not cause TDP-43 aggregation or mislocalisation. 
This is in agreement with the majority of other (G4C2)n gain of function cellular and 
animal models of C9ORF72-ALS (section 1.8.2). In fact, TDP-43 pathology has only been 
described in one model – 6 month old mice that over express a (G4C2)66 repeat 
construct in the CNS (O'Rourke et al., 2015). Several other (G4C2)n gain of function 
animal models do not recapitulate TDP-43 pathology (section 1.8.2). In conclusion 
though, the subtle biochemical effects described in the NSC34 (G4C2)102 cells model 
early events that occur before TDP-43 aggregation and mislocalisation, and any 
therapeutic targets identified may prevent downstream events that culminate in TDP-
43 pathology and/or ALS pathogenesis. Additionally, the subtle phenotype described in 
the NSC34 (G4C2)102 cells is arguably more relevant for disease with age-related onset.  
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A pipeline of work was previously used to identify potential therapeutic targets in SOD1-
ALS. Firstly, transcriptomic analysis was performed on NSC34 cell models expressing 
G93A SOD1, and identified transcriptomic dysregulation in genes encoding antioxidant 
response proteins (Kirby et al., 2005). In particular, nuclear erythroid 2-related-factor 2 
(NRF2) was identified as a potential therapeutic target because it promotes expression 
of the cytoprotective Phase II detoxification and antioxidant enzymes (McMahon et al., 
2001; Nguyen et al., 2003). NRF2 was down regulated in the G93A SOD1 NSC34 cell 
models, and also in spinal motor neurons and motor cortex of SALS cases (Kirby et al., 
2005; Sarlette et al., 2008). Secondly, small molecules were screened and S[+] 
Apomorphine was identified as a CNS penetrant NRF2 activator, which is a promising 
therapeutic candidate for ALS patients (Mead et al., 2013). 
Here, we aimed to repeat the pipeline of work described above to identify therapeutic 
targets, and eventually drug candidates, for C9ORF72-ALS. Previous transcriptomic 
studies on C9ORF72-ALS have used either patient derived cell lines or post-mortem CNS 
tissue. These transcriptomic changes may therefore reflect the end stage of the disease, 
and the crucial early transcriptomic changes associated with (G4C2)n repeat toxicity may 
be lost or more difficult to identify. Also, these studies did not interrogate the (G4C2)n 
expression in a reductionist manner. However, transcriptomic analysis of the NSC34 
(G4C2)102 cells identified dysregulated pathways that may be crucial in the early 
pathogenesis of C9ORF72-ALS. Specifically, transcriptomic dysregulation was identified 
in RNA metabolism, and particularly in RNA splicing. Further, differential splicing analysis 
of the NSC34 (G4C2)102 cells showed that (G4C2)102 expression functionally affected 
the splicing. This corroborates several other transcriptomic studies performed on 
C9ORF72-ALS patient derived cells and post-mortem tissue (Cooper-Knock et al., 2015a; 
Prudencio et al., 2015), and critically suggests that RNA metabolism and splicing 
dysregulation is an early event in C9ORF72-ALS pathogenesis caused by the sense 
(G4C2)n repeat.  
Also using the GEP analysis, significant dysregulation in the PI3K/Akt signalling pathway 
was identified in the NSC34 (G4C2)102 cells. Again, this was validated in LCM motor 
neurons from C9ORF72-ALS patients, suggesting this is an early transcriptomic change 
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in C9ORF72-ALS. Given that the PI3K/AKT signalling pathway regulates cellular survivial 
(amongst other functions) it could represent a particularly potent therapeutic target in 
prolonguing motor neuron survival in C9ORF72-ALS. This also demonstrates that the 
NSC34 (G4C2)102 cells can successfully be used to identify disease relevant early 
transcriptomic changes in C9ORF72-ALS. Additionally, previous work had also identified 
the PI3K/Akt signalling pathway, and Pten in particular, as potential therapeutic targets 
in ALS, which therefore encouraged further interrogation. 
Although the microarray analysis identified transcriptomic dysregulation in the NSC34 
(G4C2)102 cells, and this was also found in C9ORFF72-ALS LCM motor neurons, qRT-PCR 
and immunoblot validation did not find any significant differences in Pten or Akt levels 
in the NSC34 (G4C2)102 cells. This is likely due to reduced sensitivity in validation 
methods compared to the microarray technology. Additionally, there was no 
measurable change in Akt signalling at basal levels in the NSC34 (G4C2)102 cells. 
However, Pten knock-down did provide a rescue effect against the (G4C2)102 induced 
toxicity described in the NSC34 (G4C2)102 cells. Further, the Pten knock-down did not 
affect Akt signalling, and suggests that the rescue effect associated with the Pten knock-
down could be independent of the PI3K/Akt signalling pathway. In conclusion though, 
the transcriptomic validation in C9ORF72-ALS patient motor neurons, and the Pten 
knock-down rescue effect suggest Pten deserves further study in different models of 
C9ORF72-ALS. 
7.1. Future Work 
The relative contributions of C9ORF72 haploinsufficiency, RNA toxicity and DPR toxicity 
in ALS pathogenesis still remain far from clear, and therefore future work should be 
invested in this direction. In terms of C9ORF72 haploinsufficiency, there are two key 
problems: there are no reliable antibodies available for C9ORF72 detection, and also the 
function of C9ORF72 is still unknown. Therefore investment in developing reliable 
C9ORF72 antibodies will allow research into the function of C9ORF72, and also identify 
whether C9ORF72 protein levels are affected by the presence of the (G4C2)n repeat 
expansion. 
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Additionally, it is also unclear which cell types are affected directly and indirectly by the 
(G4C2)n repeat expansion. Elegant studies using the Cre-LoxP system in SOD1 mouse 
models of ALS, show that deleting the mutant SOD1 in astrocytes and microglia slows 
disease progression, whilst deleting mutant SOD1 in the motor neurons delays disease 
onset (Boillée et al., 2006b; Wang et al., 2011; Yamanaka et al., 2008a; Yamanaka et al., 
2008b). Additionally, co-culture models show that FALS and SALS patient derived 
astrocytes (including C9ORF72-ALS patient derived astrocytes) and microglial cells 
confer in vitro toxicity when cultured with Hb9-GFP murine motor neurons (Di Giorgio 
et al., 2008; Haidet-Phillips et al., 2011; Meyer et al., 2014; Nagai et al., 2007). Therefore, 
further investigation into which cell types contribute to motor neuron death in vivo in 
C9ORF72-ALS is crucial for identifying effective therapeutics. 
The first line of future work I would consider is to interrogate PTEN as a therapeutic 
target in different models of both C9ORF72-ALS, but also other genetic forms of FALS 
and SALS. Firstly, in vitro co-culture models (described above) would be used, and if 
PTEN modulation provided rescue effects, secondary in vivo mouse models would be 
used. The Hb9-GFP murine motor neurons would be treated with Pten shRNA, and then 
co-cultured with C9ORF72-ALS derived astrocytes or microglial cells to see whether Pten 
knock-down rescues the motor neurons from glial toxicity. Additionally, other 
pharmacological PTEN inhibitors such as BpV(Phen) would be trialled for efficacy in 
these motor neuron cells as well. Further, astrocytes and microglial cells would also be 
treated with PTEN shRNA, and co-cultured with PTEN shRNA treated and untreated Hb9-
GFP murine motor neurons. This would identify whether PTEN knock-down in ALS 
patient derived glial cells would exacerbate their toxicity toward motor neurons, in 
which case, a motor neuron specific PTEN knock-down would be required for in vivo 
models as opposed to a pan-CNS PTEN shRNA delivery. Experiments using other genetic 
forms of FALS, and also SALS derived glial cells would also be performed alongside the 
C9ORF72-ALS work. 
Dependent on the efficacy of the PTEN shRNA and/or PTEN inhibition in the co-culture 
system, this strategy would then be taken forward for in vivo work. Mice provide a 
robust and widely used model organism for studying human disease, and would 
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therefore be used as the in vivo model. Since the aim of the in vivo work would be to 
identify whether PTEN knock-down and/or inhibition can prevent motor neuron 
degeneration, a mouse model with a clear phenotype would be required. At present, 
only one C9ORF72-ALS mouse model exists that recapitulates TDP-43 pathology, and 
behavioural and motor defects similar to the clinical symptoms of C9ORF72-ALS/FTD 
patients (Chew et al., 2015). Therefore, this model would be selected, unless a more 
convincing mouse model was generated. In this model, a (G4C2)66 construct would be 
delivered to the CNS via adeno-associated virus, with the addition of either Pten shRNA 
or scrambled shRNA. The mice would then be assessed for TDP-43 inclusions in the CNS, 
astrogliosis, cortical and cerebellar degeneration, as well as cognitive and motor 
performance (all of which have been described in this mouse model previously (Chew 
et al., 2015)). 
Finally, ALS is a complex multifactorial disease, and there are several known 
dysregulated biological pathways but also many different cell types involved in disease 
onset and progression. Therefore, effective treatment of the disease will likely require 
modulation of more than one target, and also multiple cell types. Also, successful early 
diagnosis of ALS is likely to critical in treating the disease effectively, and therefore the 
development of better biomarkers will be necessary.  
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Appendices 
Appendix 1 Sequence chromatogram of pcDNA5/FRT/TO-(G4C2)10 sequenced using 
CMV-Forward primer. 
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Appendix 2 Sequence chromatogram of pcDNA5/FRT/TO-(G4C2)51 sequenced using 
CMV-Forward primer. 
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Appendix 3 Sequence chromatogram of pcDNA5/FRT/TO-(G4C2)51 sequenced using 
CMV-Forward primer.  
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Appendix 4 Arrays were hybridised, washed and stained in three separate batches on 
different days.  
Batch 1 Batch 2 Batch 3 
0_0_A 0_0_C 0_0_B 
0_5_A 0_1_A 0_1_C 
0_5_B 0_1_B 0_5_C 
10_0_A 10_0_C 10_5_A 
10_0_B 51_0_A 51_0_B 
10_5_B 51_5_B 51_0_C 
10_5_C 51_5_C 102_0_B 
51_5_A 102_0_C 102_1_A 
102_0_A 102_5_B 102_1_C 
102_1_B 102_5_C 102_5_A 
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Appendix 5 Differentially expressed transcripts within the human PI3K/Akt signalling 
pathway (KEGG) measured on the Human Genome microarray platform in the Laser 
Captured Microdissected motor neurons. Transcript ID, Gene symbol, Fold change, and 
P-value are included for a comparison between C9ORF72-ALS patients and control LCM 
MNs. 
Transcript ID Gene Symbol Fold Change P-value 
228006_at PTEN 11.2546 1.35E-05 
201125_s_at ITGB5 5.5843 0.00119 
212777_at SOS1 3.35696 0.01979 
209341_s_at IKBKB 3.16884 0.11631 
202686_s_at AXL 3.10927 0.01269 
201124_at ITGB5 2.86889 0.02358 
213093_at PRKCA 2.80256 0.00332 
226731_at ITGA1 2.73413 0.0494 
203685_at BCL2 2.70459 0.06485 
202723_s_at FOXO1 2.60666 0.0276 
203809_s_at AKT2 2.55388 0.07866 
210482_x_at MAP2K5 2.43459 0.14357 
1555612_s_at G6PC 2.42838 0.06008 
1552610_a_at JAK1 2.33472 0.18949 
217399_s_at FOXO3 2.2105 0.16448 
202887_s_at DDIT4 2.16861 0.00045 
223196_s_at SESN2 2.10237 0.0907 
208536_s_at BCL2L11 2.0825 0.3364 
203379_at RPS6KA1 2.08204 0.14381 
226068_at SYK 2.03705 0.07781 
202284_s_at CDKN1A 2.01865 0.16422 
225691_at CDK12 2.01056 0.079 
236664_at AKT2 2.00531 0.278 
201834_at PRKAB1 2.00507 0.32642 
202830_s_at SLC37A4 2.00107 0.14823 
212590_at RRAS2 1.87414 0.15224 
232068_s_at TLR4 1.86715 0.20452 
222999_s_at CCNL2 1.82949 0.04503 
201739_at SGK1 1.82899 0.01689 
202340_x_at NR4A1 1.82347 0.34816 
202530_at MAPK14 1.76965 0.42941 
209666_s_at CHUK 1.73936 0.28304 
226441_at MAP3K2 1.71589 0.09514 
204054_at PTEN 1.69351 0.3928 
202431_s_at MYC 1.67664 0.40172 
202847_at PCK2 1.6713 0.37293 
221060_s_at TLR4 1.6664 0.50849 
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236459_at PRKCE 1.62936 0.24505 
224889_at FOXO3 1.62723 0.51267 
209342_s_at IKBKB 1.61255 0.38191 
239201_at CDK15 1.5972 0.22748 
1558143_a_at BCL2L11 1.57667 0.05218 
204297_at PIK3C3 1.57353 0.24559 
202853_s_at RYK 1.55959 0.0062 
210449_x_at MAPK14 1.55875 0.50136 
212589_at RRAS2 1.5542 0.33377 
212628_at PKN2 1.53559 0.24039 
208712_at CCND1 1.51291 0.32986 
209364_at BAD 1.49379 0.43723 
206398_s_at CD19 1.48899 0.4906 
202449_s_at RXRA 1.44284 0.36684 
202426_s_at RXRA 1.44084 0.55632 
241453_at PTK2 1.43103 0.41771 
207540_s_at SYK 1.42509 0.46612 
201234_at ILK 1.42441 0.50657 
241387_at PTK2 1.41725 0.44044 
225066_at PPP2R2D 1.4018 0.26905 
241722_x_at MCL1 1.38925 0.55755 
212332_at RBL2 1.35227 0.25134 
208824_x_at CDK16 1.346 0.05766 
208823_s_at CDK16 1.33674 0.33747 
200797_s_at MCL1 1.33354 0.16695 
227073_at MAP3K2 1.31735 0.50772 
225690_at CDK12 1.30615 0.51302 
206854_s_at MAP3K7 1.28559 0.56793 
226310_at RICTOR 1.28358 0.42508 
211333_s_at FASLG 1.28012 0.61041 
206952_at G6PC 1.27975 0.52706 
206853_s_at MAP3K7 1.26817 0.33893 
208820_at PTK2 1.25554 0.33508 
202161_at PKN1 1.23813 0.67904 
209184_s_at IRS2 1.23611 0.24619 
202210_x_at GSK3A 1.23529 0.59625 
219226_at CDK12 1.2304 0.71416 
211087_x_at MAPK14 1.2267 0.61045 
211561_x_at MAPK14 1.21891 0.60994 
202724_s_at FOXO1 1.21878 0.7646 
212312_at BCL2L1 1.20808 0.70595 
215195_at PRKCA 1.20301 0.71054 
201984_s_at EGFR 1.20112 0.42889 
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225606_at BCL2L11 1.19905 0.70546 
204906_at RPS6KA2 1.19762 0.33186 
229705_at PIK3C3 1.18909 0.0324 
205271_s_at CDK20 1.187 0.8061 
207163_s_at AKT1 1.18606 0.42615 
1569272_at PIK3C3 1.17994 0.67476 
235254_at MAP3K2 1.16993 0.75392 
223195_s_at SESN2 1.15593 0.71007 
214265_at ITGA8 1.13662 0.55785 
204924_at TLR2 1.1327 0.77274 
228177_at CREBBP 1.12985 0.82862 
204131_s_at FOXO3 1.12735 0.51347 
1556655_s_at CDK12 1.12495 0.86831 
231017_at STK11 1.12286 0.60075 
228248_at RICTOR 1.11708 0.75622 
202160_at CREBBP 1.11546 0.39302 
238733_at MDM2 1.10799 0.78926 
226979_at MAP3K2 1.10251 0.57574 
203984_s_at CASP9 1.09459 0.78315 
205386_s_at MDM2 1.09264 0.87372 
208641_s_at RAC1 1.08706 0.75898 
240964_at PTEN 1.08698 0.87875 
226156_at AKT2 1.08531 0.86743 
225471_s_at AKT2 1.08322 0.86043 
203836_s_at MAP3K5 1.07841 0.84902 
237451_x_at CASP9 1.07679 0.71896 
220587_s_at MLST8 1.07642 0.82245 
202685_s_at AXL 1.0668 0.90898 
211372_s_at IL1R2 1.06204 0.88368 
227627_at SGK3 1.04972 0.87686 
225160_x_at MDM2 1.04866 0.80214 
244616_x_at MDM2 1.04365 0.90974 
227426_at SOS1 1.04007 0.87069 
211832_s_at MDM2 1.03989 0.91227 
203837_at MAP3K5 1.03634 0.79284 
217492_s_at PTEN 1.03561 0.9246 
1557970_s_at RPS6KA2 1.03377 0.9432 
212629_s_at PKN2 1.03248 0.93566 
212719_at PHLPP1 1.02015 0.88671 
209185_s_at IRS2 1.00973 0.97333 
226299_at PKN3 1.00887 0.98546 
202670_at MAP2K1 1.00733 0.98816 
229711_s_at MDM2 1.00646 0.96837 
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225694_at CDK12 1.00449 0.99428 
632_at GSK3A 1.004 0.9922 
224891_at FOXO3 1.00182 0.99447 
208640_at RAC1 1.00142 0.996 
207239_s_at CDK16 1.00006 0.99989 
213012_at NEDD4 -1.0189 0.95973 
223049_at GRB2 -1.0198 0.90722 
204756_at MAP2K5 -1.0261 0.93618 
215394_at PIK3C3 -1.0303 0.95529 
224999_at EGFR -1.0322 0.93724 
205798_at IL7R -1.0369 0.93805 
212331_at RBL2 -1.0382 0.89007 
232876_at MAPK14 -1.0426 0.93159 
201983_s_at EGFR -1.043 0.9245 
1555804_a_at MAP3K19 -1.052 0.89459 
205498_at GHR -1.053 0.89839 
200980_s_at PDHA1 -1.0565 0.80341 
226218_at IL7R -1.0576 0.90887 
211808_s_at CREBBP -1.0638 0.89116 
202288_at MTOR -1.0738 0.89435 
200798_x_at MCL1 -1.0766 0.77284 
209112_at CDKN1B -1.0849 0.59406 
214328_s_at HSP90AA1 -1.0922 0.75804 
208743_s_at YWHAB -1.0965 0.85556 
201389_at ITGA5 -1.098 0.85649 
208456_s_at RRAS2 -1.1005 0.91845 
212912_at RPS6KA2 -1.1034 0.70576 
204247_s_at CDK5 -1.1084 0.78323 
217718_s_at YWHAB -1.1126 0.69372 
210655_s_at FOXO3 -1.1146 0.78924 
204369_at PIK3CA -1.117 0.84573 
201452_at RHEB -1.1221 0.7603 
226046_at MAPK8 -1.1322 0.83582 
239300_at PIK3C3 -1.1323 0.36348 
210775_x_at CASP9 -1.134 0.84706 
225363_at PTEN -1.1397 0.55908 
218852_at PPP2R3C -1.1406 0.81561 
44654_at G6PC3 -1.1408 0.50127 
210969_at PKN2 -1.1422 0.69294 
209390_at TSC1 -1.145 0.55561 
210211_s_at HSP90AA1 -1.1507 0.74048 
1567458_s_at RAC1 -1.1544 0.43336 
202647_s_at NRAS -1.1576 0.6594 
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1560074_at PRKCA -1.1632 0.59213 
243492_at THEM4 -1.1728 0.76346 
214172_x_at RYK -1.1758 0.31314 
201437_s_at EIF4E -1.1808 0.43703 
1552611_a_at JAK1 -1.1818 0.4436 
224985_at NRAS -1.182 0.50934 
229664_at MAPK8 -1.1907 0.38632 
215037_s_at BCL2L1 -1.1949 0.60974 
217542_at MDM2 -1.2027 0.61732 
204798_at MYB -1.2095 0.72784 
211814_s_at CCNE2 -1.2099 0.77485 
211550_at EGFR -1.2172 0.62589 
1555864_s_at PDHA1 -1.2181 0.59782 
1552559_a_at CDK15 -1.2221 0.64683 
1553118_at THEM4 -1.2253 0.41306 
226312_at RICTOR -1.2291 0.45219 
211938_at EIF4B -1.2444 0.29075 
211937_at EIF4B -1.2454 0.35644 
204053_x_at PTEN -1.2478 0.56041 
201835_s_at PRKAB1 -1.2561 0.35571 
217557_s_at MDM2 -1.2589 0.63174 
200979_at PDHA1 -1.2615 0.28516 
235980_at PIK3CA -1.2619 0.26671 
221759_at G6PC3 -1.2629 0.51812 
214660_at ITGA1 -1.2897 0.67717 
211536_x_at MAP3K7 -1.3006 0.63566 
212688_at PIK3CB -1.3077 0.21645 
209269_s_at SYK -1.3122 0.67354 
215152_at MYB -1.3244 0.58063 
217717_s_at YWHAB -1.3264 0.37399 
217373_x_at MDM2 -1.3282 0.4774 
210865_at FASLG -1.3454 0.37793 
1861_at BAD -1.3604 0.55135 
201453_x_at RHEB -1.3606 0.33799 
232274_at CCNL2 -1.3634 0.32902 
201648_at JAK1 -1.3726 0.24825 
211027_s_at IKBKB -1.3764 0.51877 
217289_s_at SLC37A4 -1.3774 0.48497 
200796_s_at MCL1 -1.3778 0.59702 
211711_s_at PTEN -1.3861 0.07704 
207005_s_at BCL2 -1.3874 0.48661 
221772_s_at PPP2R2D -1.3948 0.37502 
205403_at IL1R2 -1.3959 0.49143 
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220357_s_at SGK2 -1.4124 0.60431 
204531_s_at BRCA1 -1.424 0.43404 
1552734_at RICTOR -1.4243 0.42119 
216976_s_at RYK -1.426 0.53413 
230573_at SGK2 -1.4367 0.34697 
209953_s_at CDC37 -1.4471 0.28938 
206248_at PRKCE -1.4513 0.26208 
237891_at MDM2 -1.477 0.46615 
221695_s_at MAP3K2 -1.4853 0.60004 
212780_at SOS1 -1.4936 0.02532 
1565483_at EGFR -1.5092 0.42247 
227633_at RHEB -1.5105 0.40547 
242674_at EIF4E -1.5226 0.17335 
231228_at BCL2L1 -1.5388 0.33907 
206665_s_at BCL2L1 -1.5422 0.43553 
213404_s_at RHEB -1.5462 0.14498 
217620_s_at PIK3CB -1.5471 0.33664 
231854_at PIK3CA -1.5474 0.46198 
226101_at PRKCE -1.5479 0.16316 
214621_at GYS2 -1.5577 0.37259 
215075_s_at GRB2 -1.5756 0.1419 
201436_at EIF4E -1.5766 0.13533 
208711_s_at CCND1 -1.5776 0.45561 
211370_s_at MAP2K5 -1.5799 0.48471 
41657_at STK11 -1.5864 0.34306 
225715_at RPTOR -1.5905 0.2525 
222343_at BCL2L11 -1.5914 0.36242 
232086_at PIK3C3 -1.5963 0.38617 
221427_s_at CCNL2 -1.6199 0.04162 
224341_x_at TLR4 -1.6213 0.36125 
220038_at SGK3 -1.6288 0.39196 
211851_x_at BRCA1 -1.6346 0.4612 
1560359_at ITGA1 -1.6459 0.49152 
1553096_s_at BCL2L11 -1.6518 0.05439 
221180_at MAP3K19 -1.689 0.28863 
1553088_a_at BCL2L11 -1.6899 0.10844 
211968_s_at HSP90AA1 -1.6902 0.25214 
239188_at PPP2R3C -1.6926 0.34661 
229253_at THEM4 -1.702 0.07348 
203684_s_at BCL2 -1.7119 0.40501 
242071_x_at ITGA8 -1.7283 0.2544 
206341_at IL2RA -1.7288 0.33477 
211537_x_at MAP3K7 -1.7619 0.39267 
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215735_s_at TSC2 -1.7706 0.11829 
211969_at HSP90AA1 -1.7979 0.28924 
226048_at MAPK8 -1.8355 0.09455 
225697_at CDK12 -1.8525 0.06182 
1565484_x_at EGFR -1.8622 0.36031 
1556654_at CDK12 -1.8706 0.16327 
207821_s_at PTK2 -1.8783 0.33951 
210226_at NR4A1 -1.8816 0.25831 
201020_at YWHAH -1.9019 0.08157 
209239_at NFKB1 -1.996 0.11918 
235011_at MAP3K2 -2.0338 0.26344 
211607_x_at EGFR -2.0762 0.11823 
237718_at EIF4E -2.0795 0.16652 
206923_at PRKCA -2.0808 0.0805 
1552798_a_at TLR4 -2.1097 0.17767 
239092_at ITGA8 -2.1243 0.1596 
240437_at CASP9 -2.1861 0.10184 
1560689_s_at AKT2 -2.2126 0.16275 
210984_x_at EGFR -2.2755 0.19676 
205034_at CCNE2 -2.367 0.0156 
1554826_at CDK15 -2.3986 0.23223 
211453_s_at AKT2 -2.411 0.03222 
201435_s_at EIF4E -2.4361 0.08987 
211269_s_at IL2RA -2.4806 0.17388 
1555780_a_at RHEB -2.5578 0.23684 
211297_s_at CDK7 -2.6093 0.03151 
204132_s_at FOXO3 -2.7727 0.02473 
210671_x_at MAPK8 -2.7942 0.043 
235666_at ITGA8 -3.2363 0.0632 
210477_x_at MAPK8 -3.4604 0.02917 
204292_x_at STK11 -4.5009 0.00704 
 
 
 
 
